Introducing PHARMAC 2

September 2014

Volume 21 Number 2

Editors: Kaye Wilson,

Donna Jennings & Sarah Le Leu email: enquiry@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 9, 40 Mercer Street PO Box 10 254 Wellington

Freephone Information Line 0800 66 00 50 (9am – 5pm weekdays)

Circulation

Published each April, August and December. Changes to the contents are published in monthly updates.

Accessible in an electronic format at no cost from the Health Professionals section of the PHARMAC website www.pharmac.govt.nz

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month. Alternatively there is a nominal charge for an annual subscription to the printed Schedule publications. To access either of these subscriptions visit our subscription website www.schedule.co.nz.

Production

Typeset automatically from XML and T_EX. XML version of the Schedule available from www.pharmac.govt.nz/schedule/archive/

Programmers

Anrik Drenth & John Geering email: texschedule@pharmac.govt.nz

© Pharmaceutical Management Agency



ISSN 1179-3686 pdf ISSN 1172-9376 print

This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit:

creativecommons.org/licenses/by/3.0/nz/.

Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Section /	4
-----------	---

Section B

Section G

Section I

General Rules 10

В	Alimentary Tract & Metabolism	24
	Blood & Blood Forming Organs	44
	Cardiovascular System	53

- Dermatologicals 66 Genito Urinary System 78
- Hormone Preparations Systemic 84
- Infections Agents For Systemic Use 96
 - Musculoskeletal System 120
 - Nervous System 129
- Oncology Agents & Immunosuppressants 161
 - Respiratory System & Allergies 195
 - Sensory Organs 202

Various 207

Section C Extemporaneous Compounds (ECPs) 208

Section DSpecial Foods215Section EPractitioner's Supply Orders236
Rural Areas240Section FDispensing Period Exemptions241

Safety Cap Medicines 243

National Immunisation Schedule 246

Index 252

Introducing PHARMAC

PHARMAC, the Pharmaceutical Management Agency, is a Crown entity established pursuant to the New Zealand Public Health and Disability Act 2000 (The Act). The primary objective of PHARMAC is to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided.

The PHARMAC Board consists of up to six members appointed by the Minister of Health. All decisions relating to PHARMAC's operation are made by or under the authority of the Board. The functions of PHARMAC are to perform, within the amount of funding provided to it in the Pharmaceutical Budget or to DHBs from their own budgets for the use of pharmaceuticals within their hospitals, as applicable, and in accordance with its statement of intent and any directions given by the Minister (Section 103 of the Crown Entities Act).

Members of the PHARMAC Board

 Stuart McLauchlan
 Nicole Anderson
 David Kerr

 Jens Mueller
 Jan White

Decisions taken by the PHARMAC Board members, or made under the authority of the Board, incorporate a balanced view of the needs of prescribers and patients. The aim is to achieve long-term gains and efficient ways of making pharmaceuticals available to the community and for DHB Hospitals to purchase them.

The following attend PHARMAC's Board meetings as observers

- Murray Georgel, CE MidCentral DHB
- Kate Russell, Chair Consumer Advisory Committee
- Sisira Jayathissa, Chair Pharmacology and Therapeutics Advisory Committee (PTAC)

The functions of PHARMAC are to perform the following, within the amount of funding provided to it in the Pharmaceutical Budget or to DHBs from their own budgets for the use of pharmaceuticals in their hospitals, as applicable, and in accordance with its annual plan and any directions given by the Minister (Section 103 of the Crown Entities Act):

- a) to maintain and manage a pharmaceutical schedule that applies consistently throughout New Zealand, including determining eligibility and criteria for the provision of subsidies;
- b) to manage incidental matters arising out of (a), including in exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the pharmaceutical schedule;
- c) to engage as it sees fit, but within its operational budget, in research to meet its objectives as set out in Section 47(a) of the Act;
- d) to promote the responsible use of pharmaceuticals;
- e) to manage the purchasing of any or all pharmaceuticals, whether used either in a hospital or outside it, on behalf of DHBs;
- f) any other functions given to PHARMAC by or under any enactment or authorised by the Minister.

The policies and criteria set out in the Pharmaceutical Schedule and PHARMAC's Operating Policies and Procedures arise out of, and are designed to help PHARMAC achieve and perform, PHARMAC's objective and functions under the Act.

However PHARMAC may, having regard to its public law obligations, depart from the strict application of those policies and criteria in certain exceptional cases where it considers this necessary or appropriate in the proper exercise of its statutory discretion and to give effect to its objective and functions, particularly with respect to:

- Determining eligibility and criteria for the provision of subsidies; and
- In exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the Pharmaceutical Schedule.

Decision Criteria

PHARMAC updates the Pharmaceutical Schedule at regular intervals to notify prescribers, pharmacists, hospital managers and patients of changes to Community Pharmaceutical subsidies and the prices for Hospital Pharmaceuticals. In making decisions about amendments to the Pharmaceutical Schedule, PHARMAC is guided by its Operating Policies and Procedures, as amended or supplemented from time to time. PHARMAC takes into account the following criteria when making decisions about Community Pharmaceuticals:

- the health needs of all eligible people within New Zealand (eligible defined by the Government's then current rules of eligibility);
- the particular health needs of Māori and Pacific peoples;
- the availability and suitability of existing medicines, therapeutic medical devices and related products and related things;
- the clinical benefits and risks of pharmaceuticals;
- the cost-effectiveness of meeting health needs by funding pharmaceuticals rather than using other publicly funded health and disability support services;
- the budgetary impact (in terms of the pharmaceutical budget and the Government's overall health budget) of any changes to the Pharmaceutical Schedule;
- the direct cost to health service users;

- the Government's priorities for health funding, as set out in any objectives notified by the Crown to PHARMAC, or in PHARMAC's Funding Agreement, or elsewhere; and
- such other criteria as PHARMAC thinks fit. PHARMAC will carry out appropriate consultation when it intends to take any such "other criteria" into account.

The Operating Policies and Procedures, including any supplements, also describe the way in which PHARMAC determines the level of subsidy or purchase price payable for each Community Pharmaceutical or Hospital Pharmaceutical, respectively.

The decision criteria for Hospital Pharmaceuticals are set out in the hospital supplement to the Operating Policies and Procedures and in the introductory part of Section H of the Pharmaceutical Schedule.

Copies of PHARMAC's Operating Policies and Procedures and of any applicable supplements are available on the PHARMAC website (www.pharmac.govt.nz), or on request.

PHARMAC's clinical advisors

Pharmacology and Therapeutics Advisory Committee (PTAC)

PHARMAC works closely with the Pharmacology and Therapeutics Advisory Committee (PTAC), an expert medical committee which provides independent advice to PHARMAC on health needs and the clinical benefits of particular pharmaceuticals for use in the community and/or in DHB Hospitals.

The committee members are all senior, practising clinicians. The chair of PTAC sits with the PHARMAC Board in an advisory capacity.

PTAC helps decide which community pharmaceuticals are to be subsidised from public monies by making recommendations to PHARMAC. Part of the role of PTAC is to review whether Community Pharmaceuticals already listed on the Schedule should continue to receive Government funds. The resources freed up can be used to subsidise other community pharmaceuticals with a greater therapeutic worth.

PHARMAC may obtain clinical advice from PTAC in relation to national purchasing strategies for Hospital Pharmaceuticals. There may be additional specialist hospital representatives on PTAC subcommittees, or additional PTAC subcommittees, where PHARMAC considers this necessary.

PTAC members are:

Sisira Jayathissa	MMBS, MMedSc (Clin Epi), MD, FRCP (Lon, Edin), FRACP, FAFPHM, FNZCPHM, Dip Clin Epi, Dip OHP, DipHSM, MBS, Chair
Melissa Copland	PhD, BPharm(Hons), RegPharmNZ, FNZCP
Stuart Dalziel	MBChB, PhD, FRACP
lan Hosford	MBChB, FRANZCP, psychiatrist
George Laking	PhD, MD, FRACP
Graham Mills	MBChB, MTropHlth, MD, FRACP, infectious disease specialist and general physician
Marius Rademaker	BM (Soton), FRCP (Edn), FRACP DM
Jane Thomas	MBChB, FANZGL
Mark Weatherall	BA, MBChB, MApplStats, FRACP
Sean Hanna	MB ChB, FRNZCGP, FRACGP, PGDipGP, PGCertClinEd
Jennifer Martin	MBChB, MA(Oxon.), FRACP, PhD
Simon Wynn Thomas	BMedSci (UK), MRCP (UK), MRCGP (UK)DFFP, FRNZCGP

Contact PTAC C/- PTAC Secretary, Pharmaceutical Management Agency, PO Box 10 254, WELLINGTON, Email: PTAC@pharmac.govt.nz

PHARMAC's consumer advisors

Consumer Advisory Committee (CAC)

The Consumer Advisory Committee is an advisory committee to the PHARMAC Board. It provides written reports to the Board, and its Chair attends Board meetings as an observer to report on the activities and findings of the Committee, and to comment on consumer issues. While accountable to the Board, the Committee's general working relationship is with the staff of PHARMAC.

The Committee is made up of people from a range of backgrounds and interests including the health of Māori people, Pacific peoples, older people, women and mental health.

For current membership of the Consumer Advisory Committee, visit our website. The Consumer Advisory Committee can be contacted by email: CAC@pharmac.govt.nz, or you can write to the Consumer Advisory Committee at PHARMAC's postal address.

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price (if it differs from the Subsidy) and any access conditions that may apply; and
- some Hospital Pharmaceuticals that are purchased and used by DHB Hospitals, including those for which national prices have been negotiated by PHARMAC.

The purpose of the Schedule is not to show the final cost to Government of subsidising each Community Pharmaceutical or to DHBs in purchasing each Hospital Pharmaceutical since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for some Hospital Pharmaceuticals, on any logistics arrangements put in place by individual DHB Hospitals.

Finding Information in the Pharmaceutical Schedule

Community Pharmaceuticals

For Community Pharmaceuticals, the Schedule is organised in a way to help the reader find Community Pharmaceuticals, which may be used to treat similar conditions. To do this, Community Pharmaceuticals are first classified anatomically, originally based on the Anatomical Therapeutic Chemical (ATC) system, and then further classified under section headings structured for the New Zealand medical system.

- Section A lists the General Rules in relation to Community Pharmaceuticals and related products.
- Section B lists Community Pharmaceuticals and related products by anatomical classification, which are further divided into one or more therapeutic headings. Community Pharmaceuticals used to treat similar conditions are grouped together.
- Section C lists the rules in relation to Extemporaneously Compounded Products (ECPs) and Community Pharmaceuticals
 that will be subsidised when extemporaneously compounded.
- Section D lists the rules in relation to Special Foods and the Special Foods that are subsidised.
- Section E Part I lists the Community Pharmaceuticals that are subsidised on a Practitioner's Supply Order (PSO).
- Section E Part II lists rural areas for the purpose of PSOs.
- Section F lists the Community Pharmaceuticals dispensing period exemptions.
- Section G lists the Community Pharmaceuticals eligible for reimbursement of safety cap and related rules.
- Section I lists the National Immunisation Schedule.

The listings are displayed alphabetically (where practical) within each level of the classification system. Each anatomical section contains a series of therapeutic headings, some of which may contain a further classification level.

The therapeutic headings in the Pharmaceutical Schedule do not necessarily correspond to the therapeutic groups and therapeutic subgroups, which PHARMAC establishes for the separate purpose of determining the level of subsidy to be paid for each Community Pharmaceutical.

The index located at the back of the book in which Sections A-G and I of the Pharmaceutical Schedule are published can be used to find page numbers for generic chemical entities, or product brand names.

Hospital Pharmaceuticals

Section H lists Pharmaceuticals that can be used in DHB Hospitals, and is split into the following parts:

- Part I lists the rules in relation to use of Pharmaceuticals by DHB Hospitals.
- Part II lists Hospital Pharmaceuticals that are funded for use in DHB Hospitals. These are classified based on the Anatomical Therapeutic Chemical (ATC) system used for Community Pharmaceuticals. It also provides information on any national contracts that exist, and an indication of which products have Hospital Supply Status (HSS).
- Part III lists Optional Pharmaceuticals for which national contracts exist, and DHB Hospitals may choose to fund. These
 are listed alphabetically by generic chemical entity name and line item, the relevant Price negotiated by PHARMAC and, if
 applicable, an indication of whether it has Hospital Supply Status (HSS) and any associated Discretionary Variance Limit
 (DV Limit).

The index located at the back of the Section H can be used to find page numbers for generic chemical entities, or product brand names, for Hospital Pharmaceuticals.


The listings are displayed alphabetically (where practical) within each level of the classification system. Each anatomical section contains a series of therapeutic headings, some of which may contain a further classificationlevel.

Community Pharmaceuticals are listed in a separate publication with Sections A to I (excluding Section H).

Explaining drug entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the amount of that subsidy paid to contractors, the supplier's price and the access conditions that may apply.

Example



Glossary

Units of Measure

gramg	microgrammcg	millimolemmol
kilogramkg	milligrammg	unitu
international unitiu	millilitreml	

Abbreviations

Ampoule	Amp	Granules	Gran	Suppository	Supp
Capsule	Сар	Infusion	Inf	Tablet	Tab
Cream	Crm	Injection	Inj	Tincture	Tinc
Device	Dev	Linctus	Linc	Trans Dermal Delivery	
Dispersible	Disp	Liquid	Liq	System	TDDS
Effervescent	Eff	Long Acting	LA	-	
Emulsion	Emul	Ointment	Oint		
Enteric Coated	EC	Sachet	Sach		
Gelatinous	Gel	Solution	Soln		

BSO Bulk Supply Order.

CBS Cost Brand Source. There is no set manufacturer's price, and the Government subsidises the product at the price it is obtained by the pharmacy.

- CE Compounded Extemporaneously.
- CPD Cost Per Dose. The Funder (as defined in Part I of the General Rules) cost of a standard dose, without mark-ups or fees and excluding GST.
- ECP Extemporaneously Compounded Preparation.
- HSS Hospital Supply Status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.
- OP Original Pack subsidy is rounded up to a multiple at whole packs.
- PSO Practitioner's Supply Order.

Sole Subsidised

Supplier Only brand of this medicine subsidised.

XPharm Pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements.

- ▲ Three months supply may be dispensed at one time if the exempted medicine is endorsed 'certified exemption' by the practitioner or pharmacist.
- * Three months dispensed all-at-once or, in the case of oral contraceptives, six months dispensed all-at-once, unless the medicine meets the Dispensing Frequency Rule criteria.
- [‡] Safety cap required for oral liquid formulations, including extemporaneously compounded preparations.
- Fully subsidised brand of a given medicine. Brands without the tick are not fully subsidised and may cost the patient a
 manufacturer's surcharge.
- S29 This medicine is an unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should:
 - a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984;
 - b) be aware of and comply with their obligations under the Health and disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
 - c) exercise their own skill, judgement, expertise and discretions, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.

Note: Where medicines supplied under Section 29 that are used for emergency situations, patient details required under Section 29 of the Medicines Act may be retrospectively provided to the supplier.

	Definitions				
Abbrev.	Pharmacy Services Agreement	All other Pharmacy Agreements			
[HP3]	Subsidised when dispensed from pharmacies that have a Special Foods Service appended to their Phar- macy Services Agreement by their DHB.	Available from selected pharmacies that have an ex- clusive contract to dispense Special Foods.			
[HP4]	Subsidised when dispensed from pharmacies that have the Monitored Therapy Variation (for Clozapine Services)	Avaliable from selected pharmacies that have an ex- clusive contract to dispense 'Hospital Pharmacy' [HP4] pharmaceuticals.			

Patient costs

Community Pharmaceutical costs met by the Government

Most of the cost of a subsidised prescription Community Pharmaceutical is met by the Government through the Pharmaceutical Budget. The Government pays a subsidy for the Community Pharmaceutical to Contractors, and a fee covering distribution and pharmacy dispensing services. The subsidy paid to Contractors does not necessarily represent the final cost to Government of subsidising a particular Community Pharmaceutical. The final cost will depend on the nature of PHARMAC's contractual arrangements with the supplier. Fully subsidised medicines are identified with a \checkmark in the product's Schedule listing.

SALBUTAMOL		
Aerosol inhaler 100 mcg per dose	3.80	 Fully subsidised brand
	(6.00)	Higher priced brand

Pharmaceutical Co-Payments

Some Community Pharmaceutical costs are met by the patient. Generally a patient pays a prescription charge. In addition a patient will sometimes pay a manufacturer's surcharge, after hours service fee and any special packaging fee. PRESCRIPTION CHARGE

From 1 January 2013, everyone who is eligible for publicly funded health and disability services should in most circumstances pay only \$5 for subsidised medicines.

All prescriptions from a public hospital, a midwife and a Family Planning Clinic are covered for \$5 co-payments.

Prescriptions from the following providers are approved for \$5 co-payments on subsidised medicines if they meet the specified criteria:

- After Hours Accident and Medical Services with a DHB or a PHO contract.
- Youth Health Clinics with a DHB or a PHO contract.
- Dentists who write a prescription that relates to a service being provided under a DHB contract.
- Private specialists (for example, ophthalmologists and orthopaedics) who write a prescription for a patient receiving a
 publicly funded service contracted by the DHB.
- General practitioners who write a prescription during normal business hours to a person who is not enrolled in the general
 practice provided the person is eligible for publicly funded health and disability services and the general practice is part of
 a PHO.
- Hospices that have a contract with a DHB.

Patients can check whether they are eligible for publicly funded health and disability services by referring to the Eligibility Direction on the Ministry of Health's website.

To check if a medicine is fully subsidised, refer to the Pharmaceutical Schedule on PHARMAC's website or ask your pharmacist or general practitioner.

DHBs have a list of eligible providers in their respective regions. Any provider/prescriber not specifically listed by a DHB as an approved provider/prescriber should be regarded as not approved.

NOTE: Information sourced from Ministry of Health Website, for more information please visit www.moh.govt.nz

MANUFACTURER'S SURCHARGE

Not all Community Pharmaceuticals are fully subsidised. Although PHARMAC endeavours to fully subsidise at least one Community Pharmaceutical in each therapeutic group, and has contracts with some suppliers to maintain the price of a particular product, manufacturers are able to set their own price to pharmacies. When these prices exceed the subsidy, the pharmacist may recoup the difference from the patient.

To estimate the amount a patient will pay on top of the prescription charge, take the difference between the manufacturer's price and the subsidy, and multiply this by 1.86. The 1.86 factor represents the pharmacy mark-up on the surcharge plus other costs such as GST. Pharmacies charge different mark-ups so this may vary.

Manufacturer's surcharge to patient = (price - subsidy) $\times 1.86$

For example, a Community Pharmaceutical with a supplier (ex-manufacturer) cost of \$11.00 per pack with a \$10.00 subsidy will cost the patient a surcharge of \$1.86 on top of the prescription charge. The most a patient should pay is therefore \$16.86 - being \$15.00 maximum prescription charge, plus \$1.86.

Hospital Pharmaceutical and Pharmaceutical Cancer Treatment Costs

The cost of purchasing Hospital Pharmaceuticals (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) is met by the relevant DHB hospital Funder from its own budget. Pharmaceutical Cancer Treatments (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) are funded through the Combined Pharmaceutical Budget. As required by section 23(7) of the Act, in performing any of their functions in relation to the supply of Pharmaceuticals including Pharmaceutical Cancer Treatments, DHBs must not act inconsistently with the Pharmaceutical Schedule.

PHARMAC web site

PHARMAC has set up an interactive Schedule on the Internet.

Other information about PHARMAC is also available on our website. This includes copies of the Annual Review, Annual Report and Annual Plan, as well as information such as the Pharmaceutical Schedule, Pharmaceutical Schedule Updates, National Hospital Pharmaceutical Strategy, other publications and recent press releases.

Special Authority Applications

Special Authority is an application process in which a prescriber requests government subsidy on a Community Pharmaceutical for a particular person. Applications must be submitted to the Ministry of Health by the prescriber for the request to be processed.

Subsidy

Once approved, the presciber will be provided a Special Authority number which must appear on the prescription. Specialists who make an application must communicate the valid authority number to the prescriber who will be writing the prescriptions.

The authority number can provide access to subsidy, increased subsidy, or waive certain restrictions otherwise present on the Community Pharmaceutical.

Some approvals are dependent on the availability of funding from the Pharmaceutical Budget.

Criteria

The criteria for approval of Special Authority applications are included below each Community Pharmaceutical listing, and on the application forms available on PHARMAC's website.

For some Special Authority Community Pharmaceuticals, not all indications that have been approved by Medsafe are subsidised. Criteria for each Special Authority Community Pharmaceutical are updated regularly, based on the decision criteria of PHARMAC. The appropriateness of the listing of a Community Pharmaceutical in the Special Authority category will also be regularly reviewed. Applications for inclusion of further Community Pharmaceuticals in the Special Authority category will generally be made by a pharmaceutical supplier.

Special Authority Applications

Application forms can be found at www.pharmac.govt.nz. Requests for fax copies should be made to PHARMAC, phone 04 460 4990. Applications are processed by the Ministry of Health, and should be sent to:

Ministry of Health Sector Services, Fax: (06) 349 1983 or free fax 0800 100 131

Private Bag 3015, WANGANUI 4540

For enquiries, phone the Ministry of Health Sector Services Call Centre, free phone 0800 243 666

Note: The Ministry of Health can only provide information on Special Authority applications to prescribers and pharmacists.

Each application must:

- Include the patients name, date of birth and NHI number (codes for AIDS patients' applications)
- · Include the practitioner's name, address and registration number
- Clearly indicate that the relevant criteria, have been met.
- Be signed by the practitioner.

Named Patient Pharmaceutical Assessment policy

The Named Patient Pharmaceutical Assessment (NPPA) Policy is PHARMAC's process for considering applications about named patients seeking funding for treatments not listed on the Schedule, either at all or for the named patient's clinical circumstances. For PHARMAC to perform its legislative function of maintaining and managing a Schedule that applies consistently throughout New Zealand, the NPPA Policy will, and must, operate in a way that does not undermine the Schedule decision making process. Together, the Schedule process and the NPPA Policy, ensure there is a pathway for consideration of an individual's clinical circumstances. If an individual has a set of clinical circumstances not covered by the NPPA Policy, the Schedule decision making process is available.

It is not the purpose of the NPPA Policy to provide access to every treatment not listed on the Schedule.

There are two main pathways by which named patients can be considered for funding under the NPPA Policy. PHARMAC will exercise its discretion to determine the most appropriate pathway for an application under the NPPA Policy based on the information that is provided.

Information concerning NPPA in hospital use can be forund at http://www.pharmac.health.nz/tools-resources/forms/named-patientpharmaceutical-assessment-nppa-forms.

PHARMAC will assess applications that meet the prerequisites described below according to its Decision Criteria before deciding whether to approve applications for funding. The Decision Criteria will be used to assess both the individual clinical circumstances of each NPPA applicant, and the implications of each NPPA funding decision on PHARMAC's ability to carry out its legislative functions. For more information on NPPA, or to apply, visit the PHARMAC website at http://www.pharmac.govt.nz/nppa, or call the Panel Coordinators at 0800 66 00 50 option 3.

Unusual Clinical Circumstance (UCC)

The purpose of the Unusual Clinical Circumstances (UCC) pathway is to provide a process for consideration for funding for named patients whose clinical circumstances are so unusual that PHARMAC is unlikely, for administrative reasons, to consider listing treatments for these circumstances on the Schedule. The prerequisite requirements for UCC consideration are:

- The patient has reasonably tried and failed all alternative funded treatments (or alternative treatments have been contraindicated, or there are no other treatments available), or the patient has experienced such serious side effects with all other relevant funded treatments that treatment has been ceased or cannot reasonably be continued; and
- The patient is experiencing an indication or set of clinical circumstances that are so unusual that PHARMAC is unlikely to consider listing treatments for these on the Schedule; and
- Generally, PHARMAC has not already considered/is not considering, through the Schedule decision making process, the treatment for the patient's clinical circumstances, or has not considered the treatment at all.

Urgent Assessment (UA)

The purpose of the Urgent Assessment (UA) pathway is to provide a process for PHARMAC to consider funding treatments for named patients where PHARMAC is also considering or is likely to consider the treatment for Schedule listing, but the patient's clinical circumstances justify urgent assessment, prior to a decision on Schedule listing. The prerequisite requirements for UA are:

- The patient has reasonably tried and failed all alternative funded treatments (or alternative treatments have been contraindicated, or there are no other treatments available), or the patient has experienced such serious side effects with all other relevant funded treatments that treatment has been ceased or cannot reasonably be continued; and
- The patient is experiencing an indication or set of clinical circumstances that may be experienced by a population group (either currently or over time); and
- The patient has serious clinical circumstances and not receiving the treatment within six to 12 months would lead to either a
 significant deterioration in a serious clinical condition or the patient would miss the opportunity for significant improvement
 in clinical outcome (length or quality of life); and
- The treatment has either not been prioritised by PHARMAC, or if it has, PHARMAC has funded the treatment under the NPPA Policy for the same clinical circumstances prior to prioritisation.
- PHARMAC has not declined to list, on the Schedule, this treatment for these clinical circumstances.

INTRODUCTION

Section A contains the restrictions and other general rules that apply to Subsidies on Community Pharmaceuticals. The amounts payable by the Funder to Contractors are currently determined by:

- the quantities, forms, and strengths, of subsidised Community Pharmaceuticals dispensed under valid prescription by each Contractor;
- the amount of the Subsidy on the Manufacturer's Price payable for each unit of the Community Pharmaceuticals dispensed by each Contractor and;
- the contractual arrangements between the Contractor and the Funder for the payment of the Contractor's dispensing services.

The Pharmaceutical Schedule shows the level of subsidy payable in respect of each Community Pharmaceutical so that the amount payable by the Government to Contractors, for each Community Pharmaceutical, can be calculated. The Pharmaceutical Schedule also shows the standard price (exclusive of GST) at which a Community Pharmaceutical is supplied ex-manufacturer to wholesalers if it differs from the subsidy. The manufacturer's surcharge to patients can be estimated using the subsidy and the standard manufacturer's price as set out in this Schedule.

The cost to Government of subsidising each Community Pharmaceutical and the manufacturer's prices may vary, in that suppliers may provide rebates to other stakeholders in the primary health care sector, including dispensers, wholesalers, and the Government. Rebates are not specified in the Pharmaceutical Schedule.

This Schedule is dated 1 September 2014 and is to be referred to as the Pharmaceutical Schedule Volume 21 Number 2, 2014. Distribution will be from 20 September 2014. This Schedule comes into force on 1 September 2014.

PART I INTERPRETATIONS AND DEFINITIONS

1.1 In this Schedule, unless the context otherwise requires:

"90 Day Lot", means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 90 consecutive days' treatment;

"180 Day Lot", means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 180 consecutive days' treatment;

"Access Exemption Criteria", means the criteria under which patients may receive greater than one Month's supply of a Community Pharmaceutical covered by Section F Part II (b) subsidised in one Lot. The specifics of these criteria are conveyed in the Ministry of Health guidelines, which are issued from time to time. The criteria the patient must meet are that they:

- a) have limited physical mobility;
- b) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- c) are relocating to another area;
- d) are travelling extensively and will be out of town when the repeat prescriptions are due.
- "Act", means the New Zealand Public Health and Disability Act 2000.

"Advisory Committee", means the Pharmaceutical Services Advisory Committee convened by the Ministry of Health under the terms of the Advice Notice issued to Contractors pursuant to Section 88 of the Act.

"Alternate Subsidy", means a higher level of subsidy that the Government will pay contractors for a particular community Pharmaceutical dispensed to a person who has either been granted a Special Authority for that pharmaceutical, or where the prescription is endorsed in accordance with the requirements of this Pharmaceutical Schedule.

"Annotation", means written annotation of a prescription by a dispensing pharmacist in the pharmacist's own handwriting following confirmation from the Prescriber if required, and "Annotated" has a corresponding meaning. The Annotation must include the details specified in the Schedule, including the date the prescriber was contacted (if applicable) and be initialled by the dispensing pharmacist.

"Authority to Substitute", means an authority for the dispensing pharmacist to change a prescribed medicine in accordance with regulation 42(4) of the Medicines Regulations 1984. An authority to substitute letter, which may be used by Practitioners, is available on the final page of the Schedule.

"Bulk Supply Order", means a written order, on a form supplied by the Ministry of Health, or approved by the Ministry of Health, made by the licensee or manager of an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 for the supply of such Community Pharmaceuticals as are expected to be required for the treatment of persons who are under the medical or dental supervision of such a Private Hospital or institution.

"Class B Controlled Drug", means a Class B controlled drug within the meaning of the Misuse of Drugs Act 1975. "Community Pharmaceutical", means a Pharmaceutical listed in Sections A to G and Section I of the Pharmaceutical Schedule that is subsidised by the Funder from the Pharmaceutical Budget for use in the community.

"Contractor", means a person who is entitled to receive a payment from the Crown or a DHB under a notice issued by the Crown or a DHB under Section 88 of the Act or under a contract with the Ministry of Health or a DHB for the supply of Community Pharmaceuticals.

"Controlled Drug", means a controlled drug within the meaning of the Misuse of Drugs Act 1975 (other than a controlled drug specified in Part VI of the Third Schedule to that Act).

"Cost, Brand, Source of Supply", means that the Community Pharmaceutical is eligible for Subsidy on the basis of the Contractor's annotated purchase price, brand, and source of supply. Alternatively a copy of the invoice for the purchase of the Pharmaceutical may be attached to the prescription, in the place of an annotation, in order to be eligible for Subsidy.

"Dentist", means a person registered with the Dental Council, and who holds a current annual practising certificate, under the HPCA Act 2003.

"Diabetes Nurse Prescriber", means a nurse who is a Designated Prescriber—Registered Nurses Practising in Diabetes Health as determined by the Nursing Council of New Zealand to practice in diabetes health and has authority to prescribe specified diabetes medicines in accordance with regulations made under the Medicines Act 1981.

"Dietitian", means a person registered as a dietitian with the Dietitians Board, and who holds a current annual practicing certificate under the HPCA Act 2003.

"DHB", means an organisation established as a District Health Board by or under Section 19 of the Act.

"DHB Hospital", means a DHB, including its hospital or associated provider unit that the DHB purchases Hospital Pharmaceuticals for.

"Dispensing Frequency Rule", means the rule in Part IV, Section A of the Pharmaceutical Schedule that defines patient groups or medicines eligible for more frequent dispensing periods.

"Doctor", means a medical Practitioner registered with the Medical Council of New Zealand and, who holds a current annual practising certificate under the HPCA Act 2003.

"DV Limit", means, for a particular Hospital Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

"DV Pharmaceutical", means a discretionary variance Pharmaceutical, that does not have HSS and which:

- a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or
- b) is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical.

"Endorsements", - unless otherwise specified, endorsements should be either handwritten or computer generated by the practitioner prescribing the medication. The endorsement can be written as "certified condition", or state the condition of the patient, where that condition is specified for the Community Pharmaceutical in Section B of the Pharmaceutical Schedule. Where the practitioner writes "certified condition" as the endorsement, he/she is making a declaration that the patient meets the criteria as set out in Section B of the Pharmaceutical Schedule.

"Funder", means the body or bodies responsible, pursuant to the Act, for the funding of pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

"GST", means goods and services tax under the Goods and Services Tax Act 1985.

"Hospital Care Operator", means a person for the time being in charge of providing hospital care, in accordance with the Health and Disability Services (Safety) Act 2001.

"Hospital Pharmaceuticals", means the list of pharmaceuticals set out in Section H part II of the Schedule which includes some National Contract Pharmaceuticals.

"Hospital Pharmacy", means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an person on the Prescription of a Practitioner.

"Hospital Pharmacy-Specialist", means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an Outpatient either:

- a) on a Prescription signed by a Specialist, or
- b) where the treatment with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a practitioner which is either:
 - endorsed with the words "recommended by [name of specialist and year of authorisation]" and signed by the Practitioner, or
 - endorsed with the word 'protocol' which means "initiated in accordance with DHB hospital approved protocol",
 - iii) annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and date of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as either:

- i) follows a substantive consultation with an appropriate Specialist;
- ii) the consultation to relate to the Patient for whom the Prescription is written;
- iii) consultation to mean communication by referral, telephone, letter, facsimile or email;
- iv) except in emergencies consultation to precede annotation of the Prescription; and
- v) both the specialist and the General Practitioner must keep a written record of the consultation; or
- a) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.

For the purposes of the definition it makes no difference whether or not the Specialist is employed by a hospital.

"Hospital Pharmacy-Specialist Prescription", means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy:

- a) to an Outpatient; and
- b) on a Prescription signed by a Specialist.

For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"HSS", means hospital supply status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

"In Combination", means that the Community Pharmaceutical is only subsidised when prescribed in combination with another subsidised pharmaceutical as specified in Section B or C of the Pharmaceutical Schedule.

"Individual DV Limit", means, for a particular Hospital Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital's Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"Licensed Hospital", means a place or institution that is certified to provide hospital care within the meaning of the Health and Disability Services (Safety) Act 2001.

"Lot", means a quantity of a Community Pharmaceutical supplied in one dispensing.

"Manufacturer's Price", means the standard price at which a Community Pharmaceutical is supplied to wholesalers (excluding GST), as notified to PHARMAC by the supplier.

"Maternity hospital", means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied pursuant to a Bulk Supply Order to a maternity hospital certified under the Health and Disability Services (Safety) Act 2001.

"Midwife", means a person registered as a midwife with the Midwifery Council, and who holds a current annual practising certificate under the HPCA Act 2003.

"Month", means a period of 30 consecutive days.

"Monthly Lot", means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 30 consecutive days' treatment;

"Named Patient Pharmaceutical Assessment Advisory Panel", means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for advising, within its Terms of Reference, on Named Patient Pharmaceutical Assessment applications and Exceptional Circumstances renewal applications submitted after 1 March 2012 (EC renewal application form located at http://www.pharmac.govt.nz/healthpros/EC/ECForms)

"National Contract Pharmaceutical", means a Hospital Pharmaceutical for which PHARMAC has negotiated a

national contract and the Price.

"National DV Limit", means, for a particular Hospital Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"National Immunisation Schedule", means Section I of the Pharmaceutical Schedule, which is a schedule administered by PHARMAC, being a schedule specifying a programme of vaccinations to promote immunity against the diseases specified in the schedule.

"Not In Combination", means that no Subsidy is available for any Prescription containing the Community Pharmaceutical in combination with other ingredients unless the particular combination of ingredients is separately specified in Section B or C of the Schedule, and then only to the extent specified.

"Nurse Precriber", means a person who is a nurse practitioner in terms of the Medicines Act 1981, or a Diabetes Nurse Prescriber

"Optional Pharmaceuticals", means the list of National Contract Pharmaceuticals set out in Section H Part II of the Schedule

"Optometrist", means a person registered with the Optometrists and Dispensing Opticians Board with a scope of practice that includes prescribing medicines (TPA endorsement)

"Outpatient", in relation to a Community Pharmaceutical, means a person who, as part of treatment at a hospital or other institution under the control of a DHB, is prescribed the Community Pharmaceutical for consumption or use in the person's home.

"PCT", means Pharmaceutical Cancer Treatment in respect of which DHB hospital pharmacies and other Contractors can claim Subsidies.

"PCT only", means Pharmaceutical Cancer Treatment in respect of which only DHB hospital pharmacies can claim Subsidies.

"Penal Institution", means a penal institution, as that term is defined in The Penal Institutions Act 1954;

"PHARMAC", means the Pharmaceutical Management Agency established by Section 46 of the Act (PHARMAC). "Pharmaceutical", means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to I of the Schedule.

"Pharmaceutical Benefits", means the right of:

- a) a person; and
- b) any member under 16 years of age of that person's family, to have made by the Government on his or her behalf, subject to any conditions for the time being specified in the Schedule, such payment in respect of any Community Pharmaceutical supplied to that person or family member under the order of a Practitioner in the course of his or her practice.

"Pharmaceutical Budget", means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances.

"Pharmaceutical Cancer Treatment", means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a "PCT" or "PCT only" Pharmaceutical that DHBs must provide access to, for use in their hospitals, and/or in association with Outpatient services provided in their DHB Hospitals, in relation to the treatment of cancers.

"Pharmacist Prescriber", means a person registered with the Pharmacy Council of New Zealand, who holds a current annual practising certificate under the HPCA Act 2003, and is approved by the Pharmacy Council of New Zealand to prescribe specified prescription medicines relating to his/her scope of practice.

"Pharmacist", means a person registered with the Pharmacy Council of New Zealand and who holds a current annual practicing certificate under the HPCA Act 2003.

"Practitioner", means a Doctor, a Dentist, a Dietitian, a Midwife, a Nurse Prescriber, an Optometrist, a Quitcard Provider, or a Pharmacist Prescriber as those terms are defined in the Pharmaceutical Schedule.

"Practitioner's Supply Order", means a written order made by a Practitioner on a form supplied by the Ministry of Health, or approved by the Ministry of Health, for the supply of Community Pharmaceuticals to the Practitioner, which the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.

"Prescription", means a quantity of a Community Pharmaceutical prescribed for a named person on a document signed by a Practitioner.

"Prescription Medicine", means any Pharmaceutical listed in Part I of Schedule 1 of the Medicines Regulations

1984.

"Private Hospital", means a hospital certified under the Health and Disability Services (Safety) Act 2001 that is not owned or operated by a DHB.

"Quitcard Provider", means a person registered with the Ministry of Health as a Quitcard Provider.

"Residential Disability Care Institution", means premises used to provide residential disability care in accordance with the Health and Disability Services (Safety) Act 2001.

"Rest Home", means premises used to provide rest home care in accordance with the Health and Disability Services (Safety) Act 2001.

"Restricted Medicine", means any Pharmaceutical listed in Part II of Schedule 1 of the Medicines Regulations 1984.

"Retail Pharmacy-Specialist", means that the Community Pharmaceutical is only eligible for Subsidy if it is either:

- a) supplied on a Prescription or Practitioner's Supply Order signed by a Specialist, or,
- b) in the case of treatment recommended by a Specialist, supplied on a Prescription or Practitioner's Supply Order and either:
 - endorsed with the words "recommended by [name of Specialist and year of authorisation]" and signed by the Practitioner, or
 - ii) endorsed with the word 'protocol' which means "initiated in accordance with DHB hospital approved protocol", or
 - iii) Annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and year of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as either:

- a) i) follows a substantive consultation with an appropriate Specialist;
 - ii) the consultation to relate to the Patient for whom the Prescription is written;
 - iii) consultation to mean communication by referral, telephone, letter, facsimile or email;
 - iv) except in emergencies consultation to precede annotation of the Prescription; and
 - v) both the Specialist and the General Practitioner must keep a written record of consultation; or
- b) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.

"Retail Pharmacy-Specialist Prescription", means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription, or Practitioner's Supply Order, signed by a Specialist.

For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"Safety Medicine", means a Community Pharmaceutical defined in Section A, Part IV of the Pharmaceutical Schedule.

"Schedule", means this Pharmaceutical Schedule and all its sections and appendices.

"Special Authority", means that the Community Pharmaceutical or Pharmaceutical Cancer Treatment is only eligible for Subsidy or additional Subsidy for a particular person if an application meeting the criteria specified in the Schedule has been approved, and the valid Special Authority number is present on the prescription.

"Specialist", in relation to a Prescription, means a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) or (d) below:

- a) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the Prescription in the course of practising in that area of medicine; or
- b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that prescription in the course of practising in that area of competency; or
- c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of competency; or
- d) the doctor writes the prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so.

"Subsidy", means the maximum amount that the Government will pay Contractors for a Community Pharmaceutical dispensed to a person eligible for Pharmaceutical Benefits and is different from the cost to Government of subsidising that Community Pharmaceutical. For the purposes of a DHB hospital pharmacy claiming for Pharmaceutical Cancer Treatments, Subsidy refers to any payment made to the DHB hospital pharmacy or service provider to which that pharmacy serves, and does not relate to a specific payment that might be made on submission of a claim.

"Supply Order", means a Bulk Supply Order or a Practitioner's Supply Order.

"Unapproved Indication", means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Practitioners prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in Section A: General Rules, Part IV (Miscellaneous Provisions) rule 5.5.

"Unlisted Pharmaceutical", means a Pharmaceutical that is within the scope of a Hospital Pharmaceutical but is not listed in Section H part II

"Unusual Clinical Circumstances (UCC)", means the pathway under the Named Patient Pharmaceutical Assessment policy for funding consideration for named patients whose clinical circumstances are so unusual that PHARMAC is unlikely, for administrative reasons, to consider listing treatments for these circumstances on the Schedule.

"Urgent Assessment (UA)", means the pathway under the Named Patient Pharmaceutical Assessment policy for funding consideration for treatments for named patients where PHARMAC is also considering or is likely to consider the treatment for Schedule listing, but the patient's clinical circumstances justify urgent assessment, prior to a decision on Schedule listing.

- 1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:
 - a) the singular includes the plural; and
 - b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under that legislation, where that legislation, regulation, Order in Council or other instrument has an effect on the prescribing, dispensing or subsidising of Community Pharmaceuticals.

PART II COMMUNITY PHARMACEUTICALS SUBSIDY

- 2.1 Community Pharmaceuticals eligible for Subsidy include every medicine, therapeutic medical device or related product, or related thing listed in Sections B to G and I of the Schedule subject to:
 - 2.1.1 clauses 2.2 of the Schedule; and
 - 2.1.2 clauses 3.1 to 5.4 of the Schedule; and
 - 2.1.3 the conditions (if any) specified in Sections B to G and I of the Schedule;
- 2.2 No claim by a Contractor for payment in respect of the supply of Community Pharmaceuticals will be allowed unless the Community Pharmaceuticals so supplied:
 - 2.2.1 comply with the appropriate standards prescribed by regulations for the time being in force under the Medicines Act 1981; or
 - 2.2.2 in the absence of any such standards, comply with the appropriate standards for the time being prescribed by the British Pharmacopoeia; or
 - 2.2.3 in the absence of the standards prescribed in clauses 2.2.1 and 2.2.2, comply with the appropriate standards for the time being prescribed by the British Pharmaceutical Codex; or
 - 2.2.4 in the absence of the standards prescribed in clauses 2.2.1, 2.2.2 and 2.2.3 are of a grade and quality not lower than those usually applicable to Community Pharmaceuticals intended to be used for medical purposes.

PART III PERIOD AND QUANTITY OF SUPPLY

3.1 Doctors', Dentists', Dietitians', Midwives', Nurse Prescribers', Optometrists and Pharmacist Prescribers' Prescriptions (other than oral contraceptives) The following provisions apply to all Prescriptions, other than those for an oral contraceptive, written by a Doctor, Dentist, Dietitian, Midwife, Nurse Prescriber, an Optometrist, or a Pharmacist Prescriber unless specifically excluded:

- 3.1.1 For a Community Pharmaceutical other than a Class B Controlled Drug, only a quantity suffcient to provide treatment for a period not exceeding three Months will be subsidised.
- 3.1.2 For methylphenidate hydrochloride and dexamphetamine sulphate (except for Dentist prescriptions), only a quantity sufficient to provide treatment for a period not exceeding one Month will be subsidised.
- 3.1.3 For a Class B Controlled Drug:
 - a) other than Dentist prescriptions and methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity:
 - i) sufficient to provide treatment for a period not exceeding 10 days; and
 - ii) which has been dispensed pursuant to a Prescription sufficient to provide treatment for a period not exceeding one Month, will be subsidised.
 - b) for a Dentist prescription only such quantity as is necessary to provide treatment for a period not exceeding five days will be subsidised.
- 3.1.4 Subject to clauses 3.1.3 and 3.1.7, for a Doctor, Dentist, Dietitian, Midwife or Nurse Prescriber and 3.1.7 for an Optometrist, where a practitioner has prescribed a quantity of a Community Pharmaceutical sufficient to provide treatment for:
 - A) one Month or less than one Month, but dispensed by the Contractor in quantities smaller than the quantity prescribed, the Community Pharmaceutical will only be subsidised as if that Community Pharmaceutical had been dispensed in a Monthly Lot;
 - B) more than one Month, the Community Pharmaceutical will be subsidised only if it is dispensed:
 - i) in a 90 Day Lot, where the Community Pharmaceutical is a Pharmaceutical covered by Section F Part I of the Pharmaceutical Schedule; or
 - ii) if the Community Pharmaceutical is not a Pharmaceutical referred to in Section F Part I of the Pharmaceutical Schedule, in Monthly Lots, unless:
 - a) the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect; or
 - b) both:
 - the Practitioner endorses the Community Pharmaceutical on the Prescription with the words "certified exemption" written in the Practitioner's own handwriting, or signed or initialled by the Practitioner; and
 - every Community Pharmaceutical endorsed as "certified exemption" is covered by Section F Part II of the Pharmaceutical Schedule.
- 3.1.5 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor:
 - a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or
 - b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written.
- 3.1.6 No subsidy will be paid for any Prescription, or part thereof, that is not fulfilled within:
 - a) in the case of a Prescription for a total supply of from one to three Months, three Months from the date the Community Pharmaceutical was first dispensed; or
 - b) in any other case, one Month from the date the Community Pharmaceutical was first dispensed. Only that part of any Prescription that is dispensed within the time frames specified above is eligible for Subsidy.
- 3.1.7 If a Community Pharmaceutical:
 - a) is stable for a limited period only, and the Practitioner has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that may be dispensed at any one time; or
 - b) is stable for a limited period only, and the Contractor has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that should be dispensed at any one time in all the circumstances of the particular case; or
 - c) is under the Dispensing Frequency Rule,

The actual quantity dispensed will be subsidised in accordance with any such specification.

3.2 Oral Contraceptives

The following provisions apply to all Prescriptions written by a Doctor, Midwife, Nurse Prescriber or a Pharmacist Prescriber for an oral contraceptive:

- 3.2.1 The prescribing Doctor, Midwife, Nurse Prescriber or a Pharmacist Prescriber must specify on the Prescription the period of treatment for which the Community Pharmaceutical is to be supplied. This period must not exceed six Months.
- 3.2.2 Where the period of treatment specified in the Prescription does not exceed six Months, the Community Pharmaceutical is to be dispensed:
 - a) in Lots as specified in the Prescription if the Community Pharmaceutical is under the Dispensing Frequency Rule; or
 - b) where no Lots are specified, in one Lot sufficient to provide treatment for the period prescribed.
- 3.2.3 An oral contraceptive is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor within three Months of the date on which it was written.
- 3.2.4 Where a Community Pharmaceutical on a Prescription is under the Dispensing Frequency Rule and a repeat on the Prescription remains unfulfilled after six Months from the date the Community Pharmaceutical was first dispensed only the actual quantity supplied by the Contractor within this time limit will be eligible for Subsidy.

3.3 Original Packs, Certain Antibiotics and Unapproved Medicines

- 3.3.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community Pharmaceutical that is identified as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an amount or quantity eligible for Subsidy, is deemed to be a reference:
 - a) where an amount by weight or volume of the Community Pharmaceutical is specified in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufficient to provide that amount; and
 - b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand.
- 3.3.2 If a Community Pharmaceutical is either:
 - a) the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing; or
 - b) an unapproved medicine supplied under Section 29 of the Medicines Act 1981, but excluding any medicine listed as Cost, Brand, Source of Supply, or
 - c) any other pharmaceutical that PHARMAC determines, from time to time and notes in the Pharmaceutical Schedule

and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where:

- a) the difference between the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and
- b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner.

Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

3.4 Pharmacist Prescribers' Prescriptions

The following apply to every prescription written by a Pharmacist Prescriber

- 3.4.1 Prescriptions written by a Pharmacist Prescriber for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) a Community Pharmaceutical classified as a Prescription Medicine and which a Pharmacist Prescriber is permitted under regulations to prescribe; or

- b) any other Community Pharmaceutical that is a Restricted Medicine (Pharmacist Only Medicine), a Pharmacy Only Medicine or a General Sales Medicine.
- 3.4.2 Any Pharmacist Prescribers' prescriptions for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed).

3.5 Dietitians' Prescriptions

- The following provisions apply to every Prescription written by a Dietitian:
- 3.5.1 Prescriptions written by a Dietitian for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) special foods, as listed in Section D; or
 - b) any other Pharmaceutical that has been identified in Section D of the Pharmaceutical Schedule as being able to be prescribed by a Dietitian, providing that the products being prescribed are not classified as Prescription Medicines or Restricted Medicines.
- 3.5.2 For the purposes of Dietitians prescribing pursuant to this clause 3.5, the prescribing and dispensing of these products is required to be in accordance with regulations 41 and 42 of the Medicines Regulations 1984.

3.6 Diabetes Nurse Prescribers' Prescriptions

The following provisions apply to every Prescription written by a Diabetes Nurse Prescriber:

- 3.6.1 Prescriptions written by a Diabetes Nurse Prescriber for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) a Community Pharmaceutical classified as a Prescription Medicine or a Restricted Medicine and which a Diabetes Nurse Prescribers is permitted under regulations to prescribe; or
 - b) any other Community Pharmaceutical listed below:

aspirin, blood glucose diagnostic test meter, blood glucose diagnostic test strip, blood ketone diagnostic test meter, glucagon hydrochloride inj 1 mg syringe kit, insulin pen needles, insulin syringes disposable with attached needle, insulin pump accessories, insulin pump infusion set, insulin pump reservoir, ketone blood beta-ketone electrodes test strip, nicotine, sodium nitroprusside test strip,

3.6.2 Any Diabetes Nurse Prescribers' prescription for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed).

3.7 Quitcard Providers' Prescriptions

Prescriptions written by a Quitcard Provider will only be subsidised where they are:

- a) for any of the following Community Pharmaceuticals: nicotine patches, nicotine lozenges or nicotine gum; and
- b) written on a Quitcard.

PART IV DISPENSING FREQUENCY RULE

Rule 3.1.4 of the Pharmaceutical Schedule specifies, for community patients, a default period of supply for each Community Pharmaceutical (a Monthly Lot, 90 Day Lot or for oral contraceptives 180 Day Lot). This Dispensing Frequency Rule defines patient groups or medicines eligible for more frequent dispensing periods for Community Pharmaceuticals; and the conditions that must be met to enable any pharmacy to claim for payment of handling fees for the additional dispensings made. This Dispensing Frequency Rule relates to the circumstances in which a subsidy is payable for the Community Pharmaceutical; it does not override alternative dispensing frequencies as expressly stated in the Medicines Act, Medicines Regulations, Pharmacy Services Agreement or Pharmaceutical Schedule.

For the purposes of this Dispensing Frequency Rule:

"Frequent Dispensing" means:

- i) for a Community Pharmaceutical referred to in Section F Part I, (the Stat exemption) dispensing in quantities less than one 90 Day Lot (or for oral contraceptives, less than one 180 Day Lot); or
- ii) for any other Community Pharmaceutical dispensing in quantities less than a Monthly Lot "Safety Medicine"
 - i) an antidepressant listed under the "Cyclic and Related Agents" subheading;
 - ii) an antipsychotic;

- iii) a benzodiazepine;
- iv) a Class B Controlled Drug;
- v) codeine (includes combination products);
- vi) buprenorphine with naloxone; or
- vii) zopiclone.

The Dispensing Frequency Rule covers 5 different circumstances where Frequent Dispensing for patients may be clinically or otherwise appropriate. These are:

- 1) Long Term Condition (LTC) patients and Core patients, or
- 2) Persons in residential care, or
- 3) Trial periods, or
- 4) Safety and co-prescribed medicines, or
- 5) Pharmaceutical Supply Management.

4.1 Frequent Dispensing for patients registered as Long Term Condition (LTC) or Core patients

If a Pharmacist considers Frequent Dispensing is required, then:

- 4.1.1 For LTC registered patients, Frequent Dispensing can occur as often as the dispensing Pharmacist deems appropriate to meet that patient's compliance and adherence needs;
- 4.1.2 For Core (non-LTC) patients, Frequent Dispensing should be no more often than a Monthly Lot. Pharmacists may authorise monthly dispensing on a Stat exemption Community Pharmaceutical without prescriber authority. If the Pharmacist considers more frequent (than monthly) dispensing is necessary, prescriber approval is required. Verbal approval from the prescriber is acceptable provided it is annotated by the Pharmacist on the Prescription and dated.

4.2 Frequent Dispensings for persons in residential care

- 4.2.1 Community Pharmaceuticals can be dispensed to:
 - any person whose placement in a Residential Disability Care Institution is funded by the Ministry of Health or a DHB; or
 - a person assessed as requiring long term residential care services and residing in an age related residential care facility;

on the request of the person, their agent or caregiver or community residential service provider via Frequent Dispensing, provided the following conditions are met:

- a) the quantity or period of supply to be dispensed at any one time is not less than:
 - i) 7 days' supply for a Class B Controlled Drug; or
 - ii) 7 days' supply for clozapine in accordance with a Clozapine Dispensing Protocol; or
 - iii) 28 days' supply for any other Community Pharmaceutical (except under conditions outlined in 4.3 (Trial periods) below; and
- b) the prescribing Practitioner or dispensing Pharmacist has
 - i) included the name of the patient's residential placement or facility on the Prescription; and
 - ii) included the patient's NHI number on the Prescription; and
 - iii) specified the maximum quantity or period of supply to be dispensed at any one time.
- 4.2.2 Any person meeting the criteria above who is being initiated onto a new medicine or having their dose changed is able to have their medicine dispensed in accordance with 4.3 (Trial periods) below.

4.3 Frequent Dispensings for Trial Periods

Frequent Dispensing can occur when a Community Pharmaceutical has been prescribed for a patient who requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient's first changed Prescription only) and the prescribing Practitioner has:

- endorsed each Community Pharmaceutical on the Prescription clearly with the words "Trial Period", or "Trial"; and
- specified the maximum quantity or period of supply to be dispensed for each Community Pharmaceutical at any one time.

Patients who reside in Penal Institutions are not eligible for Trial Periods.

4.4 Frequent Dispensing for Safety and co-prescribed medicines

- 4.4.1 For a Safety Medicine to be dispensed via Frequent Dispensing, both of the following conditions must be met:
 - a) The patient is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in 4.2 on the previous page; and
 - b) The prescribing Practitioner has:
 - i) Assessed clinical risk and determined the patient requires increased Frequent Dispensing; and
 - ii) Specified the maximum quantity or period of supply to be dispensed for each Safety Medicine at each dispensing.
- 4.4.2 A Community Pharmaceutical that is co-prescribed with a Safety Medicine, which can be dispensed in accordance with rule 4.4.1 above, may be dispensed at the same frequency as the Safety Medicine if the dispensing pharmacist has:
 - Assessed clinical risk and determined the patient requires Frequent Dispensing of their co-dispensed medicines; and
 - Annotated the Prescription with the amended dispensing quantity and frequency.

4.5 Frequent Dispensing for Pharmaceutical Supply Management

- 4.5.1 Frequent Dispensing may be required from time to time to manage stock supply issues or emergency situations. Pharmacists may dispense more frequently than the Schedule would otherwise allow when all of the following conditions are met:
 - a) PHARMAC has approved and notified pharmacists to annotate Prescriptions for a specified Community Pharmaceutical(s) "out of stock" without prescriber endorsement for a specified time; and
 - b) the dispensing pharmacist has:
 - clearly annotated each of the approved Community Pharmaceuticals that appear on the Prescription with the words "out of stock" or "OOS"; and
 - ii) initialled the annotation in their own handwriting; and
 - iii) has complied with maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification.

Note – no claim shall be made to any DHB for subsidised dispensing under this rule where dispensing occurs more frequently than specified by PHARMAC to manage the supply management issue.

PART V MISCELLANEOUS PROVISIONS

5.1 Bulk Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals under Bulk Supply Orders:

- 5.1.1 No Community Pharmaceutical supplied under a Bulk Supply Order will be subsidised unless all the requirements in Section B, C or D of the Schedule applicable to that pharmaceutical are met.
- 5.1.2 The person who placed the Bulk Supply Order may be called upon by the Ministry of Health to justify the amount ordered.
- 5.1.3 Class B Controlled Drugs will be subsidised only if supplied under Bulk Supply Orders placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001.
- 5.1.4 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Bulk Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 5.1.5 Community Pharmaceuticals listed in Part I of the First Schedule to the Medicines Regulations 1984 will be subsidised only if supplied under a Bulk Supply Order placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 and:
 - a) that institution employs a registered general nurse, registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003; and
 - b) the Bulk Supply Order is supported by a written requisition signed by a Hospital Care Operator.
- 5.1.6 No Subsidy will be paid for any quantity of a Community Pharmaceutical supplied under a Bulk Supply Order in excess of what is a reasonable monthly allocation for the particular institution, after taking into account stock on hand.
- 5.1.7 The Ministry of Health may, at any time, by public notification, declare that any approved institution within its particular region, is not entitled to obtain supplies of Community Pharmaceuticals under Bulk Supply Orders

with effect from the date specified in that declaration. Any such notice may in like manner be revoked by the Ministry of Health at any time.

5.2 Practitioner's Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under a Practitioner's Supply Order:

- 5.2.1 Subject to clause 5.2.3 and 5.2.6, a Practitioner may only order under a Practitioner's Supply Order those Community Pharmaceuticals listed in Section E Part I and only in such quantities as set out in Section E Part I that the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.
- 5.2.2 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Practitioner's Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 5.2.3 A Practitioner may order such Community Pharmaceuticals as he or she expects to be required for personal administration to patients under the Practitioner's care if:
 - a) the Practitioner's normal practice is in the specified areas listed in Section E Part II of the Schedule, or if the Practitioner is a locum for a Practitioner whose normal practice is in such an area.
 - b) the quantities ordered are reasonable for up to one Month's supply under the conditions normally existing in the practice. (The Practitioner may be called on by the Ministry of Health to justify the amounts of Community Pharmaceuticals ordered.)
- 5.2.4 No Community Pharmaceutical ordered under a Practitioner's Supply order will be eligible for Subsidy unless:
 - a) the Practitioner's Supply Order is made on a form supplied for that purpose by the Ministry of Health, or approved by the Ministry of Health and which:
 - i) is personally signed and dated by the Practitioner; and
 - ii) sets out the Practitioner's address; and
 - iii) sets out the Community Pharmaceuticals and quantities, and;
 - b) all the requirements of Sections B and C of the Schedule applicable to that pharmaceutical are met.
- 5.2.5 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notification, declare that a Practitioner specified in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Practitioner's Supply Orders until such time as the Ministry of Health notifies otherwise.
- 5.2.6 A Practitioner working in the Rheumatic Fever Prevention Programme (RFPP) may order under a Practitioner's Supply Order such Community Pharmaceuticals (identified below) as he or she requires to ensure medical supplies are available for patients with suspected or confirmed Group A Streptococcal throat infections for the purposes of the RFPP in the following circumstances:
 - a) the RFPP provider name is written on the Practitioner's Supply Order; and
 - b) the total quantity ordered does not exceed a multiple of:
 - ten times the Practitioner's Supply Order current maximum listed in Section E Part I for amoxicillin grans for oral liq 250 mg per 5 ml, amoxicillin cap 250 mg and amoxicillin cap 500 mg; or
 - ii) two times the Practitioner's Supply Order current maximum listed in Section E Part I for phenoxymethyl penicillin grans for oral liquid 250 mg per 5 ml, phenoxymethyl penicillin cap 500 mg, erythromycin ethyl succinate grans for oral liq 200 mg per 5 ml and erythromycin ethyl succinate tab 400 mg; and
 - c) the practitioner must specify the order quantity in course-specific amounts on the Practitioner's Supply Order (e.g. 10 x 300 ml amoxicillin grans for oral liq 250 mg per 5 ml). This will enable the pharmacy to dispense each course separately and claim multiple service fees as per the Community Pharmacy Services Agreement.

5.3 Retail Pharmacy and Hospital Pharmacy-Specialist Restriction

The following provisions apply to Prescriptions for Community Pharmaceuticals eligible to be subsidised as "Retail Pharmacy-Specialist" and "Hospital Pharmacy-Specialist":

5.3.1 Record Keeping

It is expected that a record will be kept by both the General Practitioner and the Specialist of the fact of consultation and enough of the clinical details to justify the recommendation. This means referral by telephone will need to be followed up by written consultation.

5.3.2 Expiry

The recommendation expires at the end of two years and can be renewed by a further consultation.

- 5.3.3 The circulation by Specialists of the circumstances under which they are prepared to recommend a particular Community Pharmaceutical is acceptable as a guide. It must however be followed up by the procedure in subclauses 5.3.1 and 5.3.2, for the individual Patient.
- 5.3.4 The use of preprinted forms and named lists of Specialists (as circulated by some pharmaceutical companies) is regarded as inappropriate.
- 5.3.5 The Rules for Retail Pharmacy-Specialist and Hospital Pharmacy-Specialist will be audited as part of the Ministry of Health's routine auditing procedures.

5.4 Pharmaceutical Cancer Treatments

- 5.4.1 DHBs must provide access to Pharmaceutical Cancer Treatments for the treatment of cancers in their DHB hospitals, and/or in association with Outpatient services provided in their DHB hospitals.
- 5.4.2 DHBs must only provide access to Pharmaceuticals for the treatment of cancer that are listed as Pharmaceutical Cancer Treatments in Sections A to G of the Schedule, provided that DHBs may provide access to an unlisted pharmaceutical for the treatment of cancer where that unlisted pharmaceutical:
 - a) has Named Patient Pharmaceutical Assessment (NPPA) approval;
 - b) is being used as part of a bona fide clinical trial which has Ethics Committee approval;
 - c) is being used and funded as part of a paediatric oncology service; or
 - d) was being used to treat the patient in question prior to 1 July 2005.
- 5.4.3 A DHB hospital pharmacy that holds a claiming agreement for Pharmaceutical Cancer Treatements with the Funder may claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" or "PCT only" in Sections A to G of this Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with:
 - a) Part 1;
 - b) clauses 2.1 to 2.2;
 - c) clauses 3.1 to 3.4; and
 - d) clause 5.4,
 - of Section A of the Schedule
- 5.4.4 A Contractor (other than a DHB hospital pharmacy) may only claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" in Sections A to G of the Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with the rules applying to Sections A to G of the Schedule.
- 5.4.5 Some indications for Pharmaceutical Cancer Treatments listed in the Schedule are Unapproved Indications. Some of these formed part of the October 2001 decision by the Minister of Health as to pharmaceuticals and indications for which DHBs must provide access. As far as reasonably practicable, these Unapproved Indications are marked in the Schedule. However, PHARMAC makes no representation and gives no guarantee as to the accuracy of this information. Practitioners prescribing Pharmaceutical Cancer Treatments for such Unapproved Indications should:
 - a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that act and the Medicines Regulations 1984;
 - b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
 - c) exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical Cancer Treatment or a Pharmaceutical Cancer Treatment for an Unapproved Indication.
- 5.4.6 Applications to add pharmaceuticals, and add or amend indications for Pharmaceutical Cancer Treatments, may be made in writing by pharmaceutical suppliers and/or clinicians to PHARMAC. Applications should follow the Guidelines for Funding Applications to PHARMAC 2010 and Recommended methods to derive clinical inputs for proposals to PHARMAC, copies of which are available from PHARMAC or PHARMAC's website.

5.5 Practitioners prescribing unapproved Pharmaceuticals

Practitioners should, where possible, prescribe Pharmaceuticals that are approved under the Medicines Act 1981. However, the access criteria under which a Pharmaceutical is listed on the Pharmaceutical Schedule may:

a) in some case, explicitly permit Government funded access to a Pharmaceutical that is not approved under

the Medicines Act 1981 or for an Unapproved Indication; or

b) not explicitly preclude Government funded access to a Pharmaceutical when it is used for an Unapproved Indication;

Accordingly, if Practitioners are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, Practitioners should:

- a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Practitioners should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

5.6 Substitution

Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer's Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical available, a Contractor may dispense the fully subsidised Community Pharmaceutical, unless either or both of the following circumstances apply:

- a) there is a clinical reason why substitution should not occur; or
- b) the prescriber has marked the prescription with a statement such as 'no brand substitution permitted'

Such an Authority to Substitute is valid whether or not there is a financial implication for the Pharmaceutical Budget. When dispensing a subsidised alternative brand, the Contractor must annotate and sign the prescription and inform the patient of the brand change.

5.7 Alteration to Presentation of Pharmaceutical Dispensed

A Contractor, when dispensing a subsidised Community Pharmaceutical, may alter the presentation of a Pharmaceutical dispensed to another subsidised presentation but may not alter the dose, frequency and/or total daily dose. This may only occur when it is not practicable for the contractor to dispense the requested presentation. If the change will result in additional cost to the DHBs, then annotation of the prescription by the dispensing pharmacist must occur stating the reason for the change, and the Contractor must initial the change for the purposes of Audit.

5.8 Other DHB Funding

A DHB may fund a Community Pharmaceutical outside of the mechanisms established in the Pharmaceutical Schedule, provided that:

- a) specific prior agreement is obtained from PHARMAC for such funding;
- any funding restrictions set out in the Pharmaceutical Schedule for those Community Pharmaceuticals are applied; and
- c) a Contractor (including a DHB Hospital Pharmacy) may not claim a Subsidy for a Community Pharmaceutical dispensed and funded by the DHB via such an alternate mechanism.

5.9 Conflict in Provisions

If any rules in Sections B-G and Section I of this Schedule conflict with the rules in Section A, the rules in Sections B-G and Section I apply.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subaidy		Eulb	Propd or
	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	
Antacids and Antiflatulants				
Antacids and Reflux Barrier Agents				
ALGINIC ACID				
Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet	4.50	30	~	Gaviscon Infant
SIMETHICONE				
 Oral liq aluminium hydroxide 200 mg with magnesium hydrox- ide 200 mg and activated simethicone 20 mg per 5 ml 		500 ml		Mylanta P
SODIUM ALGINATE				
 Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour 		60		Gaviscon Double Strength
 * Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml 		500 ml		Acidex
Phosphate Binding Agents				
ALUMINIUM HYDROXIDE				
* Tab 600 mg CALCIUM CARBONATE	12.56	100	V .	Alu-Tab
Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) – Subsidy by endorsement Only when prescribed for children under 12 years of age endorsed accordingly.		500 ml sphate I	-	Roxane gent and the prescription i
Antidiarrhoeals				
Agents Which Reduce Motility				
LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a	PSO			
* Tab 2 mg * Cap 2 mg		400 400		Nodia <u>Diamide Relief</u>
Rectal and Colonic Anti-inflammatories				
BUDESONIDE				
Cap 3 mg – Special Authority see SA1155 below – Retail pharmacy		90	V	Entocort CIR
SA1155 Special Authority for Subsidy Initial application — (Crohn's disease) from any relevant pract following criteria: Both:	itioner. Approvals v	alid for (6 months	for applications meeting th
 Mild to moderate ileal, ileocaecal or proximal Crohn's dise Any of the following: 	ease; and			

24

Subsidy	Fu	ully Brand or	
(Manufacturer's Price)	Subsidis	sed Generic	
\$	Per	✔ Manufacture	r

continued...

- 2.1 Diabetes; or
- 2.2 Cushingoid habitus; or
- 2.3 Osteoporosis where there is significant risk of fracture; or
- 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
- 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
- 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
- 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initial application — (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid for 6 months where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initial application — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogenic bone marrow transplantation*.

Note: Indication marked with * is an Unapproved Indication.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.

HYDROCORTISONE ACETATE

Rectal foam 10%, CFC-Free (14 applications)	25.30	21.1 g OP	✓ Colifoam
MESALAZINE			
Tab 400 mg		100	Asacol
Tab EC 500 mg		100	🗸 Asamax
Tab long-acting 500 mg	59.05	100	Pentasa
Modified release granules, 1 g	141.72	120 OP	Pentasa
Enema 1 g per 100 ml	44.12	7	Pentasa
Suppos 500 mg	22.80	20	Asacol
Suppos 1 g	54.60	30	Pentasa
OLSALAZINE			
Tab 500 mg		100	 Dipentum
Cap 250 mg	31.51	100	 Dipentum
SODIUM CROMOGLYCATE			
Cap 100 mg		100	 Nalcrom
SULPHASALAZINE			
* Tab 500 mg – For sulphasalazine oral liquid formulation refe	er,		
page 209		100	 Salazopyrin
* Tab EC 500 mg		100	✓ Salazopyrin

Local preparations for Anal and Rectal Disorders

Antihaemorrhoidal Preparations

FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVALATE AND CINCHOCAINE

Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cin- chocaine hydrochloride 5 mg per g	. 6.35	30 g OP	 Ultraproct
Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and		0	•
cinchocaine hydrochloride 1 mg	.2.66	12	 Ultraproct

EN

	Subsidy (Manufacturer's P \$	rice) Su Per	Fully Brand or bsidised Generic ✔ Manufacturer
HYDROCORTISONE WITH CINCHOCAINE Oint 5 mg with cinchocaine hydrochloride 5 mg per g Suppos 5 mg with cinchocaine hydrochloride 5 mg per g		30 g OP 12	ProctosedylProctosedyl
Management of Anal Fissures			
GLYCERYL TRINITRATE – Special Authority see SA1329 belo ★ Oint 0.2% →SA1329 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals va chronic anal fissure that has persisted for longer than three week	alid without further	30 g OP	✓ Rectogesic ss notified where the patient has
Antispasmodics and Other Agents Altering Gu	t Motility		
HYOSCINE N-BUTYLBROMIDE * Tab 10 mg * Inj 20 mg, 1 ml – Up to 5 inj available on a PSO MEBEVERINE HYDROCHLORIDE	9.57	20 5	 ✔ Gastrosoothe ✔ Buscopan
Tab 135 mg Colofac to be Sole Supply on 1 October 2014 Antiulcerants	18.00	90	Colofac
Antisecretory and Cytoprotective			
/IISOPROSTOL ₭ Tab 200 mcg	52.70	120	✓ Cytotec
Helicobacter Pylori Eradication			
CLARITHROMYCIN Tab 500 mg – Subsidy by endorsement a) Maximum of 14 tab per prescription b) Subsidised only if prescribed for helicobacter pylori er Note: the prescription is considered endorsed if clarithromycin amoxicillin or metronidazole. c) Apo-Clarithromycin to be Sole Supply on 1 October 20	adication and prese is prescribed in cor		
H2 Antagonists			
CIMETIDINE – Only on a prescription ₭ Tab 200 mg	5.00 (7.50)	100	Apo-Cimetidine
₭ Tab 400 mg		100	Apo-Cimetidine
ANITIDINE – Only on a prescription • Tab 150 mg	6.79 10.30	250 500	 Arrow-Ranitidine Ranitidine Relief
₭ Tab 300 mg	9.34 14.73	250 500	 Arrow-Ranitidine Ranitidine Relief
 Oral liq 150 mg per 10 ml Peptisoothe to be Sole Supply on 1 October 2014 Ini 25 mg por ml 2 ml 		300 ml	 Peptisoothe Zantac
* Inj 25 mg per ml, 2 ml	ð./ð	5	

26

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
Proton Pump Inhibitors				
LANSOPRAZOLE				
* Cap 15 mg	2.00	28	~	Solox
* Cap 30 mg	2.32	28	~	Solox
OMEPRAZOLE				
For omeprazole suspension refer Standard Formulae, page 2	12			
* Cap 10 mg	2.91	90	~	Omezol Relief
* Cap 20 mg	3.78	90		Omezol Relief
* Cap 40 mg		90		Omezol Relief
Powder – Only in combination		5 g	~	Midwest
Only in extemporaneously compounded omeprazole suspe		_		
₭ Inj 40 mg		5	V	Dr Reddy's
				Omeprazole
PANTOPRAZOLE				.
* Tab EC 20 mg	2.68	100	V	Pantoprazole
* Tab EC 40 mg	2 5 4	100		<u>Actavis 20</u> Pantoprazole
* Tab EC 40 Tilg		100	•	Actavis 40
Oite Ducto ative America				Holdvid Ho
Site Protective Agents				
BISMUTH TRIOXIDE				
Tab 120 mg		112	~	De Nol S29
SUCRALFATE				
Tab 1 g	35 50	120		
140 I 9	(48.28)	120		Carafate
	(
Bile and Liver Therapy				
RIFAXIMIN – Special Authority see SA1461 below – Retail pharm	nacy			
Tab 550 mg		56	~	Xifaxan
SSA1461 Special Authority for Subaidy				

➡SA1461 Special Authority for Subsidy

Initial application only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid for 6 months where the patient has hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

Renewal only from a gastroenterologist, hepatologist or Practitioner on the recommendation of a gastroenterologist or hepatologist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Hyperglycaemic Agents

DIAZOXIDE - Special Authority see SA1320 on the next page - Retail pharmacy

Cap 25 mg 110.00	100
Cap 100 mg	100
Oral liq 50 mg per ml620.00	30 ml OP

- ✔ Proglicem S29
- ✓ Proglicem S29
- Proglycem S29

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully sidised	Brand or Generic Manufacturer
SA1320 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals valid glycaemia caused by hyperinsulinism.	l for 12 months	where used for	the trea	tment of confirmed hyp
Renewal from any relevant practitioner. Approvals valid without fu priate and the patient is benefiting from treatment.	rther renewal ur	less notified wl	here the	treatment remains appr
GLUCAGON HYDROCHLORIDE Inj 1 mg syringe kit – Up to 5 kit available on a PSO		1	🖌 Gl	ucagen Hypokit
Insulin - Short-acting Preparations				
NSULIN NEUTRAL ▲ Inj human 100 u per ml	25.26	10 ml OP		trapid mulin R
▲ Inj human 100 u per ml, 3 ml	42.66	5	🖌 Ac	trapid Penfill mulin R
Insulin - Intermediate-acting Preparations				
NSULIN ASPART WITH INSULIN ASPART PROTAMINE ▲ Inj 100 iu per ml, 3 ml prefilled pen	52.15	5	🖌 No	voMix 30 FlexPen
NSULIN ISOPHANE Inj human 100 u per ml	17.68	10 ml OP		mulin NPH otaphane
Inj human 100 u per ml, 3 ml	29.86	5	🖌 Hu	mulin NPH otaphane Penfill
NSULIN ISOPHANE WITH INSULIN NEUTRAL Inj human with neutral insulin 100 u per ml	25.26	10 ml OP		mulin 30/70 xtard 30
Inj human with neutral insulin 100 u per ml, 3 ml	42.66	5	✓ Hu ✓ Pe ✓ Pe	mulin 30/70 nMix 30 nMix 40 nMix 50
NSULIN LISPRO WITH INSULIN LISPRO PROTAMINE ▲ Inj lispro 25% with insulin lispro protamine 75% 100 u per ml,				
3 ml Inj lispro 50% with insulin lispro protamine 50% 100 u per ml, 3 ml		5		malog Mix 25 malog Mix 50
Insulin - Long-acting Preparations		5	• no	
NSULIN GLARGINE				
Inj 100 u per ml, 10 ml Inj 100 u per ml, 3 ml	94.50	1 5 5	✔ La ✔ La	
Inj 100 u per ml, 3 ml disposable pen Insulin - Rapid Acting Preparations	94.50	5	₩ La	11105 30103181
NSULIN ASPART ▲ Inj 100 u per ml, 3 ml ▲ Inj 100 u per ml, 10 ml		5 1		voRapid Penfill voRapid

28

	Subsidy (Manufacturer's Pr	rice) S	Full	
	\$	Per	v	 Manufacturer
INSULIN GLULISINE				
▲ Inj 100 u per ml, 10 ml	27.03	1	~	Apidra
Inj 100 u per ml, 3 ml		5		Apidra
Inj 100 u per ml, 3 ml disposable pen	46.07	5	~	Apidra SoloStar
INSULIN LISPRO				
▲ Inj 100 u per ml, 10 ml		10 ml OP		Humalog
▲ Inj 100 u per ml, 3 ml	59.52	5	~	Humalog
Alpha Glucosidase Inhibitors				
ACARBOSE				
* Tab 50 mg	9.82	90	~	Accarb
* Tab 100 mg	15.83	90	~	Accarb
Oral Hypoglycaemic Agents				
GLIBENCLAMIDE				
* Tab 5 mg	5.00	100	~	Daonil
GLICLAZIDE				
* Tab 80 mg	11.50	500	~	Glizide
-	17.60		~	Apo-Gliclazide
GLIPIZIDE				
* Tab 5 mg	3.00	100	~	Minidiab
METFORMIN HYDROCHLORIDE				
* Tab immediate-release 500 mg	12.30	1,000	~	Apotex
* Tab immediate-release 850 mg	10.10	500	~	Apotex
PIOGLITAZONE				
* Tab 15 mg		28		Pizaccord
* Tab 30 mg		28		Pizaccord
* Tab 45 mg	3.50	28	V	Pizaccord
Diabetes Management				
Ketone Testing				
BLOOD KETONE DIAGNOSTIC TEST METER – Up to 1 mete Meter funded for the purposes of blood ketone diagnostics at risk of future episodes or patient is on an insulin pump. C Meter	only. Patient has h only one meter per	ad one or n	be subs	
KETONE BLOOD BETA-KETONE ELECTRODES		-	-	

a) Maximum of 20 strip per prescription b) Up to 10 strip available on a PSO

Test strip – Not on a BSO......15.50

 Freestyle Optium Ketone

Ketur-Test

Accu-Chek

✓ Ketostix

10 strip OP

50 strip OP

14.14

	Subsidy (Manufacturer's Pri \$	ice) Per	Fully Subsidised	Brand or Generic Manufacturer
Blood Glucose Testing				
 LOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by er a) Up to 1 pack available on a PSO b) Maximum of 1 pack per prescription c) A diagnostic blood glucose test meter is subsidised for a pa 1) is receiving insulin or sulphonylurea therapy; or 2) is pregnant with diabetes; or 3) is on home TPN at risk of hypoglycaemia or hyperglycaer 4) has a genetic or an acquired disorder of glucose homeosta non CareSens meter per patient. No further prescriptions will or the avoidance of doubt patients who have previously received a teter. The prescription must be endorsed accordingly. Pharmacis record of prior dispensing of insulin or sulphonylureas. Meter with 50 lancets, a lancing device and 10 diagnostic test 	tient who: nia; or asis excluding typ be subsidised fo a funded meter, o	r patients ther than	who alread CareSens,	ly have a CareSens mete are eligible for a CareSer
strips	20.00	1 OP		<u>areSens II</u> areSens N
				areSens N POP
Note: Only 1 meter available per PSO				
)		
 CODD GLOCOSE DIAGNOSTIC TEST STAIP – Op to so test a The number of test strips available on a prescription is restrict Prescribed for a patient on insulin or a sulphonylurea and e as endorsed where there exists a record of prior dispensi Prescribed on the same prescription as insulin or a sulpho or Prescribed for a pregnant woman with diabetes and endo Prescribed for a patient on home TPN at risk of hypoglycz Prescribed for a patient with a genetic or an acquired disc and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirements 	ed to 50 unless: endorsed accordir ng of insulin or su nylurea in which o rsed accordingly; aemia or hypergly	ngly. Phai Iphonylui case the p or caemia a	rea; or prescription and endorse	is deemed to be endorsed d accordingly; or
 The number of test strips available on a prescription is restrict Prescribed for a patient on insulin or a sulphonylurea and e as endorsed where there exists a record of prior dispensi Prescribed on the same prescription as insulin or a sulpho or Prescribed for a pregnant woman with diabetes and endo Prescribed for a patient on home TPN at risk of hypoglyca Prescribed for a patient with a genetic or an acquired disc and metabolic syndrome and endorsed accordingly. 	ed to 50 unless: endorsed accordir ng of insulin or su nylurea in which o rsed accordingly; aemia or hypergly rder of glucose h	ngly. Phai Iphonylui case the p or caemia a	rea; or prescription and endorse sis excluding OP ✓ <u>C</u>	is deemed to be endorsed d accordingly; or g type 1 or type 2 diabete areSens
 Prescribed for a patient on insulin or a sulphonylurea and e as endorsed where there exists a record of prior dispensii Prescribed on the same prescription as insulin or a sulpho or Prescribed for a pregnant woman with diabetes and endo Prescribed for a patient on home TPN at risk of hypoglyca Prescribed for a patient with a genetic or an acquired disc and metabolic syndrome and endorsed accordingly. Blood glucose test strips – Note differing brand requirements 	ed to 50 unless: endorsed accordir ng of insulin or su nylurea in which o rsed accordingly; aemia or hypergly rder of glucose h	ngly. Phai Ilphonylui case the p or caemia a omeostas	rea; or prescription and endorse sis excluding OP <u>C</u> C A	is deemed to be endorsed d accordingly; or g type 1 or type 2 diabete

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz and can be sent to: PHARMAC

PO Box 10 254 Facsimile: (04) 974 4788 Wellington Email: bgstrips@pharmac.govt.nz

30

		Subsidy (Manufacturer's Prio \$	ce) Su Per	Fully Ibsidised	Brand or Generic Manufacturer
L	OOD GLUCOSE TEST STRIPS (VISUALLY IMPAIRED)				
	The number of test strips available on a prescription is restri	cted to 50 unless:			
	1) Prescribed for a patient on insulin or a sulphonylurea and	d endorsed accordin	gly. Pharma	acists may	y annotate the prescripti
	as endorsed where there exists a record of prior dispen				
	2) Prescribed on the same prescription as insulin or a sulpl	nonylurea in which c	ase the pre	scription i	s deemed to be endorse
	or				
	 Prescribed for a pregnant woman with diabetes and end 	0.7.			
	4) Prescribed for a patient on home TPN at risk of hypogly				
	5) Prescribed for a patient with a genetic or an acquired di	sorder of glucose ho	omeostasis	excluding	g type 1 or type 2 diabe
	and metabolic syndrome and endorsed accordingly.				
	Blood glucose test strips		50 test OP	V Se	ensoCard
n	sulin Syringes and Needles				
uk	sidy is available for disposable insulin syringes, needles, a	nd pen needles if p	rescribed of	on the sa	me form as the one us
	he supply of insulin or when prescribed for an insulin patier				
	otate the prescription as endorsed where there exists a reco				
IS	ULIN PEN NEEDLES – Maximum of 100 dev per prescription	n			
	29 g × 12.7 mm		30	🖌 В-	D Micro-Fine
	5	10.50	100	🖌 В-	D Micro-Fine
	31 g $\times5$ mm		100	🖌 В-	D Micro-Fine
	$31 \text{ g} \times 6 \text{ mm}$		100	🗸 Al	BM
	$31 \text{ g} \times 8 \text{ mm}$	3.15	30	🖌 В-	D Micro-Fine
	°	10.50	100	🖌 В-	D Micro-Fine
				🖌 Al	BM
-	32 g \times 4 mm		100	🖌 В-	D Micro-Fine
IS	ULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLI	E – Maximum of 10	0 dev per p	rescriptio	n
	Syringe 0.3 ml with 29 g \times 12.7 mm needle		10	·	
		(1.99)		B-	D Ultra Fine
		13.00	100	🖌 В-	D Ultra Fine
	Syringe 0.3 ml with 31 g \times 8 mm needle	1.30	10		
		(1.99)			D Ultra Fine II
		13.00	100	🖌 В-	D Ultra Fine II
	Syringe 0.5 ml with 29 g \times 12.7 mm needle $\hfill \ldots$		10		
		(1.99)			D Ultra Fine
		13.00	100	✔ В-	D Ultra Fine
	Syringe 0.5 ml with 31 g \times 8 mm needle $\hfill \hfill \$		10	-	
		(1.99)			D Ultra Fine II
	0 1 4 1 11 00 40 7 11	13.00	100	• =	D Ultra Fine II
	Syringe 1 ml with 29 g \times 12.7 mm needle		100	V AI	BIM
		1.30	10	P	D Lilltra Fina
		(1.99)	100		D Ultra Fine D Ultra Fine
	Suringo 1 ml with 21 a × 9 mm poodle	13.00	100	V B-	
	Syringe 1 ml with 31 g \times 8 mm needle	1.30	100	✓ Al	
			10	D	D Ultra Fine II
•		(1 00)			
		(1.99) 13.00	100	-	D Ultra Fine II

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
Insulin Pumps				
INSULIN PUMP – Special Authority see SA1237 below – Retail (a) Maximum of 1 dev per prescription b) Only on a prescription c) Maximum of 1 insulin pump per patient each four year perior Min basal rate 0.025 U/h; black colour Min basal rate 0.025 U/h; blue colour	od. 4,500.00	1	• •	Animas Vibe Animas Vibe
Min basal rate 0.025 U/h; green colour Min basal rate 0.025 U/h; pink colour Min basal rate 0.025 U/h; silver colour	4,500.00 4,500.00	1 1 1	V	Animas Vibe Animas Vibe Animas Vibe
Min basal rate 0.05 U/h; blue colour	4,400.00	1		Paradigm 522 Paradigm 722
Min basal rate 0.05 U/h; clear colour		1	~	Paradigm 522 Paradigm 722 Paradigm 522
Min basal rate 0.05 U/h; purple colour		1	 <td>Paradigm 722 Paradigm 522 Paradigm 522 Paradigm 722</td>	Paradigm 722 Paradigm 522 Paradigm 522 Paradigm 722
Min basal rate 0.05 U/h; smoke colour	4,400.00	1	~	Paradigm 522 Paradigm 722

SA1237 Special Authority for Subsidy

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The IPP Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 974 7806
PO Box 10 254	Email: ipp@pharmac.govt.nz
Wellington	

Insulin Pump Consumables

➡SA1240 Special Authority for Subsidy

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The IPP Co-ordinator	Phone: (04) 460 4990			
PHARMAC	Facsimile: (04) 974 7806			
PO Box 10 254	Email: ipp@pharmac.govt.nz			
Wellington				
INSULIN PUMP ACCESS	ORIES - Special Authority see SA1240) above – Retail pl	harmacy	
a) Maximum of 1 cap	per prescription			
b) Only on a prescrip	tion			
c) Maximum of 1 pres	scription per 180 days.			
Battery cap			1	🖌 Animas Battery Cap

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
 INSULIN PUMP INFUSION SET (STEEL CANNULA) – Special a) Maximum of 3 sets per prescription 	Authority see SA1240) on the	e previous	page – Retail pharmacy
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
10 mm steel needle; 29 G; manual insertion; 60 cm tubing \times				
10 with 10 needles	130.00	1 OP	🖌 Pa	aradigm Sure-T MMT-884
10 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$				
10 with 10 needles; luer lock	130.00	1 OP	🗸 S	ure-T MMT-883
10 mm steel needle; 29 G; manual insertion; 80 cm tubing $ imes$				
10 with 10 needles	130.00	1 OP	🖌 Pa	aradigm Sure-T MMT-886
10 mm steel needle; 29 G; manual insertion; 80 cm tubing $ imes$				
10 with 10 needles; luer lock	130.00	1 OP	🗸 S	ure-T MMT-885
6 mm steel cannula; straight insertion; 60 cm grey line \times 10				
with 10 needles	130.00	1 OP	🖌 C	ontact-D
6 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$				
10 with 10 needles	130.00	1 OP	V P	aradigm Sure-T
			• •	MMT-864
6 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$				
10 with 10 needles; luer lock	130.00	1 OP	19	ure-T MMT-863
6 mm steel needle; 29 G; manual insertion; 80 cm tubing \times			• 3	
				anadiana Cuna T
10 with 10 needles	130.00	1 OP	V Pa	aradigm Sure-T MMT-866
				IVIIVI 1-800
6 mm steel needle; 29 G; manual insertion; 80 cm tubing \times	400.00			
10 with 10 needles; luer lock		1 OP	VS	ure-T MMT-865
8 mm steel cannula; straight insertion; 110 cm grey line $ imes$ 10				_
with 10 needles	130.00	1 OP	✔ C	ontact-D
8 mm steel cannula; straight insertion; 60 cm grey line \times 10				
with 10 needles		1 OP	🖌 C	ontact-D
8 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$				
10 with 10 needles	130.00	1 OP	🖌 Pa	aradigm Sure-T
				MMT-874
8 mm steel needle; 29 G; manual insertion; 60 cm tubing $ imes$				
10 with 10 needles; luer lock	130.00	1 OP	🗸 S	ure-T MMT-873
8 mm steel needle; 29 G; manual insertion; 80 cm tubing \times				
10 with 10 needles	130.00	1 OP	V Pa	aradigm Sure-T
			• •	MMT-876
8 mm steel needle; 29 G; manual insertion; 80 cm tubing $ imes$				
10 with 10 needles; luer lock		1 OP	~ 9	ure-T MMT-875

•		~	Manufacturer
NSERTION W/) – Special Authority se
_			
140.00	1 OP	🖌 Ins	set 30
140.00	1 OP	🖌 Ins	set 30
0 140.00	1 OP	🖌 Ins	set 30
0 140.00	1 OP	🖌 Ins	set 30
NSERTION) -	- Special Auth	nority see SA	1240 on page 32 – Reta
5			
120.00 h	1 OP	V Co	omfort Short
130.00	1 OP		aradigm Silhouette MMT-382
h 130.00	1 OP		aradigm Silhouette MMT-368
h 130.00	1 OP		aradigm Silhouette MMT-381
h 120.00	1.00		
	TOP		aradigm Silhouette MMT-383
120.00	1 OP	🖌 Co	omfort
h 130.00	1 OP	🖌 Pa	aradigm Silhouette
h		I	MMT-377
130.00	1 OP	🖌 Si	Ihouette MMT-371
120.00	1 OP	🖌 Co	omfort
n 130.00	1 OP		aradigm Silhouette MMT-378
h 130.00	1 OP		Ihouette MMT-373
h 130.00	1 OP		aradigm Silhouette
	0 140.00 0 140.00 0 NSERTION) - 5 120.00 h 130.00		

34

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGH see SA1240 on page 32 – Retail pharmacy a) Maximum of 3 sets per prescription b) Only on a prescription	T INSERTION WITH	INSEF	TION DEV	/ICE) – Special Authority
 c) Maximum of 13 infusion sets will be funded per year. 6 mm teflon cannula; straight insertion, insertion device; 110 				
cm grey line \times 10 with 10 needles	140.00	1 OP	🖌 In	set II
6 mm teflon cannula; straight insertion; insertion device; 45 cm blue tubing × 10 with 10 needles		1 OP	🖌 Pa	aradigm Mio
		-		MMT-941
6 mm teflon cannula; straight insertion; insertion device; 45 cm pink tubing \times 10 with 10 needles	130.00	1 OP		aradigm Mio MMT-921
6 mm teflon cannula; straight insertion; insertion device; 60 cm blue tubing \times 10 with 10 needles	130.00	1 OP	🗸 Pa	aradigm Mio
6 mm teflon cannula; straight insertion; insertion device; 60 cm pink tubing $ imes$ 10 with 10 needles	130.00	1 OP		MMT-943 aradigm Mio
				ММТ-923
6 mm teflon cannula; straight insertion; insertion device; 80 cm blue tubing × 10 with 10 needles	130.00	1 OP		aradigm Mio MMT-945
6 mm teflon cannula; straight insertion; insertion device; 80 cm clear tubing \times 10 with 10 needles	130.00	1 OP	🗸 Pa	aradigm Mio MMT-965
6 mm teflon cannula; straight insertion; insertion device; 80 cm pink tubing \times 10 with 10 needles	130.00	1 OP	🗸 Pa	aradigm Mio MMT-925
6 mm teflon cannula; straight insertionl insertion device; 60 cm blue line × 10 with 10 needles	140.00	1 OP	🗸 In	
6 mm teflon cannula; straight insertionl insertion device; 60 cm grey line × 10 with 10 needles		1 OP	🖌 In	set II
6 mm teflon cannula; straight insertionl insertion device; 60 cm pink line × 10 with 10 needles	140.00	1 OP	🖌 In	set II
9 mm teflon cannula; straight insertion; insertion device; 60 cm blue line × 10 with 10 needles	140.00	1 OP	🖌 In	set II
9 mm teflon cannula; straight insertion; insertion device; 60 cm grey line × 10 with 10 needles	140.00	1 OP	🖌 In	set II
9 mm teflon cannula; straight insertion; insertion device; 60 cm pink line × 10 with 10 needles	140.00	1 OP	🖌 In	set II
9 mm teflon cannula; straight insertion; insertion device; 80 cm clear tubing \times 10 with 10 needles	130.00	1 OP		aradigm Mio MMT-975
9 mm teflon cannula; straight insertionl insertion device; 110 cm grey line \times 10 with 10 needles \ldots	140.00	1 OP	🗸 In	set II

	Subsidy (Manufacturer's Price) S		Fully Brand or subsidised Generic	
	\$	Per	✓ Manufacturer	
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGH	T INSERTION)	 Special A 	uthority see SA1240 on page 32 -	
Retail pharmacy a) Maximum of 3 sets per prescription				
b) Only on a prescription				
c) Maximum of 13 infusion sets will be funded per year.				
6 mm teflon cannula; straight insertion; 110 cm tubing \times 10				
with 10 needles	130.00	1 OP	 Paradigm Quick-Set MMT-398 	
6 mm teflon cannula; straight insertion; 110 cm tubing $ imes$ 10				
with 10 needles; luer lock		1 OP	Quick-Set MMT-391	
6 mm teflon cannula; straight insertion; 60 cm tubing $ imes$ 10				
with 10 needles	130.00	1 OP	 Paradigm Quick-Set MMT-399 	
6 mm teflon cannula; straight insertion; 60 cm tubing $ imes$ 10				
with 10 needles; luer lock		1 OP	Quick-Set MMT-393	
6 mm teflon cannula; straight insertion; 80 cm tubing \times 10				
with 10 needles	130.00	1 OP	 Paradigm Quick-Set MMT-387 	
9 mm teflon cannula; straight insertion; 106 cm tubing $ imes$ 10			101001-387	
with 10 needles		1 OP	Paradigm Quick-Set	
		1.01	MMT-396	
9 mm teflon cannula; straight insertion; 110 cm tubing $ imes$ 10				
with 10 needles; luer lock		1 OP	Quick-Set MMT-390	
9 mm teflon cannula; straight insertion; 60 cm tubing $ imes$ 10				
with 10 needles	130.00	1 OP	Paradigm Quick-Set	
			MMT-397	
9 mm teflon cannula; straight insertion; 60 cm tubing \times 10		4.05		
with 10 needles; luer lock		1 OP	Quick-Set MMT-392	
9 mm teflon cannula; straight insertion; 80 cm tubing \times 10 with 10 needles		1 OP	 Paradigm Quick-Set MMT-386 	
INSULIN PUMP RESERVOIR - Special Authority see SA1240 o	n nago 22 Pot	ail pharmaou		
a) Maximum of 3 sets per prescription	n page 32 – nei	ali phannacy		
b) Only on a prescription				
 c) Maximum of 13 packs of reservoir sets will be funded per y 	vear.			
$10 \times$ luer lock conversion cartridges 1.8 ml for Paradigm				
pumps		1 OP	ADR Cartridge 1.8	
10 \times luer lock conversion cartridges 3.0 ml for Paradigm				
pumps		1 OP	✓ ADR Cartridge 3.0	
Cartridge 200 U, luer lock × 10		1 OP	Animas Cartridge	
Cartridge for 5 and 7 series pump; 1.8 ml \times 10		1 OP	 Paradigm 1.8 Reservoir 	
Cartridge for 7 series pump; 3.0 ml \times 10		1 OP	 Paradigm 3.0 Reservoir 	
Syringe and cartridge for 50X pump, 3.0 ml $ imes$ 10		1 OP	✓ 50X 3.0 Reservoir	
		-		

36

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Digestives Including Enzymes				
PANCREATIC ENZYME Cap EC 10,000 BP u lipase, 9,000 BP u amylase and				
210 BP u protease Cap EC 25,000 BP u lipase, 18,000 BP u amylase,		100	✔ C	reon 10000
1,000 BP u protease Cap EC 25,000 BP u lipase, 22,500 BP u amylase,	94.38	100	✔ C	reon 25000
1,250 BP u protease	94.40	100	🖌 P	anzytrat
URSODEOXYCHOLIC ACID – Special Authority see SA1383 belo Cap 250 mg – For ursodeoxycholic acid oral liquid formula-				
tion refer, page 209 Ursosan to be Sole Supply on 1 October 2014		100	V U	rsosan

SA1383 Special Authority for Subsidy

Initial application — (Alagille syndrome or progressive familial intrahepatic cholestasis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Initial application — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Initial application — (Cirrhosis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 umol/l; decompensated cirrhosis).

Initial application — (Pregnancy) from any relevant practitioner. Approvals valid for 6 months where the patient diagnosed with cholestasis of pregnancy.

Initial application — (Haematological Transplant) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Initial application — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by Total Parenteral Nutrition (TPN); and
- 2 Liver function has not improved with modifying the TPN composition.

continued...

Subsidy (Manufacturer's Price)	Subs	Fully sidised	Brand or Generic
\$	Per	~	Manufacturer

continued...

Renewal — (Chronic severe drug induced cholestatic liver injury) from any relevant practitioner. Approvals valid for 6 months where the patient continues to benefit from treatment.

Renewal — (Pregnancy/Cirrhosis) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Total parenteral nutrition induced cholestasis) from any relevant practitioner. Approvals valid for 6 months where the paediatric patient continues to require TPN and who is benefiting from treatment, defined as a sustained improvement in bilirubin levels.

Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 100 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

Laxatives

Bulk-forming Agents

ISPAGHULA (PSYLLIUM) HUSK – Only on a prescription * Powder for oral soln	5.51	500 g OP	✓ Konsyl-D	
MUCILAGINOUS LAXATIVES WITH STIMULANTS		•		
* Dry	2.41	200 g OP		
	(8.72)	•	Normacol Plus	
	6.02	500 g OP		
	(17.32)	-	Normacol Plus	

Faecal Softeners

DOCUSATE SODIUM - Only on a prescription * Cap 50 mg 2.57 * Cap 120 mg 3.48 * Enema conc 18% 5.40 DOCUSATE SODIUM WITH SENNOSIDES 5.40 DOCUSATE SODIUM WITH SENNOSIDES 6.38 POLOXAMER - Only on a prescription Not funded for use in the ear. 6.37 * Oral drops 10% 3.78 Coloxyl to be Sole Supply on 1 October 2014 3.78	100 100 100 ml OP 200 30 ml OP	 ✓ Laxofast 50 ✓ Laxofast 120 ✓ Coloxyl ✓ Laxsol ✓ Coloxyl
Osmotic Laxatives		
GLYCEROL * Suppos 3.6 g – Only on a prescription	20 500 ml	 ✓ <u>PSM</u> ✓ <u>Laevolac</u>
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE A SA0891 on the next page – Retail pharmacy Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chlo- ride 350.7 mg – Maximum of 60 sach per prescription7.65	AND SODIUM CH 30	ILORIDE – Special Authority see

	Subsidy		Fully Brand or
	(Manufacturer's Pr \$	rice) Su Per	bsidised Generic Manufacturer
	ð	Fei	
►SA0891 Special Authority for Subsidy Initial application from any relevant practitioner. A requiring intervention with a per rectal preparation do where lactulose is not contraindicated. Renewal from any relevant practitioner. Approvals of	espite an adequate trial of ot	her oral pha	rmacotherapies including lactulose
benefit from treatment.	n		
SODIUM ACID PHOSPHATE – Only on a prescriptio Enema 16% with sodium phosphate 8%		1	 Fleet Phosphate Enema
SODIUM CITRATE WITH SODIUM LAURYL SULPHO	DACETATE – Only on a preso	cription	
Enema 90 mg with sodium lauryl sulphoacetate 9 5 ml) mg per ml,	50	✓ Micolette
Stimulant Laxatives		00	
Sumulant Laxauves			
BISACODYL – Only on a prescription * Tab 5 mg * Suppos 5 mg * Suppos 10 mg	3.00	200 6 6	✓ Lax-Tab ✓ Dulcolax ✓ Dulcolax
 DANTHRON WITH POLOXAMER – Only on a presc Note: Only for the prevention or treatment of cons Oral liq 25 mg with poloxamer 200 mg per 5 ml Oral liq 75 mg with poloxamer 1 g per 5 ml (Pinorax Oral liq 25 mg with poloxamer 200 mg per 5 (Pinorax Forte Oral liq 75 mg with poloxamer 1 g per 	tipation in the terminally ill. 21.30 43.60 ml to be delisted 1 January 2	,	 Pinorax Pinorax Forte
SENNA – Only on a prescription * Tab, standardised	0.43 (1.72) 2.17	20 100	Senokot
	(6.16)	100	Senokot
Metabolic Disorder Agents			
Gaucher's Disease			
IMIGLUCERASE – Special Authority see SA0473 be Inj 40 iu per ml, 200 iu vial Inj 40 iu per ml, 400 iu vial ⇒SA0473 Special Authority for Subsidy	1,072.00	1 1	 ✔ Cerezyme ✔ Cerezyme
Special Authority approved by the Gaucher's Treatme Notes: Subject to a budgetary cap. Applications will b Application details may be obtained from PHARMAC' The Co-ordinator, Gaucher's Treatment Panel P PHARMAC, PO Box 10 254	e considered and approved s	c.govt.nz or:	ding availability.

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or sidised Generic ✔ Manufacturer
Mouth and Throat			
Agents Used in Mouth Ulceration			
BENZYDAMINE HYDROCHLORIDE			
Soln 0.15%		200 ml	
	(8.50)	500 ml	Difflam
	9.00 (17.01)	500 ml	Difflam
	(17.01)		Dimani
			4 .
Mouthwash 0.2%		200 ml OP	healthE
CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE			
₭ Adhesive gel 8.7% with cetalkonium chloride 0.01%		15 g OP	
	(5.62)		Bonjela
ODIUM CARBOXYMETHYLCELLULOSE			
With pectin and gelatin paste		56 g OP	 Stomahesive
	1.52	5 g OP	
	(3.60)	45 00	Orabase
	4.55	15 g OP	Orahaaa
With pectin and gelatin powder	(7.90)	28 g OP	Orabase
	(10.95)	20 y OF	Stomahesive
	(10.00)		Otomanesive
RIAMCINOLONE ACETONIDE 0.1% in Dental Paste USP	4.24	5 g OP	✓ Oracort
	4.04	5 y OF	
Oropharyngeal Anti-infectives			
MPHOTERICIN B			
Lozenges 10 mg	5.86	20	🗸 Fungilin
/ICONAZOLE			
Oral gel 20 mg per g	4.95	40 g OP	✓ <u>Decozol</u>
IYSTATIN			
Oral lig 100,000 u per ml	3.19	24 ml OP	✓ Nilstat
Other Oral Agents			
or folinic mouthwash, pilocarpine oral liquid or saliva substitute	formula refer Cto	ndard Earmula	n nago 212
		nualu Funnula	e, paye 212
IYDROGEN PEROXIDE	1.00	100 ml	
Soln 10 vol – Maximum of 200 ml per prescription	1.28	100 ml	✔ PSM
HYMOL GLYCERIN			4
Compound, BPC	9.15	500 ml	✓ PSM

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subs	idised	Generic	
\$	Per	~	Manufacturer	

Vitamins

Alpha tocopheryl acetate is available fully subsidised for specific patients at the Medical Director of PHARMAC's discretion. Refer to PHARMAC website www.pharmac.govt.nz for the "Alpha tocopheryl acetate information sheet and application form".

Vitamin A

VITAMIN A WITH VITAMINS D AND C * Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops4.50	10 ml OP	✔ Vitadol C
Vitamin B	10 111 01	
HYDROXOCOBALAMIN * Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO5.10	3	✓ <u>ABM</u> Hydroxocobalamin
PYRIDOXINE HYDROCHLORIDE a) No more than 100 mg per dose b) Only on a prescription		
* Tab 25 mg - No patient co-payment payable	90	PyridoxADE
* Tab 50 mg11.55	500	Apo-Pyridoxine
THIAMINE HYDROCHLORIDE – Only on a prescription		
* Tab 50 mg5.62	100	Apo-Thiamine
VITAMIN B COMPLEX		
* Tab, strong, BPC4.30	500	✓ Bplex
Vitamin C		
ASCORBIC ACID a) No more than 100 mg per dose b) Only on a prescription * Tab 100 mg	500	✓ <u>Cvite</u>
Vitamin D		
ALFACALCIDOL		
* Cap 0.25 mcg	100	One-Alpha
* Cap 1 mcg	100	One-Alpha
* Oral drops 2 mcg per ml60.68	20 ml OP	One-Alpha
CALCITRIOL		
* Cap 0.25 mcg	30	✓ Airflow
10.10	100	Calcitriol-AFT
* Cap 0.5 mcg	30	✓ Airflow
18.73	100	 Calcitriol-AFT
CHOLECALCIFEROL	10	4 A L L F L
* Tab 1.25 mg (50,000 iu) – Maximum of 12 tab per prescription7.76	12	 Cal-d-Forte
Multivitamin Preparations		
MULTIVITAMINS – Special Authority see SA1036 on the next page – Retail phan * Powder	rmacy 200 g OP	✓ Paediatric Seravit

	Subsidy (Manufacturer's Price \$) Sut Per	Fully osidised	Brand or Generic Manufacturer
►SA1036 Special Authority for Subsidy	id without further re	nowel unl	no notif	ind where the potient be
nitial application from any relevant practitioner. Approvals val nborn errors of metabolism.		newai unit	55 11001	ieu where the patient na
Renewal from any relevant practitioner. Approvals valid without f	further renewal unle	ss notified	where p	patient has had a previou
approval for multivitamins.				
/ITAMINS				
Tab (BPC cap strength)		1,000	✓ <u>M</u>	vite
Cap (fat soluble vitamins A, D, E, K) – Special Authority see				
SA1002 below – Retail pharmacy	23.40	60	V	itabdeck
SA1002 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals valid he following criteria: Either:		ewal unles	s notifie	d for applications meetir
 Patient has cystic fibrosis with pancreatic insufficiency; o Patient is an infant or child with liver disease or short gut 				
Minerals				
Calcium				
CALCIUM CARBONATE				
* Tab eff 1.75 g (1 g elemental)	6.21	30	🖌 C	alsource
* Tab 1.25 g (500 mg elemental)	5.38	250	🗸 A	rrow-Calcium
Arrow-Calcium to be Sole Supply on 1 October 2014				
	01.40	10	1 1	
k Inj 10%, 10 ml	21.40	10	VI	ospira
Fluoride				
SODIUM FLUORIDE				
K Tab 1.1 mg (0.5 mg elemental)	5.00	100	🗸 P	SM
lodine				
POTASSIUM IODATE				
 Tab 256 mcg (150 mcg elemental iodine) 	6.28	90	🖌 N	euroKare
Iron				
ERROUS FUMARATE				
K Tab 200 mg (65 mg elemental)	4.35	100	V Fe	erro-tab
ERROUS FUMARATE WITH FOLIC ACID				
 Tab 310 mg (100 mg elemental) with folic acid 350 mcg 	4.75	60	V Fo	erro-F-Tabs
ERROUS SULPHATE	0.00			
Tab long-acting 325 mg (105 mg elemental) the organization of the second sec		30 500 ml		errograd erodan
k‡ Oral liq 30 mg (6 mg elemental) per 1 ml	10.20	500 III	✓ <u>r</u>	
ERROUS SULPHATE WITH FOLIC ACID				
Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg		30		
		~~		

	Subsidy (Manufacturer's Price) \$	S Per	Fully ubsidised	Brand or Generic Manufacturer
IRON POLYMALTOSE * Inj 50 mg per ml, 2 ml ampoule Ferrum H to be Sole Supply on 1 October 2014	15.22	5	🖌 Fo	errum H
Magnesium				
For magnesium hydroxide mixture refer Standard Formulae, page MAGNESIUM SULPHATE * Inj 2 mmol per ml, 5 ml ampoule		10	✓ D ✓ M	BL artindale
Zinc				
ZINC SULPHATE * Cap 137.4 mg (50 mg elemental)	11.00	100	🗸 Z	incaps

Subsidy		Fully	Brand or
(Manufacturer's Price)	Su	bsidised	Generic
\$	Per	~	Manufacturer

Antianaemics

Hypoplastic and Haemolytic

SA1469 Special Authority for Subsidy

Initial application — (chronic renal failure) from any specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin ≤ 100g/L; and
- 3 Any of the following:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate \leq 30ml/min; or
 - 3.2 Both:
 - 3.2.1 Patient has diabetes mellitus; and
 - 3.2.2 Glomerular filtration rate \leq 45ml/min; or
 - 3.3 Patient is on haemodialysis or peritoneal dialysis.

Note: Erythropoietin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

Initial application — (myelodysplasia) from any specialist. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS)*; and
- 2 Has had symptomatic anaemia with haemoglobin <100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum erythropoietin level of <500 IU/mL; and
- 6 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an Unapproved Indication

Renewal — (chronic renal failure) from any specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Erythropoietin alfa is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

Renewal — (myelodysplasia) from any specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Note: Indication marked with * is an Unapproved Indication

			-	
	Subsidy (Manufacturer's Price \$	e) Sub Per	Fully sidised	Brand or Generic Manufacturer
ERYTHROPOIETIN ALFA – Special Authority see SA1469 on th	e previous page – R	letail pharm	acy	
Wastage claimable – see rule 3.3.2 on page 17				
Inj 1,000 iu in 0.5 ml, syringe		6	🖌 E	prex
Inj 2,000 iu in 0.5 ml, syringe		6	🖌 E	prex
Inj 3,000 iu in 0.3 ml, syringe		6	🖌 E	prex
Inj 4,000 iu in 0.4 ml, syringe		6	🖌 E	prex
Inj 5,000 iu in 0.5 ml, syringe		6	🖌 E	prex
Inj 6,000 iu in 0.6 ml, syringe		6	🖌 E	prex
Inj 10,000 iu in 1 ml, syringe		6	🖌 E	prex
ERYTHROPOIETIN BETA – Special Authority see SA1469 on th Wastage claimable – see rule 3.3.2 on page 17 Inj 2,000 iu, prefilled syringe Inj 3,000 iu, prefilled syringe Inj 4,000 iu, prefilled syringe Inj 5,000 iu, prefilled syringe Inj 6,000 iu, prefilled syringe Inj 10,000 iu, prefilled syringe Inj 10,000 iu, prefilled syringe		Retail pharm 6 6 6 6 6 6		eoRecormon eoRecormon eoRecormon eoRecormon eoRecormon eoRecormon
FOLIC ACID				
* Tab 0.8 mg		1,000	🗸 A	po-Folic Acid
* Tab 5 mg		500	🖌 A	po-Folic Acid
Oral liq 50 mcg per ml		25 ml OP	🖌 В	iomed
Antifibrinolytics, Haemostatics and Local Sclere	osants			
ELTROMBOPAG – Special Authority see SA1418 below – Retail Wastage claimable – see rule 3.3.2 on page 17	pharmacy			
Tab 25 mg	1,771.00	28	🖌 R	evolade
Tab 50 mg	3,542.00	28	🖌 R	evolade

➡SA1418 Special Authority for Subsidy

Initial application — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 6 weeks for applications meeting the following criteria:

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Any of the following:
 - 3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
 - 3.2 Patient has a platelet count of ≤ 20,000 platelets per microlitre and has evidence of active bleeding; or
 - 3.3 Patient has a platelet count of \leq 10,000 platelets per microlitre.

Initial application — (idiopathic thrombocytopenic purpura - preparation for splenectomy) only from a haematologist. Approvals valid for 6 weeks where the patient requires eltrombopag treatment as preparation for splenectomy.

Renewal — (idiopathic thrombocytopenic purpura - post-splenectomy) only from a haematologist. Approvals valid for 12 months where the patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of >30,000 platelets per microlitre.

BLOOD AND BLOOD FORMING ORGANS

	Subsidy		Fully Brand or
	(Manufacturer's Price) \$	Si Per	ubsidised Generic Manufacturer
EPTACOG ALFA [RECOMBINANT FACTOR VIIA] – [Xpharn	n]		
For patients with haemophilia, whose treatment is manag Haemophilia Management Group.		eaters Gr	roup in conjunction with the Nationa
Inj 1 mg syringe	1 163 75	1	NovoSeven RT
Inj 2 mg syringe		1	✓ Novoseven RT
Inj 5 mg syringe		1	✓ Novoseven RT
Inj 8 mg syringe		1	✓ Novoseven RT
FACTOR EIGHT INHIBITORS BYPASSING AGENT - [Xpha	rml		
For patients with haemophilia, whose treatment is manag		eaters Gi	roup in conjunction with the Nationa
Haemophilia Management Group.	4 0 4 0 0 0		
Inj 500 U		1	✓ FEIBA
Inj 1,000 U		1	🖌 FEIBA
MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – [Xp	pharm]		
For patients with haemophilia, whose treatment is manage Haemophilia Management Group.	ed by the Haemophilia Tre	eaters Gi	roup in conjunction with the Nationa
Inj 250 iu vial	225.00	1	🖌 Xyntha
Ini 500 iu vial		1	✓ Xyntha
Inj 1,000 iu vial		1	✓ Xyntha
,		1	
Inj 2,000 iu vial		1	✓ Xyntha
Inj 3,000 iu vial		I	 Xyntha
NONACOG ALFA [RECOMBINANT FACTOR IX] – [Xpharm] For patients with haemophilia, whose treatment is manag		eaters Gi	roup in conjunction with the Nationa
Haemophilia Management Group.	co by the Hacmophina h		
Inj 250 iu vial	310.00	1	✓ BeneFIX
Inj 500 iu vial		1	✓ BeneFIX
Inj 1.000 iu vial		1	✓ BeneFIX
Inj 2,000 iu vial	,	1	✓ BeneFIX
OCTOCOG ALFA [RECOMBINANT FACTOR VIII] - [Xpharm	nl		
For patients with haemophilia, whose treatment is manage		eaters Gi	roup in conjunction with the Nationa
Haemophilia Management Group.			
Inj 250 iu vial	237.50	1	Advate
·· , · -	250.00		✓ Kogenate FS
Ini 500 iu vial		1	✓ Advate
	500.00	•	✓ Kogenate FS
Inj 1.000 iu vial		1	✓ Advate
		•	
			Kogenate FS
	1,000.00	1	✓ Kogenate FS
Inj 1,500 iu vial	1,000.00 1,425.00	1	Advate
	1,000.00 1,425.00 1,900.00	1 1	 Advate Advate
Inj 1,500 iu vial Inj 2,000 iu vial	1,000.00 1,425.00 1,900.00 2,000.00	1	 ✓ Advate ✓ Advate ✓ Kogenate FS
Inj 1,500 iu vial	1,000.00 1,425.00 1,900.00 2,000.00 2,850.00		 ✓ Advate ✓ Advate ✓ Kogenate FS ✓ Advate
Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial	1,000.00 1,425.00 1,900.00 2,000.00	1	 ✓ Advate ✓ Advate ✓ Kogenate FS
Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial SODIUM TETRADECYL SULPHATE	1,000.00 1,425.00 2,000.00 2,850.00 3,000.00	1	 ✓ Advate ✓ Advate ✓ Kogenate FS ✓ Advate
Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial	1,000.00 1,425.00 2,000.00 2,850.00 3,000.00	1	 Advate Advate Kogenate FS Advate Kogenate FS
Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial SODIUM TETRADECYL SULPHATE	1,000.00 1,425.00 2,000.00 2,850.00 3,000.00	1	 ✓ Advate ✓ Advate ✓ Kogenate FS ✓ Advate
Inj 1,500 iu vial Inj 2,000 iu vial Inj 3,000 iu vial SODIUM TETRADECYL SULPHATE	1,000.00 1,425.00 2,000.00 2,850.00 3,000.00	1	 Advate Advate Kogenate FS Advate Kogenate FS

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Vitamin K				
PHYTOMENADIONE Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO		5 5	• •	Conakion MM Conakion MM
Antithrombotic Agents Antiplatelet Agents				
ASPIRIN * Tab 100 mg CLOPIDOGREL		990	✓ <u>■</u>	thics Aspirin EC
 * Tab 75 mg – For clopidogrel oral liquid formulation refer, page 209 DIPYRIDAMOLE 		84	✓ <u>A</u>	rrow - Clopid
 * Tab 25 mg – For dipyridamole oral liquid formulation refer, page 209 * Tab long-acting 150 mg 	8.36	84 60	• •	ersantin lytazen SR
PRASUGREL – Special Authority see SA1201 below – Retail pha Tab 5 mg Tab 10 mg ■•SA1201 Special Authority for Subsidy	108.00	28 28		ffient ffient

Initial application — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months

where the patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic*.

Initial application — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where the patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Initial application — (stent thromobosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Renewal — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty or had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Renewal — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergio*.

Note: * Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

TICAGRELOR – Special Authority see SA1382 below – Retail pharmacy

* Tab 90 mg90.00 56 V Brilinta

SA1382 Special Authority for Subsidy

Initial application — (acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and
- 2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

Renewal — (subsequent acute coronary syndrome) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both:

1 Patient has recently been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome; and

2 Fibrinolytic therapy has not been given in the last 24 hours and is not planned.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
Heparin and Antagonist Preparations				
DALTEPARIN SODIUM – Special Authority see SA1270 below –	Retail pharmacy			
Inj 2,500 iu per 0.2 ml prefilled syringe		10	~	Fragmin
Inj 5,000 iu per 0.2 ml prefilled syringe		10	~	Fragmin
Inj 7,500 iu per 0.75 ml graduated syringe	60.03	10	~	Fragmin
Inj 10,000 iu per 1 ml graduated syringe	77.55	10	~	Fragmin
Inj 12,500 iu per 0.5 ml prefilled syringe		10	~	Fragmin
Inj 15,000 iu per 0.6 ml prefilled syringe		10	~	Fragmin
Inj 18,000 iu per 0.72 ml prefilled syringe	158.47	10	~	Fragmin

SA1270 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, Acute Coronary Syndrome, cardioversion, or prior to oral anti-coagulation).

ENOXAPARIN SODIUM – Special Authority see SA1174 on the next page – Retail pharmacy

Inj 20 mg	 10	Clexane
Inj 40 mg	 10	Clexane
Inj 60 mg	10	Clexane
Inj 80 mg	 10	Clexane
Inj 100 mg	 10	Clexane
Inj 120 mg	 10	Clexane
Inj 150 mg	10	 Clexane

(Mar	Subsidy nufacturer's Price)	F Subsidi	ully	Brand or Generic	
	\$	Per	~	Manufacturer	

SA1174 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

- Any of the following:
 - 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment; or
 - 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
 - 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
 - 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
 - 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

10	 Hospira
50	✓ Hospira
10	✓ Pfizer
50	✓ Pfizer
1	✓ Hospira
5	✓ Hospira
50	✓ Pfizer
5	✓ Hospira
	·
50	Dinar
50	Pfizer
10	
	Artex \$29
60	🖌 Pradaxa
	✓ Pradaxa
••	✓ Pradaxa
00	• I Iudunu
15	✓ Xarelto
	50 10 50 1 5 50 5 50 10 60 60 60

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

SA1066 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 weeks for applications meeting the following criteria: Either:

- 1 For the prophylaxis of venous thromboembolism following a total hip replacement; or
- 2 For the prophylaxis of venous thromboembolism following a total knee replacement.

Note: Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.

Renewal from any relevant practitioner. Approvals valid for 5 weeks where prophylaxis for venous thromboembolism is required for patients following a subsequent total hip or knee replacement.

WARFARIN SODIUM

Note: Marevan and Coumadin are not interchangeable.

*	Tab 1 mg	50	Coumadin
	6.86	100	Marevan
*	Tab 2 mg4.31	50	Coumadin
*	Tab 3 mg9.70	100	Marevan
*	Tab 5 mg5.93	50	Coumadin
	11.75	100	Marevan

Blood Colony-stimulating Factors

FILGRASTIM – Special Authority see SA1259 below – Retail pha	armacy		
Inj 300 mcg per 0.5 ml prefilled syringe		5	Zarzio
Inj 480 mcg per 0.5 ml prefilled syringe		5	 Zarzio

➡SA1259 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk \geq 20%*); or
- 2 Peripheral blood stem cell mobilisation in patients undergoing haematological transplantation; or
- 3 Peripheral blood stem cell mobilisation or bone marrow donation from healthy donors for transplantation; or
- 4 Treatment of severe chronic neutropenia (ANC < 0.5×10^9 /L); or
- 5 Treatment of drug-induced prolonged neutropenia (ANC < 0.5×10^{9} /L).

Note: *Febrile neutropenia risk $\geq 20\%$ after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

PEGFILGRASTIM - Special Authority see SA1384 below - Retail pharmacy

Inj 6 mg per 0.6 ml syringe 1,080.00 1 🖌 Veulastim

SA1384 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where used for prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk $\geq 20\%^*$).

Note: *Febrile neutropenia risk \geq 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
Fluids and Electrolytes				
Intravenous Administration				
GLUCOSE [DEXTROSE]				
 Inj 50%, 10 ml ampoule – Up to 5 inj available on a PSO Inj 50%, 90 ml bottle – Up to 5 inj available on a PSO 		5 1		Biomed Biomed
POTASSIUM CHLORIDE * Inj 75 mg per ml, 10 ml		50	🗸 A	straZeneca
SODIUM BICARBONATE				
Inj 8.4%, 50 ml a) Up to 5 inj available on a PSO b) Not in combination	19.95	1	✔ B	liomed
a) Up to 5 inj available on a PSO b) Not in combination	20.50	1	✔ B	liomed
SODIUM CHLORIDE				
Not funded for use as a nasal drop. Only funded for nebulise use.	r use when in conjur	nction wi	th an antib	viotic intended for nebuliser
Inf 0.9% – Up to 2000 ml available on a PSO		500 ml 1,000 ml	· · · -	laxter Baxter
Only if prescribed on a prescription for renal dialysis, ma for emergency use. (500 ml and 1,000 ml packs)	ternity or post-natal	care in t	he home c	of the patient, or on a PSO
Inj 23.4%, 20 ml For Sodium chloride oral liquid formulation refer Standard		5	✔ 🛛	liomed
Inj 0.9%, 5 ml – Up to 5 inj available on a PSO		50		lultichem
Inj 0.9%, 10 ml – Up to 5 inj available on a PSO	15.50 11.50	50		fizer Iultichem
Inj 0.9%, 20 ml	15.50	c		fizer
IIIJ 0.9%, 20 IIII	4.72 11.79	6 30		harmacia harmacia
	8.41	20	🗸 N	lultichem
TOTAL PARENTERAL NUTRITION (TPN) – Retail pharmacy-Sp Infusion		1 OP	√ T	PN
WATER				
 On a prescription or Practitioner's Supply Order only wh Schedule requiring a solvent or diluent; or On a bulk supply order; or 		n as an	injection lis	sted in the Pharmaceutical
 When used in the extemporaneous compounding of eye Purified for inj, 5 ml – Up to 5 inj available on a PSO 	•	50		lultichem
Purified for inj, 30 ml – Up to 5 inj available on a PSO Purified for inj, 10 ml – Up to 5 inj available on a PSO Purified for inj, 20 ml – Up to 5 inj available on a PSO	11.25	50 50 20	V N	lultichem Iultichem
Oral Administration		20	÷ N	
CALCIUM POLYSTYRENE SULPHONATE				
Powder		800 g OF	· • •	alcium Resonium
COMPOUND ELECTROLYTES Powder for oral soln – Up to 10 sach available on a PSO	1.80	10	✓ <u>E</u>	nerlyte

	Subsidy (Manufacturer's F \$	Price) Subs Per	Fully sidised	Brand or Generic Manufacturer
DEXTROSE WITH ELECTROLYTES				
Soln with electrolytes	6.55	1,000 ml OP		edialyte - Bubblegum
PHOSPHORUS				
Tab eff 500 mg (16 mmol)	82.50	100	🖌 Pl	hosphate-Sandoz
POTASSIUM CHLORIDE				
* Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)	5.26	60		
	(11.85)		С	hlorvescent
* Tab long-acting 600 mg	7.42	200	🗸 S	pan-K
SODIUM BICARBONATE				
Cap 840 mg		100	🗸 S	odibic
SODIUM POLYSTYRENE SULPHONATE				
Powder	89.10	450 g OP	V B	esonium-A

	Subsidy		Full	v Brand or
	(Manufacturer's Pric	,	Subsidise	d Generic
	\$	Per	~	Manufacturer
Alpha Adrenoceptor Blockers				
DOXAZOSIN				
* Tab 2 mg	6.75	500	~	Apo-Doxazosin
Apo-Doxazosin to be Sole Supply on 1 October 2014				•
* Tab 4 mg	9.67	500	~	Apo-Doxazosin
Apo-Doxazosin to be Sole Supply on 1 October 2014				
PHENOXYBENZAMINE HYDROCHLORIDE				
* Cap 10 mg	65.00	30	~	Dibenyline S29
	26.05	100	~	Dibenyline S29
	65.00	30	~	BNM S29
(Dibenyline S29 Cap 10 mg to be delisted 1 November 2014)				
PRAZOSIN				
* Tab 1 mg	5.53	100	V	Apo-Prazo
				Apo-Prazosin
* Tab 2 mg	7.00	100	~	Apo-Prazo
			~	Apo-Prazosin
* Tab 5 mg	11.70	100	~	Apo-Prazo
			~	Apo-Prazosin
TERAZOSIN				
* Tab 1 mg	0.50	28	~	Arrow
* Tab 2 mg	0.45	28	~	Arrow
* Tab 5 mg	0.68	28	~	Arrow
Agents Affecting the Renin-Angiotensin System	n			
ACE Inhibitors				
CAPTOPRIL				
*‡ Oral liq 5 mg per ml		95 ml OF	· ·	Capoten
Oral liquid restricted to children under 12 years of age.			-	
CILAZAPRIL				
* Tab 0.5 mg		90	~	Zapril
* Tab 2.5 mg		90		Zapril
* Tab 5 mg		90	~	Zapril
ENALAPRIL MALEATE				
* Tab 5 mg	1.19	100	~	Ethics Enalapril
* Tab 10 mg		100		Ethics Enalapril
* Tab 20 mg - For enalapril maleate oral liquid formulation re	-			
fer, page 209		100	~	Ethics Enalapril
LISINOPRIL				
* Tab 5 mg	3.58	90	~	Arrow-Lisinopril
* Tab 10 mg		90		Arrow-Lisinopril
* Tab 20 mg		90		Arrow-Lisinopril
PERINDOPRIL				-
* Tab 2 mg	3.75	30	~	Apo-Perindopril
	(18.50)		-	Coversyl
* Tab 4 mg		30	~	Apo-Perindopril
	(25.00)			Coversyl

	Subsidy (Manufacturer's Price) \$		Fully Subsidised	Brand or Generic Manufacturer
QUINAPRIL				
* Tab 5 mg	3.44	90	🖌 <u>A</u>	rrow-Quinapril 5
* Tab 10 mg	4.64	90	🗸 🗸	rrow-Quinapril 10
* Tab 20 mg	6.34	90	✓ A	rrow-Quinapril 20

TRANDOLAPRIL

Higher subsidy by endorsement is available for patients who were taking trandolapril for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". For the purposes of this endorsement, congestive heart failure includes patients post myocardial infarction with an ejection fraction of less than 40%. Patients who started on trandolapril after 1 June 1998 are not eligible for full subsidy by endorsement.

* Cap 1 mg – Higher subsidy of \$18.67 per 28 cap with En- dorsement	3.06	28	
	(18.67)		Gopten
* Cap 2 mg - Higher subsidy of \$27.00 per 28 cap with En-			
dorsement	4.43	28	
	(27.00)		Gopten
ACE Inhibitors with Diuretics			
CILAZAPRIL WITH HYDROCHLOROTHIAZIDE			
* Tab 5 mg with hydrochlorothiazide 12.5 mg	10.72	100	✔ Apo-
			Cilazapril/Hydrochlorothiazide
ENALAPRIL MALEATE WITH HYDROCHLOROTHIAZIDE			
* Tab 20 mg with hydrochlorothiazide 12.5 mg	3.32	30	
	(8.70)		Co-Renitec

QUINAPRIL WITH HYDROCHLOROTHIAZIDE		
* Tab 10 mg with hydrochlorothiazide 12.5 mg	30	Accuretic 10
* Tab 20 mg with hydrochlorothiazide 12.5 mg4.57	30	✓ <u>Accuretic 20</u>

Angiotensin II Antagonists

CA	NDESARTAN CILEXETIL – Special Authority see SA1223 below –	Retail pharma	су	
*	Tab 4 mg	4.13	90	✓ Candestar
*	Tab 8 mg	6.10	90	Candestar
*	Tab 16 mg	10.18	90	Candestar
*	Tab 32 mg	17.66	90	✓ Candestar

► SA1223 Special Authority for Subsidy

Initial application — (ACE inhibitor intolerance) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

- - 1 Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor); ٥r
 - 2 Patient has a history of angioedema.

Initial application - (Unsatisfactory response to ACE inhibitor) from any relevant practitioner. Approvals valid without further renewal unless notified where patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.

LOSARTAN POTASSIUM

*	Tab 12.5 mg2.88	90	Lostaar
*	Tab 25 mg	90	Lostaar
*	Tab 50 mg5.22	90	Lostaar
	Tab 100 mg8.68	90	 Lostaar

	Subsidy (Manufacturer's P \$	rice) Su Per	ibsidised G	rand or eneric anufacturer
Angiotensin II Antagonists with Diuretics	پ 			
OSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE				
Tab 50 mg with hydrochlorothiazide 12.5 mg	2.18	30		w-Losartan & drochlorothiazic
Antiarrhythmics				
or lignocaine hydrochloride refer to NERVOUS SYSTEM, Ar MIODARONE HYDROCHLORIDE	naesthetics, Local, pa	ge 129		
Tab 100 mg – Retail pharmacy-Specialist		30	✓ Arata	ac Iarone-X
Tab 200 mg - Retail pharmacy-Specialist		30	 Arata 	
Inj 50 mg per ml, 3 ml ampoule – Up to 6 inj available PSO		6		arone-X
TROPINE SULPHATE		0	• <u>corc</u>	aione-A
 Inj 600 mcg per ml, 1 ml ampoule – Up to 5 inj available PSO 		50	✓ <u>Astra</u>	Zeneca
IGOXIN	0.07	040		win DO
Tab 62.5 mcg – Up to 30 tab available on a PSO		240	Lance	
Tab 250 mcg – Up to 30 tab available on a PSO ‡ Oral liq 50 mcg per ml		240 60 ml	 Lance Lance 	
SOPYRAMIDE PHOSPHATE				
Cap 100 mg	15.00	100		
	(23.87)		Ryth	modan
Cap 150 mg		100	🖌 Ryth	modan
ECAINIDE ACETATE – Retail pharmacy-Specialist				
Tab 50 mg		60	🖌 Taml	oocor
Tab 100 mg – For flecainide acetate oral liquid formula				
refer, page 209		60	 Taml 	
Cap long-acting 100 mg		30		bocor CR
Cap long-acting 200 mg		30		bocor CR
Inj 10 mg per ml, 15 ml ampoule		5	🗸 Taml	bocor
EXILETINE HYDROCHLORIDE				
Cap 150 mg	65.00	100	•	letine drochloride P S29
Cap 250 mg	102.00	100	•	letine drochloride P S29
ROPAFENONE HYDROCHLORIDE - Retail pharmacy-Sp	ecialist			
Tab 150 mg	40.90	50	🖌 Rytn	nonorm
Antihypotensives				
IDODRINE - Special Authority see SA0934 on the next pa	ge – Retail pharmacv			
Tab 2.5 mg	• • •	100	🖌 Gutr	on
Tab 5 mg		100	🗸 Gutr	

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Sub	bsidised	Generic	
\$	Per	~	Manufacturer	

SA0934 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Disabling orthostatic hypotension not due to drugs; and
- 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and
- 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night.

Notes: Treatment should be started with small doses and titrated upwards as necessary.

Hypertension should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Beta Adrenoceptor Blockers

** Tab 50 mg .5.56 500 ✓ Mylan Atenolol ** Tab 100 mg .9.12 500 ✓ Mylan Atenolol ** Orall ig 25 mg per 5 ml .21.25 300 ml OP ✓ Atenolol AFT Restricted to children under 12 years of age. .3.88 30 ✓ Bosvate BISOPROLOL .3.88 .4.74 30 ✓ Bosvate Tab 5 mg .4.74 .30 ✓ Bosvate Tab 10 mg .9.18 .30 ✓ Bosvate Tab 5 mg .21.00 .4.74 .5.56 .500 ✓ Dilatrend ** Tab 12.5 mg .21.00 .30 ✓ Dilatrend .5.56 .500 ✓ Dilatrend ** Tab 2.5 mg .50 mg .21.00 .30 ✓ Dilatrend .5.56 .500 ✓ Dilatrend ** Tab 2.5 mg .60 mg .33.75 .30 ✓ Dilatrend .5.56 .500 ✓ Dilatrend ** Tab 200 mg .19.00 180 ✓ Celol .4.82 .5.23 .500 .500 .500 .500 .500 .500 .500 .500 .500 .500 .500 .500 .500	ATI	ENOLOL			
** Oral liq 25 mg per 5 ml	*	Tab 50 mg	5.56	500	Mylan Atenolol
Restricted to children under 12 years of age. BISOPROLOL Tab 2.5 mg 3.88 Tab 5 mg 4.74 Tab 10 mg 9.18 CARVEDILOL * Bosvate * Tab 10 mg 30 * Bosvate CARVEDILOL * Tab 6.25 mg 21.00 * Tab 12.5 mg 21.00 30 * Dilatrend * Tab 25 mg 27.00 30 * Dilatrend * Tab 20 mg - For carvedilol oral liquid formulation refer, page 209 33.75 30 * Dilatrend CELIPROLOL * * Tab 200 mg 19.00 180 * Celol LABETALOL * * Tab 50 mg 8.23 100 * Hybloc * Tab 100 mg - For labetalol oral liquid formulation refer, page 209 10.06 100 * Hybloc * Tab 100 mg - For labetalol oral liquid formulation refer, page 10.06 100 * Hybloc * Tab long-acting 23.75 mg 0.96 5 5 100 * Tab long-acting 23.75 mg 0.96 30 * Metoprolol - AFT CR * Tab long-acting 95 mg 2.42 30 * Metoprolol - AFT CR </td <td>*</td> <td>Tab 100 mg</td> <td>9.12</td> <td>500</td> <td>Mylan Atenolol</td>	*	Tab 100 mg	9.12	500	Mylan Atenolol
BISOPROLOL Tab 2.5 mg 3.88 30 ✓ Bosvate Tab 5 mg 4.74 30 ✓ Bosvate Tab 10 mg 9.18 30 ✓ Bosvate CARVEDILOL * Tab 6.25 mg 21.00 30 ✓ Dilatrend * Tab 6.25 mg 21.00 30 ✓ Dilatrend * Tab 2.5 mg 27.00 30 ✓ Dilatrend * Tab 2.5 mg - For carvedilol oral liquid formulation refer, page 209 33.75 30 ✓ Dilatrend * Tab 20 mg 19.00 180 ✓ Celol LABETALOL * Tab 200 mg 19.00 180 ✓ Celol LABETALOL * Tab 200 mg 19.00 180 ✓ Hybloc * Tab 200 mg 10.06 100 ✓ Hybloc * * Tab 200 mg 10.06 5 Trandate METOPROLOL SUCCINATE (88.60) Trandate * Tab long-acting 23.75 mg 0.96 5 * Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR <td>*</td> <td></td> <td>21.25</td> <td>300 ml OP</td> <td>Atenolol AFT</td>	*		21.25	300 ml OP	Atenolol AFT
Tab 2.5 mg 3.88 30 ✓ Bosvate Tab 5 mg 4.74 30 ✓ Bosvate Tab 10 mg 9.18 30 ✓ Bosvate CARVEDILOL * Tab 6.25 mg 21.00 30 ✓ Dilatrend * Tab 12.5 mg 21.00 30 ✓ Dilatrend * Tab 2.5 mg 27.00 30 ✓ Dilatrend * Tab 2.5 mg 27.00 30 ✓ Dilatrend * Tab 2.5 mg 27.00 30 ✓ Dilatrend * Tab 2.5 mg 209 33.75 30 ✓ Dilatrend * Tab 200 mg 19.00 180 ✓ Celoi LABETALOL * Tab 50 mg For labetalol oral liquid formulation refer, page 209 10.06 100 ✓ Hybloc * Tab 100 mg - For labetalol oral liquid formulation refer, page 209 10.06 100 ✓ Hybloc * Tab 200 mg 17.55 100 ✓ Hybloc ✓ Hybloc * * Tab long-acting 47.5 mg 0.96 5 Trandate METOPROLOL SUCCINATE		Restricted to children under 12 years of age.			
Tab 5 mg 4.74 30 ✓ Bosvate Tab 10 mg 9.18 30 ✓ Bosvate CARVEDILOL * Tab 6.25 mg 21.00 30 ✓ Dilatrend * Tab 2.5 mg Point 27.00 30 ✓ Dilatrend * Tab 25 mg For carvedilol oral liquid formulation refer, page 209 33.75 30 ✓ Dilatrend CELIPROLOL * Tab 200 mg 19.00 180 ✓ Celol LABETALOL * Tab 50 mg 8.23 100 ✓ Hybloc * Tab 200 mg For labetalol oral liquid formulation refer, page 209 ✓ Hybloc ✓ Hybloc * Tab 200 mg For labetalol oral liquid formulation refer, page 209 ✓ Hybloc ✓ Hybloc * Tab 200 mg 10.06 100 ✓ Hybloc ✓ Hybloc * Tab 200 mg 11.01 59.06 5 Trandate METOPROLOL SUCCINATE (88.60) Trandate * Tab long-acting 23.75 mg 0.96 30 ✓ Metoprolol - AFT CR * Tab long-acting 95 mg 2.42 30 ✓ Metoprolol - AFT CR * Tab long-acting 190	BIS	OPROLOL			
Tab 10 mg9.1830✓ BosvateCARVEDILOL*Tab 6.25 mg21.0030✓ Dilatrend*Tab 12.5 mg27.0030✓ Dilatrend*Tab 25 mg- For carvedilol oral liquid formulation refer, page20933.7530✓ Dilatrend20920933.7530✓ Dilatrend✓ CelolLABETALOL*Tab 50 mg19.00180✓ CelolLABETALOL*Tab 50 mg10.06100✓ Hybloc*Tab 50 mg17.55100✓ Hybloc*Tab 200 mg17.55100✓ Hybloc*Tab 200 mg17.55100✓ Hybloc*Tab 100 mg - For labetalol oral liquid formulation refer, page 209209✓ Hybloc*Tab 100 mg - For labetalol oral mpoule59.065*Tab long-acting 23.75 mg0.965*Tab long-acting 23.75 mg14.130*Metoprolol - AFT CR**Tab long-acting 95 mg2.4230*Tab long-acting 190 mg4.6630*Tab long-acting 190 mg4.6630*Tab 100 mg- For metoprolol tartrate oral liquid formulation refer, page 20916.00*Tab 100 mg- For metoprolol tartrate oral liquid formulation refer, page 20916.00*Tab 100 mg- For metoprolol tartrate oral liquid formulation refer, page 20916.00*Tab long-acting 200 mg21.00<		Tab 2.5 mg	3.88	30	Bosvate
CARVEDILOL * Tab 6.25 mg 21.00 30 ✓ Dilatrend * Tab 12.5 mg 27.00 30 ✓ Dilatrend * Tab 25 mg - For carvedilol oral liquid formulation refer, page 209 33.75 30 ✓ Dilatrend CELIPROLOL * Tab 200 mg 19.00 180 ✓ Celol LABETALOL * Tab 200 mg 19.00 180 ✓ Celol LABETALOL * Tab 200 mg 10.06 100 ✓ Hybloc * Tab 200 mg 9 10.06 100 ✓ Hybloc * Tab 200 mg 2.07 mg 17.55 100 ✓ Hybloc * Tab long-acting 23.75 mg 0.96 30 ✓ Metoprolol - AFT CR * Tab long-acting 95 mg 2.42 30 ✓ Metoprolol - AFT CR * Tab long-act		Tab 5 mg	4.74	30	Bosvate
** Tab 6.25 mg 21.00 30 ✓ Dilatrend ** Tab 12.5 mg 27.00 30 ✓ Dilatrend ** Tab 25 mg -For carvedilol oral liquid formulation refer, page 33.75 30 ✓ Dilatrend CELIPROLOL ** Tab 200 mg 19.00 180 ✓ Celol LABETALOL ** Tab 50 mg -For labetalol oral liquid formulation refer, page 209 ✓ Hybloc ** Tab 200 mg -For labetalol oral liquid formulation refer, page 209 ✓ Hybloc ✓ ** Tab 200 mg -For labetalol oral liquid formulation refer, page 209 ✓ Hybloc ✓ Hybloc ** Tab 200 mg 10.06 100 ✓ Hybloc ✓ Hybloc ✓ Hybloc ** Tab 200 mg 10.06 100 ✓ Hybloc ✓ Tad 200 mg ✓ Hybloc ✓ Metoprolol - AFT CR ✓ <td></td> <td>Tab 10 mg</td> <td>9.18</td> <td>30</td> <td>Bosvate</td>		Tab 10 mg	9.18	30	Bosvate
** Tab 6.25 mg 21.00 30 ✓ Dilatrend ** Tab 12.5 mg 27.00 30 ✓ Dilatrend ** Tab 25 mg -For carvedilol oral liquid formulation refer, page 33.75 30 ✓ Dilatrend CELIPROLOL ** Tab 200 mg 19.00 180 ✓ Celol LABETALOL ** Tab 50 mg -For labetalol oral liquid formulation refer, page 209 10.06 100 ✓ Hybloc ** Tab 200 mg -For labetalol oral liquid formulation refer, page 209 10.06 100 ✓ Hybloc ** Tab 200 mg -For labetalol oral liquid formulation refer, page 209 10.06 100 ✓ Hybloc ** Tab 200 mg 10.06 100 ✓ Hybloc ✓ Hybloc 14 190 ** Tab 200 mg 20.75 mg 0.96 5 5 Trandate METOPROLOL SUCCINATE (88.60) Trandate ✓ Metoprolol - AFT CR ** Tab long-acting 95 mg 2.42 30 ✓ Metoprolol - AFT CR ** Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR ** Tab 100 mg - For metoprolol tartrate oral liquid formulation refer, page 209 16.00	CA	BVEDILOI			
** Tab 12.5 mg 27.00 30 ✓ Dilatrend ** Tab 25 mg -For carvedilol oral liquid formulation refer, page 33.75 30 ✓ Dilatrend CELIPROLOL ** Tab 200 mg 19.00 180 ✓ Celol LABETALOL ** Tab 50 mg 8.23 100 ✓ Hybloc ** Tab 100 mg - For labetalol oral liquid formulation refer, page 209 10.06 100 ✓ Hybloc ** Tab 200 mg 17.55 100 ✓ Hybloc ✓ Hybloc ** Tab 200 mg 17.55 100 ✓ Hybloc ** Tab 200 mg 17.55 100 ✓ Hybloc ** Tab long-acting 23.75 mg 0.96 30 ✓ Metoprolol - AFT CR ** Tab long-acting 23.75 mg .9.96 30 ✓ Metoprolol - AFT CR ** Tab long-acting 190 mg .4.66 30 ✓ Metoprolol - AFT CR ** Tab long-acting 190 mg .4.66 30 ✓ Metoprolol - AFT CR ** Tab long-acting 190 mg .4.66 30 ✓ Metoprolol - AFT CR ** Tab long-acting 190 mg .4.66 30 ✓ Metoprolol - AFT CR ** Tab long-acting 190 mg .4.66 .4.66 <td></td> <td></td> <td>21.00</td> <td>30</td> <td>✔ Dilatrend</td>			21.00	30	✔ Dilatrend
* Tab 25 mg - For carvedilol oral liquid formulation refer, page 33.75 30 ✓ Dilatrend CELIPROLOL * Tab 200 mg 19.00 180 ✓ Celol LABETALOL * Tab 50 mg 8.23 100 ✓ Hybloc * Tab 50 mg 8.23 100 ✓ Hybloc * Tab 50 mg 8.23 100 ✓ Hybloc * Tab 100 mg - For labetalol oral liquid formulation refer, page 00 ✓ Hybloc * Tab 200 mg 17.55 100 ✓ Hybloc * Tab 200 mg 17.55 100 ✓ Hybloc * Tab 200 mg 17.55 100 ✓ Hybloc * Tab long-acting 23.75 mg 0.96 5 5 (B8.60) Trandate ✓ Metoprolol - AFT CR * Tab long-acting 95 mg 2.42 30 ✓ Metoprolol - AFT CR * Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR * Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR * Tab 100 mg For metoprolol tartrate oral liquid formulation refer, page 209 16.00 100 ✓ Lopresor * Tab 100 mg 21.00 60 ✓ Lopreso		6			
209	•			00	• Bhatona
CELIPROLOL * Tab 200 mg LABETALOL * Tab 50 mg * Tab 50 mg 209 209 209 100 * Tab 200 mg 209 209 100 * Tab 200 mg 209 209 100 * Tab 200 mg * Tab long-acting 23.75 mg (88.60) * Tab long-acting 95 mg * Tab long-acting 95 mg * Tab long-acting 95 mg * Tab long-acting 190 mg * Ac66 30 * Metoprolol - AFT CR * Tab 50 mg - For metoprolol tartrate oral liquid formulation refer, page 209 * Tab 100 mg	~		33 75	30	✔ Dilatrend
** Tab 200 mg 19.00 180 ✓ Celol LABETALOL * Tab 50 mg 8.23 100 ✓ Hybloc ** Tab 100 mg – For labetalol oral liquid formulation refer, page 209 10.06 100 ✓ Hybloc ** Tab 200 mg	~-			00	• Bhatona
LABETALOL * Tab 50 mg			10.00	100	
** Tab 50 mg 8.23 100 ✓ Hybloc ** Tab 100 mg - For labetalol oral liquid formulation refer, page 10.06 100 ✓ Hybloc ** Tab 200 mg 17.55 100 ✓ Hybloc ** Inj 5 mg per ml, 20 ml ampoule 59.06 5 Trandate METOPROLOL SUCCINATE (88.60) Trandate ** Tab long-acting 23.75 mg 0.96 30 ✓ Metoprolol - AFT CR ** Tab long-acting 95 mg 2.42 30 ✓ Metoprolol - AFT CR ** Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR ** Tab 50 mg - For metoprolol tartrate oral liquid formulation refer, page 209 16.00 100 ✓ Lopresor ** Tab 100 mg 21.00 60 ✓ Lopresor ✓ Lopresor ** Tab long-acting 200 mg 18.00 28 ✓ Slow-Lopresor	*	Tab 200 mg		180	V Celoi
* Tab 100 mg - For labetalol oral liquid formulation refer, page 10.06 100 ✓ Hybloc * Tab 200 mg 17.55 100 ✓ Hybloc * Tab 200 mg 17.55 100 ✓ Hybloc * Inj 5 mg per ml, 20 ml ampoule 59.06 5 Trandate METOPROLOL SUCCINATE (88.60) Trandate * Tab long-acting 23.75 mg 0.96 30 ✓ Metoprolol - AFT CR * Tab long-acting 95 mg 2.42 30 ✓ Metoprolol - AFT CR * Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR * Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR * Tab 50 mg - For metoprolol tartrate oral liquid formulation refer, page 209 16.00 100 ✓ Lopresor * Tab 100 mg 21.00 60 ✓ Lopresor ✓ Lopresor * Tab long-acting 200 mg 18.00 28 ✓ Slow-Lopresor	LA	BETALOL			
209 10.06 100 ✓ Hybloc * Tab 200 mg 17.55 100 ✓ Hybloc * Inj 5 mg per ml, 20 ml ampoule 59.06 5 Trandate METOPROLOL SUCCINATE 88.60) Trandate * Tab long-acting 23.75 mg 0.96 30 ✓ Metoprolol - AFT CR * Tab long-acting 23.75 mg 1.41 30 ✓ Metoprolol - AFT CR * Tab long-acting 95 mg 2.42 30 ✓ Metoprolol - AFT CR * Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR * Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR * Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR * Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR * Tab long-acting 200 mg 16.00 100 ✓ Metoprolol - AFT CR * Tab 100 mg 21.00 60 ✓ Lopresor * Tab long-acting 200 mg 18.00 28 ✓ Slow-Lopresor	*	Tab 50 mg	8.23	100	Hybloc
** Tab 200 mg 17.55 100 ✓ Hybloc ** Inj 5 mg per ml, 20 ml ampoule 59.06 5 Trandate METOPROLOL SUCCINATE (88.60) Trandate ** Tab long-acting 23.75 mg 0.96 30 ✓ Metoprolol - AFT CR ** Tab long-acting 23.75 mg 1.41 30 ✓ Metoprolol - AFT CR ** Tab long-acting 95 mg 2.42 30 ✓ Metoprolol - AFT CR ** Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR ** Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR ** Tab 50 mg - For metoprolol tartrate oral liquid formulation refer, page 209 16.00 100 ✓ Lopresor ** Tab 100 mg 21.00 60 ✓ Lopresor ✓ Lopresor ** Tab long-acting 200 mg 18.00 28 ✓ Slow-Lopresor	*	Tab 100 mg – For labetalol oral liquid formulation refer, page			
** Inj 5 mg per ml, 20 ml ampoule .59.06 5 (88.60) Trandate METOPROLOL SUCCINATE		209	10.06	100	 Hybloc
(88.60) Trandate METOPROLOL SUCCINATE	*	Tab 200 mg	17.55	100	Hybloc
METOPROLOL SUCCINATE ** Tab long-acting 23.75 mg ** Tab long-acting 23.75 mg ** Tab long-acting 23.75 mg ** Tab long-acting 47.5 mg ** Tab long-acting 95 mg ** Tab long-acting 95 mg ** Tab long-acting 95 mg ** Tab long-acting 190 mg ** Tab long-acting 200 mg ** Tab 100 mg ** Tab 100 mg ** Tab 100 mg ** Tab long-acting 200 mg	*	Inj 5 mg per ml, 20 ml ampoule	59.06	5	
** Tab long-acting 23.75 mg 0.96 30 ✓ Metoprolol - AFT CR ** Tab long-acting 47.5 mg 1.41 30 ✓ Metoprolol - AFT CR ** Tab long-acting 95 mg 2.42 30 ✓ Metoprolol - AFT CR ** Tab long-acting 95 mg 2.42 30 ✓ Metoprolol - AFT CR ** Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR METOPROLOL TARTRATE * * Metoprolol - AFT CR ** Tab 50 mg - For metoprolol tartrate oral liquid formulation refer, page 209 16.00 100 ✓ Lopresor ** Tab 100 mg 21.00 60 ✓ Lopresor ✓ Lopresor ** Tab long-acting 200 mg 18.00 28 ✓ Slow-Lopresor			(88.60)		Trandate
** Tab long-acting 23.75 mg 0.96 30 ✓ Metoprolol - AFT CR ** Tab long-acting 47.5 mg 1.41 30 ✓ Metoprolol - AFT CR ** Tab long-acting 95 mg 2.42 30 ✓ Metoprolol - AFT CR ** Tab long-acting 95 mg 2.42 30 ✓ Metoprolol - AFT CR ** Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR METOPROLOL TARTRATE * * Metoprolol - AFT CR ** Tab 50 mg - For metoprolol tartrate oral liquid formulation refer, page 209 16.00 100 ✓ Lopresor ** Tab 100 mg 21.00 60 ✓ Lopresor ✓ Lopresor ** Tab long-acting 200 mg 18.00 28 ✓ Slow-Lopresor	ME	TOPROLOL SUCCINATE			
* Tab long-acting 47.5 mg 1.41 30 ✓ Metoprolol - AFT CR * Tab long-acting 95 mg 2.42 30 ✓ Metoprolol - AFT CR * Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR METOPROLOL TARTRATE 4.66 30 ✓ Metoprolol - AFT CR * Tab 50 mg - For metoprolol tartrate oral liquid formulation refer, page 209 16.00 100 ✓ Lopresor * Tab 100 mg 21.00 60 ✓ Lopresor ✓ Lopresor * Tab long-acting 200 mg 18.00 28 ✓ Slow-Lopresor			0.96	30	Metoprolol - AFT CR
* Tab long-acting 95 mg 2.42 30 ✓ Metoprolol - AFT CR * Tab long-acting 190 mg 4.66 30 ✓ Metoprolol - AFT CR METOPROLOL TARTRATE 30 ✓ Metoprolol - AFT CR * Tab 50 mg – For metoprolol tartrate oral liquid formulation refer, page 209 16.00 100 ✓ Lopresor * Tab 100 mg 21.00 60 ✓ Lopresor ✓ Lopresor * Tab long-acting 200 mg 18.00 28 ✓ Slow-Lopresor	*			30	
METOPROLOL TARTRATE * Tab 50 mg - For metoprolol tartrate oral liquid formulation refer, page 209 * Tab 100 mg * Tab long-acting 200 mg * Tab long-acting 200 mg	*			30	Metoprolol - AFT CR
METOPROLOL TARTRATE * Tab 50 mg - For metoprolol tartrate oral liquid formulation refer, page 209 * Tab 100 mg * Tab long-acting 200 mg * Tab long-acting 200 mg	*	Tab long-acting 190 mg	4.66	30	Metoprolol - AFT CR
** Tab 50 mg − For metoprolol tartrate oral liquid formulation refer, page 209 100 100 ✓ Lopresor ** Tab 100 mg 21.00 60 ✓ Lopresor ** Tab long-acting 200 mg 18.00 28 ✓ Slow-Lopresor	ME				
refer, page 209 16.00 100 ✓ Lopresor ★ Tab 100 mg 21.00 60 ✓ Lopresor ★ Tab long-acting 200 mg 18.00 28 ✓ Slow-Lopresor					
* Tab 100 mg 60 ✓ Lopresor * Tab long-acting 200 mg 18.00 28 ✓ Slow-Lopresor	不		16.00	100	
★ Tab long-acting 200 mg18.00 28 ✓ Slow-Lop resor	*				
		5		••	
	~~			5	

		Subsidy (Manufacturer's Pi \$	rice) Su Per	bsidised Ge	and or neric nufacturer
NADOLOL					
* Tab 40 mg			100	✓ Apo-N	
* Tab 80 mg		23.74	100	✓ <u>Apo-N</u>	ladolol
PINDOLOL					
* Tab 5 mg			100	✓ <u>Apo-F</u>	
* Tab 10 mg			100	✓ <u>Apo-F</u>	
* Tab 15 mg		23.46	100	✓ <u>Apo-F</u>	Pindolol
PROPRANOLOL					
* Tab 10 mg		3.65	100	🖌 Аро-	
				Pro	pranolol S29
* Tab 40 mg		4 65	100	🖌 Аро-	
		4.00	100	•	pranolol \$29
				110	
* Cap long-acting 160 mg		16.06	100	 Cardi 	nol LA
* Oral liq 4 mg per ml – Specia	•				
Retail pharmacy		CBS	500 ml	🗸 Roxai	ne \$29
► SA1327 Special Authority for Initial application from any releva Either:	ant practitioner. Approvals			Ū	0
 For the treatment of a chi only); or 		0 0			
2 For the treatment of a chi	ld under 12 years with card	liac arrthymias or cong	genital cardia	ic abnormaliti	es.
Renewal from any relevant practit Either:	ioner. Approvals valid for 2	years for applications	meeting the	following crite	eria:
 For the treatment of a chi only); or 	ld under 12 years with an h	aemangioma causing	functional im	pairment (no	t for cosmetic reasons
2 For the treatment of a chi	ld under 12 years with card	liac arrthymias or cong	genital cardia	ic abnormaliti	es.
SOTALOL					

*	Tab 80 mg - For sotalol oral liquid formulation refer, page 20927.50	500	🖌 Mylan	
*	Tab 160 mg10.50	100	🖌 Mylan	
*	Inj 10 mg per ml, 4 ml ampoule65.39	5	✓ Sotacor	
TIM	OLOL			
*	Tab 10 mg 10.55	100	Apo-Timol	

Calcium Channel Blockers

Dihydropyridine Calcium Channel Blockers

MLODIPINE		
: Tab 2.5 mg2.	45 100	Apo-Amlodipine
Tab 5 mg – For amlodipine oral liquid formulation refer, page		
209	65 100	Apo-Amlodipine
- Tab 10 mg4.	15 100	Apo-Amlodipine
ELODIPINE		
Tab long-acting 2.5 mg2	90 30	Plendil ER
Tab long-acting 5 mg3.	10 30	Plendil ER
Tab long-acting 10 mg4.	50 30	Plendil ER

(Subsidy (Manufacturer's Price) \$	Sub: Per	Fully sidised	Generic
RADIPINE				
Cap long-acting 2.5 mg	7.50	30	~	Dynacirc-SRO
Cap long-acting 5 mg	7.85	30	1	Dynacirc-SRO
FEDIPINE				
Tab long-acting 10 mg		60	~	Adalat 10
Tab long-acting 20 mg	9.59	100	1	Nyefax Retard
Tab long-acting 30 mg		30	V	Adefin XL
			V	Arrow-Nifedipine XR
	(19.90)			Adalat Oros
Tab long-acting 60 mg	5.75	30		Adefin XL
				Arrow-Nifedipine XR
	(29.50)		1	Adalat Oros
rrow-Nifedipine XR Tab long-acting 30 mg to be delisted 1 Decen Idalat Oros Tab long-acting 30 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 Decen	4)			
dalat Oros Tab long-acting 30 mg to be delisted 1 December 201- rrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 Decem dalat Oros Tab long-acting 60 mg to be delisted 1 December 201-	4) nber 2014)			
dalat Oros Tab long-acting 30 mg to be delisted 1 December 201 Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 Decem	4) nber 2014)			
dalat Oros Tab long-acting 30 mg to be delisted 1 December 201- rrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 Decem dalat Oros Tab long-acting 60 mg to be delisted 1 December 201-	4) nber 2014)			
Idalat Oros Tab long-acting 30 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 Decem Idalat Oros Tab long-acting 60 mg to be delisted 1 December 201- Dther Calcium Channel Blockers	4) nber 2014) 4)	100	~	<u>Dilzem</u>
Adalat Oros [*] Tab long-acting 30 mg to be delisted 1 December 201- nrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 Decem Idalat Oros Tab long-acting 60 mg to be delisted 1 December 201- Other Calcium Channel Blockers LTIAZEM HYDROCHLORIDE	4) nber 2014) 4)	100	•	Dilzem
Idalat Oros ⁻ Tab long-acting 30 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 Decem Idalat Oros Tab long-acting 60 mg to be delisted 1 December 201- Dther Calcium Channel Blockers LTIAZEM HYDROCHLORIDE Tab 30 mg	4) nber 2014) 4) 	100	-	<u>Dilzem</u> Dilzem
Idalat Oros Tab long-acting 30 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 Decem- Idalat Oros Tab long-acting 60 mg to be delisted 1 December 201- Dther Calcium Channel Blockers LTIAZEM HYDROCHLORIDE Tab 30 mg Tab 60 mg – For diltiazem hydrochloride oral liquid formula-	4) nber 2014) 4) 4.60 8.50		~	
Idalat Oros Tab long-acting 30 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 December 201- Dther Calcium Channel Blockers LTIAZEM HYDROCHLORIDE Tab 30 mg Tab 60 mg – For diltiazem hydrochloride oral liquid formula- tion refer, page 209 Cap long-acting 120 mg	4) hber 2014) 4) 4.60 8.50 1.91 31.83	100 30 500		<u>Dilzem</u> Cardizem CD Apo-Diltiazem CD
Idalat Oros Tab long-acting 30 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 Decem Idalat Oros Tab long-acting 60 mg to be delisted 1 December 201- Dther Calcium Channel Blockers LTIAZEM HYDROCHLORIDE Tab 30 mg Tab 60 mg – For diltiazem hydrochloride oral liquid formula- tion refer, page 209	4) hber 2014) 4) 4.60 8.50 1.91 31.83 7.56	100 30 500 30		<u>Dilzem</u> Cardizem CD Apo-Diltiazem CD Cardizem CD
Idalat Oros Tab long-acting 30 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 December 201- Dther Calcium Channel Blockers LTIAZEM HYDROCHLORIDE Tab 30 mg Tab 60 mg – For diltiazem hydrochloride oral liquid formula- tion refer, page 209 Cap long-acting 120 mg	4) hber 2014) 4) 4.60 8.50 1.91 31.83 7.56 47.67	100 30 500 30 500	レンシン	<u>Dilzem</u> Cardizem CD Apo-Diltiazem CD Cardizem CD Apo-Diltiazem CD
Idalat Oros Tab long-acting 30 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 December 201- Dther Calcium Channel Blockers LTIAZEM HYDROCHLORIDE Tab 30 mg Tab 60 mg – For diltiazem hydrochloride oral liquid formula- tion refer, page 209 Cap long-acting 120 mg	4) hber 2014) 4) 4.60 8.50 1.91 31.83 7.56 47.67 10.22	100 30 500 30 500 30 30		<u>Dilzem</u> Cardizem CD Apo-Diltiazem CD Cardizem CD Apo-Diltiazem CD Cardizem CD
Idalat Oros Tab long-acting 30 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 December 201- Dther Calcium Channel Blockers LTIAZEM HYDROCHLORIDE Tab 30 mg Tab 60 mg – For diltiazem hydrochloride oral liquid formula- tion refer, page 209 Cap long-acting 120 mg	4) hber 2014) 4) 4.60 8.50 1.91 31.83 7.56 47.67	100 30 500 30 500		<u>Dilzem</u> Cardizem CD Apo-Diltiazem CD Cardizem CD Apo-Diltiazem CD
Idalat Oros Tab long-acting 30 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 December 201- Irrow-Nifedipine XR Tab long-acting 60 mg to be delisted 1 December 201- Dther Calcium Channel Blockers LTIAZEM HYDROCHLORIDE Tab 30 mg Tab 60 mg – For diltiazem hydrochloride oral liquid formula- tion refer, page 209 Cap long-acting 120 mg	4) hber 2014) 4) 4.60 1.91 31.83 7.56 47.67 10.22 63.58	100 30 500 30 500 30 30		<u>Dilzem</u> Cardizem CD Apo-Diltiazem CD Cardizem CD Apo-Diltiazem CD Cardizem CD

➡SA1260 Special Authority for Subsidy

Initial application only from a cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 Patient has refractory angina; and
- 2 Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate.

Renewal only from a cardiologist or any relevant practitioner on the recommendation of a cardiologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

VERAPAMIL HYDROCHLORIDE

*	Tab 40 mg	7.01	100	 Isoptin
*	Tab 80 mg – For verapamil hydrochloride oral liquid formula-			
	tion refer, page 209	11.74	100	🖌 Isoptin
	Isoptin to be Sole Supply on 1 October 2014			
*	Tab long-acting 120 mg	15.20	250	Verpamil SR
*	Tab long-acting 240 mg	25.00	250	Verpamil SR
*	Inj 2.5 mg per ml, 2 ml ampoule - Up to 5 inj available on a			
	PSO	7.54	5	 Isoptin

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
Centrally-Acting Agents				
CLONIDINE				
* Patch 2.5 mg, 100 mcg per day – Only on a prescription		4	✓ <u>C</u>	atapres-TTS-1
* Patch 5 mg, 200 mcg per day – Only on a prescription		4		atapres-TTS-2
* Patch 7.5 mg, 300 mcg per day – Only on a prescription		4	✓ <u>C</u>	atapres-TTS-3
CLONIDINE HYDROCHLORIDE				
* Tab 25 mcg		112		Ionidine BNM
* Tab 150 mcg		100		atapres
* Inj 150 mcg per ml, 1 ml ampoule		5	✓ <u>C</u>	atapres
METHYLDOPA				
* Tab 125 mg		100		rodopa
* Tab 250 mg		100		rodopa
* Tab 500 mg	23.15	100	🗸 P	rodopa
Loop Diuretics BUMETANIDE				
* Tab 1 mg		100	🗸 В	urinex
* Inj 500 mcg per ml, 4 ml vial	7.95	5	🖌 В	urinex
FUROSEMIDE [FRUSEMIDE]				
* Tab 40 mg – Up to 30 tab available on a PSO		1,000	🖌 <u>D</u>	iurin 40
* Tab 500 mg		50		rex Forte
*‡ Oral liq 10 mg per ml		30 ml O		
* Inj 10 mg per ml, 25 ml ampoule		5	🖌 Li	asix
* Inj 10 mg per ml, 2 ml ampoule – Up to 5 inj available on a		-		rusemide-Claris
PSO	1.30	5	V F	rusemide-Claris
Potassium Sparing Diuretics				
AMILORIDE HYDROCHLORIDE				
* Tab 5 mg	17.50	100		po-Amiloride
Oral liq 1 mg per ml		25 ml O	Р 🖌 В	iomed
METOLAZONE – Special Authority see SA1349 below – Retail p	oharmacy			
Tab 5 mg	CBS	1	🖌 M	letolazone S29
-		50	🗸 Z	aroxolyn S29
➡SA1349 Special Authority for Subsidy				•

SA1349 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where used for the treatment of patients with refractory heart failure who are intolerant or have not responded to loop diuretics and/or loop-thiazide combination therapy.

SPIRONOLACTONE

* Tab 25 mg		100	Spiractin
* Tab 100 mg	11.80	100	Spiractin
* Tab Too Ting		100	
			Spirotone
t Oral lig 5 mg per ml		25 ml OP	Biomed
(Spirotone Tab 100 mg to be delisted 1 December 2014)			

	Subsidy (Manufacturer's Price \$) Su Per	Fully Brand or ubsidised Generic Manufacturer
Potassium Sparing Combination Diuretics			
AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE * Tab 5 mg with furosemide 40 mg	8.63	28	✓ Frumil
AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIE * Tab 5 mg with hydrochlorothiazide 50 mg		50	✓ Moduretic
Thiazide and Related Diuretics			
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE] * Tab 2.5 mg – Up to 150 tab available on a PSO	5.48	500	✓ Arrow- Bendrofluazide
a) May be supplied on a PSO for reasons other than emerge b) Arrow-Bendrofluazide to be Sole Supply on 1 October 20	014	500	✓ Arrow-
 Tab 5 mg Arrow-Bendrofluazide to be Sole Supply on 1 October 2014 		500	Bendrofluazide
CHLOROTHIAZIDE ‡ Oral liq 50 mg per ml CHLORTALIDONE [CHLORTHALIDONE]		5 ml OP	✓ Biomed
* Tab 25 mg	8.00	50	✓ Hygroton
INDAPAMIDE * Tab 2.5 mg Lipid-Modifying Agents	2.25	90	✓ Dapa-Tabs
Fibrates			
BEZAFIBRATE * Tab 200 mg * Tab long-acting 400 mg		90 30	 ✓ <u>Bezalip</u> ✓ <u>Bezalip Retard</u>
GEMFIBROZIL * Tab 600 mg		60	✓ Lipazil
Other Lipid-Modifying Agents			
ACIPIMOX * Cap 250 mg		30	✓ Olbetam
NICOTINIC ACID * Tab 50 mg * Tab 500 mg		100 100	 Apo-Nicotinic Acid Apo-Nicotinic Acid
Resins			
CHOLESTYRAMINE Powder for oral liq 4 g		50	Questran-Lite
COLESTIPOL HYDROCHLORIDE Grans for oral liq 5 g	, , , , , , , , , , , , , , , , , , ,	30	✓ Colestid

	C	ARD	OVASC	ULAR SYSTEM
	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
HMG CoA Reductase Inhibitors (Statins)				
Prescribing Guidelines Treatment with HMG CoA Reductase Inhibitors (statins) is re cardiovascular risk of 15% or greater. ATORVASTATIN – See prescribing guideline above		with d		
Tab 10 mg	0.04	30	✓ Li ✓ Pi	fizer atorvastatin
	2.52	90	🖌 Za	arator
Tab 20 mg	1.39	30	🖌 Li	pitor
č			🖌 P	fizer atorvastatin
	4.17	90	🖌 Za	arator
Tab 40 mg	2.44	30		pitor
				fizer atorvastatin
	7.32	90		arator
Tab 80 mg	5.41	30		initor

4.1 Tab 40 mg2.4		 ✓ <u>Zarator</u> ✓ Lipitor
		 Pfizer atorvastatin
7.3	32 90	✓ Zarator
Tab 80 mg5.4	1 30	 Lipitor
		 Pfizer atorvastatin
16.2	23 90	✓ Zarator
PRAVASTATIN – See prescribing guideline above		
* Tab 20 mg	15 30	Cholvastin
* Tab 40 mg6.3	36 30	Cholvastin
SIMVASTATIN – See prescribing guideline above		
* Tab 10 mg0.9	95 90	Arrow-Simva 10mg
Arrow-Simva 10mg to be Sole Supply on 1 October 2014		
* Tab 20 mg1.6	61 90	Arrow-Simva 20mg
Arrow-Simva 20mg to be Sole Supply on 1 October 2014		
* Tab 40 mg2.8	33 90	Arrow-Simva 40mg
Arrow-Simva 40mg to be Sole Supply on 1 October 2014		
* Tab 80 mg7.9	91 90	Arrow-Simva 80mg
Arrow-Simva 80mg to be Sole Supply on 1 October 2014		
Selective Cholesterol Absorption Inhibitors		
EZETIMIBE – Special Authority see SA1045 below – Retail pharmacy		4
Tab 10 mg34.4	13 30	 Ezetrol

►SA1045 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater: and
- 3 Any of the following:

- 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 \times normal) when treated with one statin: or
- 3.2 The patient is intolerant to both simvastatin and atorvastatin: or
- 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

continued.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

Notes: A patient who has failed to reduce their LDL cholesterol to < 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

EZETIMIBE WITH SIMVASTATIN - Special Authority see SA1046 below - Retail pharmacy

Tab 10 mg with simvastatin 10 mg	30	🖌 Vytorin
Tab 10 mg with simvastatin 20 mg	30	Vytorin
Tab 10 mg with simvastatin 40 mg41.40	30	Vytorin
Tab 10 mg with simvastatin 80 mg45.45	30	 Vytorin

➡SA1046 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to ≤ 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Nitrates

GLYCERYL TRINITRATE

ЧL			
*	Tab 600 mcg – Up to 100 tab available on a PSO	100 OP	Lycinate
*	Oral spray, 400 mcg per dose – Up to 250 dose available on		
	a PSO	250 dose OP	🖌 Glytrin
*	Patch 25 mg, 5 mg per day15.73	30	Nitroderm TTS
	Nitroderm TTS to be Sole Supply on 1 October 2014		
*		30	Nitroderm TTS
不	Patch 50 mg, 10 mg per day	30	
	Nitroderm TTS to be Sole Supply on 1 October 2014		
ISC	SORBIDE MONONITRATE		
*	Tab 20 mg	100	🖌 Ismo 20
	Ismo 20 to be Sole Supply on 1 October 2014	100	
	11.3		4 • • • •
*	Tab long-acting 40 mg7.50	30	Ismo 40 Retard
*	Tab long-acting 60 mg	90	Duride
	5 5 5		

	0.1.11		- "	
	Subsidy (Manufacturer's Price)	S	Fully ubsidised	Brand or Generic
	\$	Per	~	Manufacturer
Sympathomimetics				
ADRENALINE				
Inj 1 in 1,000, 1 ml ampoule – Up to 5 inj available on a PSO	4.98 5.25	5		spen Adrenaline Iospira
Inj 1 in 10,000, 10 ml ampoule - Up to 5 inj available on a				
PSO		5		lospira
	49.00	10	V A	spen Adrenaline
ISOPRENALINE	00.00	05		
* Inj 200 mcg per ml, 1 ml ampoule		25	le	suprel
	(135.00)		13	suprer
Vasodilators				
AMYL NITRITE				
* Liq 98% in 0.3 ml cap	62.92	12		
	(73.40)		В	axter
HYDRALAZINE HYDROCHLORIDE				
* Tab 25 mg - Special Authority see SA1321 below - Retail				
pharmacy	CBS	1		lydralazine
* Inj 20 mg ampoule	25.00	56 5		onelink ^{S29} Apresoline
SA1321 Special Authority for Subsidy	20.90	5	•	presonne
Initial application from any relevant practitioner. Approvals valid the following criteria: Either: 1 For the treatment of refractory hypertension; or				
2 For the treatment of heart failure in combination with a nit inhibitors and/or angiotensin receptor blockers.	rate, in patients who	are intol	erant or h	ave not responded to ACE
MINOXIDIL - Special Authority see SA1271 below - Retail pharm				
▲ Tab 10 mg	70.00	100	V L	oniten
► SA1271 Special Authority for Subsidy				
Initial application only from a relevant specialist. Approvals valid refractory hypertension which has failed to respond to extensive m		val unles	ss notified	d where patient has severe
NICORANDIL - Special Authority see SA1263 below - Retail pha				
▲ Tab 10 mg		60	• ••	korel
▲ Tab 20 mg		60	v 1	korel
► SA1263 Special Authority for Subsidy Initial application only from a cardiologist or general physician.	Approvale valid for 2	voare fo	r applica	tions mosting the following
criteria:	Approvais valiu ior 2	years io	i applica	
Both:				
1 Patient has refractory angina; and 2 Patient is on the maximal tolerated dose of a beta-blocker	r, a calcium channel l	blocker a	and a long	g acting nitrate.
Renewal only from a cardiologist or any relevant practitioner on the where the treatment remains appropriate and the patient is benefit	ne recommendation of			
PAPAVERINE HYDROCHLORIDE				
* Inj 12 mg per ml, 10 ml ampoule	73.12	5	🗸 Н	lospira

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
PENTOXIFYLLINE [OXPENTIFYLLINE] Tab 400 mg		50	Tr	rental 400
Endothelin Receptor Antagonists				
SA0967 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertensio Notes: Application details may be obtained from PHARMAC's web The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.go	osite http://www.phar	mac.g	govt.nz or:	
AMBRISENTAN – Special Authority see SA0967 above – Retail p Tab 5 mg Tab 10 mg	4,585.00	30 30	• •	olibris olibris
BOSENTAN – Special Authority see SA0967 above – Retail pharr Tab 62.5 mg	macy	60		ms-Bosentan racleer
Tab 125 mg		60	🖌 pi	ms-Bosentan racleer

Phosphodiesterase Type 5 Inhibitors

SA1293 Special Authority for Subsidy

Initial application — (Raynaud's Phenomenon* - for Pulmonary Arterial Hypertension see note below)) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following:

- 1 Patient has Raynaud's Phenomenon*; and
- 2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
- 3 Patient is following lifestyle management (avoidance of cold exposure, sufficient protection, smoking cessation support, avoidance of sympathomimetic drugs); and
- 4 Patient is being treated with calcium channel blockers and nitrates (or these are contraindicated/not tolerated).

Notes: Sildenafil is also funded for patients with Pulmonary Arterial Hypertension who are approved by the Pulmonary Arterial Hypertension Panel (an application must be made using form <u>SA1293-PAH</u>).

Application details may be obtained from: The Coordinator, PAH Panel

PHARMAC, PO Box 10 254, Wellington

Phone: (04) 916 7512 Facsimile: (04) 974 4858 Email: PAH@pharmac.govt.nz

Indications marked with * are Unapproved Indications.

SILDENAFIL - Special Authority see SA1293 above - Retail pharn	nacy		
Tab 25 mg	1.85	4	Silagra
Tab 50 mg		4	Silagra
Tab 100 mg – For sildenafil oral liquid formulation refer, page			-
209	7.45	4	 Silagra

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
Prostacyclin Analogues			
► SA0969 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertensis Notes: Application details may be obtained from PHARMAC's we The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.g	bsite <u>http://www.pharr</u>	mac.govt.nz or:	
ILOPROST – Special Authority see SA0969 above – Retail phan Nebuliser soln 10 mcg per ml, 2 ml	,	30 🖌 V	/entavis

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Generic
Antiacne Preparations			
For systemic antibacterials, refer to INFECTIONS, Antibacterials,	page 96		
ADAPALENE			
a) Maximum of 30 g per prescription			
b) Only on a prescription			
Crm 0.1%)gOP 🖌	Differin
Gel 0.1%)gOP 🖌	Differin
ISOTRETINOIN - Special Authority see SA0955 below - Retail	oharmacy		
Cap 10 mg		120	Oratane
Cap 20 mg		120 🖌	Oratane

➡SA0955 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated; and
- 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 4 Either:
 - 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 4.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- All of the following:
 - 1 Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated; and
 - 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
 - 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
 - 4 Either:
 - 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 4.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

TRETINOIN

Crm 0.5 mg per g – Maximum of 50 g per prescription	13.90	50 g OP	ReTrieve
---	-------	---------	----------

DERMATOLOGICALS

	Subsidy (Manufacturer's Price \$	e) ; Per	Fully Subsidised	Brand or Generic Manufacturer
Antibacterials Topical				
For systemic antibacterials, refer to INFECTIONS, Antibacterials,	page 96			
FUSIDIC ACID				
Crm 2%a) Maximum of 15 g per prescription b) Only on a prescription c) Not in combination	3.25	15 g OP	✔ F	oban
Oint 2% a) Maximum of 15 g per prescription b) Only on a prescription c) Not in combination	3.45	15 g OP	✓ <u>F</u>	<u>oban</u>
HYDROGEN PEROXIDE * Crm 1%	8.56	15 g OP	~ (Crystaderm
MUPIROCIN Oint 2%	6.60 (9.26)	15 g OP	E	Bactroban
a) Only on a prescription b) Not in combination	. ,			
SILVER SULPHADIAZINE Crm 1%	12.30	50 g OP	✔ F	lamazine
a) Up to 250 g available on a PSO b) Not in combination				
Antifungals Topical				
For systemic antifungals, refer to INFECTIONS, Antifungals, page	102			
AMOROLFINE a) Only on a prescription b) Not in combination				
Nail soln 5%	37.86 (61.87)	5 ml OP	L	oceryl
CICLOPIROX OLAMINE a) Only on a prescription b) Not in combination				
Nail-soln 8%	8.23	7 ml OP	•	Apo-Ciclopirox
 Crm 1%	0.52	20 g OP	v (Clomazol
* Soln 1%	4.36 2 (7.55)	20 ml OF		Canesten
a) Only on a prescription b) Not in combination				

DERMATOLOGICALS

	Subsidy		Fully Brand or	
	(Manufacturer's) \$	Price) Sul Per	bsidised Generic Manufacturer	
CONAZOLE NITRATE	•	-		
Crm 1%	1.00	20 g OP		
CIIII 176	(7.48)	20 y OF	Pevaryl	
a) Only on a prescription	(7.40)		rovaryr	
b) Not in combination				
Foaming soln 1%, 10 ml sachets	9.89	3		
0	(17.23)		Pevaryl	
a) Only on a prescription				
b) Not in combination				
1ICONAZOLE NITRATE				
₭ Crm 2%	0.46	15 g OP	✓ Multichem	
a) Only on a prescription		-		
b) Not in combination				
₭ Lotn 2%	4.36	30 ml OP		
	(10.03)		Daktarin	
a) Only on a prescription				
b) Not in combination	4.00			
 Tinct 2% 		30 ml OP	Doltorin	
a) Only on a proparintian	(12.10)		Daktarin	
a) Only on a prescription b) Not in combination				
,				
IYSTATIN	1 00	15 ~ OD		
Crm 100,000 u per g	(7.90)	15 g OP	Mycostatin	
a) Only on a prescription	(7.30)		Wycostauri	
b) Not in combination				
Antipruritic Preparations				
CALAMINE				
a) Only on a prescription				
b) Not in combination				
Crm, aqueous, BP	1.77	100 g	Pharmacy Health	
Lotn, BP	13.45	2,000 ml	✓ <u>PSM</u>	
ROTAMITON				
a) Only on a prescription				
b) Not in combination				
Órm 10%	3.48	20 g OP	✓ Itch-Soothe	
IENTHOL – Only in combination				
Only in combination with aqueous cream, 10% urea crea	m, wool fat with mine	eral oil lotion. 1	% hydrocortisone with wool fat a	
mineral oil lotion, and glycerol, paraffin and cetyl alcohol			,	
Crystals		25 g	🖌 PSM	
-	6.92	-	✓ MidWest	
	29.60	100 g	✓ MidWest	

	Subsidy (Manufacturer's F	Price) Cub	Fully	Brand or Generic
	(Manulacturer S F	Per Sub		Manufacturer
Corticosteroids Topical				
For systemic corticosteroids, refer to CORTICOSTEROIDS AND F	RELATED AGEN	ITS, page 84		
Corticosteroids - Plain				
BETAMETHASONE DIPROPIONATE				
Crm 0.05%	2.96	15 g OP		iprosone
	8.97	50 g OP		iprosone
Crm 0.05% in propylene glycol base		30 g OP		iprosone OV
Oint 0.05%		15 g OP		iprosone
	8.97	50 g OP		iprosone
Oint 0.05% in propylene glycol base	4.33	30 g OP	V D	iprosone OV
BETAMETHASONE VALERATE				
* Crm 0.1%	3.50	50 g OP	🖌 В	eta Cream
* Oint 0.1%	3.50	50 g OP	🖌 В	eta Ointment
₭ Lotn 0.1%		50 ml OP	🖌 В	etnovate
CLOBETASOL PROPIONATE				
★ Crm 0.05%	3.68	30 g OP	V D	ermol
k Oint 0.05%		30 g OP		ermol
		00 g 0.	• -	••••••
Crm 0.05%	F 00	20 <i>~</i> OD		
GIII 0.05%		30 g OP	г.	umovate
	(7.09) 16.13	100 ~ 00		umovale
	(22.00)	100 g OP	5	umovate
	(22.00)			umovale
DIFLUCORTOLONE VALERATE				
Crm 0.1%		50 g OP		
	(15.86)		N	erisone
Fatty oint 0.1%		50 g OP		
	(15.86)		N	erisone
HYDROCORTISONE				
& Crm 1% – Only on a prescription	3.75	100 g	🖌 Pl	harmacy Health
	14.00	500 g	🖌 Pl	harmacy Health
Powder – Only in combination		25 g	🖌 A	
Up to 5% in a dermatological base (not proprietary Topi galenicals. Refer, page 208	cal Corticosterio	od – Plain) with	h or wit	hout other dermatologic
HYDROCORTISONE BUTYRATE				
Lipocream 0.1%	2.30	30 g OP	🖌 <u>L</u>	ocoid Lipocream
	6.85	100 g OP		ocoid Lipocream
Oint 0.1%	6.85	100 g OP	✓ L	ocoid
Milky emul 0.1%	6.85	100 ml OP		ocoid Crelo
HYDROCORTISONE WITH WOOL FAT AND MINERAL OIL				
Lotn 1% with wool fat hydrous 3% and mineral oil – Only on				
a prescription	9 95	250 ml	🖌 D	P Lotn HC
		200 111		
	4.05	45 . 00		
Crm 0.1%		15 g OP		dvantan
Oint 0.1%	4.95	15 g OP	V A	dvantan

69

DERMATOLOGICALS

DERMATOLOGICALS

IOMETASONE FUROATE Crm 0.1%	(Manufacturer's I \$	Price) Sub Per	osidised Generic
			 Manufacturer
Crm 0.1%			
	1.78	15 g OP	✓ m-Mometasone
	3.42	45 g OP	✓ m-Mometasone
Oint 0.1%	1.78	15 g OP	m-Mometasone
	3.42	45 g OP	✓ m-Mometasone
Lotn 0.1%	7.35	30 ml OP	
	(11.13)		Elocon
RIAMCINOLONE ACETONIDE			
Crm 0.02%	6.63	100 g OP	 Aristocort
Oint 0.02%	6.69	100 g OP	 Aristocort
Corticosteroids - Combination			
ETAMETHASONE VALERATE WITH CLIOQUINOL - Only on	a prescription		
Crm 0.1% with clioquinol 3%		15 g OP	
	(4.90)		Betnovate-C
Oint 0.1% with clioquinol 3%		15 g OP	
·	(4.90)	0	Betnovate-C
Betnovate-C Oint 0.1% with clioquinol 3% to be delisted 1 Janu	uary 2015)		
ETAMETHASONE VALERATE WITH FUSIDIC ACID			
Crm 0.1% with fusidic acid 2%		15 g OP	
	(10.45)		Fucicort
a) Maximum of 15 g per prescription	· · · ·		
b) Only on a prescription			
YDROCORTISONE WITH MICONAZOLE - Only on a prescri	intion		
Crm 1% with miconazole nitrate 2%		15 g OP	✓ Micreme H
YDROCORTISONE WITH NATAMYCIN AND NEOMYCIN - C		0	
Crm 1% with natamycin 1% and neomycin sulphate 0.5%.		15 g OP	Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5%		15 g OP	✓ Pimafucort
		-	
RIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYC		IN	
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 m		15 - 00	
and gramicidin 250 mcg per g – Only on a prescription		15 g OP	Viodorm KC
	(6.60)		Viaderm KC
Disinfecting and Cleansing Agents			
HLORHEXIDINE GLUCONATE – Subsidy by endorsement			
a) No more than 500 ml per month			
b) Only if prescribed for a dialysis patient and the prescription		cordingly.	
Handrub 1% with ethanol 70%		500 ml	✓ <u>healthE</u>
Soln 4%	5.90	500 ml	Orion
RICLOSAN – Subsidy by endorsement			
a) Maximum of 500 ml per prescription			
 b) a) Only if prescribed for a patient identified with Methicillin 	-resistant Stanbul	ococcue aurou	s (MRSA) prior to elective surge
in hospital and the prescription is endorsed accordingly			is the rective surger
 b) Only if prescribed for a patient with recurrent Staphyloco 		ction and the pr	rescription is endorsed according
Soln 1%		500 ml OP	 Pharmacy Health
	4.50 5.90	500 mi OP	✓ Phannacy nearth ✓ healthE
	5.50		

DERMATOLOGICALS

	Subsidy (Manufacturer's \$	Price) Subs Per	Fully Brand or sidised Generic Manufacturer
Barrier Creams and Emollients			
Barrier Creams			
DIMETHICONE * Crm 5% pump bottle	4.73	500 ml OP	✓ <u>healthE</u> Dimethicone 5%
ZINC AND CASTOR OIL * Oint BP		500 g	✓ Multichem
Emollients			
AQUEOUS CREAM * Crm CETOMACROGOL	1.96	500 g	🗸 AFT
Crm BP Crm BP Crm COUL COUL	3.15	500 g	🖌 PSM
Crm 90% with glycerol 10%	4.50	500 ml OP	 Pharmacy Health Sorbolene with Glycerin
	6.50	1,000 ml OP	 Pharmacy Health Sorbolene with Glycerin
EMULSIFYING OINTMENT * Oint BP		500 g	🗸 AFT
DIL IN WATER EMULSION		-	
₭ Crm JREA	2.63	500 g	healthE Fatty Cream
* Crm 10%	1.65	100 g OP	healthE Urea Cream
 NOOL FAT WITH MINERAL OIL − Only on a prescription ★ Lotn hydrous 3% with mineral oil 	(3.50)	250 ml OP	Hydroderm Lotion
	5.60 (9.54) 1.40	1,000 ml 250 ml OP	Hydroderm Lotion
	(4.53) 5.60	1,000 ml	DP Lotion
	(11.95) (20.53)	050 105	DP Lotion Alpha-Keri Lotion
	1.40 (7.73) 5.60	250 ml OP 1.000 ml	BK Lotion
(Hydroderm Lotion Lotn hydrous 3% with mineral oil to be delist	(23.91)	,	BK Lotion

	Subsidy (Manufacturer's F	Price) Sut	Fully Brand or osidised Generic
	\$	Per	 Manufacturer
Other Dermatological Bases			
PARAFFIN			
White soft – Only in combination	3.58	500 g	
	(7.78)		IPW
	20.20	2,500 g	✓ IPW
	3.58	500 g	2011
Only in combination with a dermotal grian galaxies or as	(8.69)	nriatari / Tania	PSM
Only in combination with a dermatological galenical or as	a ulluent for a pro	ophetary topic	ai Conticosteroiu – Plain.
Minor Skin Infections			
POVIDONE IODINE			
Oint 10%	3.27	25 g OP	Betadine
 a) Maximum of 100 g per prescription 			
b) Only on a prescription			
Antiseptic soln 10%		15 ml	
	(4.45)	100	Betadine
	1.28	100 ml	Datadiaa
	(8.25) 6.20	500 ml	Betadine
	1.28	100 ml	• Delaume
	(4.20)	100 111	Riodine
	6.20	500 ml	✓ Riodine
Skin preparation, povidone iodine 10% with 30% alcohol		100 ml	
	(3.65)		Betadine Skin Prep
	10.00	500 ml	 Betadine Skin Prep
Skin preparation, povidone iodine 10% with 70% alcohol	1.63	100 ml	
	(6.04)		Orion
	8.13	500 ml	0.1
	(18.63)		Orion
Parasiticidal Preparations			
GAMMA BENZENE HEXACHLORIDE			
Crm 1%	3.50	50 g OP	Benhex
VERMECTIN – Special Authority see SA1225 below – Retail ph	narmacy		
Tab 3 mg - Up to 100 tab available on a PSO		4	 Stromectol
1) PSO for institutional use only. Must be endorsed with th		titution for whi	ch the PSO is required and a val
Special Authority for patient of that institution.			
 Ivermectin available on BSO provided the BSO includes Earth and the bid of the second se			
 For the purposes of subsidy of ivermectin, institution m or popul institutions 	eans age related	residential cal	re raciinties, disability care facilitie
or penal institutions.			

➡SA1225 Special Authority for Subsidy

Initial application — (Scables) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and
- 2 Either:

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

2.1 Both:

- 2.1.1 The patient is in the community; and
- 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
- 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Initial application — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 Filaricides; or
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

Renewal — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria: Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 The patient is in the community; and
 - 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
 - 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

continued...

(M	Subsidy lanufacturer's Price)	Subsidi	ully sed	Brand or Generic
	\$	Per	V	Manufacturer

continued...

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Renewal — (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 Filaricides; or
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

MALATHION

Liq 0.5%		A-LicesA-Lices
MALATHION WITH PERMETHRIN AND PIPERONYL BUTOXIDE Spray 0.25% with permethrin 0.5% and piperonyl butoxide 2%11.15	5 90 g OP	🗸 Para Plus
PERMETHRIN Crm 5%		✓ Lyderm ✓ A-Scabies
Lotn 5%	9 30 mi OP	A-Scables

Psoriasis and Eczema Preparations

ACITRETIN - Special Authority see SA0954 on the next page - F	Retail pharmacy
---	-----------------

Cap 10 mg	, ,	 .17.86	60	Novatretin
		35.95	100	Neotigason
Cap 25 mg		 .41.36	60	Novatretin
		85.40	100	Neotigason

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

SA0954 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and
- 3 Either:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
 - 3.2 Patient is male.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and
- 3 Either:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
 - 3.2 Patient is male.

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

Oint 500 mag with coloinstrial 50 mag	20 a OB	
Oint 500 mcg with calcipotriol 50 mcg	30 g OP	 Daivobet
Topical gel 500 mcg with calcipotriol 50 mcg26.12	30 g OP	 Daivobet
CALCIPOTRIOL		
Crm 50 mcg per g16.00	30 g OP	Daivonex
45.00	100 g OP	Daivonex
Oint 50 mcg per g45.00	100 g OP	Daivonex
Soln 50 mcg per ml16.00	30 ml OP	Daivonex
COAL TAR		
Soln – Only in combination12.55	200 ml	✓ Midwest
Up to 10 % Only in combination with a dermatological base or proprietary	Topical Corticos	teriod – Plain, refer dermatological
base, page 208 With or without other dermatological galenicals.		,
COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULPHUR		
Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and		
allantoin crm 2.5%	30 g OP	
(4.35)	•	Egopsoryl TA
6.59	75 g OP	
(8.00)	- 3 -	Egopsoryl TA
COAL TAR WITH SALICYLIC ACID AND SULPHUR		
Soln 12% with salicylic acid 2% and sulphur 4% oint7.95	40 g OP	Coco-Scalp

DERMATOLOGICALS

	Subsidy (Manufacturer's		Fully Brand or osidised Generic
	\$	Per	✓ Manufacturer
ALICYLIC ACID			(
Powder – Only in combination		250 g Corticosteroid	 PSM Plain or collodion flexible, re
dermatological base, page 208 2) With or without other dermatological galenicals.			
ULPHUR			
Precipitated – Only in combination	6.35	100 g	✓ Midwest
 Only in combination with a dermatological base or pro page 208 	prietary Topical C	Corticosteroid -	Plain, refer dermatological ba
With or without other dermatological galenicals.			
AR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLU	JORESCEIN - O	only on a prescr	iption
Soln 2.3% with triethanolamine lauryl sulphate and fluores			
cein sodium		500 ml	✓ Pinetarsol
	5.82	1,000 ml	Pinetarsol
Scalp Preparations			
ETAMETHASONE VALERATE			
Scalp app 0.1%	7.75	100 ml OP	Beta Scalp
OBETASOL PROPIONATE			
Scalp app 0.05%	6.96	30 ml OP	Dermol
YDROCORTISONE BUTYRATE			
Scalp lotn 0.1%		100 ml OP	✓ Locoid
ETOCONAZOLE			
Shampoo 2%		100 ml OP	✓ Sebizole
a) Maximum of 100 ml per prescription			
b) Only on a prescription			
Sunscreens			
JNSCREENS, PROPRIETARY – Subsidy by endorsement			
Only if prescribed for a patient with severe photosensitivity	secondary to a	defined clinica	I condition and the prescriptior
endorsed accordingly. Crm	2 20	100 a OB	
		100 g OP	Hamilton Sunscreen
Lotn.		100 g OP	✓ Marine Blue Lotion
,		jer ger	SPF 50+
	5.10	200 g OP	 Marine Blue Lotion SPF 50+
Lotn	4.13	125 ml OP	
	(6.94)		Aquasun 30+
Wart Preparations			
or salicylic acid preparations refer to PSORIASIS AND ECZEM		NS page 74	
IQUIMOD – Special Authority see SA0923 on the next page -			

DERMATOLOGICALS

(Ma	Subsidy nufacturer's Price)	l Subsid	Fully ised	Brand or Generic	
	\$	Per	~	Manufacturer	

SA0923 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria: Any of the following:

- 1 The patient has external anogenital warts and podophyllotoxin has been tried and failed (or is contraindicated); or
- 2 The patient has external anogenital warts and podophyllotoxin is unable to be applied accurately to the site; or
- 3 The patient has confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate.

Notes: Superficial basal cell carcinoma

- Surgical excision remains first-line treatment for superficial basal cell carcinoma as it has a higher cure rate than imiquimod and allows histological assessment of tumour clearance.
- Imiquimod has not been evaluated for the treatment of superficial basal cell carcinoma within 1 cm of the hairline, eyes, nose, mouth or ears.

• Imiquimod is not indicated for recurrent, invasive, infiltrating, or nodular basal cell carcinoma.

- External anogenital warts
 - Imiquimod is only indicated for external genital and perianal warts (condyloma acuminata).

Renewal from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria: Any of the following:

- 1 Inadequate response to initial treatment for anogenital warts; or
- 2 New confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate; or
- 3 Inadequate response to initial treatment for superficial basal cell carcinoma.

Note: Every effort should be made to biopsy the lesion to confirm that it is a superficial basal cell carcinoma.

PODOPHYLLOTOXIN Soln 0.5% a) Maximum of 3.50 ml per prescription b) Only on a prescription	.33.60	3.5 ml OP	✔ Condyline
Other Skin Preparations			
Antineoplastics			
FLUOROURACIL SODIUM Crm 5%	.25.16	20 g OP	✓ <u>Efudix</u>

GENITO-URINARY SYSTEM

		Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Contraceptives - Nor	-hormonal				
Condoms					
ONDOMS					
49 mm – Up to 144 dev	available on a PSO	13.36	144		arquisTantiliza hield 49
52 mm – Up to 144 dev	available on a PSO	13.36	144	🖌 M	arquis Selecta arquis Sensolite arquis Supalite
52 mm extra strength -	Up to 144 dev available on a PSO	13.36	144		arquis Supante arquis Protecta
	available on a PSO		12		hield Blue
		13.36	144		hield Blue
		1.11	12		old Knight
		13.36	144		old Knight
		10.00	177		arquis Black
					arquis Titillata
53 mm (chocolate) – Up	to 144 dev available on a PSO	1 11	12		old Knight
		13.36	144		old Knight
53 mm (strawberrv) – U	p to 144 dev available on a PSO		12		old Knight
·····(······))		13.36	144		old Knight
54 mm. shaped - Up to	144 dev available on a PSO		12		j
		(1.24)		Lit	festyles Flared
		13.36	144		
		(14.84)		Lit	festyles Flared
55 mm – Up to 144 dev	available on a PSO	· · · ·	144		arquis Conforma
	available on a PSO		12		old Knight
		13.36	144		old Knight
				🖌 Di	urex Extra Safe
					urex Select Flavours
56 mm, shaped – Up to	144 dev available on a PSO	1.11	12	🖌 Di	urex Confidence
		13.36	144	🖌 Di	urex Confidence
60 mm - Up to 144 dev	available on a PSO	13.36	144	🖌 SI	hield XL
Contraceptive Device	es				
IAPHRAGM – Up to 1 dev	available on a PSO				
One of each size is perm					
			1		rtho All-flex
			1		rtho All-flex
			1		rtho All-flex
80 mm			1	✓ 0	rtho All-flex
ITRA-UTERINE DEVICE a) Up to 40 dev available	on a PSO				
b) Only on a PSO					
: IUD			1	🖌 M	ultiload Cu 375
				🖌 M	ultiload Cu 375 SL
IUD 29.1 mm length × 2	3.2 mm width		1	🖌 M	iniTT380 Slimline
IUD 33.6 mm length × 2 Aultiload Cu 375 IUD to be Aultiload Cu 375 SL IUD to	,	31.60	1	✓ TI	T380 Slimline

GENITO-URINARY SYSTEM

Fullv

Subsidised

Subsidy (Manufacturer's Price) \$ Per Brand or Generic Manufacturer

Contraceptives - Hormonal

Combined Oral Contraceptives

SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient is on a Social Welfare benefit; or
- 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

ETHINYLOESTRADIOL WITH DESOGESTREL

*	Tab 20 mcg with desogestrel 150 mcg and 7 inert tab	6 62	84		
*	Tab 20 micy with desogestier 100 micy and 7 ment tab		04		Marailan 00
		(16.50)			Mercilon 28
	 a) Higher subsidy of \$13.80 per 84 tab with Special Authority 	/ see SA0500 ab	ove		
	b) Up to 84 tab available on a PSO				
*	Tab 30 mcg with desogestrel 150 mcg and 7 inert tab	6.62	84		
		(16.50)			Marvelon 28
	a) Llinker autoidu af ¢10.00 nau 04 tak with Onasial Authorit	()			
	a) Higher subsidy of \$13.80 per 84 tab with Special Authority	/ see SA0500 at	ove		
	 b) Up to 84 tab available on a PSO 				
ETI	HINYLOESTRADIOL WITH LEVONORGESTREL				
*	Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tab – Up				
~	to 84 tab available on a PSO	0.65	84		Ava 20 ED
		2.00	04	•	AVA ZU ED
*	Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab – Up				
	to 84 tab available on a PSO	9.45	84	~	Microgynon 50 ED
*	Tab 30 mcg with levonorgestrel 150 mcg	6.62	63		
	5 5 5	(16.50)			Microgynon 30
	a) Higher subsidy of \$15.00 per 63 tab with Special Authority	· · ·			
	, , , , , , , , , , , , , , , , , , , ,	7 SEE OA0500 al	000		
	b) Up to 63 tab available on a PSO				
*	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tab – Up				
	to 84 tab available on a PSO	2.30	84	~	Ava 30 ED

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
ETHINYLOESTRADIOL WITH NORETHISTERONE					
* Tab 35 mcg with norethisterone 1 mg – Up to 63 tab available on a PSO		63	✔ E	Brevinor 1/21	
* Tab 35 mcg with norethisterone 1 mg and 7 inert tab – Up to 84 tab available on a PSO		84	🖌 E	Brevinor 1/28	
* Tab 35 mcg with norethisterone 500 mcg – Up to 63 tab avail- able on a PSO		63	🖌 E	Brevinor 21	
 * Tab 35 mcg with norethisterone 500 mcg and 7 inert tab – Up to 84 tab available on a PSO 		84	~ N	lorimin	

Progestogen-only Contraceptives

SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient is on a Social Welfare benefit; or
- 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

LEVONORGESTREL

* Tab 30 mcg	6.62	84	
C C C C C C C C C C C C C C C C C C C	(16.50)		Microlut
 a) Higher subsidy of \$13.80 per 84 tab with Special Auth b) Up to 84 tab available on a PSO 	ority see SA0500 at	ove	
* Subdermal implant (2 × 75 mg rods)	133.65	1	 Jadelle
MEDROXYPROGESTERONE ACETATE * Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a F	PSO7.00	1	✓ <u>Depo-Provera</u>
NORETHISTERONE * Tab 350 mcg – Up to 84 tab available on a PSO	6.00	84	✓ Noriday 28

GENITO-URINARY SYSTEM

	Subsidy		Fully Brand or
	(Manufacturer's F \$	Price) Sul Per	osidised Generic Manufacturer
Emergency Contraceptives			
LEVONORGESTREL * Tab 1.5 mg a) Up to 5 tab available on a PSO b) Maximum of 2 tab per prescription	3.50	1	✓ Postinor-1
Antiandrogen Oral Contraceptives			
Prescribers may code prescriptions "contraceptive" (code "O") who prescription charge will be as per other contraceptives, as follows \$5.00 prescription charge (patient co-payment) will apply prescriptions coded in any other way are subject to the non cont of supply. ie. Prescriptions may be written for up to three months CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL	: raceptive prescri		
Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs – Up to 84 tab available on a PSO		84	✔ Ginet 84
Gynaecological Anti-infectives			
ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC A Jelly with glacial acetic acid 0.94%, hydroxyquinoline sul- phate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator	- 	100 g OP	Aci-Jel
CLOTRIMAZOLE	(2 1.00)		
* Vaginal crm 1% with applicators		35 g OP	Clomazol
Yaginal crm 2% with applicators IICONAZOLE NITRATE	2.20	20 g OP	✓ <u>Clomazol</u>
₭ Vaginal crm 2% with applicator	3.95	40 g OP	✓ Micreme
VYSTATIN Vaginal crm 100,000 u per 5 g with applicator(s)	4.71	75 g OP	✓ Nilstat
Myometrial and Vaginal Hormone Preparations		. e g e	
ERGOMETRINE MALEATE Inj 500 mcg per ml, 1 ml ampoule – Up to 5 inj available on a	l		
PSO		5	 DBL Ergometrine
	6 00	15 ~ OP	• Overtin
Crm 1 mg per g with applicator		15 g OP 15	✓ Ovestin✓ Ovestin
 Crm 1 mg per g with applicator Pessaries 500 mcg DXYTOCIN – Up to 5 inj available on a PSO 	6.53	0	
DESTRIOL Crm 1 mg per g with applicator	6.53 4.75	0	

GENITO-URINARY SYSTEM

	Subsidy (Manufacturer's F	Price) Subs	Fully Brand or sidised Generic
	\$	Per	✓ Manufacturer
Pregnancy Tests - hCG Urine			
PREGNANCY TESTS - HCG URINE a) Up to 200 test available on a PSO b) Only on a PSO			
Cassette	22.80	40 test OP	 Innovacon hCG One Step Pregnancy Test
Urinary Agents			
For urinary tract Infections refer to INFECTIONS, Antibacterials,	page 116		
5-Alpha Reductase Inhibitors			
FINASTERIDE – Special Authority see SA0928 below – Retail * Tab 5 mg		30	Rex Medical
► SA0928 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals va the following criteria: Both:	lid without further	renewal unless	notified for applications meeting
 Patient has symptomatic benign prostatic hyperplasia; a Either: 	and		
2.1 The patient is intolerant of non-selective alpha b 2.2 Symptoms are not adequately controlled with no	on-selective alpha	blockers.	
Note: Patients with enlarged prostates are the appropriate cand	idates for therapy	with finasteride	
Alpha-1A Adrenoreceptor Blockers			
TAMSULOSIN HYDROCHLORIDE – Special Authority see SA1		il pharmacy 100	✓ <u>Tamsulosin-Rex</u>
SA1032 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals va the following criteria: Both:	lid without further	renewal unless	notified for applications meeting
 Patient has symptomatic benign prostatic hyperplasia; The patient is intolerant of non-selective alpha blockers 		raindicated.	
Other Urinary Agents			
OXYBUTYNIN * Tab 5 mg * Oral liq 5 mg per 5 ml POTASSIUM CITRATE		500 473 ml	 ✓ <u>Apo-Oxybutynin</u> ✓ <u>Apo-Oxybutynin</u>
Oral liq 3 mmol per ml – Special Authority see SA1083 of the next page – Retail pharmacy		200 ml OP	✓ Biomed

GENITO-URINARY	SYSTEM

		GLINI	10-011	NART STSTEM
	Subsidy (Manufacturer's Pric \$	ce) Su Per	Fully ubsidised	Brand or Generic Manufacturer
SA1083 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid Both:	I for 12 months for a	pplications	meeting	the following criteria:
 The patient has recurrent calcium oxalate urolithiasis; ar The patient has had more than two renal calculi in the tw 		application	۱.	
Renewal from any relevant practitioner. Approvals valid for 2 y benefitting from the treatment.	ears where the trea	atment rem	ains app	ropriate and the patient i
SODIUM CITRO-TARTRATE # Grans eff 4 g sachets	3.93	28	🗸 U	ral
SOLIFENACIN SUCCINATE – Special Authority see SA0998 be	low – Retail pharma	асу		
Tab 5 mg Tab 10 mg		30 30	• •	esicare esicare
SA0998 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals va overactive bladder and a documented intolerance of, or is non-re			less notif	ied where the patient ha
OLTERODINE - Special Authority see SA1272 below - Retail	pharmacy			
Tab 1 mg		56		rrow-Tolterodine
Tab 2 mg	14.56	56	V A	rrow-Tolterodine
SA1272 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals valid ive bladder and a documented intolerance of, or is non-responsi		ewal unles	s notified	where patient has overage
Detection of Substances in Urine				
ORTHO-TOLIDINE				
Compound diagnostic sticks	7.50 (8.25)	50 test OP	Н	emastix

ΤE	TRABROMOPHENOL			
*	Blue diagnostic strips		100 test OP	
	0	(13.92)		Albustix

(Ma	Subsidy nufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Calcium Homeostasis				
CALCITONIN				
* Inj 100 iu per ml, 1 ml ampoule	.121.00	5	🗸 N	liacalcic
Corticosteroids and Related Agents for Systemic U	se			
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASON				
 Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml 		5		
	(33.60)	Ū	C	elestone
	. ,			Chronodose
DEXAMETHASONE				
* Tab 1 mg – Retail pharmacy-Specialist	5.87	100		ouglas
Up to 30 tab available on a PSO				
* Tab 4 mg – Retail pharmacy-Specialist	8.16	100		ouglas
Up to 30 tab available on a PSO	45.00 07	5 ml OF		liomed
Oral liq 1 mg per ml – Retail pharmacy-Specialist Oral lig prescriptions:	45.00 25	o mi Ol		oonea
 Must be written by a Paediatrician or Paediatric Cardiologist; 	or			
2) On the recommendation of a Paediatrician or Paediatric Card				
DEXAMETHASONE PHOSPHATE	Ū			
Dexamethasone phosphate injection will not be funded for oral us	e.			
Inj 4 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSO	25.80	10		examethasone-
				hameln
Inj 4 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO	17.98	5		examethasone-
				hameln
	14.00	100		lavinof
* Tab 100 mcg	14.32	100	VF	lorinef
HYDROCORTISONE	0.40	100		· · · · · · · · · · ·
* Tab 5 mg	8.10	100	•	ouglas
Tab 20 mg – For hydrocortisone oral liquid formulation refer, page 200	20.22	100	1	ouglas
page 209 ₭ Inj 100 mg vial		1		olu-Cortef
a) Up to 5 inj available on a PSO			• •	
b) Only on a PSO				
METHYLPREDNISOLONE – Retail pharmacy-Specialist				
* Tab 4 mg	60.00	100	🗸 N	ledrol
* Tab 100 mg		20	\[\] \[\[\] \[ledrol
METHYLPREDNISOLONE ACETATE				
Inj 40 mg per ml, 1 ml	33.50	5	\[\begin{aligned} &	epo-Medrol
METHYLPREDNISOLONE ACETATE WITH LIDOCAINE [LIGNOCAIN				
Inj 40 mg per ml with lidocaine [lignocaine] 1 ml		1	🗸 🖸	epo-Medrol with
			_	Lidocaine
METHYLPREDNISOLONE SODIUM SUCCINATE – Retail pharmacy	-Specialist			
Inj 40 mg per ml, 1 ml		1		olu-Medrol
Inj 62.5 mg per ml, 2 ml		1		olu-Medrol
lnj 500 mg		1		olu-Medrol
Inj 1 g	37.50	1	✓ <u>s</u>	olu-Medrol

	Subsidy (Manufacturer's P		Fully Brand or osidised Generic
	\$	Per	 Manufacturer
REDNISOLONE SODIUM PHOSPHATE			
 Oral liq 5 mg per ml – Up to 30 ml available on a PSO Restricted to children under 12 years of age. 	10.45	30 ml OP	 Redipred
REDNISONE			
* Tab 1 mg	2.13	100	 Apo-Prednisone S29 S29
	10.68	500	Apo-Prednisone
€ Tab 2.5 mg		500	Apo-Prednisone
Tab 5 mg – Up to 30 tab available on a PSO		500	Apo-Prednisone
🗧 Tab 20 mg		500	Apo-Prednisone
ETRACOSACTRIN			
Inj 250 mcg per ml, 1 ml ampoule	17 71	1	Synacthen
	177.18	10	✓ Synacthen
F Inj 1 mg per ml, 1 ml		1	Synacthen Depot
		·	e officiality popul
	01.00	~	. / Kanasark A
Inj 10 mg per ml, 1 ml		5	✓ Kenacort-A ✓ Kenacort-A40
Inj 40 mg per ml, 1 ml		5	Kenacort-A40
Sex Hormones Non Contraceptive			
Androgen Agonists and Antagonists			
YPROTERONE ACETATE – Retail pharmacy-Specialist			
Tab 50 mg		50	Siterone
Tab 100 mg	34.25	50	Siterone
ESTOSTERONE			
Transdermal patch, 2.5 mg per day	80.00	60	Androderm
ESTOSTERONE CYPIONATE – Retail pharmacy-Specialist	76 50	1	✓ Depo-Testosterone
Inj 100 mg per ml, 10 ml vial		I	• Depo-residsierone
Depo-Testosterone to be Sole Supply on 1 October 2014			
ESTOSTERONE ESTERS – Retail pharmacy-Specialist	10.00		4 a b b b b
Inj 250 mg per ml, 1 ml	12.98	1	 Sustanon Ampoules
ESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist			
Cap 40 mg	31.17	60	Andriol Testocaps
Inj 250 mg per ml, 4 ml		1	Reandron 1000

SA1018 Special Authority for Alternate Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following:

- 1 acute or significant liver disease where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record; or
- 2 oestrogen induced hypertension requiring antihypertensive therapy documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens; or
- 3 hypertriglyceridaemia documented evidence must be kept on file that triglyceride levels increased to at least 2 × normal triglyceride levels post oral oestrogens; or

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

4 Somatropin co-therapy - patient is being prescribed somatropin with subsidy provided under a valid approval issued under Special Authority.

Note: Prescriptions with a valid Special Authority (CHEM) number will be reimbursed at the level of the lowest priced TDDS product within the specified dose group.

Renewal from any relevant practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment, or the patient remains on subsidised somatropin co-therapy.

Prescribing Guideline

HRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG "Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004".

Oestrogens

OESTRADIOL - See prescribing guideline above			
* Tab 1 mg	4.12	28 OP	
	(11.10)		Estrofem
* Tab 2 mg	4.12	28 OP	
-	(11.10)		Estrofem
* TDDS 25 mcg per day		8	
	(10.86)		Estradot
a) Higher subsidy of \$10.86 per 8 patch with Spec	ial Authority see SA1018	on the previo	ous page
b) No more than 2 patch per week			
c) Only on a prescription			
* TDDS 3.9 mg (releases 50 mcg of oestradiol per day)4.12	4	
	(13.18)		Climara 50
	(32.50)		Femtran 50
a) Higher subsidy of \$13.18 per 4 patch with Spec	al Authority see SA1018	on the previo	ous page
b) No more than 1 patch per week			
c) Only on a prescription			
* TDDS 50 mcg per day	4.12	8	
	(13.18)		Estradot 50 mcg
a) Higher subsidy of \$13.18 per 8 patch with Spec	al Authority see SA1018	on the previo	ous page
b) No more than 2 patch per week			
c) Only on a prescription			
* TDDS 7.8 mg (releases 100 mcg of oestradiol per da	ıy)7.05	4	
	(16.14)		Climara 100
	(35.00)		Femtran 100
a) Higher subsidy of \$16.14 per 4 patch with Spec	al Authority see SA1018	on the previo	ous page
b) No more than 1 patch per week	,		1 0
c) Only on a prescription			
* TDDS 100 mcg per day	7.05	8	
	(16.14)		Estradot
a) Higher subsidy of \$16.14 per 8 patch with Spec	al Authority see SA1018	on the previo	ous page
b) No more than 2 patch per week			
c) Only on a prescription			
(Femtran 50 TDDS 3.9 mg (releases 50 mcg of oestradio	I per day) to be delisted 1	February 20	15)
(Femtran 100 TDDS 7.8 mg (releases 100 mcg of oestrat	diol per day) to be delisted	1 February	2015)
OESTRADIOL VALERATE – See prescribing guideline a	hove		
* Tab 1 mg		84	Progynova
* Tab 2 mg		84	 Progynova Progynova
	12.00	т	+ riogynova

	Subsidy (Manufacturer's Pric \$	e) Su Per	Fully Brand or Ibsidised Generic Manufacturer
ESTROGENS – See prescribing guideline on the previous pag	e		
Conjugated, equine tab 300 mcg	3.01	28	
	(11.48)		Premarin
Conjugated, equine tab 625 mcg	4.12	28	
	(11.48)		Premarin
Progestogens			
EDROXYPROGESTERONE ACETATE - See prescribing guid	eline on the previou	s page	
← Tab 2.5 mg		30	Provera
← Tab 5 mg		100	Provera
€ Tab 10 mg		30	✓ <u>Provera</u>
Progestogen and Oestrogen Combined Prepara	tions		
ESTRADIOL WITH NORETHISTERONE – See prescribing gu	ideline on the previo	ous page	
 Tab 1 mg with 0.5 mg norethisterone acetate 		28 OP	
	(18.10)		Kliovance
Tab 2 mg with 1 mg norethisterone acetate	· · · ·	28 OP	
	(18.10)	20 0.	Kliogest
Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg	1		-
oestradiol tab (12) and 1 mg oestradiol tab (6)		28 OP	
	(18.10)		Trisequens
ESTROGENS WITH MEDROXYPROGESTERONE - See pres	scribina auideline o	n the previo	Dus page
 Tab 625 mcg conjugated equine with 2.5 mg medroxyproges 			
terone acetate tab (28)		28 OP	
	(22.96)	20 01	Premia 2.5
	(22.50)		Continuous
Tab 625 mcg conjugated equine with 5 mg medroxyproges			Continuous
terone acetate tab (28)		28 OP	
	(22.96)	20 UF	Premia 5 Continuous
	(22.90)		Fremia 5 Continuous
Other Oestrogen Preparations			
THINYLOESTRADIOL			
	17.60	100	VZ Madical and
 Tab 10 mcg 	17.00	100	✓ <u>NZ Medical and</u>
			<u>Scientific</u>
DESTRIOL	7.00	00	
 Tab 2 mg 		30	 Ovestin
Other Progestogen Preparations			
EVONORGESTREL			
 Levonorgestrel - releasing intrauterine system 20 mcg/24 h 			
 Special Authority see SA0782 on the next page – Retai 			
		1	Miropo
pharmacy	209.50	I	Mirena

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	bsidised	Generic	
\$	Per	~	Manufacturer	

SA0782 Special Authority for Subsidy

Initial application — (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and
- 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and
- 3 Either:
 - 3.1 serum ferritin level < 16 mcg/l (within the last 12 months); or
 - 3.2 haemoglobin level < 120 g/l.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

Initial application — (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and
- 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and
- 3 Applicant to state date of the previous insertion.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or
 - 1.2 Previous insertion was removed or expelled within 3 months of insertion; and
- 2 Applicant to state date of the previous insertion.

MEDROXYPROGESTERONE ACETATE

* Tab 100 mg – Retail pharmacy-Specialist		100	Provera
* Tab 200 mg - Retail pharmacy-Specialist	70.50	30	Provera
(Provera Tab 200 mg to be delisted 1 February 2015)			
NORETHISTERONE			
* Tab 5 mg - Up to 30 tab available on a PSO		100	Primolut N
PROGESTERONE			
Cap 100 mg – Special Authority see SA1392 below – Ret	ail		
pharmacy		30	Utrogestan
BASA1302 Special Authority for Subsidy			

SA1392 Special Authority for Subsidy

Initial application only from an obstetrician or gynaecologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 For the prevention of pre-term labour*; and
- 2 Either:
 - 2.1 The patient has a short cervix on ultrasound (defined as < 25 mm at 16 to 28 weeks); or
 - 2.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are Unapproved Indications (refer to Interpretations and Definitions).

	Subsidy (Manufacturer's Pr	rice) Si	Fully Brand or Ibsidised Generic
	\$	Per	✓ Manufacturer
Thuroid and Antithuroid Agapta			
Thyroid and Antithyroid Agents			
CARBIMAZOLE			
Tab 5 mg	10.80	100	✓ AFT \$29
			Neo-Mercazole
AFT S29 Tab 5 mg to be delisted 1 December 2014)			
EVOTHYROXINE	0.00		
Tab 25 mcg		90	 Synthroid
\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$		90	Synthroid
	64.28	1,000	✓ Eltroxin
‡ Safety cap for extemporaneously compounded oral lic	quid preparations.		
₭ Tab 100 mcg		90	 Synthroid
	66.78	1,000	 Eltroxin
\$ Safety cap for extemporaneously compounded oral lice	quid preparations.		
EVOTHYROXINE (MERCURY PHARMA)	1 71	00	
Tab 50 mcg ‡ Safety cap for extemporaneously compounded oral lic		28	 Mercury Pharma
Tab 100 mcg		28	Mercury Pharma
‡ Safety cap for extemporaneously compounded oral lic	quid preparations.		,
PROPYLTHIOURACIL - Special Authority see SA1199 below			
Propylthiouracil is not recommended for patients under the	age of 18 years unle	ess the patie	ent is pregnant and other treatment
are contraindicated			
are contraindicated.	05.00	100	
Tab 50 mg	35.00	100	✓ PTU \$29
Tab 50 mg SA1199 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals va			
Tab 50 mg SA1199 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals va	lid for 2 years for ap		
Tab 50 mg Special Authority for Subsidy nitial application from any relevant practitioner. Approvals va Both: The patient has hyperthyroidism; and The patient is intolerant of carbimazole or carbimazole Renewal from any relevant practitioner. Approvals valid for 2	lid for 2 years for ap	plications me	eeting the following criteria:
Tab 50 mg Special Authority for Subsidy nitial application from any relevant practitioner. Approvals value the patient has hyperthyroidism; and The patient is intolerant of carbimazole or carbimazole Renewal from any relevant practitioner. Approvals valid for 2 enefitting from the treatment.	lid for 2 years for ap	plications me	eeting the following criteria:
Tab 50 mg Special Authority for Subsidy nitial application from any relevant practitioner. Approvals value to the patient has hyperthyroidism; and The patient is intolerant of carbimazole or carbimazole Renewal from any relevant practitioner. Approvals valid for 2 enefitting from the treatment. Trophic Hormones	lid for 2 years for ap	plications me	eeting the following criteria:
Tab 50 mg ⇒SA1199 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals va 8oth: 1 The patient has hyperthyroidism; and 2 The patient is intolerant of carbimazole or carbimazole Renewal from any relevant practitioner. Approvals valid for 2 benefitting from the treatment. Trophic Hormones	lid for 2 years for ap	plications me	eeting the following criteria:
Tab 50 mg	lid for 2 years for ap e is contraindicated. I years where the tra	plications me	eeting the following criteria:
Tab 50 mg	lid for 2 years for ap e is contraindicated. years where the tra 79 below – [Xpharm 	plications me eatment rem]	eeting the following criteria:
Tab 50 mg Second State	lid for 2 years for ap e is contraindicated. years where the tra 79 below – [Xpharm 	plications me eatment rem	eeting the following criteria: ains appropriate and the patient
Tab 50 mg	lid for 2 years for ap e is contraindicated. years where the tra 79 below – [Xpharm 	plications me eatment rem]	eeting the following criteria: ains appropriate and the patient Genotropin
Tab 50 mg	lid for 2 years for ap e is contraindicated. years where the tra 79 below – [Xpharm 	plications me eatment rem] 1 1	eeting the following criteria: ains appropriate and the patient ✓ Genotropin ✓ Genotropin
Tab 50 mg	lid for 2 years for ap e is contraindicated. years where the tra 79 below – [Xpharm 	plications me eatment rem] 1 1	eeting the following criteria: ains appropriate and the patient ✓ Genotropin ✓ Genotropin
Tab 50 mg Special Authority for Subsidy Itial application from any relevant practitioner. Approvals value toth: 1 The patient has hyperthyroidism; and 2 The patient is intolerant of carbimazole or carbimazole tenewal from any relevant practitioner. Approvals valid for 2 enefitting from the treatment. Trophic Hormones COMATROPIN (GENOTROPIN) – Special Authority see SA12 Inj cartridge 16 iu (5.3 mg) SA1279 Special Authority for Subsidy pecial Authority approved by the Growth Hormone Committee lotes: Application details may be obtained from PHARMAC's of IZGHC Coordinator	lid for 2 years for ap e is contraindicated. years where the tra 79 below – [Xpharm 	plications me eatment rem] 1 1	eeting the following criteria: ains appropriate and the patient ✓ Genotropin ✓ Genotropin
Tab 50 mg	lid for 2 years for ap e is contraindicated. years where the tre years where the tre 279 below – [Xpharm 	plications me eatment rem] 1 1 oharmac.gov	eeting the following criteria: ains appropriate and the patient ✓ Genotropin ✓ Genotropin
Tab 50 mg	lid for 2 years for ap e is contraindicated. 2 years where the tre 279 below – [Xpharm 	plications me eatment rem] 1 1 oharmac.gov	eeting the following criteria: ains appropriate and the patient Genotropin Genotropin
Tab 50 mg	lid for 2 years for ap e is contraindicated. 2 years where the tre 279 below – [Xpharm 	plications me eatment rem] 1 1 oharmac.gov	eeting the following criteria: ains appropriate and the patient Genotropin Genotropin
Tab 50 mg	lid for 2 years for ap e is contraindicated. years where the tra r79 below – [Xpharm 	plications me eatment rem] 1 1 oharmac.gov	eeting the following criteria: ains appropriate and the patient Genotropin Genotropin
Tab 50 mg	lid for 2 years for ap e is contraindicated. years where the tra 279 below – [Xpharm 	plications me eatment rem] 1 2 bharmac.gov - Retail phar	eeting the following criteria: ains appropriate and the patient Genotropin Cenotropin t.nz or:

Subsidy		Fully	Brand or	
(Manufacturer's Price)	:	Subsidised	Generic	
\$	Per	~	Manufacturer	

SA1451 Special Authority for Subsidy

Initial application — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

Either:

- 1 Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or</p>
- 2 All of the following:
 - 2.1 Height velocity < 25th percentile for age adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
 - 2.2 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
 - 2.3 Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and</p>
 - 2.4 If the patient has been treated for a malignancy, they should be disease free for at least one year based upon followup laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
 - 2.5 Appropriate imaging of the pituitary gland has been obtained.

Renewal — (growth hormone deficiency in children) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 2 Height velocity is ≥ 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- 3 Height velocity is ≥ 2.0 cm per year, as calculated over 6 months; and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

Renewal — (Turner syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity \geq 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is \geq 2 cm per year, calculated over six months; and
- 3 A current bone age is \leq 14 years; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initial application — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria: All of the following:

continued...

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Renewal — (short stature without growth hormone deficiency) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

- All of the following:
 - 1 Height velocity is ≥ 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
 - 2 Height velocity is ≥ 2 cm per year as calculated over six months; and
 - 3 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
 - 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initial application — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient's height is more than 2 standard deviations below the mean; and
- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is \leq to 14 years (female patients) or \leq to 16 years (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:
 - 6.1 The patient has a GFR \leq 30 ml/min/1.73m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l) \times 40 = corrected GFR (ml/min/1.73m² in a child who may or may not be receiving dialysis; or
 - 6.2 The patient has received a renal transplant and has received < 5mg/ m²/day of prednisone or equivalent for at least 6 months..

Renewal — (short stature due to chronic renal insufficiency) only from a paediatric endocrinologist, endocrinologist or renal physician on the recommendation of a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is ≥ 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is \geq 2 cm per year as calculated over six months; and
- 3 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

continued...

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	bsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Initial application — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient's height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 Either:
 - 3.1 The patient is under two years of age and height velocity has been assessed over a minimum six month period from the age of 12 months, with at least three supine length measurements over this period demonstrating clear and consistent evidence of linear growth failure (with height velocity < 25th percentile); or</p>
 - 3.2 The patient is aged two years or older; and
- 4 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 5 Sleep studies or overnight eximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 6 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by ≥ 0.5 standard deviations in the preceding 12 months.

Renewal — (Prader-Willi syndrome) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Height velocity is ≥ 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is ≥ 2 cm per year as calculated over six months; and
- 3 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by ≥ 0.5 standard deviations in the preceding 12 months.

Initial application — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA[®]).

continued...

(Man	Subsidy	Fully	Brand or
	nufacturer's Price)	Subsidised	Generic
(\$ Pe		Manufacturer

continued...

Notes: For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of \leq 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of ≤ 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until the serum IGF-I is within 1 standard deviation of the mean normal value for age and sex; and

Dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Renewal — (adults and adolescents) only from a paediatric endocrinologist or endocrinologist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has been treated with somatropin for < 12 months; and
 - 1.2 There has been an improvement in Quality of Life defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA[®]) score from baseline; and
 - 1.3 Serum IGF-I levels have been increased within ±1SD of the mean of the normal range for age and sex; and
 - 1.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients, or 1 mg per day for female patients; or
- 2 All of the following:
 - 2.1 The patient has been treated with somatropin for more than 12 months; and
 - 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA[®] score on treatment (other than due to obvious external factors such as external stressors); and
 - 2.3 Serum IGF-I levels have continued to be maintained within ±1SD of the mean of the normal range for age and sex (other than for obvious external factors); and
 - 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

GnRH Analogues

GOSERELIN ACETATE

L

Inj 3.6 mg		1	Zoladex
lnj 10.8 mg		1	Zoladex
LEUPRORELIN			
Inj 3.75 mg prefilled syringe		1	Lucrin Depot PDS
Inj 7.5 mg		1	Eligard
Inj 11.25 mg prefilled syringe		1	Lucrin Depot PDS
Inj 22.5 mg		1	Eligard
Inj 30 mg		1	Eligard
Inj 30 mg prefilled syringe	1,109.40	1	Lucrin Depot PDS
Inj 45 mg		1	Eligard

	Subsidy (Manufacturer's P \$	rice) Sul Per	Fully osidised	Brand or Generic Manufacturer
Vasopressin Agonists				
DESMOPRESSIN ACETATE				
Tab 100 mcg – Special Authority see SA1401 below – Retail pharmacy		30	✔ M	inirin
Tab 200 mcg – Special Authority see SA1401 below – Retail pharmacy		30	✔ M	inirin
▲ Nasal drops 100 mcg per ml – Retail pharmacy-Specialist		2.5 ml OP	🖌 M	inirin
▲ Nasal spray 10 mcg per dose – Retail pharmacy-Specialist	22.95	6 ml OP		esmopressin- PH&T
Desmopressin-PH&T to be Sole Supply on 1 October 2014 Inj 4 mcg per ml, 1 ml – Special Authority see SA1401 below				
- Retail pharmacy	67.18	10	🗸 M	linirin

SA1401 Special Authority for Subsidy

Initial application — (Desmopressin tablets for Nocturnal enuresis) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has primary nocturnal enuresis; and
- 2 The nasal forms of desmopressin are contraindicated; and
- 3 An enuresis alarm is contraindicated.

Initial application — (Desmopressin tablets for Diabetes insipidus) from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has cranial diabetes insipidus; and
- 2 The nasal forms of desmopressin are contraindicated.

Renewal — (Desmopressin tablets) from any relevant practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from the treatment.

Initial application — (Desmopressin injection) only from a relevant specialist. Approvals valid for 2 years where the patient cannot use desmopressin nasal spray or nasal drops.

Renewal — (Desmopressin injection) only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Other Endocrine Agents

CABERGOLINE

Tab 0.5 mg - Maximum of 2 tab per prescription; can be			
waived by Special Authority see SA1370 below	6.25	2	Dostinex
	25.00	8	Dostinex

➡SA1370 Special Authority for Waiver of Rule

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 pathological hyperprolactinemia; or
- 2 acromegaly*.

Renewal — (for patients who have previously been funded under Special Authority form SA1031) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has previously held a valid Special Authority which has expired and the treatment remains appropriate and the patient is benefiting from treatment. Note: Indication marked with * is an Unapproved indication.

(Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
CLOMIPHENE CITRATE				
Tab 50 mg	29.84	10	✓ <u>s</u>	erophene
DANAZOL				
Cap 100 mg		100	🖌 A	zol
Cap 200 mg	97.83	100	🗸 A	zol
METYRAPONE				
Cap 250 mg – Retail pharmacy-Specialist	520.00	50	🗸 M	letopirone

	Subsidy		Fully Brand or
	(Manufacturer's F \$	Price) Su Per	bsidised Generic Manufacturer
Anthelmintics			
LBENDAZOLE – Special Authority see SA1318 below – R	Retail pharmacy		
Tab 400 mg		60	Eskazole S29
SA1318 Special Authority for Subsidy	0-0.00	00	
itial application only from an infectious disease special attent has hydatids.	ist or clinical microbic	ologist. Appro	ovals valid for 6 months where t
tenewal only from an infectious disease specialist or clini- emains appropriate and the patient is benefitting from the tr		provals valid	for 6 months where the treatme
IEBENDAZOLE – Only on a prescription			
Tab 100 mg		24	De-Worm
Oral liq 100 mg per 5 ml		15 ml	
	(7.17)		Vermox
PRAZIQUANTEL			
Tab 600 mg		8	 Biltricide
Antibacterials			
) For anti-infective eye preparations, refer to SENSORY OF	BGANS page 202		
) For topical antibacterials, refer to DERMATOLOGICALS,			
Cenhalosporins and Cenhamycins			
Cephalosporins and Cephamycins CEFACLOR MONOHYDRATE Cap 250 mg		100	✓ Ranbaxy-Cefaclor
EFACLOR MONOHYDRATE		100	✓ Ranbaxy-Cefaclor
CEFACLOR MONOHYDRATE Cap 250 mg	- see	100 100 ml	 ✓ <u>Ranbaxy-Cefaclor</u> ✓ <u>Ranbaxy-Cefaclor</u>
CEFACLOR MONOHYDRATE Cap 250 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17	- see		
CEFACLOR MONOHYDRATE Cap 250 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 CEFALEXIN MONOHYDRATE Cap 500 mg	– see 3.53 		
 CEFACLOR MONOHYDRATE Cap 250 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 CEFALEXIN MONOHYDRATE Cap 500 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable 	– see 	100 ml 20	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u>
 EFACLOR MONOHYDRATE Cap 250 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 EFALEXIN MONOHYDRATE Cap 500 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 	- see 	100 ml 20 100 ml	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u>
 EFACLOR MONOHYDRATE Cap 250 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 EFALEXIN MONOHYDRATE Cap 500 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 Note: Cefalexin grans for oral liq will not be funded in 	– see 	100 ml 20 100 ml	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u>
 EFACLOR MONOHYDRATE Cap 250 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 EFALEXIN MONOHYDRATE Cap 500 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 Note: Cefalexin grans for oral liq will not be funded in Grans for oral liq 250 mg per 5 ml – Wastage claimable 	- see 	100 ml 20 100 ml 4 days treatn	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u> tent per dispensing.
 EFACLOR MONOHYDRATE Cap 250 mg	- see 	100 ml 20 100 ml 4 days treatn 100 ml	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u>
 EFACLOR MONOHYDRATE Cap 250 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 EFALEXIN MONOHYDRATE Cap 500 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 Note: Cefalexin grans for oral liq will not be funded in Grans for oral liq 250 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 Note: Cefalexin grans for oral liq will not be funded in Grans for oral liq 250 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 Note: Cefalexin grans for oral liq will not be funded in Note: Cefalexin grans for oral liq will not be funded in 	- see 	100 ml 20 100 ml 4 days treatn 100 ml	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u>
EFACLOR MONOHYDRATE Cap 250 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 EFALEXIN MONOHYDRATE Cap 500 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 Note: Cefalexin grans for oral liq will not be funded in Grans for oral liq 250 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 Note: Cefalexin grans for oral liq will not be funded in Grans for oral liq 250 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 Note: Cefalexin grans for oral liq will not be funded in EFAZOLIN – Subsidy by endorsement	- see 	100 ml 20 100 ml 4 days treatm 100 ml 4 days treatm	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> nent per dispensing.
 EFACLOR MONOHYDRATE Cap 250 mg	- see 	100 ml 20 100 ml 4 days treatm 100 ml 4 days treatm	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> nent per dispensing.
 EFACLOR MONOHYDRATE Cap 250 mg	- see 	100 ml 20 100 ml 4 days treatm 100 ml 4 days treatm	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> nent per dispensing.
 EFACLOR MONOHYDRATE Cap 250 mg	- see 	100 ml 20 100 ml 4 days treatm 100 ml 4 days treatm protocol and t	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Marce Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Marce Cefalexin Sandoz</u><
 EFACLOR MONOHYDRATE Cap 250 mg	- see 	100 ml 20 100 ml 4 days treatm 100 ml 4 days treatm protocol and t	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>tent per dispensing.</u> <u>hent per dispensing.</u>
 EFACLOR MONOHYDRATE Cap 250 mg	- see 	100 ml 20 100 ml 4 days treatm 100 ml 4 days treatm protocol and t	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Marce Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Marce Cefalexin Sandoz</u><
 EFACLOR MONOHYDRATE Cap 250 mg	- see 	100 ml 20 100 ml 4 days treatm 100 ml 4 days treatm protocol and t	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Marce Cefalexin Sandoz</u> <u>Cefalexin Sandoz</u> <u>Marce Cefalexin Sandoz</u><
 EFACLOR MONOHYDRATE Cap 250 mg	- see 	100 ml 20 100 ml 4 days treatm 100 ml 4 days treatm protocol and t 5 5	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u> Ment per dispensing. <u>Cefalexin Sandoz</u> Ment per dispensing. AFT AFT
 EFACLOR MONOHYDRATE Cap 250 mg	- see 	100 ml 20 100 ml 4 days treatm 100 ml 4 days treatm protocol and t 5 5	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u> the predispensing. <u>Cefalexin Sandoz</u> the prescription is endorsed acco AFT AFT AFT
 EFACLOR MONOHYDRATE Cap 250 mg	- see 	100 ml 20 100 ml 4 days treatm 100 ml 4 days treatm protocol and t 5 5	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u> tent per dispensing. <u>Cefalexin Sandoz</u> tent per dispensing. he prescription is endorsed acco AFT AFT AFT
 CEFACLOR MONOHYDRATE Cap 250 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 CEFALEXIN MONOHYDRATE Cap 500 mg Grans for oral liq 125 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 Note: Cefalexin grans for oral liq will not be funded in Grans for oral liq 250 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 Note: Cefalexin grans for oral liq will not be funded in Grans for oral liq 250 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 Note: Cefalexin grans for oral liq will not be funded in Grans for oral liq 250 mg per 5 ml – Wastage claimable rule 3.3.2 on page 17 Note: Cefalexin grans for oral liq will not be funded in CEFAZOLIN – Subsidy by endorsement Only if prescribed for dialysis or cellulitis in accordance v ingly. Inj 500 mg vial AFT to be Sole Supply on 1 October 2014 Inj 1 g vial AFT to be Sole Supply on 1 October 2014 CEFTRIAXONE – Subsidy by endorsement a) Up to 5 inj available on a PSO b) Subsidised only if prescribed for a dialysis or cystic pelvic inflammatory disease, or the treatment of suspect 	- see 	100 ml 20 100 ml 4 days treatm 100 ml 4 days treatm protocol and t 5 5	 <u>Ranbaxy-Cefaclor</u> <u>Cephalexin ABM</u> <u>Cefalexin Sandoz</u> the predispensing. <u>Cefalexin Sandoz</u> the prescription is endorsed acco AFT AFT AFT

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
CEFUROXIME AXETIL – Subsidy by endorsement	aviation in an damand a		l	
Only if prescribed for prophylaxis of endocarditis and the pres Tab 250 mg		accordii 50		linnat
CEFUROXIME SODIUM				
Inj 750 mg – Maximum of 1 inj per prescription; can be waived by endorsement Waiver by endorsement must state that the prescription is f	6.96	5 brosis i		n-Cefuroxime
Macrolides			outonti	
 AZITHROMYCIN – Maximum of 5 days treatment per prescription For Endorsement, patient has either: 1) Received a lung transplant and requires treatment or prop 2) Cystic fibrosis and has chronic infection with Pseudomo isms*. 	phylaxis for bronchiol	itis oblit	erans syr	
Indications parked with * are Unapproved Indications				
Tab 250 mg Tab 500 mg – Up to 8 tab available on a PSO		30 2		Apo-Azithromycin Apo-Azithromycin
Grans for oral liq 200 mg per 5 ml - Wastage claimable - see				
rule 3.3.2 on page 17		15 ml		lithromax
CLARITHROMYCIN – Maximum of 500 mg per prescription; can Tab 250 mg Apo-Clarithromycin to be Sole Supply on 1 October 2014 Grans for oral lig 125 mg per 5 ml – Wastage claimable – see	3.98	l Autho 14		A1131 below Apo-Clarithromycin
rule 3.3.2 on page 17		70 ml	🖌 K	lacid
 SA1131 Special Authority for Waiver of Rule Initial application — (Mycobacterial infections) only from a res Approvals valid for 2 years for applications meeting the following c Either: Atypical mycobacterial infection; or Mycobacterium tuberculosis infection where there is drug 	riteria:			
$\label{eq:constraint} \begin{array}{l} \textbf{Renewal} - (\textbf{Mycobacterial infections}) \ \text{only from a respiratory s} \\ \text{valid for 2 years where the treatment remains appropriate and the} \end{array}$				or paediatrician. Approvals
ERYTHROMYCIN ETHYL SUCCINATE	10.05	100		Musia
Tab 400 mga) Up to 20 tab available on a PSO	10.95	100	~	-Mycin
b) Up to 2 x the maximum PSO quantity for RFPP – see ru	le 5.2.6 on page 21			
Grans for oral liq 200 mg per 5 mla) Up to 300 ml available on a PSO	4.35 1	00 ml	V E	-Mycin
 b) Up to 2 x the maximum PSO quantity for RFPP – see ru c) Wastage claimable – see rule 3.3.2 on page 17 	le 5.2.6 on page 21			
Grans for oral liq 400 mg per 5 ml a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 17	5.85 1	00 ml	V E	-Mycin
ERYTHROMYCIN LACTOBIONATE				
Inj 1 g	10.00	1		rythrocin IV

	Subsidy (Manufacturer's P	(rico)	Fully Subsidised	Brand or Generic
	(Manufacturer's P \$	rice) Per	Subsidised	Manufacturer
RYTHROMYCIN STEARATE				
Tab 250 mg – Up to 30 tab available on a PSO	14.95	100		
	(22.29)		E	RA
Tab 500 mg		100		
3	(44.58)		E	RA
OXITHROMYCIN				
Tab 150 mg	7.48	50	🖌 A	rrow-
,			_	Roxithromycin
Tab 300 mg	14.40	50	✓ <u>A</u>	rrow-
				Roxithromycin
Penicillins				
MOXICILLIN				
Cap 250 mg		500	ν Δ	po-Amoxi
a) Up to 30 cap available on a PSO			• <u>n</u>	
b) Up to 10 x the maximum PSO quantity for RFPP – see r	ule 5.2.6 on pag	e 21		
Cap 500 mg		500	🖌 A	po-Amoxi
	(26.50)			phamox
a) Up to 30 cap available on a PSO	()			
b) Up to 10 x the maximum PSO quantity for RFPP – see r	ule 5.2.6 on pag	e 21		
c) Apo-Amoxi to be Sole Supply on 1 October 2014	ale elle ell pag			
Grans for oral lig 125 mg per 5 ml	0.88	100 ml	🖌 A	moxicillin Actavis
				anmoxy
	1.55			spamox
a) Up to 200 ml available on a PSO				
b) Wastage claimable – see rule 3.3.2 on page 17				
Grans for oral liq 250 mg per 5 ml	0.97	100 ml	🖌 A	moxicillin Actavis
			🖌 R	anmoxy
	1.10			spamox
a) Up to 300 ml available on a PSO				•
b) Up to 10 x the maximum PSO quantity for RFPP – see r	ule 5.2.6 on pag	e 21		
c) Wastage claimable - see rule 3.3.2 on page 17				
Inj 250 mg vial		10	🖌 lb	iamox
Inj 500 mg vial		10	🖌 lb	iamox
Inj 1 g vial – Up to 5 inj available on a PSO		10	🖌 lb	iamox
Alphamox Cap 500 mg to be delisted 1 October 2014)				
MOXICILLIN WITH CLAVULANIC ACID				
Tab 500 mg with clavulanic acid 125 mg – Up to 30 tab avail-				
able on a PSO	1 05	20	1 A	ugmentin
	12.55	100		uram Duo
Grans for oral lig amoxicillin 125 mg with clavulanic acid	12.00	100	• 0	
31.25 mg per 5 ml	1.61	100 ml		uamontin
51.25 mg per 5 mi		100 m		<u>ugmentin</u> uram
a) Lin to 200 ml available on a PSO			v (uram
a) Up to 200 ml available on a PSO b) Wastage claimable – see rule 3.3.2 on page 17				
Grans for oral lig amoxicillin 250 mg with clavulanic acid				
· · · · · ·	2 10	100 ml		uamontin
62.5 mg per 5 ml	2.19	100 ml		ugmentin
a) Lin ta 000 mi avrijabla ar i 5000			V C	uram
a) Up to 200 ml available on a PSO				
 b) Wastage claimable – see rule 3.3.2 on page 17 				

	Subsidy (Manufacturer's \$	Price) Su Per	Fully Brand or ubsidised Generic ✔ Manufacturer	
BENZATHINE BENZYLPENICILLIN				
Inj 1.2 mega u per 2.3 ml – Up to 5 inj available on a PSO	315.00	10	Bicillin LA	
BENZYLPENICILLIN SODIUM (PENICILLIN G)				
Inj 600 mg (1 million units) vial - Up to 5 inj available on a	L			
PS0		10	Sandoz	
Sandoz to be Sole Supply on 1 October 2014				
FLUCLOXACILLIN				
Cap 250 mg – Up to 30 cap available on a PSO		250	Staphlex	
Cap 500 mg		500	Staphlex	
Grans for oral liq 125 mg per 5 ml	2.49	100 ml	✓ <u>AFT</u>	
 a) Up to 200 ml available on a PSO 				
b) Wastage claimable – see rule 3.3.2 on page 17				
Grans for oral liq 250 mg per 5 ml	3.25	100 ml	✓ <u>AFT</u>	
a) Up to 200 ml available on a PSO				
b) Wastage claimable – see rule 3.3.2 on page 17	0.00	10	· / Fluelauin	
Inj 250 mg vial Flucloxin to be Sole Supply on 1 October 2014	8.80	10	 Flucloxin 	
Inj 500 mg vial	0.20	10	Flucloxin	
Flucloxin to be Sole Supply on 1 October 2014	9.20	10		
Inj 1 g vial – Up to 10 inj available on a PSO	11.60	10	Flucloxin	
Flucloxin to be Sole Supply on 1 October 2014		10		
PHENOXYMETHYLPENICILLIN (PENICILLIN V)				
Cap potassium salt 250 mg – Up to 30 cap available on a				
PSO		50	Cilicaine VK	
Cap potassium salt 500 mg		50	✓ Cilicaine VK	
a) Up to 20 cap available on a PSO		00		
b) Up to 2 x the maximum PSO quantity for RFPP – see ru	le 5.2.6 on page	e 21		
Grans for oral liq 125 mg per 5 ml		100 ml	✓ AFT	
a) Up to 200 ml available on a PSO				
b) Wastage claimable – see rule 3.3.2 on page 17				
Grans for oral liq 250 mg per 5 ml	1.74	100 ml	✓ <u>AFT</u>	
a) Up to 300 ml available on a PSO				
b) Up to 2 x the maximum PSO quantity for RFPP – see ru	ule 5.2.6 on page	e 21		
c) Wastage claimable – see rule 3.3.2 on page 17				
PROCAINE PENICILLIN				
Inj 1.5 g in 3.4 ml syringe – Up to 5 inj available on a PSO	123.50	5	 Cilicaine 	
Cilicaine to be Sole Supply on 1 October 2014				
Tetracyclines				
DOXYCYCLINE				
* Tab 50 mg – Up to 30 tab available on a PSO	2.90	30		
	(6.00)		Doxy-50	
* Tab 100 mg – Up to 30 tab available on a PSO	6.75	250	Doxine	
Doxine to be Sole Supply on 1 October 2014				
MINOCYCLINE HYDROCHLORIDE				
* Tab 50 mg - Additional subsidy by Special Authority see				
SA1355 on the next page – Retail pharmacy	5.79	60		
	(12.05)		Mino-tabs	
* Cap 100 mg		100		
	(52.04)		Minomycin	

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	
SA1355 Special Authority for Manufacturers Price nitial application from any relevant practitioner. Approvals vali osacea.	d without further re	newal u	inless no	tified where the patient h
ETRACYCLINE – Special Authority see SA1332 below – Retail Cap 500 mg		30	~	Tetracyclin Wolff \$29
SA1332 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals valid Both:	for 3 months for app	lication	s meeting	
 For the eradication of helicobacter pylori following unsucc For use only in combination with bismuth as part of a qua 			priate firs	st-line therapy; and
Other Antibiotics				
 for topical antibiotics, refer to DERMATOLOGICALS, page 67 CIPROFLOXACIN Recommended for patients with any of the following: i) microbiologically confirmed and clinically significant pseufii) prostatitis; or iii) pyelonephritis; or iv) gonorrhoea. 				
Tab 250 mg – Up to 5 tab available on a PSO Cipflox to be Sole Supply on 1 October 2014	1.75	28	~	Cipflox
Tab 500 mg – Up to 5 tab available on a PSO Tab 750 mg		28 28 30		Cipflox Cipflox
Ciprofloxacin Rex Tab 750 mg to be delisted 1 December 2014)	(5.52)	50		Ciprofloxacin Rex
LINDAMYCIN Cap hydrochloride 150 mg – Maximum of 4 cap per prescrip-				
tion; can be waived by endorsement - Retail pharmacy - Specialist	5.80	16	V	Clindamycin ABM
Inj phosphate 150 mg per ml, 4 ml – Retail pharmacy- Specialist	100.00	10	~	Dalacin C
O-TRIMOXAZOLE				
 Tab trimethoprim 80 mg and sulphamethoxazole 400 mg – Up to 30 tab available on a PSO 		500	~	Trisul
 Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml – Up to 200 ml available on a PSO 	2.15	100 ml	~	Deprim
OLISTIN SULPHOMETHATE – Retail pharmacy-Specialist – Su Only if prescribed for dialysis or cystic fibrosis patient and the Inj 150 mg	prescription is endo			Colistin-Link
USIDIC ACID Tab 250 mg – Retail pharmacy-Specialist		12	~	Fucidin

	Subsidy	Cube	Fully	Brand or
	(Manufacturer's Price) \$	Per	sidised V	Generic Manufacturer
GENTAMICIN SULPHATE				
Inj 10 mg per ml, 1 ml – Subsidy by endorsement	8 56	5	И Н	ospira
Only if prescribed for a dialysis or cystic fibrosis patient or c				
accordingly.	in the second		i ana a	
Inj 10 mg per ml, 2 ml – Subsidy by endorsement	175.10	25	🖌 A	PP
				Pharmaceuticals S29
Only if prescribed for a dialysis or cystic fibrosis patient or c	complicated urinary tra	et infectior	n and th	ne prescription is endorsed
accordingly.	omplicated annuly re		i unu u	
Inj 40 mg per ml, 2 ml – Subsidy by endorsement		10	✓ P	
Only if prescribed for a dialysis or cystic fibrosis patient or c	complicated urinary tra	ct infectior	n and th	ne prescription is endorsed
accordingly.				
MOXIFLOXACIN - Special Authority see SA1358 below - Retail	pharmacy			
No patient co-payment payable	50.00	_		
Tab 400 mg		5	VA	velox
► SA1358 Special Authority for Subsidy	a sialist av infastions of			
Initial application — (Tuberculosis) only from a respiratory spector applications meeting the following criteria:	ecialist of intectious u	sease spe	cialist.	Approvais valid for T year
Either:				
1 Both:				
1.1 Active tuberculosis*; and				
1.2 Any of the following:				
1.2.1 Documented resistance to one or more firs	st-line medications; or			
1.2.2 Suspected resistance to one or more first	t-line medications (tul	perculosis	assum	ed to be contracted in an
area with known resistance), as part of reg			ne age	nts; or
1.2.3 Impaired visual acuity (considered to prech	/ .		al: a a 4: a	
1.2.4 Significant pre-existing liver disease or hep 1.2.5 Significant documented intolerance and/or				
		a 1643011		
2 Mycobacterium avium-intracellulare complex not respond	ding to other therapy of	or where su	uch the	rapy is contraindicated.*.
Note: Indications marked with * are Unapproved Indications (refer	•			
Renewal only from a respiratory specialist or infectious disease s			'	ere the treatment remains
appropriate and the patient is benefiting from treatment.				
Initial application - (Mycoplasma genitalium) from any rel	evant practitioner. A	pprovals v	alid for	1 month for applications
meeting the following criteria:				
All of the following:				
 Has nucleic acid amplification test (NAAT) confirmed Myo Has tried and failed to clear infection using azithromycin; 		and		
3 Treatment is only for 7 days.	anu			
Initial application — (Penetrating eye injury) only from an o	onhthalmologist Ann	rovals vali	d for 1	month where the natient
requires prophylaxis following a penetrating eye injury and treatm				monar where the patient
Note: Indications marked with * are Unapproved Indications (refer		d Definitior	าร).	
PAROMOMYCIN - Special Authority see SA1324 below - Retail	pharmacy			
Cap 250 mg		16	🖌 Н	umatin S29
►SA1324 Special Authority for Subsidy				
Initial application only from an infectious disease specialist or clin	nical microbiologist. A	pprovals v	alid for	1 month where the patient
has confirmed cryptosporidium infection.				

Renewal only from an infectious disease specialist or clinical microbiologist. Approvals valid for 1 month where the patient has confirmed cryptosporidium infection.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
PYRIMETHAMINE – Special Authority see SA1328 below – Reta	il pharmacy			
Tab 25 mg	26.14	30		Daraprim S29
	36.95	50	v [Daraprim S29
 SA1328 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid the following criteria: Any of the following: For the treatment of toxoplasmosis in patients with HIV fo For pregnant patients for the term of the pregnancy; or For infants with congenital toxoplasmosis until 12 months 	r a period of 3 month		nless notifi	ed for applications meeting
SULFADIAZINE SODIUM – Special Authority see SA1331 below		50		Ma . 1. h 11
Tab 500 mg ⇒SA1331 Special Authority for Subsidy		56	•	Wockhardt S29
 the following criteria: Any of the following: For the treatment of toxoplasmosis in patients with HIV fo For pregnant patients for the term of the pregnancy; or For infants with congenital toxoplasmosis until 12 months 		is; or		
TOBRAMYCIN	-			
Inj 40 mg per ml, 2 ml – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and t		5 dorsed		DBL Tobramycin gly.
TRIMETHOPRIM Tab 300 mg – Up to 30 tab available on a PSO 	9.28	50	~ 1	ГМР
VANCOMYCIN – Subsidy by endorsement Only if prescribed for a dialysis or cystic fibrosis patient or for following metronidazole failure and the prescription is endorse	prophylaxis of endoc	arditis	or for treat	tment of Clostridium difficile
Inj 500 mg		1	~ 1	Mylan
Antifungals				-
a) For topical antifungals refer to DERMATOLOGICALS, page 67				
b) For topical antifungals refer to GENITO URINARY, page 81				
FLUCONAZOLE				
Cap 50 mg – Retail pharmacy-Specialist		28		Ozole
 Cap 150 mg – Subsidy by endorsement	ndorsement - Retail p er considers that a to y; can be waived by e 9.69	opical	acy - Speci imidazole sement - R V ((used intra-vaginally) is no

Subsidy	Fu	ly Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per	 Manufacturer 	

➡SA1359 Special Authority for Subsidy

Initial application — (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires prophylaxis for, or treatment of systemic candidiasis; and
- 2 Patient is unable to swallow capsules.

Initial application — (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient is immunocompromised; and
- 2 Patient is at moderate to high risk of invasive fungal infection; and
- 3 Patient is unable to swallow capsules.

Renewal — (Systemic candidiasis) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 Patient requires prophylaxis for, or treatment of systemic candidiasis; and
- 2 Patient is unable to swallow capsules.

Renewal — (Immunocompromised) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient remains immunocompromised; and
- 2 Patient remains at moderate to high risk of invasive fungal infection; and
- 3 Patient is unable to swallow capsules.

ITRACONAZOLE

Funded for tinea vesicolor where topical treatment has not been successful and diagnosis has been confirmed by mycology, or for tinea unguium where terbinafine has not been successful in eradication or the patient is intolerant to terbinafine and diagnosis has been confirmed by mycology and the prescription is endorsed accordingly. Can be waived by endorsement - Retail pharmacy - Specialist Specialist must be an infectious disease physician, clinical microbiologist, clinical immunologist or dermatologist.

Oral liq 10 mg per ml - Special Authority see SA1322 below

➡SA1322 Special Authority for Subsidy

Initial application only from an infectious disease specialist, clinical microbiologist, clinical immunologist or any relevant practitioner on the recommendation of a infectious disease physician, clinical microbiologist or clinical immunologist. Approvals valid for 6 months where the patient has a congenital immune deficiency.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefitting from the treatment.

KETOCONAZOLE

Tab 200 mg - PCT - Retail pharmacy-Specialist - Subsi by endorsement		30	✓ Nizoral S29
Prescriptions must be written by, or on the recommenda	tion of an oncologist		
NYSTATIN			
Tab 500,000 u	14.16	50	
	(17.09)		Nilstat
Cap 500,000 u		50	
	(15.47)		Nilstat

Sporanox

	Subsidy (Manufacturer's Price)		Fully	Brand or Generic
	\$	Per		Manufacturer
POSACONAZOLE - Special Authority see SA1285 below - Reta	il pharmacy			
Oral liq 40 mg per ml		15 ml OP	🖌 N	oxafil

SA1285 Special Authority for Subsidy

Initial application only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation chemotherapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppressive therapy*.

Renewal only from a haematologist or infectious disease specialist. Approvals valid for 6 weeks for applications meeting the following criteria:

Either:

- 1 Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy; or
- 2 Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression* and requires on going posaconazole treatment.

Note: * Graft versus host disease (GVHD) on significant immunosuppression is defined as acute GVHD, grade II to IV, or extensive chronic GVHD, or if they were being treated with intensive immunosuppressive therapy consisting of either high-dose corticosteroids (\geq 1 mg per kilogram of body weight per day for patients with acute GVHD or \geq 0.8 mg per kilogram every other day for patients with chronic GVHD), antithymocyte globulin, or a combination of two or more immunosuppressive agents or types of treatment.

TERBINAFINE

 * Tab 250 mg – For terbinafine oral liquid formulation refer, 		
page 2091.50	14	 Dr Reddy's Terbinafine
Dr Reddy's Terbinafine to be Sole Supply on 1 October 2014		
VORICONAZOLE – Special Authority see SA1273 below – Retail pharmacy		
Tab 50 mg730.00	56	Vfend
Tab 200 mg2,930.00	56	Vfend
Powder for oral suspension 40 mg per ml – Wastage		
claimable – see rule 3.3.2 on page 17730.00	70 ml	 Vfend

SA1273 Special Authority for Subsidy

Initial application — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

If of the following:

- 1 Patient is immunocompromised; and
- 2 Applicant is part of a multidisciplinary team including an infectious disease specialist; and
- 3 Any of the following:
 - 3.1 Patient has proven or probable invasive aspergillus infection; or
 - 3.2 Patient has possible invasive aspergillus infection; or
 - 3.3 Patient has fluconazole resistant candidiasis; or
 - 3.4 Patient has mould strain such as Fusarium spp. and Scedosporium spp.

Renewal — (invasive fungal infection) only from a haematologist, infectious disease specialist or clinical microbiologist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

If of the following:

1 Patient is immunocompromised; and

continued...

	Subsidy (Manufacturer's Price) \$	S Per	Fully subsidised	Brand or Generic Manufacturer
 continued 2 Applicant is part of a multidisciplinary team including an 3 Any of the following: 	n infectious disease spe	ecialist;	and	
3.1 Patient continues to require treatment for prove3.2 Patient continues to require treatment for possit3.3 Patient has fluconazole resistant candidiasis; or3.4 Patient has mould strain such as Fusarium spp.	ble invasive aspergillus	infectio		on; or
Antimalarials				
PRIMAQUINE PHOSPHATE – Special Authority see SA1326 b Tab 7.5 mg		/ 56	✔ P	rimacin ^{\$29}
SA1326 Special Authority for Subsidy Initial application only from an infectious disease specialist or meeting the following criteria: Both:	clinical microbiologist.	Approv	als valid fo	or 1 month for applications
1 The patient has vivax or ovale malaria; and 2 Primaquine is to be given for a maximum of 21 days.				
Antiparasitics				
Antiprotozoals				
QUININE SULPHATE * Tab 300 mg ‡ Safety cap for extemporaneously compounded oral liqu		500	✔ Q	300
Antitrichomonal Agents				
METRONIDAZOLE				
Tab 200 mg – Up to 30 tab available on a PSO		100	· · ·	richozole
Tab 400 mg Oral lig benzoate 200 mg per 5 ml		100 00 ml		richozole lagyl-S
Suppos 500 mg		10		lagyl
ORNIDAZOLE				
Tab 500 mg	16.50	10	V A	rrow-Ornidazole
Antituberculotics and Antileprotics				
Note: There is no co-payment charge for all pharmaceuticals li immigration status.	isted in the Antitubercu	lotics a	nd Antilep	protics group regardless of
CLOFAZIMINE – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommend	ation of, an infectious of	disease	physiciar	n, clinical microbiologist or
dermatologist. * Cap 50 mg		100	V L	amprene S29
CYCLOSERINE – Retail pharmacy-Specialist				
a) No patient co-payment payableb) Prescriptions must be written by, or on the recommend	ation of, an infectious	disease	physiciar	n, clinical microbiologist or
respiratory physician. Cap 250 mg	1,140.63	100	🗸 К	ing S29

	Subsidy (Manufacturer's Price) \$) Per	Fully Subsidised	Brand or Generic Manufacturer
DAPSONE – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendat	ion of, an infectious	disea	se physician	n, clinical microbiologist or
dermatologist Tab 25 mg	95.00	100	🖌 Da	apsone
Dapsone to be Sole Supply on 1 October 2014 Tab 100 mg	110.00	100	🗸 Da	apsone
Dapsone to be Sole Supply on 1 October 2014 ETHAMBUTOL HYDROCHLORIDE – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendat		disea	se physician	n, clinical microbiologist or
respiratory physician Tab 100 mg				
Tab 400 mg		56 56		lyambutol S29 lyambutol S29
 ISONIAZID – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendation biologist, dermatologist or public health physician * Tab 100 mg * Tab 100 mg with rifampicin 150 mg * Tab 150 mg with rifampicin 300 mg PARA-AMINO SALICYLIC ACID – Retail pharmacy-Specialist a) No patient co-payment payable 		licine p 100 100 100	✓ <u>P</u> ✓ R	·
 b) Specialist must be an infectious disease specialist, clinical Grans for oral liq 4 g sachet 		pirator 30		aser \$29
 PROTIONAMIDE – Retail pharmacy-Specialist a) No patient co-payment payable b) Specialist must be an infectious disease specialist, clinical Tab 250 mg PYRAZINAMIDE – Retail pharmacy-Specialist 		100	V Pe	eteha 629
 b) Prescriptions must be written by, or on the recommendat respiratory physician * Tab 500 mg - For pyrazinamide oral liquid formulation refer, page 209 		disea:		n, clinical microbiologist or FT-Pyrazinamide
 RIFABUTIN – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommendat gastroenterologist 	tion of, an infectious	disea		
* Cap 150 mg – For rifabutin oral liquid formulation refer, page 209		30	✓ <u>M</u>	lycobutin

				(M	Subsidy lanufacturer's Pri \$	ice) Per	Fully Subsidised	Brand or Generic Manufacturer
a) I b) I bas Spe	No patient co- For confirmed sed on susce ecialist. Spec	otibilities and the	e ylococcus aureus e prescription is e	endorsed acco	ordingly; can b	e waived	by endors	taphylococcal antimicrob ement - Retail pharmacy ist, paediatrician, or pub
	alth physician. h 600 mg				108 70	30	/ F	Rifadin
	0					100	· · ·	Rifadin
€ Ca	ip 300 mg				116.25	100	🖌 F	Rifadin
€ Ora	al liq 100 mg p	oer 5 ml			12.00	60 ml	🗸 F	lifadin
Antiv	virals							
or eye	e preparations	refer to Eye Pre	parations, Anti-Inf	fective Prepara	ations, page 20	2		
Нера	atitis B Tre	atment						
			thority see SA082			30	✔ H	lepsera
ll of th 1 2 3 4	Documented Patient has I Patient has I	l resistance to la aised serum AL IBV DNA greate	titis B infection (Hi amivudine, defined T (> 1 \times ULN); and er than 100,000 co V mutation; and	l as: nd	or viral load \geq	10 fold o	ver nadir; a	Ind
	5.1 Both							
	5.1.1 5.1.2	Patient is cirrh adefovir dipivo	otic; and xil to be used in c	ombination wi	th lamivudine;	or		
		Patient is not o	cirrhotic; and xil to be used as r	monotherany				
	al only from a	a gastroenterolo		disease speci			or 2 years v	vhere in the opinion of t
					0		esistance to	o adefovir dipivoxil, defin
	HBV DNA gr Detection of ir dipivoxil sho	N236T or A181	000 copies per mL T/V mutation.					BeAg+ prior to commenci
iii) defovi			tinivovil is no mor	o than 10ma d	ailv.			
iii) defovi defovi he rec n patie	commended d ents with renal	insufficiency ad		se should be r	educed in acco	ordance w	vith the data	asheet guidelines.

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	

SA1361 Special Authority for Subsidy

Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B nucleoside analogue treatment-naive; and
- 3 Entecavir dose 0.5 mg/day; and
- 4 Either:
 - 4.1 ALT greater than upper limit of normal; or
 - 4.2 Bridging fibrosis (Metavir stage 3 or greater or moderate fibrosis) or cirrhosis on liver histology; and

5 Either:

- 5.1 HBeAg positive; or
- 5.2 patient has ≥ 2,000 IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and
- 6 No continuing alcohol abuse or intravenous drug use; and
- 7 Not co-infected with HCV, HIV or HDV; and
- 8 Neither ALT nor AST greater than 10 times upper limit of normal; and
- 9 No history of hypersensitivity to entecavir; and
- 10 No previous documented lamivudine resistance (either clinical or genotypic).

Notes:

- Entecavir should be continued for 6 months following documentation of complete HBeAg seroconversion (defined as loss of HBeAg plus appearance of anti-HBe plus loss of serum HBV DNA) for patients who were HBeAg positive prior to commencing this agent. This period of consolidation therapy should be extended to 12 months in patients with advanced fibrosis (Metavir Stage F3 or F4).
- Entecavir should be taken on an empty stomach to improve absorption.

LAMIVUDINE - Special Authority see SA1360 below - Retail pharmacy

Tab 100 mg6.00	28	Zeffix
32.50		 Zetlam
Oral liq 5 mg per ml270.00	240 ml	🗸 Zeffix

SA1360 Special Authority for Subsidy

Initial application only from a gastroenterologist, infectious disease specialist, paediatrician, general physician or medical practitioner on the recommendation of a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 HBV DNA positive cirrhosis prior to liver transplantation; or
- 2 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or
- 3 Hepatitis B virus naive patient who has received a liver transplant from an anti-HBc (Hepatitis B core antibody) positive donor; or
- 4 Hepatitis B surface antigen (HbsAg) positive patient who is receiving chemotherapy for a malignancy, or high dose steroids (at least 20mg/day for at least 7 days), or who has received such treatment within the previous two months; or
- 5 Hepatitis B surface antigen positive patient who is receiving anti tumour necrosis factor treatment; or
- 6 Hepatitis B core antibody (anti-HBc) positive patient who is receiving rituximab plus high dose steroids (e.g. R-CHOP).

Renewal only from a gastroenterologist, infectious disease specialist, paediatrician, general physician or medical practitioner on the recommendation of a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

Renewal for patients who have maintained continuous treatment and response to lamivudine

1 All of the following:

continued...

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
`\$	Per	~	Manufacturer	

continued...

- 1.1 Have maintained continuous treatment with lamivudine; and
- 1.2 Most recent test result shows continuing biochemical response (normal ALT); and
- 1.3 HBV DNA <100,00 copies per ml by quantitative PCR at a reference laboratory; or

Renewal when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine 2 All of the following:

- 2.1 Lamivudine to be used in combination with adefovir dipivoxil; and
- 2.2 Patient is cirrhotic; and

Documented resistance to lamivudine, defined as:

- 2.3 Patient has raised serum ALT (> 1 \times ULN); and
- 2.4 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
- 2.5 Detection of M204I or M204V mutation; or

Renewal when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil

- 3 All of the following:
 - 3.1 Lamivudine to be used in combination with adefovir dipivoxil; and Documented resistance to adefovir, defined as:
 - 3.2 Patient has raised serum ALT (> 1 \times ULN); and
 - 3.3 Patient has HBV DNA greater than 100,000 copies per mL, or viral load = 10 fold over nadir; and
 - 3.4 Detection of N236T or A181T/V mutation.

Herpesvirus Treatments

ACICLOVIR

* Tab dispersible 200 mg1.78	25	🖌 Lovir
* Tab dispersible 400 mg5.98	56	Lovir
* Tab dispersible 800 mg6.64	35	🖌 Lovir
VALACICLOVIR – Special Authority see SA1363 below – Retail pharmacy Tab 500 mg	30	✓ Valtrex

➡SA1363 Special Authority for Subsidy

Initial application — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily.

Renewal — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (ophthalmic zoster) from any medical practitioner. Approvals valid without further renewal unless notified where the patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment.

Initial application — (CMV prophylaxis) from any medical practitioner. Approvals valid for 3 months where the patient has undergone organ transplantation.

Initial application — (immunocompromised patients) from any medical practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patients is immunocompromised; and
- 2 Patient has herpes zoster; and
- 3 Valaciclovir is to be given for a maximum of 7 days per course.

VALGANCICLOVIR - Special Authority see SA1404 on the next page - Retail pharmacy

Tab 450 mg3,000.00

Valcvte

60

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subs	sidised	Generic	
\$	Per	~	Manufacturer	

►SA1404 Special Authority for Subsidy

Initial application — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Renewal — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a solid organ transplant and received anti-thymocyte globulin and requires valganciclovir therapy for CMV prophylaxis; and
- 2 Patient is to receive a maximum of 90 days of valganciclovir prophylaxis following anti-thymocyte globulin.

Initial application — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Patient has undergone a solid organ transplant and received valganciclovir under Special Authority more than 2 years ago (27 months); and
- 2 Patient has received anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Renewal — (cytomegalovirus prophylaxis following anti-thymocyte globulin) only from a relevant specialist. Approvals valid for 3 months where the patient has received a further course of anti-thymocyte globulin and requires valganciclovir for CMV prophylaxis.

Initial application — (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
 - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
 - 2.2 The recipient is cytomegalovirus positive.

Initial application — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Renewal — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions.

Subsidy	Fu	illy	Brand or
(Manufacturer's Price)	Subsidis	ed	Generic
\$	Per	~	

Hepatitis B/ HIV/AIDS Treatment

TENOFOVIR DISOPROXIL FUMARATE – Subsidy by endorsement; can be waived by Special Authority see SA1362 below Endorsement for treatment of HIV: Prescription is deemed to be endorsed if tenofovir disoproxil fumarate is co-prescribed with another anti-retroviral subsidised under Special Authority SA1364 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Tenofovir disoproxil fumarate prescribed under endorsement for the treatment of HIV is included in the count of up to 4 subsidised antiretrovirals for the purposes of Special Authority SA1364, page 113

SA1362 Special Authority for Waiver of Rule

Initial application — (Chronic Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased \geq 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV; or
- 3 Patient has decompensated cirrhosis with a Mayo score >20.

Initial application — (Pregnant, Active hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20,000 IU/mL and ALT > ULN.

Renewal — (Confirmed Hepatitis B following funded tenofovir treatment for pregnancy within the previous two years) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased $\geq~$ 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV.

Renewal — (Subsequent pregnancy or Breastfeeding, Active hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 12 months for applications meeting the following criteria: Both:

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

- 1 Patient is HBsAg positive and pregnant or breastfeeding; and
- 2 HBV DNA > 20,000 IU/mL and ALT > ULN.

Initial application — (Pregnant, prevention of vertical transmission) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20 million IU/mL and ALT normal.

Renewal — (Subsequent pregnancy, prevention of vertical transmission) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20 million IU/mL and ALT normal.

Notes:

- Tenofovir disoproxil fumarate should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg
 positive prior to commencing this agent and 6 months following HBsAg seroconversion for patients who were HBeAg
 negative prior to commencing this agent.
- The recommended dose of Tenofovir disoproxil fumarate for the treatment of all three indications is 300 mg once daily.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Tenofovir disoproxil fumarate dose should be reduced in accordance with the approved Medsafe datasheet guidelines.
- Tenofovir disoproxil fumarate is not approved for use in children.

Hepatitis C Treatment

BOCEPREVIR - Special Authority see SA1402 below - Retail pharmacy

Cap 200 mg - Wastage claimable - see rule 3.3.2 on page

336

✓ Victrelis

➡SA1402 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, first-line) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has not received prior pegylated interferon treatment; and
- 3 Patient has IL-28B genotype CT or TT; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Patient is hepatitis C protease inhibitor treatment-naive; and
- 6 Maximum of 44 weeks therapy.

Initial application — (chronic hepatitis C - genotype 1, second-line) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has received pegylated interferon treatment; and
- 3 Any of the following:
 - 3.1 Patient was a responder relapser; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received pegylated interferon prior to 2004; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Maximum of 44 weeks therapy.

Subsidy		Fully	Brand or
(Manufacturer's Price)	:	Subsidised	Generic
\$	Per	~	Manufacturer

continued...

Notes:

- Due to risk of severe sepsis boceprevir should not be initiated if either Platelet count < 100 x10⁹ /l or Albumin <35 g/l
- The wastage rule applies to boceprevir to allow dispensing to occur more frequently than monthly

Antiretrovirals

SA1364 Special Authority for Subsidy

Initial application — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 \times total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or

2.4 Both:

- 2.4.1 Patient aged 6 years and over; and
- 2.4.2 CD4 counts < 500 cells/mm³.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Confirmed HIV) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria: Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

- 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
- 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
- 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (second or subsequent post-exposure prophylaxis) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Non-nucleosides Reverse Transcriptase Inhibitors

– Retail phar	macy	
158.33	30	Stocrin S29
474.99	90	✓ Stocrin
474.99	30	 Stocrin
145.79	180 ml OP	✓ Stocrin S29
e – Retail pha	armacy	
770.00	60	✓ Intelence
e – Retail pha	armacy	
95.94	60	Nevirapine
		Alphapharm
134.55	240 ml	Viramune
		Suspension
	158.33 474.99 474.99 e – Retail pha 770.00 e – Retail pha	474.99 90 474.99 30 e – Retail pharmacy 770.00 60 e – Retail pharmacy 95.94 60

Nucleosides Reverse Transcriptase Inhibitors

ABACAVIR SULPHATE -	Special Authority see SA1364 on the previous page	 Retail pharmacy 	
Tab 300 mg		60	Ziagen
Oral liq 20 mg per ml .		240 ml OP	 Ziagen

	Subsidy (Manufacturer's Pric	e) Su	Fully Brand or bsidised Generic
	\$	Per	Manufacturer
ABACAVIR SULPHATE WITH LAMIVUDINE – Special Authorit Note: abacavir with lamivudine (combination tablets) cour			
retroviral Special Authority. Tab 600 mg with lamivudine 300 mg	630.00	30	Kivexa
DIDANOSINE [DDI] – Special Authority see SA1364 on page 1			• NIVOAU
Cap 125 mg		y 30	Videx EC
Cap 200 mg		30	Videx EC
Cap 250 mg		30	Videx EC
Cap 400 mg		30	Videx EC
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOP – Retail pharmacy Note: Efavirenz with emtricitabine and tenofovir disoproxil fu of the anti-retroviral Special Authority Tab 600 mg with emtricitabine 200 mg and tenofovir disoprox	imarate counts as thr		
fumarate 300 mg	1,313.19	30	✓ Atripla
EMTRICITABINE – Special Authority see SA1364 on page 113	 Retail pharmacy 		
Cap 200 mg		30	 Emtriva
EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATI Note: Emtricitabine with tenofovir disoproxil fumarate cour retroviral Special Authority Tab 200 mg with tenofovir disoproxil fumarate 300 mg	nts as two anti-retrov		
LAMIVUDINE - Special Authority see SA1364 on page 113 - F	Retail pharmacy		
Tab 150 mg		60	Lamivudine <u>Alphapharm</u>
Oral liq 10 mg per ml		240 ml OP	✓ <u>3TC</u>
STAVUDINE [D4T] – Special Authority see SA1364 on page 11	3 – Retail pharmacy		
Cap 40 mg		60	 Zerit
Powder for oral soln 1 mg per ml		200 ml OP	V Zerit S29
ZIDOVUDINE [AZT] – Special Authority see SA1364 on page 1		•	
Cap 100 mg		100	Retrovir
Oral liq 10 mg per ml		200 ml OP	Retrovir
ZIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority see Note: zidovudine [AZT] with lamivudine (combination tablet anti-retroviral Special Authority.			
Tab 300 mg with lamivudine 150 mg Alphapharm to be Sole Supply on 1 October 2014		60	 Alphapharm
Protease Inhibitors			
ATAZANAVIR SULPHATE – Special Authority see SA1364 on p	ago 113 – Botail pha	armacy	
Cap 150 mg	0 1	60	✓ Reyataz
Cap 200 mg		60	✓ Reyataz
DARUNAVIR – Special Authority see SA1364 on page 113 – R			-
Tab 400 mg		60	Prezista
Tab 600 mg		60	✓ Prezista
-			
INDINAVIR – Special Authority see SA1364 on page 113 – Ret Cap 200 mg	ail pharmacy	360	Crixivan

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or sidised Generic ✔ Manufacturer
LOPINAVIR WITH RITONAVIR – Special Authority see SA1364 Tab 100 mg with ritonavir 25 mg Tab 200 mg with ritonavir 50 mg Oral liq 80 mg with ritonavir 20 mg per ml		Retail pharmacy 60 120 300 ml OP	 ✓ Kaletra ✓ Kaletra ✓ Kaletra
RITONAVIR – Special Authority see SA1364 on page 113 – Ret Tab 100 mg Oral liq 80 mg per ml		30 90 ml OP	✓ <u>Norvir</u> ✓ Norvir
Strand Transfer Inhibitors			
RALTEGRAVIR POTASSIUM – Special Authority see SA1364 or Tab 400 mg		tail pharmacy 60	✓ Isentress
Antiretrovirals - Additional Therapies HIV Fusion Inhibitors			
ENFUVIRTIDE – Special Authority see SA0845 below – Retail p Powder for inj 90 mg per ml × 60		1	✔ Fuzeon
▶ SA0845 Special Authority for Subsidy Initial application only from a named specialist. Approvals valid All of the following:	for 3 months for	applications me	eeting the following criteria:
 Confirmed HIV infection; and Enfuvirtide to be given in combination with optimized ba the patient has never previously been exposed to) for trees Either: 			east 1 other antiretroviral drug the
 3.1 Patient has evidence of HIV replication, despite 3.2 Patient has treatment-limiting toxicity to previous 	0 0 17		

- 3.2 Patient has treatment-limiting toxicity to previous antiretroviral agents; and4 Previous treatment with 3 different antiretroviral regimens has failed; and
- 5 All of the following:
 - 5.1 Previous treatment with a non-nucleoside reverse transcriptase inhibitor has failed; and
 - 5.2 Previous treatment with a nucleoside reverse transcriptase inhibitor has failed; and
 - 5.3 Previous treatment with a protease inhibitor has failed.

Renewal only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 Evidence of at least a 10 fold reduction in viral load at 12; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Immune Modulators

Guidelines for the use of interferon in the treatment of hepatitis C:

Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects.

Patients should be otherwise fit.

Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level.

Criteria for Treatment

- a) Diagnosis
 - Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or
 - PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or

	INFECTIONS	- AGENTS	FOR	SYSTEMIC USE
	Subsidy (Manufacturer's P \$	rice) Su Per	Fully Ibsidised	Brand or Generic Manufacturer
continued				
 Anti-HCV positive on at least two occasions 		mentary RIB	A test wit	h a negative PCR for HC
RNA but with a liver biopsy consistent with 2	(b) following.			
Exclusion Criteria				
a) Autoimmune liver disease. (Interferon may exacerb	ate autoimmune liver	disease as v	vell as of	her autoimmune disease
such as thyroid disease). b) Pregnancy.				
c) Neutropenia (<2.0 \times 10 ⁹) and/or thrombocytopenia				
 d) Continuing alcohol abuse and/or continuing intraven 				
Dosage	oud unug uddio.			
The current recommended dosage is 3 million units of interfe	eron alfa-2a or interfer	on alfa-2b ad	Iministere	ed subcutaneously 3 time
a week for 52 weeks (twelve months)				,
Exit Criteria				
The patient's response to interferon treatment should be rev				
liscontinued in patients who do not show a substantial reduc	tion (50%) in their me	an pre-treatr	nent ALT	level at this stage.
NTERFERON ALFA-2A – PCT – Retail pharmacy-Specialis	st			
 a) See prescribing guideline on the previous page 				
b) Prescriptions must be written by, or on the recommend				
Inj 3 m iu prefilled syringe	31.32	1	🖌 R	oferon-A
NTERFERON ALFA-2B – PCT – Retail pharmacy-Specialis	st			
a) See prescribing guideline on the previous page				
b) Prescriptions must be written by, or on the recommend		medicine phy		
Inj 18 m iu, 1.2 ml multidose pen		1		tron-A
Inj 30 m iu, 1.2 ml multidose pen		1		tron-A
Inj 60 m iu, 1.2 ml multidose pen	626.40	1	🗸 In	tron-A
PEGYLATED INTERFERON ALFA-2A - Special Authority se	ee SA1400 below – R	etail pharmad	су	
See prescribing guideline on the previous page				
Inj 135 mcg prefilled syringe	1 4 4 0 0 0	4	🖌 P	
		-	• •	egasys
Inj 180 mcg prefilled syringe		4		egasys egasys
Inj 135 mcg prefilled syringe \times 4 with ribavirin tab 200 m		4	✓ P	egasys
		-	✓ P	egasys egasys RBV
Inj 135 mcg prefilled syringe \times 4 with ribavirin tab 200 m 112		4	✓ P	egasys
Inj 135 mcg prefilled syringe \times 4 with ribavirin tab 200 n 112 Inj 135 mcg prefilled syringe \times 4 with ribavirin tab 200 n		4 1 OP	✓ <u>₽</u> ✓ <u>₽</u>	egasys egasys RBV Combination Pack
Inj 135 mcg prefilled syringe \times 4 with ribavirin tab 200 m 112		4	✓ <u>₽</u> ✓ <u>₽</u>	egasys egasys RBV Combination Pack egasys RBV
 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 m 112 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 m 168 		4 1 OP	✓ <u>₽</u> ✓ <u>₽</u>	egasys egasys RBV Combination Pack
 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 n 112 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 n 168 Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 n 		4 1 OP 1 OP	✓ <u>P</u> ✓ <u>P</u> ✓ <u>P</u>	egasys egasys <u>RBV</u> <u>Combination Pack</u> egasys <u>RBV</u> Combination Pack
Inj 135 mcg prefilled syringe \times 4 with ribavirin tab 200 m 112 Inj 135 mcg prefilled syringe \times 4 with ribavirin tab 200 m 168		4 1 OP	✓ <u>P</u> ✓ <u>P</u> ✓ <u>P</u>	egasys egasys RBV Combination Pack egasys RBV Combination Pack egasys RBV
 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 n 112 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 n 168 Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 n 112 		4 1 OP 1 OP	✓ <u>P</u> ✓ <u>P</u> ✓ <u>P</u>	egasys egasys RBV Combination Pack egasys RBV Combination Pack
 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 n 112 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 n 168 Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 n 		4 1 OP 1 OP	✓ <u>P</u> ✓ <u>P</u> ✓ <u>P</u>	egasys egasys RBV Combination Pack egasys RBV Combination Pack egasys RBV

➡SA1400 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant) from any specialist. Approvals valid for 18 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - 1.2 Patient has chronic hepatitis C and is co-infected with HIV; or

Subsidy (Manufacturer's Price)	S	Fully ubsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

- 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant; and
- 2 Maximum of 48 weeks therapy.

Notes:

- Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
- Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml

Renewal — (Chronic hepatitis C - genotype 1 infection) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Either:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Notes:

- Approved dose is 180 mcg once weekly.
- The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alfa 2a dose should be reduced to 135 mcg once weekly.
- In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
- Pegylated Interferon-alfa 2a is not approved for use in children.

HEXAMINE HIPPURATE ★ Tab 1 g 18.40 100 (38.10) Hiprex NITROFURANTOIN * Tab 50 mg - For nitrofurantoin oral liquid formulation refer, page 209 ★ Tab 100 mg 22.20 100 ✓ Nifuran * Tab 100 mg 37.50 100 ✓ Nifuran NORFLOXACIN Tab 400 mg - Subsidy by endorsement 13.50 100 ✓ Arrow-Norfloxacin			
(38.10) Hiprex NITROFURANTOIN ★ Tab 50 mg – For nitrofurantoin oral liquid formulation refer, page 209	18.40	100	
 ★ Tab 50 mg - For nitrofurantoin oral liquid formulation refer, page 209			Hiprex
page 209			
★ Tab 100 mg			
NORFLOXACIN		100	Nifuran
	37.50	100	Nifuran
Tab 400 mg – Subsidy by endorsement			
		100	Arrow-Norfloxacin
a) Only if prescribed for a patient with an uncomplicated u		(38.10) 22.20 37.50 13.50	(38.10)

b) Arrow-Norfloxacin to be Sole Supply on 1 October 2014

Mundacturer's Price Fully Brand or Studialed Generic Per Anticholinesterases NEOSTIGMINE METILSULFATE Inj 2.6 mg per ml, 1 ml ampoule AstraZeneca to be Sole Supply on 1 October 2014 98.00 50 ✓ AstraZeneca AstraZeneca Mestinon YRIDOSTIGMINE BROMIDE 100 ✓ Mestinon Tab 60 mg 38.90 100 ✓ Mestinon Non-Steroidal Anti-Inflammatory Drugs 00 ✓ Mestinon DICLOFENAC SODIUM 4.00 100 ✓ Apo-Diclo Tab 50 mg dispersible – Higher subsidy of \$8.00 per 20 tab with Endorsement. (8.00) Voltaren D Additional subsidy by endorsement for a patient who cannot swallow whole tablets and in whom ibuprofen oral liquid is imfective or not lolerated, and the prescription is endorsed accordingly. * Tab EC 5 000 ✓ Diclax SR * Tab 10 og.acting 10 00 mg 24.82 500 ✓ Diclax SR * Tab borg.doing 10 ng 4.225 500 ✓ Diclax SR * Suppos 125 mg 2.04 10 ✓ Voltaren * Suppos 125 mg 2.04 10 ✓ Voltaren * Suppos 125 mg 2.04 10 ✓ Voltaren * Suppos 100 mg 0 to supavailable on a PSO 4.22 10	_					
S Per ✓ Manufacturer Anticholinesterases NEOSTIGMINE METILSULFATE						
Anticholinesterases NEOSTIGMINE METILSULFATE Inj 2.5 mg per mi, 1 mi ampoule			· · · ·		SUDSIDISE	
NEOSTIGMINE METILSULFATE Inj 2.5 mg per ml, 1 ml ampoule	_		ψ	rei		
Inj 2.5 mg per ml, 1 ml ampoule	A	nticholinesterases				
AstraZeneca to be Sole Supply on 1 October 2014 PYRIDOSTIGMINE BROMIDE A Tab 60 mg	NE	OSTIGMINE METILSULFATE				
PYRIDOSTIGMINE BROMIDE ▲ Tab 60 mg		Inj 2.5 mg per ml, 1 ml ampoule		50	~	AstraZeneca
 ▲ Tab 60 mg		AstraZeneca to be Sole Supply on 1 October 2014				
Non-Steroidal Anti-Inflammatory Drugs DICLOFENAC SODIUM * Tab EO 28 mg .4.00 100 ✓ Apo-Diclo * Tab 50 mg dispersible – Higher subsidy of \$8.00 per 20 tab with Endorsement 1.50 20 Additional subsidy by endorsement for a patient who cannot swallow whole tablets and in whom ibuprofen oral liquid is ineffective or not tolerated, and the prescription is endorsed accordingly. Yes * Tab EO 50 mg .60.0 500 ✓ Apo-Diclo * Tab long-acting 75 mg .24.52 500 ✓ Diclax SR * Tab long-acting 100 mg .42.25 500 ✓ Diclax SR * Tab bog-seting 100 mg .24.52 500 ✓ Diclax SR * Suppos 12.5 mg .2.04 10 ✓ Voltaren * Suppos 25 mg .2.04 10 ✓ Voltaren * Suppos 20 mg .0.10 ✓ Voltaren Woltaren * Suppos 20 mg .0.10 .42.21 10 ✓ Voltaren * Suppos 20 mg .0.10 .42.21 0 ✓ Voltaren * Suppos 20 mg .0.10 .42.21 0 ✓ Voltaren * Buppos 100 mg .1.15 30 Brufen Souppost <td>PYI</td> <td>RIDOSTIGMINE BROMIDE</td> <td></td> <td></td> <td></td> <td></td>	PYI	RIDOSTIGMINE BROMIDE				
DICLOFENAC SODIUM ** Tab EC 25 mg	▲	Tab 60 mg		100	~	Mestinon
* Tab EC 25 mg	N	on-Steroidal Anti-Inflammatory Drugs				
* Tab EC 25 mg		CLOFENAC SODILIM				
 Tab 50 mg dispersible – Higher subsidy of \$8.00 per 20 tab with Endorsement			4 00	100	~	Ano-Diclo
with Endorsement. 1.50 20 (8.00) Voltaren D Additional subsidy by endorsement for a patient who cannot swallow whole tablets and in whom ibuprofen oral liquid is ineffective or not tolerated, and the prescription is endorsed accordingly. ** Tab EC 50 mg 16.00 500 ✓ Apo-Diclo ** Tab long-acting 75 mg 24.52 500 ✓ Diclax SR ** Tab long-acting 100 mg 22.25 500 ✓ Diclax SR ** Tab long-acting 100 mg 2.24 10 ✓ Voltaren ** Suppos 12.5 mg 2.04 10 ✓ Voltaren ** Suppos 25 mg 2.44 10 ✓ Voltaren ** Suppos 50 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 50 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Tab 200 mg .0.77 30 ✓ Voltaren Voltaren ** Tab 600 mg .1.15 30 ✓ Arrowcare ** Tab long-acting 800 mg .6.841 Brufen Sufficient ** Tab long-acting 200 mg .12.07 28 ✓ Oruvail SR #EreNANIC ACID KETOPROFEN .50		-		100	•	100 01010
(8.00) Voltaren D Additional subsidy by endorsement for a patient who cannot swallow whole tablets and in whom ibuprofen oral liquid is ineffective or not tolerated, and the prescription is endorsed accordingly. * Tab EC 50 mg 16.00 500 ✓ Apo-Diclo * Tab long-acting 75 mg 24.52 500 ✓ Diclax SR * Tab long-acting 100 mg 42.25 500 ✓ Diclax SR * In j25 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO. 13.20 5 ✓ Voltaren * Suppos 12.5 mg 2.04 10 ✓ Voltaren * Suppos 50 mg – Up to 10 supp available on a PSO. 4.22 10 ✓ Voltaren * Suppos 50 mg – Up to 10 supp available on a PSO. 4.22 10 ✓ Voltaren * Suppos 100 mg 12.75 1,000 ✓ Arrowcare * Tab 400 mg 0.77 30 6.84) Brufen * Tab 400 mg 1.15 30 ✓ Brufen Fenpaed * Tab 400 mg to be delisted 1 November 2014) (Brufen Tab 400 mg to be delisted 1 November 2014) Brufen Fenpaed (Brufen Tab 600 mg to be delisted 1 November 2014) (Brufen Tab 600 mg to be delisted 1 November 2014) Fenpaed Fenpaed	~	o 1 o j 1	1.50	20		
Additional subsidy by endorsement for a patient who cannot swallow whole tablets and in whom ibuprofen oral liquid is ineffective or not tolerated, and the prescription is endorsed accordingly. ** Tab EC 50 mg 16.00 500 ✓ Apo-Diclo ** Tab long-acting 75 mg 24.52 500 ✓ Diclax SR ** Tab long-acting 100 mg 42.25 500 ✓ Diclax SR ** Tab long-acting 100 mg 42.25 500 ✓ Diclax SR ** Tab long-acting 100 mg 42.25 500 ✓ Diclax SR ** Suppos 12.5 mg 2.04 10 ✓ Voltaren ** Suppos 25 mg 2.04 10 ✓ Voltaren ** Suppos 100 mg 7.00 10 ✓ Voltaren ** Suppos 100 mg 7.00 10 ✓ Voltaren ** Suppos 100 mg 7.00 10 ✓ Voltaren ** Tab 200 mg 12.75 1,000 ✓ Arrowcare ** Tab 400 mg 0.77 30 6.84) Brufen ** Tab long-acting 800 mg 8.12 30 ✓ Brufen SR ** Tab long-acting 200 mg 1.15 30 ✓ Fenpaed (Brufen Tab 400 mg to be delisted 1 November 2014) (Brufen Tab 400 mg to be de				20		Voltaren D
ineffective or not tolerated, and the prescription is endorsed accordingly. ** Tab EC 50 mg 16.00 500 ✓ Apo-Diclo ** Tab long-acting 75 mg 24.25 500 ✓ Diclax SR * Tab long-acting 100 mg 42.25 500 ✓ Diclax SR ** Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO 5 ✓ Voltaren ** Suppos 25 mg 2.44 10 ✓ Voltaren ** Suppos 50 mg – Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg 7.00 10 ✓ Voltaren ** Tab 200 mg 12.75 1,000 ✓ Arrowcare ** Tab 400 mg 0.77 30 ✓ Arrowcare ** Tab 600 mg 1.15 30 Brufen ** Tab long-acting 800 mg 8.12 30 ✓ Brufen SR ** Tab long-acting 200 mg 1.2.07 28 ✓ Oruvail SR KETOPROFEN (Brufen Tab 400 mg to be delisted 1 November 2014) KETOPROFEN ** Cap long-acting 200 mg 0.50 20 Youtan (Brufen Tab 400 mg to be delisted 1 November 2014) KETOPROFEN Youtan ** Cap long-acting 200 mg		Additional subsidy by endorsement for a patient who car	()	tablets	and in v	whom ibuprofen oral liquid is
* Tab long-acting 75 mg						
** Tab long-acting 75 mg 24.52 500 ✓ Diclax SR ** Tab long-acting 100 mg 42.25 500 ✓ Diclax SR ** Inj 25 mg per ml, 3 ml ampoule – Up to 5 inj available on a PSO 13.20 5 ✓ Voltaren ** Suppos 12.5 mg 2.04 10 ✓ Voltaren ** Suppos 25 mg 2.44 10 ✓ Voltaren ** Suppos 50 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg -On 10 ✓ Voltaren ✓ Voltaren ** Tab 200 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Tab 400 mg 0.77 30 Brufen Supp available on a PSO Feinpaed ** Tab 600 mg -Up to 115 30 Brufen Sup available on a PSO Sup available on a PSO Feinpaed (Brufen Tab 400 mg to be delisted 1 November 2014) (Brufen Tab 400 mg to be delisted 1 November 2014) Feinpaed Ponstan 1.25 So <td>*</td> <td></td> <td></td> <td>500</td> <td>~</td> <td>Apo-Diclo</td>	*			500	~	Apo-Diclo
* Inj 25 mg per ml, 3 ml ampoule - Up to 5 inj available on a PSO. 13.20 5 ✓ Voltaren * Suppos 12.5 mg 2.04 10 ✓ Voltaren * Suppos 25 mg 2.44 10 ✓ Voltaren * Suppos 25 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 50 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Tab 200 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren IBUPROFEN - - - - Arrowcare Brufen Suppos 10.5 Brufen Suppos 10.5 Brufen Supos 11.5 30 Feinpaed Feinpaed Feinpaed Feinpaed Feinpaed Feinpaed Feinpaed Feinpaed Feinpaed Suppos 10.5	*	Tab long-acting 75 mg	24.52	500		
PSO 13.20 5 ✓ Voltaren ** Suppos 12.5 mg 2.04 10 ✓ Voltaren ** Suppos 50 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg -Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren IBUPROFEN	*	Tab long-acting 100 mg		500	~	Diclax SR
** Suppos 12.5 mg 2.04 10 ✓ Voltaren ** Suppos 25 mg 2.44 10 ✓ Voltaren ** Suppos 50 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren ** Suppos 100 mg 7.00 10 ✓ Voltaren ** Suppos 100 mg 7.00 10 ✓ Voltaren IBUPROFEN ** Tab 200 mg 12.75 1,000 ✓ Arrowcare ** Tab 400 mg 0.77 30 Grufen * ** Tab 600 mg 1.15 30 Grufen * ** Tab long-acting 800 mg 8.12 30 ✓ Brufen SR ** Oral liq 20 mg per ml 1.89 200 ml ✓ Fenpaed (Brufen Tab 400 mg to be delisted 1 November 2014) KETOPROFEN ✓ Fenpaed * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID (§.16) Ponstan 1.25 50 (§.16) Ponstan 1.25 50 ✓ Noftam 250 * Tab 250 mg	*	Inj 25 mg per ml, 3 ml ampoule - Up to 5 inj available on a				
* Suppos 25 mg				5	~	Voltaren
* Suppos 50 mg - Up to 10 supp available on a PSO 4.22 10 ✓ Voltaren * Suppos 100 mg	*					
* Suppos 100 mg						
IBUPROFEN * Tab 200 mg 12.75 1,000 ✓ Arrowcare * Tab 400 mg 0.77 30 Intervention (4.56) Brufen 8 * Tab 600 mg 1.15 30 Intervention (6.84) Brufen 8 9 * Tab long-acting 800 mg 8.12 30 ✓ Brufen SR * Oral liq 20 mg per ml 1.89 200 ml ✓ Fenpaed (Brufen Tab 400 mg to be delisted 1 November 2014) (Brufen Tab 600 mg to be delisted 1 November 2014) ✓ Fenpaed KETOPROFEN 12.07 28 ✓ Oruvail SR MEFENAMIC ACID						
* Tab 200 mg 12.75 1,000 ✓ Arrowcare * Tab 400 mg 0.77 30 Brufen * Tab 600 mg 1.15 30 Brufen * Tab long-acting 800 mg 8.12 30 ✓ Brufen SR * Oral liq 20 mg per ml 8.12 30 ✓ Fenpaed (Brufen Tab 400 mg to be delisted 1 November 2014) 1.89 200 ml ✓ Fenpaed (Brufen Tab 600 mg to be delisted 1 November 2014) (Brufen Tab 600 mg to be delisted 1 November 2014) ✓ Oruvail SR KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID .0.50 20 0.50 20 0.50 20 * Cap 250 mg .0.50 20 .0.50 20 0.50 20 0.50 20 * Cap 250 mg .0.50 20 .0.50 20 0.50 20 0.50 20 0.50 20 0.50 20 0.50 20 0.50 20 0.50 20 0.50 20 0.50 20 0.50 20 0.50 20 0.50 20 0.50	*	Suppos 100 mg	7.00	10	V	voltaren
* Tab 400 mg 0.77 30 (4.56) Brufen * Tab 600 mg 1.15 30 (6.84) Brufen * Tab long-acting 800 mg 8.12 30 * Tab long-acting 800 mg 8.12 30 ✓ Brufen SR * Oral liq 20 mg per ml 1.89 200 ml ✓ Fenpaed (Brufen Tab 400 mg to be delisted 1 November 2014) ✓ Fenpaed ✓ Fenpaed (Brufen Tab 600 mg to be delisted 1 November 2014) ✓ Voruvail SR ✓ Fenpaed KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID * Cap 250 mg 0.50 20 0.50 20 (5.60) Ponstan 1.25 50 90 Ponstan NAPROXEN 21.25 500 ✓ Noflam 250 × * Tab 500 mg 22.25 250 ✓ Noflam 500 * Tab 500 mg 22.25 250 ✓ Noflam 500 * Tab b0ng-acting 750 mg 18.00 90 ✓ Naprosyn SR 750	IBU	-				
(4.56) Brufen * Tab 600 mg 1.15 30 (6.84) Brufen * Tab long-acting 800 mg 8.12 30 ✓ Brufen SR * Oral liq 20 mg per ml 1.89 200 ml ✓ Fenpaed (Brufen Tab 400 mg to be delisted 1 November 2014) ✓ Fenpaed (Brufen Tab 600 mg to be delisted 1 November 2014) ✓ Fenpaed KETOPROFEN ✓ Oruvail SR MEFENAMIC ACID	*	5		,	~	Arrowcare
* Tab 600 mg 1.15 30 (6.84) Brufen * Tab long-acting 800 mg 8.12 30 ✓ Brufen SR * Oral liq 20 mg per ml 1.89 200 ml ✓ Fenpaed (Brufen Tab 400 mg to be delisted 1 November 2014) 1.89 200 ml ✓ Fenpaed (Brufen Tab 600 mg to be delisted 1 November 2014) 1.89 200 ml ✓ Fenpaed (KETOPROFEN 12.07 28 ✓ Oruvail SR MEFENAMIC ACID 0.50 20 1.25 50 * Cap 250 mg 0.50 20 1.25 50 (9.16) Ponstan 1.25 50 ✓ Noflam 250 * Tab 250 mg 21.25 500 ✓ Noflam 250 * Tab 500 mg 22.25 250 ✓ Noflam 500 * Tab 500 mg 18.00 90 ✓ Naprosyn SR 750	*	Tab 400 mg	(30		- /
(6.84) Brufen * Tab long-acting 800 mg 8.12 30 ✓ Brufen SR * Oral liq 20 mg per ml 1.89 200 ml ✓ Fenpaed (Brufen Tab 400 mg to be delisted 1 November 2014) 1.89 200 ml ✓ Fenpaed (Brufen Tab 600 mg to be delisted 1 November 2014) V Fenpaed ✓ Fenpaed KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID .0.50 20 1.25 50 90 nstan 1.25 50 (9.16) Ponstan 1.250 × NAPROXEN .21.25 500 ✓ Noflam 250 × * Tab 250 mg .22.25 250 ✓ Noflam 500 * Tab 500 mg .22.25 250 ✓ Noflam 500 * Tab bong-acting 750 mg .18.00 90 ✓ Naprosyn SR 750		T 000	()			Bruten
** Tab long-acting 800 mg	*	Tab 600 mg		30		D (
* Oral liq 20 mg per ml 1.89 200 ml ✓ Fenpaed (Brufen Tab 400 mg to be delisted 1 November 2014) (Brufen Tab 600 mg to be delisted 1 November 2014) KETOPROFEN * Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID .0.50 20 .0.50 20 * Cap 250 mg .0.50 20 .0.50 20 (Brufen) .0.50 20 .0.50 20 (b) (B		Tab loss action 000 mm		00		
(Brufen Tab 400 mg to be delisted 1 November 2014) (Brufen Tab 600 mg to be delisted 1 November 2014) KETOPROFEN * Cap long-acting 200 mg * Cap 250 mg 0.50 20 (5.60) Ponstan 1.2.5 50 (9.16) Ponstan NAPROXEN 21.25 500 * Tab 250 mg 22.25 250 * Tab 500 mg 22.25 250 * Tab b00 mg 18.00 90						
(Brufen Tab 600 mg to be delisted 1 November 2014) KETOPROFEN * Cap long-acting 200 mg			1.09	200 111	v	renpaeu
KETOPROFEN * Cap long-acting 200 mg MEFENAMIC ACID * Cap 250 mg .0.50 20 (5.60) Ponstan 1.25 50 (9.16) Ponstan NAPROXEN * Tab 250 mg						
* Cap long-acting 200 mg 12.07 28 ✓ Oruvail SR MEFENAMIC ACID 0.50 20 * Cap 250 mg 0.50 20 (5.60) Ponstan 1.25 50 (9.16) Ponstan NAPROXEN 21.25 500 * Tab 250 mg 22.25 250 * Tab 500 mg 22.25 250 * Tab long-acting 750 mg 18.00 90	`	č ,				
MEFENAMIC ACID * Cap 250 mg 0.50 20 (5.60) Ponstan 1.25 50 (9.16) Ponstan NAPROXEN * Tab 250 mg 21.25 500 * Tab 500 mg 22.25 250 ✓ Noflam 250 * Tab long-acting 750 mg 18.00 90 ✓ Naprosyn SR 750			10.07	00		
* Cap 250 mg .0.50 20 (5.60) Ponstan 1.25 50 (9.16) Ponstan NAPROXEN 21.25 500 * Tab 250 mg 21.25 500 * Tab 500 mg 22.25 250 ✓ * Tab long-acting 750 mg			12.07	20	v	Oruvali SR
(5.60) Ponstan 1.25 50 (9.16) Ponstan NAPROXEN 21.25 500 ✓ * Tab 250 mg 22.25 250 ✓ Noflam 250 * Tab 500 mg 22.25 250 ✓ Noflam 500 * Tab long-acting 750 mg 18.00 90 ✓ Naprosyn SR 750						
1.25 50 (9.16) Ponstan NAPROXEN 21.25 500 ✓ Noflam 250 * Tab 250 mg 22.25 250 ✓ Noflam 500 * Tab long-acting 750 mg 18.00 90 ✓ Naprosyn SR 750	*	Cap 250 mg		20		
(9.16) Ponstan NAPROXEN 21.25 500 ✓ Noflam 250 * Tab 250 mg 22.25 250 ✓ Noflam 500 * Tab long-acting 750 mg 18.00 90 ✓ Naprosyn SR 750			()			Ponstan
NAPROXEN 21.25 500 ✓ Noflam 250 * Tab 250 mg				50		Develop
* Tab 250 mg 21.25 500 ✓ Noflam 250 * Tab 500 mg 22.25 250 ✓ Noflam 500 * Tab long-acting 750 mg 18.00 90 ✓ Naprosyn SR 750			(9.16)			Ponstan
* Tab 500 mg		-				
* Tab long-acting 750 mg		•				
* 1ab long-acting 1,000 mg	•					
	*	rab long-acting 1,000 mg		90	V	Naprosyn SK 1000

	Subsidy (Manufacturer's Price		Fully Subsidised	
	\$	Per		
SULINDAC				
* Tab 100 mg		50	🗸 A	clin
* Tab 200 mg	15.10	50	🗸 🗸	clin
TENOXICAM				
* Tab 20 mg		100	🖌 T	ïlcotil
* Inj 20 mg vial		1	🗸 A	FT
NSAIDs Other				
MELOXICAM - Special Authority see SA1034 below - Retail pha	rmacy			
* Tab 7.5 mg		30	🗸 A	rrow-Meloxicam
The CA1004 Connected Authority for Cubately				

➡SA1034 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating functional clotting factor; and
- 2 The patient has haemophilic arthropathy; and
- 3 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative funded treatment options, or alternative funded treatment options are contraindicated.

Topical Products for Joint and Muscular Pain

CAPSAICIN

Crm 0.025% - Special Authority see SA1289 below - Retail			
pharmacy	6.95	25 g OP	Zostrix
	9.95	45 g OP	Zostrix

➡SA1289 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

Antirheumatoid Agents

AURANOFIN		
Tab 3 mg68.99	60	Ridaura s29 S29
HYDROXYCHLOROQUINE		
* Tab 200 mg18.00	100	Plaquenil
LEFLUNOMIDE		
Tab 10 mg55.00	30	🖌 Arava
Tab 20 mg76.00	30	Arava
Tab 100 mg54.44	3	🖌 Arava
PENICILLAMINE		
Tab 125 mg61.93	100	D-Penamine
Tab 250 mg98.98	100	D-Penamine
SODIUM AUROTHIOMALATE		
Inj 10 mg in 0.5 ml ampoule76.87	10	Myocrisin
Inj 20 mg in 0.5 ml ampoule113.17	10	Myocrisin
Inj 50 mg in 0.5 ml ampoule217.23	10	✓ Myocrisin

Drugs Affecting Bone Metabolism

Alendronate for Osteoporosis

SA1039 Special Authority for Subsidy

Initial application — (Underlying cause – Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Note); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or raloxifene.

Initial application — (Underlying cause – glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is receiving systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD $\geq\,$ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score $\leq\,$ -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for zoledronic acid (Underlying cause glucocorticosteroid therapy) or raloxifene.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents).

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Note); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) or raloxifene.

Notes:

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🗸	Manufacturer	

continued...

- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALE	ALENDRONATE SODIUM – Special Authority see SA1039 on the previous page – Retail pharmacy					
*	Tab 70 mg		4	Fosamax		
ALE	NDRONATE SODIUM WITH CHOLECALCIFEROL -	Special Authority see SA103	9 on the	e previous page – Retail pharmacy		
*	Tab 70 mg with cholecalciferol 5,600 iu		4	Fosamax Plus		

Alendronate for Paget's Disease

SA0949 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
 - 2.5 Preparation for orthopaedic surgery.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

ALENDRONATE SODIUM – Special Authority see SA0949 above – Retail pharma * Tab 40 mg	acy 30	✓ Fosamax
Other Treatments		
ETIDRONATE DISODIUM – See prescribing guideline below * Tab 200 mg	100	✓ Arrow-Etidronate

Prescribing Guidelines

Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose – 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	d Generic
PAMIDRONATE DISODIUM				
Inj 3 mg per ml, 5 ml vial		1	~	Pamisol
Inj 3 mg per ml, 10 ml vial	6.80	1	~	Pamisol
	(16.00)			Pamidronate BNM
Inj 6 mg per ml, 10 ml vial		1	~	Pamisol
	(32.00)			Pamidronate BNM
Inj 9 mg per ml, 10 ml vial		1	~	Pamisol
	(48.00)			Pamidronate BNM
(Pamisol Inj 3 mg per ml, 5 ml vial to be delisted 1 December 201	(4)			
(Pamidronate BNM Inj 3 mg per ml, 10 ml vial to be delisted 1 De	cember 2014)			
(Pamidronate BNM Inj 6 mg per ml, 10 ml vial to be delisted 1 De	cember 2014)			
(Pamidronate BNM Inj 9 mg per ml, 10 ml vial to be delisted 1 De	cember 2014)			
RALOXIFENE HYDROCHLORIDE - Special Authority see SA11	38 below – Retail pha	rmac	y	
* Tab 60 mg		28	· /	Evista
SA1138 Special Authority for Subsidy				

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or alendronate (Underlying cause Osteoporosis).

Notes:

- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

RISEDRONATE SODIUM

Tab 35 mg4.00	4	 Risedronate Sandoz
TERIPARATIDE – Special Authority see SA1139 on the next page – Retail pharmacy		
Inj 250 mcg per ml, 2.4 ml	1	 Forteo

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	~	Manufacturer	

SA1139 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- d) A maximum of 18 months of treatment (18 cartridges) will be subsidised.

ZOLEDRONIC ACID – Special Authority see SA1187 below – Retail pharmacy

➡SA1187 Special Authority for Subsidy

Initial application — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score \leq -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

- 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) or raloxifene; and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD $\geq\,$ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score $\leq\,$ -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause glucocorticosteroid therapy) or raloxifene; and
- 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Renewal — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
 - 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
 - 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than one infusion in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than one infusion in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score \leq -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) or raloxifene; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

2 The patient will not be prescribed more than one infusion in a 12-month period.

Notes:

- BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Hyperuricaemia and Antigout

ALLOI OTTINOL		
* Tab 100 mg		Apo-Allopurinol
* Tab 300 mg - For allopurinol oral liquid formulation refe	r,	
page 209		Apo-Allopurinol
BENZBROMARONE - Special Authority see SA1319 below - F	Retail nharmacy	
BENZERION NOTE Opeolar Automy see of the below 1	iotali priarriady	
Tab 100 mg		Benzbromaron AL
		100 S29

SA1319 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Any of the following:
 - 1.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and appropriate doses of probenecid; or
 - 1.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite appropriate doses of probenecid; or
 - 1.3 Both:
 - 1.3.1 The patient has renal impairment and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
 - 1.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
 - 1.4 All of the following:
 - 1.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
 - 1.4.2 Allopurinol is contraindicated; and
 - 1.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and
- 2 The patient is receiving monthly liver function tests.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 The treatment remains appropriate and the patient is benefitting from the treatment; and

(Maa	Subsidy	F	ully	Brand or
	nufacturer's Price)	Subsidis	sed	Generic
	\$	Per	~	Manufacturer

continued...

2 There is no evidence of liver toxicity and patient is continuing to receive regular (at least every three months) liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity.

Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at http://www.rheumatology.org.nz/benzbromarone_prescriber_information.cfm

COLCHICINE

* Tab 500 mcg		100	✓ Colgout
FEBUXOSTAT - Special Authority see SA1431 below - Re	etail pharmacy		
Tab 80 mg		28	Adenuric
Tab 120 mg		28	Adenuric

SA1431 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Any of the following:

- 1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and appropriate doses of probenecid; or
- 2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite appropriate doses of probenecid; or

3 Both:

- 3.1 The patient has renal impairment and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
- 3.2 The patient has a rate of creatinine clearance greater than or equal to 30 ml/min.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from treatment.

Note: Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearanceadjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

Muscle Relaxants

BACLOFEN

* Tab 10 mg – For baclofen oral liquid formulation refer, page			
209		100	✓ Pacifen
Inj 0.05 mg per ml, 1 ml ampoule – Subsidy by endorsement		1	 Lioresal Intrathecal
Subsidised only for use in a programmable pump in patien caused intolerable side effects and the prescription is endor		itispastic ag	ents have been ineffective or have
Inj 2 mg per ml, 5 ml ampoule - Subsidy by endorsement	209.29	1	 Lioresal Intrathecal
Subsidised only for use in a programmable pump in patien caused intolerable side effects and the prescription is endor		itispastic ag	ents have been ineffective or have
DANTROLENE			
* Cap 25 mg	65.00	100	Dantrium
* Cap 50 mg	77.00	100	Dantrium
ORPHENADRINE CITRATE			4 x x m
Tab 100 mg		100	 Norflex

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Agents for Parkinsonism and Related Disorders	\$			
Dopamine Agonists and Related Agents				
MANTADINE HYDROCHLORIDE				
Cap 100 mg		60	🗸 S	ymmetrel
APOMORPHINE HYDROCHLORIDE				
Inj 10 mg per ml, 2 ml	110.00	5	🗸 A	pomine
ROMOCRIPTINE MESYLATE				
* Tab 2.5 mg		100	🗸 A	po-Bromocriptine
 Cap 5 mg 	60.43	100	🗸 A	po-Bromocriptine
Apo-Bromocriptine Cap 5 mg to be delisted 1 October 2014)				
NTACAPONE				
▲ Tab 200 mg	47.92	100	✓ <u>E</u>	ntapone
EVODOPA WITH BENSERAZIDE				
₭ Tab dispersible 50 mg with benserazide 12.5 mg		100	🗸 N	ladopar Rapid
Cap 50 mg with benserazide 12.5 mg	8.00	100	🖌 N	ladopar 62.5
Cap 100 mg with benserazide 25 mg	12.50	100	🗸 N	ladopar 125
 Cap long-acting 100 mg with benserazide 25 mg 		100		ladopar HBS
Cap 200 mg with benserazide 50 mg	25.00	100	✓ N	ladopar 250
EVODOPA WITH CARBIDOPA				
* Tab 100 mg with carbidopa 25 mg – For levodopa with carbidopa	ſ-			
bidopa oral liquid formulation refer, page 209	10.00	50		indopa
	20.00	100		inson
. The lange office 000 menuith contridence 50 me	47.50	100		inemet
Tab long-acting 200 mg with carbidopa 50 mg Tab 250 mg with carbidopa 25 mg		100 100		inemet CR inemet
Sindopa Tab 100 mg with carbidopa 25 mg to be delisted 1 Feb		100	• 5	inemet
ISURIDE HYDROGEN MALEATE				
Tab 200 mcg	25.00	30	VD	opergin
RAMIPEXOLE HYDROCHLORIDE				
Tab 0.125 mg	1.95	30	✓ □	r Reddy's
	0.40	00		Pramipexole
Tab 0.25 mg	2.40	30	v L	r Reddy's
	7.00	100		Pramipexole
Tab 0.5 mg	7.20	100 30		amipex s29 r Reddy's
		50	•	Pramipexole
Tab 1 mg	7 20	30	. / r	r Reddy's
		00	• •	Pramipexole
	24.39	100		amipex \$29
	21.00		Ŧ	
OPINIROLE HYDROCHLORIDE Tab 0.25 mg	2.26	100		po-Ropinirole
Tab 1 mg		100		po-Ropinirole
Tab 2 mg		100		po-Ropinirole
▲ Tab 5 mg		100		po-Ropinirole
		100	• -	ho Hohimole

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
SELEGILINE HYDROCHLORIDE * Tab 5 mg	16.06	100		Apo-Selegiline Apo-Selegiline S29 S29
TOLCAPONE ▲ Tab 100 mg	126.20	100	V	Tasmar
Anticholinergics				
BENZTROPINE MESYLATE Tab 2 mg Inj 1 mg per ml, 2 ml a) Up to 5 inj available on a PSO b) Only on a PSO ORPHENADRINE HYDROCHLORIDE		60 5		Benztrop Cogentin
Tab 50 mg (Disipal Tab 50 mg to be delisted 1 November 2014)	35.15	250	~	Disipal
PROCYCLIDINE HYDROCHLORIDE Tab 5 mg	7.40	100	V	Kemadrin
Agents for Essential Tremor, Chorea and Related	Disorders			
 RILUZOLE – Special Authority see SA1403 below – Retail pharma Wastage claimable – see rule 3.3.2 on page 17 Tab 50 mg ➡SA1403 Special Authority for Subsidy Initial application only from a neurologist or respiratory speciali 	400.00	56 I for 6	-	Rilutek
following criteria: All of the following:				
1 The patient has amyotrophic lateral sclerosis with disease	duration of 5 years	or less	s; and	

- 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
- 3 The patient has not undergone a tracheostomy; and
- 4 The patient has not experienced respiratory failure; and
- 5 Any of the following:
 - 5.1 The patient is ambulatory; or
 - 5.2 The patient is able to use upper limbs; or
 - 5.3 The patient is able to swallow.

Renewal from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 The patient has not undergone a tracheostomy; and
- 2 The patient has not experienced respiratory failure; and
- 3 Any of the following:
 - 3.1 The patient is ambulatory; or
 - 3.2 The patient is able to use upper limbs; or
 - 3.3 The patient is able to swallow.

TETRABENAZINE

Tab 25 mg	.118.00	112	✓ Motetis
-----------	---------	-----	-----------

	Subsidy		Fully Bra	and or
	(Manufacturer's Pi	rice) Su	,	neric
	\$	Per	🖌 Ma	nufacturer
Anaesthetics				
Local				
IDOCAINE [LIGNOCAINE]				
Gel 2%, 10 ml urethral syringe – Subsidy by endorsement a) Up to 5 each available on a PSO b) Subsidised only if prescribed for urethral or cervical a		10 ne prescription	Pfizer	
IDOCAINE [LIGNOCAINE] HYDROCHLORIDE				accorulingly.
Oral (viscous) soln 2%		200 ml	🖌 Xvloc	aine Viscous
Xylocaine Viscous to be Sole Supply on 1 October 2014			•	
Inj 1%, 5 ml ampoule - Up to 25 inj available on a PSO		25	🖌 Lidoc	aine-Claris
	17.50	50		
	(35.00)		Xyloca	aine
Inj 2%, 5 ml ampoule - Up to 5 inj available on a PSO	6.90	25	Lidoc	aine-Claris
Inj 1%, 20 ml ampoule - Up to 5 inj available on a PSO	2.40	1	Lidoc	aine-Claris
	12.00	5		
	(20.00)		Xyloca	aine
Inj 2%, 20 ml ampoule - Up to 5 inj available on a PSO	2.40	1	✓ Lidoc	aine-Claris
DOCAINE [LIGNOCAINE] WITH CHLORHEXIDINE				
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes	_			
, , , , , , , , , , , , , , , , , , , ,		10		
Subsidy by endorsement	43.20	10	 Pfizer 	
a) Up to 5 each available on a PSO	desinistration and th	o proporintio	n in andaraa	l accordingly
b) Subsidised only if prescribed for urethral or cervical a				accordingly.
Crm 2.5% with prilocaine 2.5%	45.00	30 g OP	🖌 EMLA	
Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes)	45.00			
Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes) SA0906 Special Authority for Subsidy itial application from any relevant practitioner. Approvals w ondition requiring frequent injections or venepuncture. enewal from any relevant practitioner. Approvals valid for 2	45.00 45.00 valid for 2 years whe	30 g OP 5 ere the patier	 EMLA EMLA Mathematical end of the second second	vith a chronic medi
Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes) SA0906 Special Authority for Subsidy itial application from any relevant practitioner. Approvals v ondition requiring frequent injections or venepuncture. enewal from any relevant practitioner. Approvals valid for 2 enefiting from treatment.	45.00 45.00 valid for 2 years whe	30 g OP 5 ere the patier	 EMLA EMLA Mathematical end of the second second	vith a chronic medi
Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes) SA0906 Special Authority for Subsidy Itial application from any relevant practitioner. Approvals w ondition requiring frequent injections or venepuncture. enewal from any relevant practitioner. Approvals valid for 2 enefiting from treatment. Analgesics	45.00 45.00 ralid for 2 years whe years where the tra	30 g OP 5 ere the patier	 EMLA EMLA Mathematical end of the second second	vith a chronic medi
Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes) SA0906 Special Authority for Subsidy Itial application from any relevant practitioner. Approvals w ondition requiring frequent injections or venepuncture. enewal from any relevant practitioner. Approvals valid for 2 enefiting from treatment. Analgesics	45.00 45.00 ralid for 2 years whe years where the tra	30 g OP 5 ere the patier	 EMLA EMLA Mathematical end of the second second	vith a chronic medi
Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes)	45.00 45.00 ralid for 2 years whe years where the tra	30 g OP 5 ere the patier	 EMLA EMLA Mathematical end of the second second	vith a chronic medi
Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes) SA0906 Special Authority for Subsidy hitial application from any relevant practitioner. Approvals wo ondition requiring frequent injections or venepuncture. Lenewal from any relevant practitioner. Approvals valid for 2 enefiting from treatment. Analgesics or Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, Non-opioid Analgesics	45.00 45.00 ralid for 2 years whe years where the tra	30 g OP 5 ere the patier	 EMLA EMLA Mathematical end of the second second	vith a chronic medi
Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes) SA0906 Special Authority for Subsidy initial application from any relevant practitioner. Approvals wo ondition requiring frequent injections or venepuncture. enewal from any relevant practitioner. Approvals valid for 2 enefiting from treatment. Analgesics or Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, Non-opioid Analgesics SPIRIN	valid for 2 years where the trap page 120	30 g OP 5 ere the patier	 EMLA EMLA Mathematical end of the second second	vith a chronic medi
Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes) SA0906 Special Authority for Subsidy itial application from any relevant practitioner. Approvals volution requiring frequent injections or venepuncture. enewal from any relevant practitioner. Approvals valid for 2 enefiting from treatment. Analgesics for Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, Non-opioid Analgesics SPIRIN	valid for 2 years where the trap page 120	30 g OP 5 ere the patier eatment rema	 EMLA EMLA Mathematical end of the second second	with a chronic medi ate and the patient
Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes) >SA0906 Special Authority for Subsidy iitial application from any relevant practitioner. Approvals v ondition requiring frequent injections or venepuncture. enewal from any relevant practitioner. Approvals valid for 2 enefiting from treatment. Analgesics or Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, Non-opioid Analgesics SPIRIN = Tab EC 300 mg	45.00 valid for 2 years whe years where the tra page 120 	30 g OP 5 ere the patier eatment rema	EMLA EMLA	with a chronic medi ate and the patient
Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes) SA0906 Special Authority for Subsidy itial application from any relevant practitioner. Approvals volution requiring frequent injections or venepuncture. enewal from any relevant practitioner. Approvals valid for 2 enefiting from treatment. Analgesics or Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, Non-opioid Analgesics SPIRIN = Tab EC 300 mg = Tab dispersible 300 mg – Up to 30 tab available on a PSC	45.00 valid for 2 years whe years where the tra page 120 	30 g OP 5 ere the patier eatment rema 100	EMLA EMLA ains appropri	with a chronic medi ate and the patient
Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes) SA0906 Special Authority for Subsidy itial application from any relevant practitioner. Approvals v ondition requiring frequent injections or venepuncture. enewal from any relevant practitioner. Approvals valid for 2 enefiting from treatment. Analgesics or Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, Non-opioid Analgesics SPIRIN Tab EC 300 mg Tab dispersible 300 mg – Up to 30 tab available on a PSC APSAICIN – Subsidy by endorsement a) For aspirin & chloroform application refer Standard Form b) Subsidised only if prescribed for post-herpetic neuralgia	45.00 valid for 2 years whe years where the tra- page 120 	30 g OP 5 ere the patier eatment rema 100 100	EMLA EMLA ains appropri Aspec Ethics	vith a chronic medi ate and the patient ate and ate and ate and ate and ate and ate ate ate ate ate ate ate ate ate ate ate
Crm 2.5% with prilocaine 2.5% (5 g tubes)		30 g OP 5 ere the patier eatment rema 100 100 ral neuropath	EMLA EMLA at is a child v ains appropri Aspec Ethic: ny and the pr	vith a chronic media ate and the patient ate and ate and ate and ate and ate ate ate ate ate ate ate ate ate ate ate
Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes) SA0906 Special Authority for Subsidy initial application from any relevant practitioner. Approvals valid ondition requiring frequent injections or venepuncture. enewal from any relevant practitioner. Approvals valid for 2 enefiting from treatment. Analgesics or Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, Non-opioid Analgesics SPIRIN © Tab EC 300 mg Frab dispersible 300 mg – Up to 30 tab available on a PSC APSAICIN – Subsidy by endorsement a) For aspirin & chloroform application refer Standard Form b) Subsidised only if prescribed for post-herpetic neuralgia accordingly. Crm 0.075%		30 g OP 5 ere the patier eatment rema 100 100	EMLA EMLA ains appropri Aspec Ethics	vith a chronic medi ate and the patient ate ate and the patient ate ate ate ate ate ate ate ate ate ate ate ate ate ate ate ate ate ate ate
Crm 2.5% with prilocaine 2.5% Crm 2.5% with prilocaine 2.5% (5 g tubes) SA0906 Special Authority for Subsidy itial application from any relevant practitioner. Approvals volid ondition requiring frequent injections or venepuncture. enewal from any relevant practitioner. Approvals valid for 2 enefiting from treatment. Analgesics or Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, Non-opioid Analgesics SPIRIN Tab EC 300 mg Tab dispersible 300 mg – Up to 30 tab available on a PSC APSAICIN – Subsidy by endorsement a) For aspirin & chloroform application refer Standard Form b) Subsidised only if prescribed for post-herpetic neuralgia accordingly.		30 g OP 5 ere the patier eatment rema 100 100 ral neuropath	EMLA EMLA at is a child v ains appropri Aspec Ethic: ny and the pr	vith a chronic media ate and the patient ate and ate and ate and ate and ate

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Sul Per	osidised Generic ✓ Manufacturer
PARACETAMOL			
* Tab 500 mg – Up to 30 tab available on a PSO	8.47	1.000	Pharmacare
· ····································	9.38	.,	✓ Parafast
∗ ‡ Oral liq 120 mg per 5 ml	2.21	500 ml	Ethics Paracetamol
	4.15	1,000 ml	✓ Paracare
a) Up to 200 ml available on a PSO			
b) Not in combination			
★ 1 Oral lig 250 mg per 5 ml	4.35	1,000 ml	Paracare Double
		,	Strength
a) Up to 100 ml available on a PSO			Jere gr
b) Not in combination			
c) Paracare Double Strength to be Sole Supply on 1	October 2014		
₭ Suppos 125 mg		20	Panadol
₭ Suppos 250 mg		20	Panadol
k Suppos 500 mg	20.70	50	Paracare
Onisid Analysiss			
Opioid Analgesics			
CODEINE PHOSPHATE – Safety medicine; prescriber may	determine dispensin	a freauencv	
Tab 15 mg		100	🖌 PSM
Tab 30 mg	5.80	100	V PSM
Tab 60 mg		100	V PSM
Tab long-acting 60 mg	13.6/	60	DHC Continus
0 0 0		00	• Drie Continus
ENTANYL			
a) Only on a controlled drug form			
b) No patient co-payment payable			
c) Safety medicine; prescriber may determine dispensin		40	
lnj 50 mcg per ml, 2 ml		10	Boucher and Muir
Inj 50 mcg per ml, 10 ml		10	Boucher and Muir
Patch 12.5 mcg per hour	8.90	5	Mylan Fentanyl Datak
		_	Patch
Patch 25 mcg per hour	9.15	5	Mylan Fentanyl
			Patch
Patch 50 mcg per hour	11.50	5	Mylan Fentanyl
			Patch
Patch 75 mcg per hour	13.60	5	 Mylan Fentanyl
			Patch
Patch 100 mcg per hour	14.50	5	🗸 Mylan Fentanyl
			Patch

	Subsidy		Fully Brand or
	(Manufacturer's F \$	Price) Su Per	bsidised Generic Manufacturer
ETHADONE HYDROCHLORIDE			
a) Only on a controlled drug form			
b) No patient co-payment payable			
c) Safety medicine; prescriber may determine dispensing freq	uencv		
d) Extemporaneously compounded methadone will only be re		rate of the ch	neapest form available (methad
powder, not methadone tablets).			
e) For methadone hydrochloride oral liquid refer Standard For	mulae, page 21	2	
Tab 5 mg		10	Methatabs
Oral lig 2 mg per ml		200 ml	✓ Biodone
Oral lig 5 mg per ml		200 ml	✓ Biodone Forte
Oral lig 10 mg per ml		200 ml	✓ Biodone Extra Forte
Inj 10 mg per ml, 1 ml		10	AFT
		10	÷ /u i
DRPHINE HYDROCHLORIDE			
a) Only on a controlled drug form			
b) No patient co-payment payable			
c) Safety medicine; prescriber may determine dispensing freq			
Oral liq 1 mg per ml		200 ml	RA-Morph
Oral liq 2 mg per ml		200 ml	RA-Morph
Oral liq 5 mg per ml	14.65	200 ml	RA-Morph
Oral liq 10 mg per ml	21.55	200 ml	RA-Morph
DRPHINE SULPHATE			
a) Only on a controlled drug form			
b) No patient co-payment payable			
c) Safety medicine; prescriber may determine dispensing freq	LIENCV		
Tab immediate-release 10 mg		10	Sevredol
Tab long-acting 10 mg		10	 Arrow-Morphine LA
Tab immediate-release 20 mg		10	✓ <u>Arrow morphile LA</u> ✓ Sevredol
Tab long-acting 30 mg		10	 Arrow-Morphine LA
Tab long-acting 60 mg		10	✓ Arrow-Morphine LA
Tab long-acting 100 mg		10	✓ Arrow-Morphine LA
Cap long-acting 10 mg		10	✓ m-Eslon
Cap long-acting 30 mg		10	✓ <u>m-Esion</u> ✓ m-Esion
Cap long-acting 60 mg		10	✓ <u>m-Esion</u> ✓ m-Esion
Cap long-acting 100 mg		10	✓ <u>m-Esion</u> ✓ m-Esion
		5	
Inj 5 mg per ml, 1 ml ampoule – Up to 5 inj available on a PSC	′1∠.40	5	 DBL Morphine Sulphate
			Sulphate
Inj 10 mg per ml, 1 ml ampoule – Up to 5 inj available on a	0.00	-	
PSO	9.09	5	DBL Morphine
			Sulphate
Inj 15 mg per ml, 1 ml ampoule – Up to 5 inj available on a			
PSO	9.77	5	DBL Morphine
			Sulphate
Inj 30 mg per ml, 1 ml ampoule - Up to 5 inj available on a			
PSO	12.43	5	DBL Morphine
			Sulphate

(N	Subsidy lanufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
ORPHINE TARTRATE				
a) Only on a controlled drug form				
 b) No patient co-payment payable 				
c) Safety medicine; prescriber may determine dispensing freque				
Inj 80 mg per ml, 1.5 ml		5		lospira
Inj 80 mg per ml, 5 ml	107.67	5		lospira
YCODONE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing freque	ncy			
Tab controlled-release 5 mg	7.51	20	v 0	DxyContin
Tab controlled-release 10 mg		20	<u> </u>	Dxycodone
				ControlledRelease
				Tablets(BNM)
				Dxydone BNM
Tab controlled-release 20 mg	11.50	20	✓	Dxycodone
				ControlledRelease
				Tablets(BNM)
				Dxydone BNM
Tab controlled-release 40 mg	18.50	20	<u> </u>	Dxycodone
				ControlledRelease
				Tablets(BNM)
Tele seguendi a la segue 20 m m	04.00	~~		Dxydone BNM
Tab controlled-release 80 mg	34.00	20	•	<u>Dxycodone</u>
				ControlledRelease
				<u>Tablets(BNM)</u> Dxydone BNM
Cap immediate-release 5 mg	2.83	20		DxyNorm
Cap immediate-release 10 mg		20		DxyNorm
Cap immediate-release 20 mg		20		DxyNorm
Oral lig 5 mg per 5 ml		50 ml		DxyNorm
Inj 10 mg per ml, 1 ml		5		Dxycodone Orion
Inj 10 mg per ml, 2 ml		5		Dxycodone Orion
Inj 50 mg per ml, 1 ml		5		DxyNorm
vdone BNM Tab controlled-release 10 mg to be delisted 1 Decen				
ydone BNM Tab controlled-release 20 mg to be delisted 1 Decen	nber 2014)			
ydone BNM Tab controlled-release 40 mg to be delisted 1 Februa	ary 2015)			
ydone BNM Tab controlled-release 80 mg to be delisted 1 Januar	y 2015)			
RACETAMOL WITH CODEINE – Safety medicine; prescriber may	/ determine dispen	sina f	requency	
Tab paracetamol 500 mg with codeine phosphate 8 mg		100		Paracetamol +
The paracetanier ood my with ooderne phoephate of my			÷ 1	

Codeine (Relieve)

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
PETHIDINE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing f				
Tab 50 mg		10		PSM DSM
Tab 100 mg Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO		10 5		<u>PSM</u> DBL Pethidine
		5	•	Hydrochloride
DBL Pethidine Hydrochloride to be Sole Supply on 1 Oc	ctober 2014			-
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	5.83	5	~	DBL Pethidine Hydrochloride
DBL Pethidine Hydrochloride to be Sole Supply on 1 Oc	ctober 2014			nyaroonionae
TRAMADOL HYDROCHLORIDE				
Tab sustained-release 100 mg	2.00	20	~	Tramal SR 100
Tab sustained-release 150 mg		20	-	Tramal SR 150
Tab sustained-release 200 mg		20	-	Tramal SR 200
Cap 50 mg	2.50	100	~	Arrow-Tramadol
Antidepressants				
Cyclic and Related Agents				
AMITRIPTYLINE – Safety medicine; prescriber may determine	e dispensing frequency			
Tab 10 mg	1.68	100	~	Arrow Amitriptyline
Tab 25 mg	1.85	100		Amitrip
Tab 50 mg	3.60	100	~	Amitrip
CLOMIPRAMINE HYDROCHLORIDE - Safety medicine; pres	criber may determine di	spens	ing freque	ency
Tab 10 mg	12.60	100	~	Apo-Clomipramine
Tab 25 mg	8.68	100	~	Apo-Clomipramine
DOTHIEPIN HYDROCHLORIDE - Safety medicine; prescribe	r may determine dispens	sing fr	equency	
Tab 75 mg	10.50	100	V	Dopress
Cap 25 mg	6.17	100	~	Dopress
DOXEPIN HYDROCHLORIDE - Safety medicine; prescriber n	nay determine dispensin	g frec	luency	
Cap 10 mg	6.30	100	~	Anten
Cap 25 mg	6.86	100		Anten
Cap 50 mg	8.55	100	~	Anten
MIPRAMINE HYDROCHLORIDE - Safety medicine; prescrib	er may determine disper	nsing	frequency	
Tab 10 mg	6.58	60	~	Tofranil s29 S29
	5.48	50	~	Tofranil
	10.96	100		Tofranil
Tab 25 mg	8.80	50	~	Tofranil
MAPROTILINE HYDROCHLORIDE – Safety medicine; prescr	iber may determine disp	ensin	g frequend	су
Tab 25 mg	• •	30		Ludiomil
	25.06	100	~	Ludiomil
Tab 75 mg		20		Ludiomil
	21.01	30	~	Ludiomil

	Outside		Fully Deceder
	Subsidy (Manufacturer's Price	e) Sut	Fully Brand or bsidised Generic
	\$	Per	Manufacturer
MIANSERIN HYDROCHLORIDE – Safety medicine; prescriber Tab 30 mg – Subsidy by endorsement Subsidised for patients who were taking mianserin hydroc ingly. Pharmacists may annotate the prescription as end hydrochloride. Note that supply of mianserin hydrochlor	24.86 chloride prior to 1 July dorsed where there ex	30 2014 and th sists a reco	✓ Tolvon he prescription is endorsed accord- rd of prior dispensing of mianserin
there will be no stock of mianserin available beyond Feb			
NORTRIPTYLINE HYDROCHLORIDE - Safety medicine; pres	•	dispensing	frequency
Tab 10 mg		100	✓ <u>Norpress</u>
Tab 25 mg		180	✓ <u>Norpress</u>
Monoamine-Oxidase Inhibitors (MAOIs) - Non S	Selective		
PHENELZINE SULPHATE			
* Tab 15 mg	95.00	100	✓ Nardil
TRANYLCYPROMINE SULPHATE			4-
* Tab 10 mg		50	Parnate
Monoamine-Oxidase Type A Inhibitors			
MOCLOBEMIDE Note: There is a significant cost differential between moclol expensive). For depressive syndromes it is therefore more ing prescribing moclobemide.	cost-effective to start t		
5		100	• Apo-mocrobernide
Selective Serotonin Reuptake Inhibitors			
CITALOPRAM HYDROBROMIDE			
* Tab 20 mg	2.34	84	Arrow-Citalopram
ESCITALOPRAM	0.05	00	A Lavalata
* Tab 10 mg * Tab 20 mg		28 28	 Loxalate Loxalate
FLUOXETINE HYDROCHLORIDE – Brand switch fee payable			
* Tab dispersible 20 mg, scored – Subsidy by endorsement Subsidised by endorsement	2.50	30	✓ <u>Arrow-Fluoxetine</u>
 When prescribed for a patient who cannot swallow who or When prescribed in a daily dose that is not a multiple of 		·	
Note: Tablets should be combined with capsules to fac			inplion is deemed to be endorsed.
* Cap 20 mg		90	✓ Arrow-Fluoxetine
PAROXETINE HYDROCHLORIDE			
* Tab 20 mg	4.32	90	Loxamine
SERTRALINE			
* Tab 50 mg * Tab 100 mg		90 90	 <u>Arrow-Sertraline</u> Arrow-Sertraline
	0.20	30	

NERVOUS	SYSTEM
---------	--------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
Other Antidepressants				
MIRTAZAPINE – Special Authority see SA0994 below – Retail p	harmacy			
Tab 30 mg	8.78	30		PO-Mirtazapine
Tab 45 mg		30	✓ <u>A</u> ✓ <u>A</u>	

➡SA0994 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 The patient has a severe major depressive episode; and
- 2 Either:
 - 2.1 The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or
 - 2.2 Both:
 - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
 - 2.2.2 The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time.

Renewal from any relevant practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

VENLAFAXINE

Tab 37.5 mg	5.06	28	 Arrow-Venlafaxine XR
Tab 75 mg	6.44	28	 Arrow-Venlafaxine XR
Tab 150 mg	8.86	28	 Arrow-Venlafaxine XR
Tab 225 mg	14.34	28	 Arrow-Venlafaxine XR
Cap 37.5 mg - Special Authority see SA1061 below - Retail			
pharmacy	8.68	28	 Efexor XR
Cap 75 mg – Special Authority see SA1061 below – Retail			
pharmacy	12.18	28	Efexor XR
Cap 150 mg - Special Authority see SA1061 below - Retail			
pharmacy	20.16	28	Efexor XR
		_0	

SA1061 Special Authority for Subsidy

Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria:

- Both:
 - 1 The patient has 'treatment-resistant' depression; and
 - 2 Either:
 - 2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or
 - 2.2 Both:
 - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
 - 2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.

Renewal from any medical practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

(M	Subsidy lanufacturer's Price \$) Per	Fully Subsidised	
Antiepilepsy Drugs				
Agents for Control of Status Epilepticus				
CLONAZEPAM - Safety medicine; prescriber may determine dispen	0 1 7	_		
Inj 1 mg per ml, 1 ml		5	V	Rivotril
DIAZEPAM – Safety medicine; prescriber may determine dispensing Inj 5 mg per ml, 2 ml – Subsidy by endorsement		5		Hospira
a) Up to 5 inj available on a PSO	9.24	5	•	позрпа
b) Only on a PSO				
c) PSO must be endorsed "not for anaesthetic procedures".				
Rectal tubes 5 mg – Up to 5 tube available on a PSO		5		Stesolid
Rectal tubes 10 mg – Up to 5 tube available on a PSO	30.50	5	V	Stesolid
	4 500 00	-		
k lnj 5 ml	1,500.00	5	V	AFT
PHENYTOIN SODIUM		_		
 Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO Inj 50 mg per ml, 5 ml – Up to 5 inj available on a PSO 		5 5		Hospira
	11.21	5	•	Hospira
Control of Epilepsy				
CARBAMAZEPINE				
₭ Tab 200 mg	14.53	100	v -	Tegretol
 Tab long-acting 200 mg 	16.98	100		Tegretol CR
K Tab 400 mg		100		Tegretol
★ Tab long-acting 400 mg		100 250 ml		Tegretol CR
€‡ Oral liq 100 mg per 5 ml		250 111	V	Tegretol
CLOBAZAM – Safety medicine; prescriber may determine dispensin		50		Frisium
Tab 10 mg ‡ Safety cap for extemporaneously compounded oral liquid pr		50	V	Frisium
2 CONAZEPAM – Safety medicine; prescriber may determine dispen				
Oral drops 2.5 mg per ml	• • •	0 ml OF	· •	Rivotril
		0 1111 01	• •	
k Cap 250 mg	32 90	200	~	Zarontin
k Cap 250 mg per 5 ml		200 ml		Zarontin
ABAPENTIN – Special Authority see SA1071 on the next page – F				
Cap 100 mg		100	~	Arrow-Gabapentin
, ,	-			Nupentin
Cap 300 mg - For gabapentin oral liquid formulation refer,				
page 209	11.00	100		Arrow-Gabapentin
0 400	10 75	100		Nupentin
Cap 400 mg	13.75	100		Arrow-Gabapentin
			•	Nupentin

Subsidy		Fully	Brand or	
(Manufacturer's Price)	5	Subsidised	Generic	
\$	Per	~	Manufacturer	

SA1071 Special Authority for Subsidy

Initial application — (Epilepsy) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Either:

- 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
- 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Initial application — (Neuropathic pain) from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant.

Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Renewal — (Neuropathic pain) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or
- 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

GABAPENTIN (NEURONTIN) - Special Authority see SA0973 below - Retail pharmacy

▲ Tab 600 mg	67.50	100	Neurontin
▲ Cap 100 mg		100	 Neurontin
▲ Cap 300 mg - For gabapentin (neurontin) oral liquid formu-			
lation refer, page 209		100	Neurontin
▲ Cap 400 mg	53.01	100	 Neurontin

SA0973 Special Authority for Subsidy

Notes: Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unless notified. No new approvals will be granted from 1 August 2009.

LACOSAMIDE - Special Authority see SA1125 below - Retail pharmacy

Tab 50 mg		14	Vimpat
Tab 100 mg		14	Vimpat
0	200.24	56	Vimpat
Tab 150 mg	75.10	14	Vimpat
J. J	300.40	56	Vimpat
Tab 200 mg		56	 Vimpat

SA1125 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

 Subsidy (Manufacturer's Price)	Sub	Fully	Brand or Generic
\$	Per	V	Manufacturer

continued...

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

LAMOTRIGINE

▲ Tab dispersible 2 mg	6.74	30	Lamictal
▲ Tab dispersible 5 mg	9.64	30	Lamictal
	15.00	56	Arrow-Lamotrigine
▲ Tab dispersible 25 mg		56	Logem
	20.40		Arrow-Lamotrigine
			✓ Mogine
	29.09		Lamictal
▲ Tab dispersible 50 mg		56	Logem
	34.70		Arrow-Lamotrigine
			Mogine
	47.89		Lamictal
▲ Tab dispersible 100 mg		56	Logem
	59.90		Arrow-Lamotrigine
			Mogine
	79.16		Lamictal
LEVETIRACETAM			
Tab 250 mg	24.03	60	Levetiracetam-Rex
Tab 500 mg – For levetiracetam oral liquid formulation		00	
page 209		60	Levetiracetam-Rex
Tab 750 mg		60	✓ Levetiracetam-Rex
•		00	
PHENOBARBITONE			
For phenobarbitone oral liquid refer Standard Formulae			4
* Tab 15 mg		500	✓ <u>PSM</u>
* Tab 30 mg		500	✓ <u>PSM</u>
PHENYTOIN SODIUM			
* Tab 50 mg		200	 Dilantin Infatab
* Cap 30 mg		200	Dilantin
* Cap 100 mg		200	Dilantin
*‡ Oral liq 30 mg per 5 ml		500 ml	Dilantin
PRIMIDONE			
* Tab 250 mg	17 25	100	Apo-Primidone
0		100	• Apo I minuone
SODIUM VALPROATE			4 4 • • • •
* Tab 100 mg		100	Epilim Crushable
* Tab 200 mg EC		100	Epilim
* Tab 500 mg EC		100	Epilim
*‡ Oral liq 200 mg per 5 ml	20.48	300 ml	Epilim S/F Liquid
			Epilim Syrup
* Inj 100 mg per ml, 4 ml	41.50	1	Epilim IV

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
STIRIPENTOL – Special Authority see SA1330 below – Retail pl	narmacy			
Cap 250 mg		60	🗸 D	iacomit S29
Powder for oral liq 250 mg sachet		60	🗸 D	iacomit S29

SA1330 Special Authority for Subsidy

Initial application only from a paediatric neurologist or Practitioner on the recommendation of a paediatric neurologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient has confirmed diagnosis of Dravet syndrome; and
- 2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

TOPIRAMATE

▲ Tab 25 mg		60	Arrow-Topiramate
0	26.04		Topamax
▲ Tab 50 mg		60	Arrow-Topiramate
	44.26		Topamax
▲ Tab 100 mg		60	 Arrow-Topiramate
	75.25		Topamax
▲ Tab 200 mg		60	Arrow-Topiramate
	129.85		🖌 Topamax
Sprinkle cap 15 mg		60	Topamax
Sprinkle cap 25 mg		60	 Topamax
VIGABATRIN - Special Authority see SA1072 below	w – Retail pharmacy		
▲ Tab 500 mg		100	Sabril

SA1072 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Patient has infantile spasms; or
 - 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and
- 2 Either:
 - 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6monthly basis thereafter); or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Subsidy (Manufacturer's Price)	S	Fully ubsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
- 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Antimigraine Preparations

For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 120

Acute Migraine Treatment

ERGOTAMINE TARTRATE WITH CAFFEINE Tab 1 mg with caffeine 100 mg	31.00	100	✓ Cafergot
METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL Tab 5 mg with paracetamol 500 mg	6.77	60	Paramax
(Paramax Tab 5 mg with paracetamol 500 mg to be delisted 1 Nover	nber 2014)		
RIZATRIPTAN			
Tab orodispersible 10 mg Rizamelt to be Sole Supply on 1 October 2014	8.10	30	 Rizamelt
SUMATRIPTAN			
Tab 50 mg		100	Arrow-Sumatriptan
Tab 100 mg	54.80	100	Arrow-Sumatriptan
Inj 12 mg per ml, 0.5 ml cartridge – Maximum of 10 inj per prescription	13.80	2 OP	✓ Arrow-Sumatriptan
Prophylaxis of Migraine			
For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYSTE PIZOTIFEN	EM, page 56		
* Tab 500 mcg	23.21	100	Sandomigran
Antinausea and Vertigo Agents			
For Antispasmodics refer to ALIMENTARY TRACT, page 26			
APREPITANT - Special Authority see SA0987 on the next page - R	Retail pharmacy		
Cap 2 × 80 mg and 1 × 125 mg Emend Tri-Pack to be Sole Supply on 1 October 2014	100.00	3 OP	Emend Tri-Pack

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	~	Manufacturer	

SA0987 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.

pharmacy	2	✓ Scopoderm TTS
13.32 Patch 1.5 mg – Special Authority see SA1387 below – Retail	10	 Martindale \$29
	-	•
HYOSCINE HYDROBROMIDE * Inj 400 mcg per ml, 1 ml	5	✓ Hospira
 * Tab 10 mg – For domperidone oral liquid formulation refer, page 209	100	✓ <u>Prokinex</u>
CYCLIZINE LACTATE Inj 50 mg per ml, 1 ml14.95 DOMPERIDONE	5	✓ Nausicalm
CYCLIZINE HYDROCHLORIDE Tab 50 mg0.59	10	✓ <u>Nausicalm</u>
BETAHISTINE DIHYDROCHLORIDE * Tab 16 mg4.95	84	✓ Vergo 16

➡SA1387 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Either:

- 1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or
- 2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective.

Renewal from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

METOCLOPRAMIDE HYDROCHLORIDE

*	Tab 10 mg – For metoclopramide hydrochloride oral liquid formulation refer, page 2091.82 Metamide to be Sole Supply on 1 October 2014	100	✓ Metamide
*	Inj 5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO4.50 Pfizer to be Sole Supply on 1 October 2014	10	 Pfizer
ON	IDANSETRON		
*	Tab 4 mg5.51	50	✓ Onrex
*	Tab disp 4 mg	10	 Dr Reddy's Ondansetron
*	Tab 8 mg6.19	50	✓ Onrex
*	Tab disp 8 mg	10	 Ondansetron ODT-DRLA
PR	OCHLORPERAZINE		
*	Tab 3 mg buccal	50	Buccastem
*	Tab 5 mg – Up to 30 tab available on a PSO	500	Antinaus
*	Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO25.81	10	✓ Stemetil
*	Suppos 25 mg	5	 Stemetil

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
PROMETHAZINE THEOCLATE					
* Tab 25 mg	1.20	10			
	(6.24)		A	vomine	
TROPISETRON					
a) Maximum of 6 cap per prescription					
b) Maximum of 3 cap per dispensing					
c) Not more than one prescription per month.					
Cap 5 mg	77.41	5	🖌 N	avoban	
(Navoban Cap 5 mg to be delisted 1 December 2014)					

Antipsychotics

Guidelines for the use of atypical antipsychotic agents

Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical antipsychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional antipsychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.

General

AMISULPRIDE - Safety medicine; prescriber may determine dis	spensing frequenc	y	
Tab 100 mg	6.22	30	Solian
Tab 200 mg	21.92	60	Solian
Tab 400 mg		60	Solian
Oral liq 100 mg per ml	52.50	60 ml	Solian
ARIPIPRAZOLE – Special Authority see SA0920 below – Retail Safety medicine; prescriber may determine dispensing frequ			
Tab 10 mg		30	🖌 Abilify
Tab 15 mg	175.28	30	Abilify
Tab 20 mg	213.42	30	🖌 Abilify
Tab 30 mg		30	Abilify

➡SA0920 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Patient is suffering from schizophrenia or related psychoses; and
- 2 Either:
 - 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
 - 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

CHLORPROMAZINE HYDROCHLORIDE - Safety medicine; prescriber may determine dispensing frequency

Tab 10 mg – Up to 30 tab available on a PSO	12.36	100	 Largactil
Tab 25 mg – Up to 30 tab available on a PSO	13.02	100	 Largactil
Tab 100 mg – Up to 30 tab available on a PSO	30.61	100	 Largactil
Inj 25 mg per ml, 2 ml - Up to 5 inj available on a PSO	25.66	10	 Largactil

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic ✓ Manufacturer
	Ŷ		
CLOZAPINE – Hospital pharmacy [HP4]			
Safety medicine; prescriber may determine dispensing freq	uency		
Tab 25 mg	13.37	50	 Clozaril
	26.74	100	 Clozaril
	6.69	50	 Clopine
	13.37	100	Clopine
Tab 50 mg	8.67	50	 Clopine
	17.33	100	 Clopine
Tab 100 mg		50	 Clozaril
	69.30	100	Clozaril
	17.33	50	Clopine
	34.65	100	Clopine
Tab 200 mg		50	Clopine
·	69.30	100	Clopine
Suspension 50 mg per ml		100 m	Clopine
HALOPERIDOL – Safety medicine; prescriber may determine	disponsing fraguancy		
Tab 500 mcg – Up to 30 tab available on a PSO		100	Serenace
Tab 1.5 mg – Up to 30 tab available on a PSO		100	✓ <u>Serenace</u>
Tab 5 mg – Up to 30 tab available on a PSO		100	✓ <u>Serenace</u>
Oral lig 2 mg per ml – Up to 200 ml available on a PSO		100 m	
Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO		10	Serenace
			<u> </u>
LEVOMEPROMAZINE MALEATE - Safety medicine; prescribe			
Tab 25 mg		100	Nozinan
Tab 100 mg		100	Nozinan
Inj 25 mg per ml, 1 ml	73.68	10	Nozinan
LITHIUM CARBONATE - Safety medicine; prescriber may dete	ermine dispensing freg	uencv	
Tab 250 mg		500	Lithicarb FC
Tab 400 mg		100	 Lithicarb FC
Tab long-acting 400 mg		100	Priadel
Cap 250 mg		100	✓ Douglas
Douglas to be Sole Supply on 1 October 2014			2
- •••			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
ANZAPINE - Safety medicine; prescriber may determine d	ispensing frequency			
Tab 2.5 mg	0.75	28	\checkmark	Dr Reddy's
				Olanzapine
	(51.07)			Zypine Zyprexa
Tab 5 mg	()	28		Dr Reddy's
				Olanzapine
			~	Zypine
	(3.85)			Olanzine
Tele availate available C was	(101.21)	00		Zyprexa Dr. De debu'e
Tab orodispersible 5 mg	1./5	28	V	Dr Reddy's Olanzapine
			~	Zypine ODT
	(6.36)			Olanzine-D
	(102.19)			Zyprexa Zydis
Tab 10 mg	2.55	28	~	Dr Reddy's
				Olanzapine
	(0.05)			Zypine
	(6.35)			Olanzine
Tab orodispersible 10 mg	(204.49)	28		Zyprexa Dr Reddy's
		20	•	Olanzapine
			~	Zypine ODT
	(8.76)			Olanzine-D
	(204.37)			Zyprexa Zydis
Reddy's Olanzapine Tab 2.5 mg to be delisted 1 December	r 2014)			
rprexa Tab 2.5 mg to be delisted 1 December 2014) r Reddy's Olanzapine Tab 5 mg to be delisted 1 December 2	2014)			
anzine Tab 5 mg to be delisted 1 December 2014)	.014)			
prexa Tab 5 mg to be delisted 1 December 2014)				
Reddy's Olanzapine Tab orodispersible 5 mg to be delisted				
anzine-D Tab orodispersible 5 mg to be delisted 1 December	,			
prexa Zydis Tab orodispersible 5 mg to be delisted 1 Decem				
Reddy's Olanzapine Tab 10 mg to be delisted 1 December anzine Tab 10 mg to be delisted 1 December 2014)	2014)			
prexa Tab 10 mg to be delisted 1 December 2014)				
Reddy's Olanzapine Tab orodispersible 10 mg to be deliste	ed 1 December 2014)			
anzine-D Tab orodispersible 10 mg to be delisted 1 Decemb	ber 2014)			
prexa Zydis Tab orodispersible 10 mg to be delisted 1 Dece	ember 2014)			
RICYAZINE - Safety medicine; prescriber may determine c				
Tab 2.5 mg		100		Neulactil
Tab 10 mg		100		Neulactil

	Subsidy (Manufacturer's Price) \$	Per	Full Subsidise	d Generic
	*	1.01		
QUETIAPINE – Safety medicine; prescriber may determine dispe				
Tab 25 mg	1.40	60	~	Dr Reddy's Quetiapine
	2.10	90	~	Quetapel
	1.40	60		•
	(7.00)			Seroquel
Tab 100 mg	· · ·	90	~	Dr Reddy's
0				Quetiapine
			~	Quetapel
	2.80	60	•	daorapo.
	(14.00)			Seroquel
Tab 200 mg	· · · ·	60	~	Dr Reddy's
·				Quetiapine
	7.20	90	~	Quetapel
	4.80	60	•	austapol
	(24.00)	00		Seroquel
Tab 300 mg	· · · ·	60	~	Dr Reddy's
			•	Quetiapine
	12.00	90	~	Quetapel
	8.00	60	•	aucupoi
	(40.00)	00		Seroquel
Dr Reddy's Quetiapine Tab 25 mg to be delisted 1 December 201	· · · ·			0010400

(Seroquel Tab 25 mg to be delisted 1 December 2014)

(Dr Reddy's Quetiapine Tab 100 mg to be delisted 1 December 2014)

(Seroquel Tab 100 mg to be delisted 1 December 2014)

(Dr Reddy's Quetiapine Tab 200 mg to be delisted 1 December 2014)

(Seroquel Tab 200 mg to be delisted 1 December 2014)

(Dr Reddy's Quetiapine Tab 300 mg to be delisted 1 December 2014)

(Seroquel Tab 300 mg to be delisted 1 December 2014)

	Subsidy (Manufacturer's Price) \$	Per	Full Subsidise	d Generic
PERIDONE – Safety medicine; prescriber may determine di	spensing frequency			
Tab orodispersible 0.5 mg - Special Authority see SA092				
below – Retail pharmacy	21.42	28	~	Risperdal Quicklet
Tab 0.5 mg	3.51	60	~	Apo-Risperidone
			~	Dr Reddy's
				Risperidone
			~	Ridal
	1.17	20		
	(2.86)			Risperdal
Tab 1 mg	6.00	60		Apo-Risperidone
			V	Dr Reddy's
				Risperidone
	(10.00)		V	Ridal
	(16.92)			Risperdal
Tab orodispersible 1 mg – Special Authority see SA0927 be				
low – Retail pharmacy		28		Risperdal Quicklet
Tab 2 mg	11.00	60		Apo-Risperidone
			V	Dr Reddy's
				Risperidone
	(00.04)		V	Ridal
The second s	(33.84)			Risperdal
Tab orodispersible 2 mg – Special Authority see SA0927 be		00		
low – Retail pharmacy		28		Risperdal Quicklet
Tab 3 mg		60		Apo-Risperidone Dr Reddy's
			v	Risperidone
				Ridal
	(50.78)		•	Risperdal
Tab 4 mg	· · · ·	60	~	Apo-Risperidone
1ab 4 mg	20.00	00		Dr Reddy's
			•	Risperidone
			~	Ridal
	(67.68)		•	Risperdal
Oral liq 1 mg per ml	(/	30 ml	~	Risperon
	(18.35)		5	Apo-Risperidone
	(25.26)			Risperdal

(Risperdal Oral liq 1 mg per ml to be delisted 1 December 2014)

►SA0927 Special Authority for Subsidy

Initial application — (Acute situations) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

- Both:
 - 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and
 - 2 The patient is under direct supervision for administration of medicine.

Initial application — (Chronic situations) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

Subsidy	F	ully	Brand or	
(Manufacturer's Price)	Subsid	ised	Generic	
\$	Per	r	Manufacturer	

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid: and
- 2 The patient is under direct supervision for administration of medicine.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Note: Risperdal Quicklets cost significantly more than risperidone tablets and should only be used where necessary.

TRIFLUOPERAZINE HYDROCHLORIDE - Safety	medicine; prescriber may detern	nine disper	sing frequency
Tab 1 mg		100	 Stelazine
Tab 2 mg	14.64	100	Stelazine
Tab 5 mg	16.66	100	Stelazine

lab 2 mg	14.64	100	🗸 Stelazi
Tab 5 mg	16.66	100	🗸 Stelazi

ZIPRASIDONE - Subsidy by endorsement

a) Safety medicine; prescriber may determine dispensing frequency

b) Ziprasidone is subsidised for patients suffering from schizophrenia or related psychoses after a trial of an effective dose of risperidone or quetiapine that has been discontinued, or is in the process of being discontinued, because of unacceptable side effects or inadequate response, and the prescription is endorsed accordingly.

Cap 20 mg		60	Zeldox
Cap 40 mg		60	Zeldox
Cap 60 mg	247.17	60	Zeldox
Cap 80 mg		60	 Zeldox

ZUCLOPENTHIXOL HYDROCHLORIDE - S	afety medicine; prescriber may	y determine	dispensing t	frequency
Tab 10 mg		45 1	00	Clopixol

Depot Injections

FLUPENTHIXOL DECANOATE - Safety medicine; prescriber may determine disper	ising freq	uency
Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO13.14	5	Fluanxol
Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO20.90	5	Fluanxol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	5	Fluanxol
FLUPHENAZINE DECANOATE - Safety medicine; prescriber may determine disper	nsing freq	uency
Inj 12.5 mg per 0.5 ml, 0.5 ml – Up to 5 inj available on a PSO17.60	5	Modecate
Inj 25 mg per ml, 1 ml – Up to 5 inj available on a PSO27.90	5	Modecate
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	5	Modecate
HALOPERIDOL DECANOATE - Safety medicine; prescriber may determine dispense	sing frequ	ency
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO	5	Haldol
Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	5	 Haldol Concentrate
OLANZAPINE – Special Authority see SA1428 on the next page – Retail pharmacy Safety medicine; prescriber may determine dispensing frequency		
Inj 210 mg vial	1	Zyprexa Relprevv
Inj 300 mg vial460.00	1	 Zyprexa Relprevv
lnj 405 mg vial560.00	1	 Zyprexa Relprevv

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Si	ubsidised	Generic	
\$	Per	~	Manufacturer	

➡SA1428 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or risperidone depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: The patient should be monitored for post-injection syndrome for at least two hours after each injection.

PALIPERIDONE - Special Authority see SA1429 below - Retail pharmacy

Safety medicine; prescriber may	determine dispensing frequency
---------------------------------	--------------------------------

Inj 25 mg syringe	 1	Invega Sustenna
Inj 50 mg syringe	 1	Invega Sustenna
Inj 75 mg syringe	 1	Invega Sustenna
Inj 100 mg syringe	1	Invega Sustenna
Inj 150 mg syringe	1	Invega Sustenna
	 -	·

SA1429 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Paliperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialling paliperidone depot injection.

PIPOTHIAZINE PALMITATE - Subsidy by endorsement

a) Safety medicine; prescriber may determine dispensing frequency

b) Subsidised for patients who were taking pipothiazine palmitate prior to 1 August 2014 and the prescription or PSO is endorsed accordingly. Pharmacists may annotate the prescription as endorsed where there exists a record of prior dispensing of pipothiazine palmitate.

Inj 50 mg per ml, 1 ml - Up to 5 inj available on a PSO 178.48	10	🖌 Piportil
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	10	🖌 Piportil

RISPERIDONE - Special Authority see SA1427 on the next page - Retail pharmacy

Safety medicine; prescriber may determine dispensing frequency

Inj 25 mg vial	1	Risperdal Consta
Inj 37.5 vial	1	Risperdal Consta
lnj 50 mg vial217.56	1	Risperdal Consta

0.1	hadaha E	ullu Duana	
Sub	bsidy F	ully Brand	1 OL
(Manufactu	turer's Price) Subsidi	sed Gene	ric
	\$ Per	 Manu 	facturer

➡SA1427 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months where the initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

Note: Risperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone depot injection.

ZUCLOPENTHIXOL DECANOATE - Safety medicine; prescriber may determine dispensing frequency

Inj 200) mg per ml, 1 ml	 Up to 5 inj availal 	ble on a PSO	19.80	5	Clopixol	

Anxiolytics

‡ Safety cap for extemporaneously compounded oral liquid preparations. 3.25 50 ✓ Xanax Tab 500 mcg 3.25 50 ✓ Xanax ‡ Safety cap for extemporaneously compounded oral liquid preparations. 5.00 50 ✓ Xanax Tab 1 mg 5.00 50 ✓ Xanax ✓ Xanax BUSPIRONE HYDROCHLORIDE 5.00 50 ✓ Xanax * Tab 5 mg 28.00 100 ✓ Pacific Buspirone * Tab 10 mg 17.00 100 ✓ Pacific Buspirone * Tab 5 mg 28.00 100 ✓ Pacific Buspirone * Tab 5 mg 28.00 100 ✓ Pacific Buspirone * Tab 2 mg 17.00 100 ✓ Pacific Buspirone CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency 7ab 2 mg 12.75 100 ✓ Paxam DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency 13.47 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.49 100 ✓ Ativan ‡ Safe	ALPRAZOLAM – Safety medicine; prescriber may determine dispensing frequency Tab 250 mcg	50	✓ Xanax
‡ Safety cap for extemporaneously compounded oral liquid preparations. 5.00 50 ✓ Xanax Tab 1 mg 5.00 50 ✓ Xanax BUSPIRONE HYDROCHLORIDE 28.00 100 ✓ Pacific Buspirone * Tab 5 mg 28.00 100 ✓ Pacific Buspirone * Tab 10 mg 500 mcg 100 ✓ Pacific Buspirone CLONAZEPAM Safety medicine; prescriber may determine dispensing frequency 6.68 100 ✓ Paxam Tab 2 mg 6.68 100 ✓ Paxam ✓ Paxam DIAZEPAM Safety medicine; prescriber may determine dispensing frequency ✓ ✓ Tab 2 mg 11.44 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ ✓ Tab 5 mg 13.71 500 ✓ ✓ ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ ✓ ✓ LORAZEPAM Safety medicine; prescriber may determine dispensing frequency ✓ ✓ ✓ ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ ✓ ✓ LORAZEPAM Saf		50	🖌 Yanay
Tab 1 mg5.0050Xanax‡ Safety cap for extemporaneously compounded oral liquid preparations.BUSPIRONE HYDROCHLORIDE**** Tab 5 mg28.00100✓ Pacific Buspirone** Tab 5 ng17.00100✓ Pacific Buspirone** Tab 10 mgSafety medicine; prescriber may determine dispensing frequency**Tab 20 mg6.68100✓ PaxamTab 2 mg12.75100✓ PaxamDIAZEPAM - Safety medicine; prescriber may determine dispensing frequency**Tab 2 mg11.44500✓ Arrow-Diazepam‡ Safety cap for extemporaneously compounded oral liquid preparations.**Tab 5 mg13.71500✓ Arrow-Diazepam‡ Safety cap for extemporaneously compounded oral liquid preparations.**LORAZEPAM - Safety medicine; prescriber may determine dispensing frequency**Tab 1 mg19.82250**Ativan19.82250**\$ Safety cap for extemporaneously compounded oral liquid preparations.**Tab 2.5 mg13.49100**\$ Safety cap for extemporaneously compounded oral liquid preparations.**Tab 2.5 mg13.49100**\$ Safety cap for extemporaneously compounded oral liquid preparations.*Ox-Pam\$ Safety cap for extemporaneously compounded oral liquid preparations.*Ox-Pam\$ Safety cap for extemporaneously compounded oral liquid preparations. <td< td=""><td></td><td>50</td><td>• <u>Adriak</u></td></td<>		50	• <u>Adriak</u>
‡ Safety cap for extemporaneously compounded oral liquid preparations. BUSPIRONE HYDROCHLORIDE * Tab 5 mg		50	🗸 Xanax
** Tab 5 mg 28.00 100 ✓ Pacific Buspirone ** Tab 10 mg 17.00 100 ✓ Pacific Buspirone CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency 6.68 100 ✓ Paxam Tab 2 mg 12.75 100 ✓ Paxam DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency ✓ Paxam ✓ Paxam Tab 2 mg 11.44 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Arrow-Diazepam Tab 1 mg 13.71 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Arrow-Diazepam LORAZEPAM – Safety medicine; prescriber may determine dispensing frequency ✓ Arrow-Diazepam * Safety cap for extemporaneously compounded oral liquid preparations. ✓ Ativan LORAZEPAM – Safety medicine; prescriber may determine dispensing frequency ✓ Ativan * Safety cap for extemporaneously compounded oral liquid preparations. ✓ Ativan * Safety cap for extemporaneously compounded oral liquid preparations. ✓ Ativan * Safety cap for extemporaneously compounded oral liquid preparations. ✓ Ativan * Safety cap for extemporaneously compounded	•		
** Tab 10 mg 17.00 100 ✓ Pacific Buspirone CLONAZEPAM - Safety medicine; prescriber may determine dispensing frequency Tab 500 mcg 6.68 100 ✓ Paxam DIAZEPAM - Safety medicine; prescriber may determine dispensing frequency Tab 2 mg 12.75 100 ✓ Paxam DIAZEPAM - Safety medicine; prescriber may determine dispensing frequency Tab 2 mg 11.44 500 ✓ Arrow-Diazepam ± Safety cap for extemporaneously compounded oral liquid preparations. Tab 5 mg 13.71 500 ✓ Arrow-Diazepam LORAZEPAM - Safety medicine; prescriber may determine dispensing frequency Tab 1 mg 19.82 250 ✓ Ativan ± Safety cap for extemporaneously compounded oral liquid preparations. Tab 2.5 mg 19.82 250 ✓ Ativan ± Safety cap for extemporaneously compounded oral liquid preparations. Tab 2.5 mg 13.49 100 ✓ Ativan ± Safety cap for extemporaneously compounded oral liquid preparations. 0XAZEPAM - Safety medicine; prescriber may determine dispensing frequency 13.49 100 ✓ Ativan ± Safety cap for extemporaneously compounded oral liquid preparations. 13.49 100 ✓ Ativan ± Safety cap for extemporaneously compounded oral liquid preparations. 5.89 100 ✓ Ox-Pam ± Safety cap for	BUSPIRONE HYDROCHLORIDE		
** Tab 10 mg 17.00 100 ✓ Pacific Buspirone CLONAZEPAM – Safety medicine; prescriber may determine dispensing frequency 6.68 100 ✓ Paxam Tab 2 mg 12.75 100 ✓ Paxam DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency ✓ Paxam ✓ Paxam Tab 2 mg 11.44 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Arrow-Diazepam Tab 5 mg 13.71 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Arrow-Diazepam LORAZEPAM – Safety medicine; prescriber may determine dispensing frequency ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Ativan LORAZEPAM – Safety medicine; prescriber may determine dispensing frequency ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Ativan Tab 2.5 mg 100 ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Ativan Tab 10 mg 5.89 100 ✓ Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Ox-Pam <td>* Tab 5 mg</td> <td>100</td> <td>Pacific Buspirone</td>	* Tab 5 mg	100	Pacific Buspirone
Tab 500 mcg 6.68 100 ✓ Paxam Tab 2 mg 12.75 100 ✓ Paxam DIAZEPAM - Safety medicine; prescriber may determine dispensing frequency 11.44 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam ± Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam LORAZEPAM - Safety medicine; prescriber may determine dispensing frequency 13.82 250 ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. 19.82 250 ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.49 100 ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. 5.89 100 ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. 5.89 100 ✓ Ox-Pam § Safety cap for extemporaneously compounded oral liquid preparations. 5.89 100 ✓ Ox-Pam § Safety cap for extemporaneously compounded oral liquid preparations. 5.89 100 ✓ Ox-Pam § Safety cap for extemporaneously compounded oral liquid preparations. <	•	100	Pacific Buspirone
Tab 500 mcg ✓ Paxam Tab 2 mg 12.75 DIAZEPAM - Safety medicine; prescriber may determine dispensing frequency 12.75 Tab 2 mg 11.44 \$\$ Safety cap for extemporaneously compounded oral liquid preparations. 500 Tab 5 mg 13.71 \$\$ Safety cap for extemporaneously compounded oral liquid preparations. 500 LORAZEPAM - Safety medicine; prescriber may determine dispensing frequency 500 Tab 1 mg 19.82 \$\$ Safety cap for extemporaneously compounded oral liquid preparations. 19.82 LORAZEPAM - Safety medicine; prescriber may determine dispensing frequency 13.49 \$\$ tab 1 mg 19.82 \$\$ safety cap for extemporaneously compounded oral liquid preparations. ✓ Ativan \$\$ tab 2.5 mg 13.49 100 \$\$ safety cap for extemporaneously compounded oral liquid preparations. ✓ Ativan \$\$ tab 2.5 mg 13.49 100 \$\$ tab 10 mg \$\$ safety cap for extemporaneously compounded oral liquid preparations. ✓ Ox-Pam \$\$ tab 10 mg \$\$ safety cap for extemporaneously compounded oral liquid preparations. ✓ Ox-Pam \$\$ tab 10 mg \$\$ safety cap for extemporaneously compounded oral liquid preparations.	CLONAZEPAM – Safety medicine: prescriber may determine dispensing frequency		
Tab 2 mg		100	Paxam
Tab 2 mg 11.44 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam LORAZEPAM – Safety medicine; prescriber may determine dispensing frequency 19.82 250 ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.49 100 ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. 00 ✓ Ativan ţ Safety cap for extemporaneously compounded oral liquid preparations. 00 ✓ Ativan t Safety cap for extemporaneously compounded oral liquid preparations. 00 ✓ Ativan t Safety cap for extemporaneously compounded oral liquid preparations. 00 ✓ Ox-Pam t Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam t Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam t Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam		100	🖌 Paxam
Tab 2 mg 11.44 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.71 500 ✓ Arrow-Diazepam LORAZEPAM – Safety medicine; prescriber may determine dispensing frequency 19.82 250 ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. 13.49 100 ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. 00 ✓ Ativan ţ Safety cap for extemporaneously compounded oral liquid preparations. 00 ✓ Ativan t Safety cap for extemporaneously compounded oral liquid preparations. 00 ✓ Ativan t Safety cap for extemporaneously compounded oral liquid preparations. 00 ✓ Ox-Pam t Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam t Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam t Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam	DIAZEPAM – Safety medicine: prescriber may determine dispensing frequency		
 ‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 5 mg		500	Arrow-Diazepam
‡ Safety cap for extemporaneously compounded oral liquid preparations. LORAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 1 mg	‡ Safety cap for extemporaneously compounded oral liquid preparations.		•
LORAZEPAM - Safety medicine; prescriber may determine dispensing frequency 19.82 250 ✓ Ativan 1 Safety cap for extemporaneously compounded oral liquid preparations. 13.49 100 ✓ Ativan 1 Safety cap for extemporaneously compounded oral liquid preparations. 13.49 100 ✓ Ativan 1 Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ativan 0 Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ativan 0 Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam 1 Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam 1 Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam	0	500	Arrow-Diazepam
Tab 1 mg 19.82 250 ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Ativan ①XAZEPAM – Safety medicine; prescriber may determine dispensing frequency 5.89 100 ✓ Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 5.89 100 ✓ Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam	‡ Safety cap for extemporaneously compounded oral liquid preparations.		
‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 2.5 mg	LORAZEPAM – Safety medicine; prescriber may determine dispensing frequency		
Tab 2.5 mg 13.49 100 ✓ Ativan ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Ativan OXAZEPAM – Safety medicine; prescriber may determine dispensing frequency 100 ✓ Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 100 ✓ Ox-Pam ‡ Safety cap for extemporaneously compounded oral liquid preparations. 8.13 100 ✓ Ox-Pam		250	🗸 Ativan
‡ Safety cap for extemporaneously compounded oral liquid preparations. OXAZEPAM – Safety medicine; prescriber may determine dispensing frequency Tab 10 mg			4.4.4
OXAZEPAM - Safety medicine; prescriber may determine dispensing frequency Tab 10 mg 5.89 ± Safety cap for extemporaneously compounded oral liquid preparations. Tab 15 mg 100 ✓ Ox-Pam		100	Ativan
Tab 10 mg \checkmark Ox-Pam \ddagger Safety cap for extemporaneously compounded oral liquid preparations.100Tab 15 mg \checkmark Ox-Pam			
‡ Safety cap for extemporaneously compounded oral liquid preparations. Tab 15 mg8.13 100 ✔ Ox-Pam			
Tab 15 mg8.13 100 🖌 Ox-Pam		100	V Ox-Pam
······································		100	V Ov-Bom
	Safety cap for extemporaneously compounded oral liquid preparations.	100	

Subsidy		Fully	Brand or
(Manufacturer's Price)	S	Subsidised	Generic
\$	Per	~	Manufacturer

Multiple Sclerosis Treatments

SA1062 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC).

Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

These agents will NOT be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their clinicians by courier.

Prescribers must send quarterly prescriptions for approved patients to the MSTAC coordinator.

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, or 20 mg glatiramer acetate daily will be subsidised.

Appeals against MSTAC's decision and/or the processing of any application may be lodged with the MSTAC coordinator. Concerns that cannot be or have not been adequately addressed by MSTAC will be forwarded to a separate Appeal Committee if necessary. Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. The MSTAC coordinator should be notified of the change and a new prescription provided.

Entry Criteria

- a) Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis should as a rule include MRI confirmation. For patients diagnosed before MRI was widely utilised in New Zealand, confirmation of diagnosis via clinical assessment and laboratory/ancillary data must be provided; and
- b) patients must have active relapsing MS (confirmed by MR scan where necessary) with or without underlying progression; and
- c) patients must have either:
 - a) EDSS score 2.5 5.5 with 2+ relapses:
 - · experienced at least 2 significant relapses of MS in the previous 12 months, and
 - an EDSS score of between 2.5 and 5.5 inclusive; or
 - b) EDSS score 2.0 with 3+ relapses:
 - experienced at least 3 significant relapses of MS in the previous 12 months, and
 - an EDSS score of 2.0; and
- d) Each relapse must:
 - a) be confirmed by a neurologist or general physician (the patient may not necessarily have been seen during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) follow a period of stability of at least one month;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke functional systems scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T>37.5°C); and

Subsidy
Manufacturer's Price)
\$

- e) applications must be made at least four weeks after the date of the onset of the last known relapse; and
- f) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate (see criteria for stopping).
- g) applications must be submitted to the Multiple Sclerosis Treatment Assessment Committee (MSTAC) by the patient's neurologist or a general physician: and
- h) patients must agree (via informed consent) to co-operate if as a result of their meeting the stopping criteria, funding is withdrawn. Patients must agree to the collection of clinical data relating to their MS and use of those data by PHARMAC; and
- i) patients must agree to allow clinical data to be collected and reviewed by MSTAC annually for each year in which they receive funding for beta-interferon or glatiramer acetate.

Stopping Criteria

- a) Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression of disability is defined as any of:
 - a) an increase of 2 EDSS points where starting EDSS was 2.0; or
 - b) an increase of 1.5 EDSS points where starting EDSS was 2.5 or 3.0; or
 - c) an increase of 1 EDSS point where starting EDSS 3.5 or greater; or
 - d) an increase in EDSS score to 6.0 or more; or
- b) stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note): or
- c) pregnancy and/or lactation; or
- d) within the 12 month approval year, intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate: or
- e) non-compliance with treatment, including refusal to undergo annual assessment or refusal to allow the results of the assessment to be submitted to MSTAC: or
- f) patients may, subject to conclusions drawn from published evidence available at the time, be excluded if they develop a high titre of neutralising anti-bodies to beta-interferon or glatiramer acetate.

Note: Patients who have a stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet any of the other Stopping Criteria at annual review may switch to a different class of funded treatment (i.e. patients may switch from either of the beta-interferons [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa). Patients may switch classes of treatment for this reason only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to stable or increasing relapse rate over 12 months of treatment).

GLATIRAMER ACETATE – Special Authority see SA1062 o	n the previous page – [[Xpharm]	
Inj 20 mg prefilled syringe	1,089.25	28	Copaxone
INTERFERON BETA-1-ALPHA - Special Authority see SA1	062 on the previous pa	age – [Xpha	rm]
Inj 6 million iu prefilled syringe	1,153.03	4	✓ Avonex
Injection 6 million iu per 0.5 ml pen injector	1,153.03	4	Avonex Pen
Inj 6 million iu per vial		4	Avonex
INTERFERON BETA-1-BETA – Special Authority see SA10 Inj 8 million iu per 1 ml		e – [Xpharn) 15	n] Betaferon
Sedatives and Hypnotics			
LORMETAZEPAM – Safety medicine; prescriber may deter	nine dispensing freque	ncy	
Tab 1 mg	3.11	30	
	(23.50)		Noctamid
1 Safety cap for extemporaneously compounded oral	liquid preparations.		

	Subsidy (Manufacturer's Price) \$	Per	Full <u>y</u> Subsidised	/
MIDAZOLAM – Safety medicine; prescriber may determine dispe Inj 1 mg per ml, 5 ml		10	-	Pfizer Hypnovel
Inj 5 mg per ml, 3 ml	11.90	5	~	Hypnovel Pfizer
NITRAZEPAM – Safety medicine; prescriber may determine disp Tab 5 mg ‡ Safety cap for extemporaneously compounded oral liquid	4.98 d preparations.	100	r	Nitrados
PHENOBARBITONE SODIUM - Special Authority see SA1386 b		•		
Inj 200 mg per ml, 1 ml ampoule		10	~	Martindale S29
 the following criteria: Both: For the treatment of terminal agitation that is unresponsively 2. The applicant is part of a multidisciplinary team working in TEMAZEPAM – Safety medicine: prescriber may determine dispersively. 	n palliative care.	ıd		
TEMAZEPAM – Safety medicine; prescriber may determine disperation of the second		25	r	Normison
b) Normison to be Sole Supply on 1 October 2014				
TRIAZOLAM – Safety medicine; prescriber may determine dispe Tab 125 mcg	5.10	100		
+ Cafet	(7.25)			Hypam
‡ Safety cap for extemporaneously compounded oral liquid Tab 250 mcg		100		
	(8.70)			Hypam
‡ Safety cap for extemporaneously compounded oral liquid				
ZOPICLONE – Safety medicine; prescriber may determine dispe		500		Ana Zanialana
Tab 7.5 mg	11.90	500	V	Apo-Zopiclone
Stimulants/ADHD Treatments				
Stimulants/ADHD treatments				
ATOMOXETINE – Special Authority see SA1416 on the next pag				
Cap 10 mg		28		Strattera
Cap 18 mg		28		Strattera
Cap 25 mg		28		Strattera

Cap 25 mg	 Strattera
Cap 40 mg	Strattera
Cap 60 mg	Strattera
Cap 80 mg	Strattera
Cap 100 mg	 Strattera

Subsidy		Fully	Brand or	
(Manufacturer's Price)	5	Subsidised	Generic	
(inalialacial ci c i ilico) \$	Per	 ✓ 	Manufacturer	

➡SA1416 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:
 - 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
 - 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
 - 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; or
 - 3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: A "subsidised formulation of a stimulant" refers to currently subsidised methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

DEXAMPHETAMINE SULPHATE - Special Authority see SA1149 below - Retail pharmacy

a) Only on a controlled drug form

b) Safety medicine; prescriber may determine dispensing frequency

Tab 5	i mg	 	 	 16.50	100

➡SA1149 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: Both:

continued...

✓ <u>PSM</u>
 ✓ PSM S29 S29

 Fully Subsidised	Brand or Generic
\$ Per 🖌	Manufacturer

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE - Special Authority see SA1150 below - Retail pharmacy

a) Only on a controlled drug form

 b) Safety medicine; prescriber may determine dispensing 	frequency		
Tab immediate-release 5 mg		30	Rubifen
Tab immediate-release 10 mg	3.00	30	Ritalin
			Rubifen
Tab immediate-release 20 mg	7.85	30	 Rubifen
Tab sustained-release 20 mg		30	Rubifen SR
-	50.00	100	Ritalin SR

SA1150 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

- Both:
 - 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
 - 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's Price) \$	Subsi Per	Fully idised	Brand or Generic Manufacturer
METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEAS a) Only on a controlled drug form b) Safety medicine; prescriber may determine dispensing fre	, ,	see SA115	51 belo	w – Retail pharmacy

b) Salety medicine, prescriber may determine dispensi	iy nequency		
Tab extended-release 18 mg		30	Concerta
Tab extended-release 27 mg	65.44	30	Concerta
Tab extended-release 36 mg		30	Concerta
Tab extended-release 54 mg		30	Concerta
Cap modified-release 10 mg		30	Ritalin LA
Cap modified-release 20 mg		30	Ritalin LA
Cap modified-release 30 mg		30	Ritalin LA
Cap modified-release 40 mg		30	Ritalin LA

SA1151 Special Authority for Subsidy

Initial application only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing; and
- 4 Either:
 - 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
 - 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

Renewal only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a paediatrician or psychiatrist (in writing). Approvals valid for 24 months for applications meeting the following criteria:

- Both:
 - 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a paediatrician or psychiatrist has been consulted within the last 2 years and has recommended treatment for the patient in writing.

MODAFINIL – Special Authority see SA1126 below – Retail pharmacy

Tab 100 mg72.50 30 🗸 Modavigil

SA1126 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and

2 Either:

- 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
- 2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

3 Either:

- 3.1 An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or
- 3.2 Methylphenidate and dexamphetamine are contraindicated.

Renewal only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Treatments for Dementia		
DONEPEZIL HYDROCHLORIDE		
* Tab 5 mg7.71	90	Donepezil-Rex
* Tab 10 mg14.06	90	Donepezil-Rex
Treatments for Substance Dependence		
BUPRENORPHINE WITH NALOXONE – Special Authority see SA1203 below – F a) No patient co-payment payable	Retail pharm	acy
b) Safety medicine; prescriber may determine dispensing frequency		
Tab sublingual 2 mg with naloxone 0.5 mg	28	Suboxone
Tab sublingual 8 mg with naloxone 2 mg166.00	28	Suboxone

➡SA1203 Special Authority for Subsidy

Initial application — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health..

Initial application — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient will not be receiving methadone; and
- 3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned; and
- 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and
- 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	~	Manufacturer	

3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient.

Renewal — (Maintenance treatment where the patient has previously had an initial application for detoxification) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Patient received but failed detoxification with buprenorphine with naloxone; and
- 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and
- 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

BUPROPION HYDROCHLORIDE Tab modified-release 150 mg	4.97	30	 Zyban
DISULFIRAM Tab 200 mg	24.30	100	 Antabuse
NALTREXONE HYDROCHLORIDE – Special Authority see Tab 50 mg			✓ Naltraccord

➡SA1408 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard.

Renewal from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
 - 2.1 Patient is still unstable and requires further treatment; or
 - 2.2 Patient achieved significant improvement but requires further treatment; or
 - 2.3 Patient is well controlled but requires maintenance therapy.

NICOTINE

Nicotine will not be funded under the Dispensing Frequency Rule in amounts less than 4 weeks of treatment.

Patch 7 mg – Up to 28 patch available on a PSO 12.40	28	Habitrol
Patch 14 mg – Up to 28 patch available on a PSO	28	Habitrol
Patch 21 mg - Up to 28 patch available on a PSO14.02	28	Habitrol
Lozenge 1 mg - Up to 216 loz available on a PSO15.15	216	Habitrol
Lozenge 2 mg – Up to 216 loz available on a PSO16.60	216	Habitrol
Gum 2 mg (Classic) - Up to 384 piece available on a PSO26.13	384	Habitrol
Gum 2 mg (Fruit) - Up to 384 piece available on a PSO26.13	384	Habitrol
Gum 2 mg (Mint) – Up to 384 piece available on a PSO26.13	384	Habitrol
Gum 4 mg (Classic) – Up to 384 piece available on a PSO30.12	384	Habitrol
Gum 4 mg (Fruit) – Up to 384 piece available on a PSO	384	Habitrol
Gum 4 mg (Mint) – Up to 384 piece available on a PSO30.12	384	Habitrol

VARENICLINE TARTRATE - Special Authority see SA1161 on the next page - Retail pharmacy

a) Varenicline will not be funded under the Dispensing Frequency	Rule in amounts	less than 2	2 weeks of treatment.	
b) A maximum of 3 months' varenicline will be subsidised on each	Special Authorit	y approval.	al.	
Tab 1 mg	67.74	28	Champix	

	20	1ab 1 mg
Champix	56	135.48
 Champix 	25 OP	Tab 0.5 mg \times 11 and 1 mg \times 1460.48

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

➡SA1161 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not used funded varenicline in the last 12 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 3 months' funded varenicline (see note).

Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 The patient has not used funded varenicline in the last 12 months; and
- 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 5 The patient is not pregnant; and
- 6 The patient will not be prescribed more than 3 months' funded varenicline (see note).

The patient must not have had an approval in the past 12 months.

Note: a maximum of 3 months' varenicline will be subsidised on each Special Authority approval.

	Subsidy (Manufacturer's		Fully	Brand or Generic
	\$	Per		Manufacturer
Chemotherapeutic Agents				
Alkylating Agents				
BUSULPHAN – PCT – Retail pharmacy-Specialist				
Tab 2 mg		100	🗸 M	lyleran
CARBOPLATIN – PCT only – Specialist				
Inj 10 mg per ml, 5 ml	20.00	1	V C	arboplatin Ebewe
Inj 10 mg per ml, 15 ml		1		arbaccord
	22.50	•		arboplatin Ebewe
Inj 10 mg per ml, 45 ml		1		arbaccord
	50.00	•		arboplatin Ebewe
	00.00			BL Carboplatin
Inj 10 mg per ml, 100 ml		1		arboplatin Ebewe
Inj 1 mg for ECP		1 mg		axter
CARMUSTINE – PCT only – Specialist	004.10	4		iCNU
Inj 100 mg		1		
Inj 100 mg for ECP	204.13	100 mg OP	VB	axter
HLORAMBUCIL – PCT – Retail pharmacy-Specialist				
Tab 2 mg	22.35	25	🖌 Li	eukeran FC
SISPLATIN – PCT only – Specialist				
Inj 1 mg per ml. 50 ml	15.00	1	V C	isplatin Ebewe
		·		ospira
Inj 1 mg per ml, 100 ml	21.00	1		isplatin Ebewe
		·		ospira
Inj 1 mg for ECP	0.27	1 mg		axter
, ,				
CYCLOPHOSPHAMIDE				
Tab 50 mg – PCT – Retail pharmacy-Specialist		50		ndoxan S29
	158.00	100	🖌 Р	rocytox S29
Wastage claimable – see rule 3.3.2 on page 17				
Inj 1 g – PCT – Retail pharmacy-Specialist		1		ndoxan
	127.80	6		ytoxan
Inj 2 g – PCT only – Specialist		1		ndoxan
Inj 1 mg for ECP – PCT only – Specialist	0.03	1 mg	∨ В	axter
FOSFAMIDE – PCT only – Specialist				
lnj 1 g		1	🖌 Н	oloxan
lnj 2 g		1	🖌 Н	oloxan
Inj 1 mg for ECP	0.10	1 mg	🖌 В	axter
OMUSTINE – PCT – Retail pharmacy-Specialist		-		
Cap 10 mg	132 50	20	v c	eeNU
Cap 40 mg		20		eeNU
		20	- 0	
IELPHALAN	~ ~ ~	67		0
Tab 2 mg – PCT – Retail pharmacy-Specialist		25		lkeran
Inj 50 mg – PCT only – Specialist		1	V A	lkeran

(Subsidy Manufacturer's Price) \$	Per	Full Subsidise	d Generic
OXALIPLATIN – PCT only – Specialist Inj 50 mg	15.32	1	~	Oxaliplatin Actavis 50
lni 100 mg	55.00 200.00 25.01	1	~	Oxaliplatin Ebewe Eloxatin Oxaliplatin Actavis
Inj 100 mg	110.00 400.00	I	~	100 Oxaliplatin Ebewe Eloxatin
Inj 1 mg for ECP THIOTEPA – PCT only – Specialist		1 mg	· · ·	Baxter
Inj 15 mg	CBS	1	V	Bedford S29 THIO-TEPA S29 Tepadina S29
Antimetabolites				
AZACITIDINE – PCT only – Specialist – Special Authority see SA Inj 100 mg vial		1	~	Vidaza

inj 100 mg viai		1	Vidaza
Inj 1 mg for ECF	96.66	1 mg	 Baxter

SA1467 Special Authority for Subsidy

Initial application only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 Any of the following:
 - 1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
 - 1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
 - 1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and
- 2 The patient has performance status (WHO/ECOG) grade 0-2; and
- 3 The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and
- 4 The patient has an estimated life expectancy of at least 3 months.

Renewal only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

	Subsidy	a) (Fully Brand or
	(Manufacturer's Pric	Per	ubsidised Generic Manufacturer
CALCIUM FOLINATE			
Tab 15 mg – PCT – Retail pharmacy-Specialist	82.45	10	DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist	17 10	5	✓ Hospira
Inj 50 mg – PCT – Retail pharmacy-Specialist		5	✓ Calcium Folinate Ebewe
Inj 100 mg – PCT only – Specialist	7.33	1	 Calcium Folinate Ebewe
Inj 300 mg – PCT only – Specialist	22.51	1	✓ Calcium Folinate Ebewe
Inj 1 g – PCT only – Specialist	67.51	1	✓ Calcium Folinate Ebewe
Inj 1 mg for ECP – PCT only – Specialist	0.06	1 mg	✓ Baxter
CAPECITABINE – Retail pharmacy-Specialist		0	
Tab 150 mg		60	 Capecitabine Winthrop
			Xeloda
Tab 500 mg	120.00	120	 Capecitabine Winthrop Xeloda
(Xeloda Tab 150 mg to be delisted 1 December 2014) (Xeloda Tab 500 mg to be delisted 1 December 2014) CLADRIBINE – PCT only – Specialist			
Inj 1 mg per ml, 10 ml	5.249.72	7	Leustatin
Inj 10 mg for ECP		10 mg OP	✓ Baxter
CYTARABINE			4
Inj 20 mg per ml, 5 ml vial – PCT – Retail pharmacy-Specialist		5	✓ Pfizer
Ini 500 mm DOT Datail sharman Canadaliat	80.00		 ✓ Hospira ✓ Pfizer
Inj 500 mg – PCT – Retail pharmacy-Specialist		1 5	✓ Prizer ✓ Hospira
Inj 100 mg per ml, 10 ml vial – PCT – Retail pharmacy-	33.30	5	
Specialist	8.83	1	✔ Pfizer
	42.65		✓ Hospira
Inj 100 mg per ml, 20 ml vial – PCT – Retail pharmacy-			· ····
Specialist	17.65	1	Pfizer
- F	34.47	-	✓ Hospira
Inj 1 mg for ECP – PCT only – Specialist		10 mg	✓ Baxter
Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist		100 mg OF	Baxter
FLUDARABINE PHOSPHATE			A T I I I I I I I I I I
Tab 10 mg – PCT – Retail pharmacy-Specialist		20	Fludara Oral
Inj 50 mg – PCT only – Specialist		5	Fludarabine Ebewe
	1,430.00		✓ Fludara
Inj 50 mg for ECP – PCT only – Specialist	105.00	50 mg OP	Baxter

	Subsidy (Manufacturer's Price \$) S Per	Fully Brand or Subsidised Generic ✔ Manufacturer
LUOROURACIL SODIUM			
Inj 50 mg per ml, 10 ml – PCT only – Specialist		5	Fluorouracil Ebewe
Inj 50 mg per ml, 20 ml – PCT only – Specialist	7.50	1	Fluorouracil Ebewe
Inj 25 mg per ml, 100 ml – PCT only – Specialist		1	 Hospira
Inj 50 mg per ml, 50 ml – PCT only – Specialist		1	Fluorouracil Ebewe
Inj 50 mg per ml, 100 ml – PCT only – Specialist		1	Fluorouracil Ebewe
Inj 1 mg for ECP – PCT only – Specialist	0.77	100 mg	 Baxter
EMCITABINE HYDROCHLORIDE - PCT only - Specialist			
lnj 1 g		1	 Gemcitabine Ebewe
, ,	62.50		DBL Gemcitabine
			Gemcitabine
			Actavis 1000
	349.20		Gemzar
Inj 200 mg		1	Gemcitabine Ebewe
,	12.50		Gemcitabine
			Actavis 200
	78.00		Gemzar
Inj 1 mg for ECP		1 mg	✓ Baxter
Gemcitabine Actavis 1000 Inj 1 g to be delisted 1 November 20 Gemcitabine Actavis 200 Inj 200 mg to be delisted 1 November RINOTECAN – PCT only – Specialist		Ū	
Inj 20 mg per ml, 2 ml	9.34	1	 Irinotecan Actavis 40
	41.00		Camptosar
			Irinotecan-Rex
Inj 20 mg per ml, 5 ml	23.34	1	Irinotecan Actavis
			100
	100.00		Camptosar
			Irinotecan-Rex
Inj 1 mg for ECP	0.24	1 mg	✓ Baxter
ERCAPTOPURINE – PCT – Retail pharmacy-Specialist		-	
Tab 50 mg	49 41	25	Puri-nethol
····· ································			

		Subsidy (Manufacturer's Pric \$	e) Per	Full Subsidised	
ME	THOTREXATE				
*	Tab 2.5 mg - PCT - Retail pharmacy-Specialist	3.82	30	~	Trexate
	Brand switch fee payable (Pharmacode 2465353) - see pa	•			
*	Tab 10 mg – PCT – Retail pharmacy-Specialist		50	~	Trexate
	Brand switch fee payable (Pharmacode 2465353) - see pa				
*	Inj 2.5 mg per ml, 2 ml - PCT - Retail pharmacy-Specialist .		5		Hospira
ŧ	Inj 7.5 mg prefilled syringe	17.19	1	~	Methotrexate
					Sandoz
*	Inj 10 mg prefilled syringe	17.25	1	V	Methotrexate
	Ini 15 and susfilled surfaces	17.00			Sandoz Mathatrouata
*	Inj 15 mg prefilled syringe	17.38	1	V	Methotrexate
*	Inj 20 mg prefilled syringe	17.50	1		Sandoz Methetrovete
2	inj 20 mg premied synnge		I	V	Methotrexate Sandoz
*	Inj 25 mg prefilled syringe	17.62	1		Methotrexate
N	ing 25 mg premied synnige		1	•	Sandoz
ŧ	Inj 30 mg prefilled syringe	17 75	1	~	Methotrexate
r	Ing 50 mg premied synnige			•	Sandoz
ŧ	Inj 25 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	20.20	5	~	Hospira
ŧ	Inj 25 mg per ml, 20 ml – PCT – Retail pharmacy-Specialist		1		Hospira
¥.	Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialis		1		Methotrexate Ebewe
₩.	Inj 100 mg per ml, 50 ml – PCT – Retail pharmacy-Specialis		1		Methotrexate Ebewe
ŧ	Inj 1 mg for ECP – PCT only – Specialist		1 mg	-	Baxter
₩	Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist		5 mg Ol		Baxter
				-	
н	OGUANINE – PCT – Retail pharmacy-Specialist	07.10	05		Lamila
	Tab 40 mg		25	V	Lanvis
0	ther Cytotoxic Agents				
M	SACRINE – PCT only – Specialist				
	Inj 75 mg	CBS	6	~	Amsidine S29
NL	AGRELIDE HYDROCHLORIDE – PCT – Retail pharmacv-Sp				
111/	· · · · · · · · · · · · · · · · · · ·		400		
	Cap 0.5 mg	CBS	100		Agrylin S29
				~	Teva S29
R	SENIC TRIOXIDE – PCT only – Specialist				
	Inj 10 mg	4.817.00	10	~	AFT S29
			10	•	
SLE	EOMYCIN SULPHATE – PCT only – Specialist	100.00			
	Inj 15,000 iu		1	V	DBL Bleomycin
			4 000 .		Sulfate
	Inj 1,000 iu for ECP	9.28	1,000 iu	u V	Baxter
	RTEZOMIB - PCT only - Specialist - Special Authority see	SA1127 on the nex	t page		
801			a a	~	Velcade
301	Inj 1 mg		1	•	Velcaue
301	Inj 1 mg Inj 3.5 mg		1		Velcade

Subsidy		Fully	Brand or	
(Manufacturer's Price)	9	Subsidised	Generic	
\$	Per	~	Manufacturer	

➡SA1127 Special Authority for Subsidy

Initial application — (Treatment naive multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 The patient has treatment-naive symptomatic multiple myeloma; or
- 1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and
- 2 Maximum of 9 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Initial application — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 The patient has relapsed or refractory multiple myeloma; or
 - 1.2 The patient has relapsed or refractory systemic AL amyloidosis * ; and
- 2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and
- 3 The patient has not had prior publicly funded treatment with bortezomib; and
- 4 Maximum of 4 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

COLASDASE ILASDADAGINASEL DOT only Specialist

Renewal — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both:

- 1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and
- 2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:

- a) a known therapeutic chemotherapy regimen and supportive treatments; or
- b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.

COLASPASE [L-ASPARAGINASE] – PC1 only – Specialist Inj 10,000 iu		1	Leunase
Inj 10,000 iu for ECP	102.32	10,000 iu OP	Baxter
DACARBAZINE – PCT only – Specialist			
Inj 200 mg vial		1	Hospira
Inj 200 mg for ECP	51.84	200 mg OP	Baxter
DACTINOMYCIN [ACTINOMYCIN D] - PCT only - Specialist			
Inj 0.5 mg		1	 Cosmegen
Inj 0.5 mg for ECP	13.52	0.5 mg OP	✓ Baxter
DAUNORUBICIN – PCT only – Specialist			
Inj 2 mg per ml, 10 ml		1	 Pfizer
Inj 20 mg for ECP	118.72	20 mg OP	Baxter
DOCETAXEL – PCT only – Specialist			
Inj 20 mg	48.75	1	 Docetaxel Sandoz
Inj 20 mg per ml, 1 ml		1	Taxotere
Inj 20 mg per ml, 4 ml	195.00	1	 Taxotere
Inj 80 mg		1	Docetaxel Sandoz
Inj 1 mg for ECP	2.63	1 mg	Baxter

	Subsidy (Manufacturer's Price)		Fully Brand or Subsidised Generic	
	(Manulacturer's Frice) \$	Per	Manufact	urer
DXORUBICIN – PCT only – Specialist				
Inj 10 mg		1	Doxorubici	in Ebewe
Inj 50 mg	17.00	1	Arrow-Dox	orubicin
	40.00		🖌 DBL Doxor	rubicin
			V DBL Doxor S29 S29	rubicin
			Doxorubici	in Ebewe
Inj 100 mg		1	Doxorubici	in Ebewe
Inj 200 mg	65.00	1	Arrow-Dox	orubicin
	150.00		Adriamycii	n
			 Doxorubici 	in Ebewe
Inj 1 mg for ECP	0.37	1 mg	Baxter	
PIRUBICIN – PCT only – Specialist				
Inj 2 mg per ml, 5 ml		1	🖌 Epirubicin	Ebewe
Inj 2 mg per ml, 25 ml		1	DBL Epirul Hydroch	
	87.50		 Epirubicin 	Ebewe
Inj 2 mg per ml, 50 ml		1	🗸 DBL Epirul	
			Hydroch	
	125.00		Epirubicin	Ebewe
Inj 2 mg per ml, 100 ml	94.50	1	✓ DBL Epirul Hydroch	
	210.00		Epirubicin	Ebewe
Inj 1 mg for ECP	0.82	1 mg	 Baxter 	
OPOSIDE		•		
Cap 50 mg – PCT – Retail pharmacy-Specialist	340.73	20	 Vepesid 	
Cap 100 mg – PCT – Retail pharmacy-Specialist		10	✓ Vepesid	
Inj 20 mg per ml, 5 ml – PCT – Retail pharmacy-Specialist		1	 Hospira 	
	612.20	10	Vepesid	
Inj 1 mg for ECP – PCT only – Specialist	0.30	1 mg	Baxter	
OPOSIDE PHOSPHATE – PCT only – Specialist		•		
Inj 100 mg (of etoposide base)	40.00	1	 Etopophos 	
Inj 1 mg (of etoposide base) for ECP		1 mg	✓ Baxter	
/DROXYUREA – PCT – Retail pharmacy-Specialist				
Cap 500 mg	31.76	100	 Hydrea 	
		100	• Hyurea	
	445.00			
Cap 5 mg – PCT – Retail pharmacy-Specialist		1	Zavedos	
Cap 10 mg – PCT – Retail pharmacy-Specialist		1	Zavedos	
Inj 5 mg – PCT only – Specialist		1 1	 Zavedos Zavedos 	
Inj 10 mg – PCT only – Specialist Inj 1 mg for ECP – PCT only – Specialist		ı 1 mg	✓ Zavedos	
avedos Cap 5 mg to be delisted 1 February 2015) avedos Cap 10 mg to be delisted 1 February 2015)	22.20	i mg	✓ Daxier	
NALIDOMIDE – Retail pharmacy-Specialist – Special Authorit	ty see SA1468 on the	e next p	age	
Wastage claimable – see rule 3.3.2 on page 17	0.007.00	04	Developed 1	
Cap 10 mg		21	Revlimid	
Cap 25 mg	1,627.00	21	Revlimid	

Subsidy		Fully	Brand or
(Manufacturer's Price)	5	Subsidised	Generic
\$	Per	~	Manufacturer

➡SA1468 Special Authority for Subsidy

Initial application — (Relapsed/refractory disease) only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has relapsed or refractory multiple myeloma with progressive disease; and
- 2 Either:
 - 2.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or
 - 2.2 Both:
 - 2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
 - 2.2.2 The patient has experienced severe (grade \geq 3), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and
- 3 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

Renewal only from a haematologist or medical practitioner on the recommendation of a haematologist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Note: Indication marked with * is an Unapproved Indication (refer to Interpretations and Definitions). A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

MESNA

Tab 400 mg – PCT – Retail pharmacy-Specialist	50	Uromitexan
Tab 600 mg – PCT – Retail pharmacy-Specialist	50	Uromitexan
Inj 100 mg per ml, 4 ml ampoule – PCT only – Specialist	15	Uromitexan
Inj 100 mg per ml, 10 ml ampoule - PCT only - Specialist	15	Uromitexan
Inj 1 mg for ECP – PCT only – Specialist2.47	100 mg	 Baxter
MITOMYCIN C – PCT only – Specialist		
Inj 5 mg vial	1	Arrow
Inj 1 mg for ECP16.43	1 mg	✓ Baxter
MITOZANTRONE – PCT only – Specialist	-	
Inj 2 mg per ml, 5 ml110.00	1	Mitozantrone Ebewe
Inj 2 mg per ml, 10 ml	1	 Mitozantrone Ebewe
Inj 2 mg per ml, 12.5 ml	1	✓ Onkotrone
Inj 1 mg for ECP	1 mg	✓ Baxter
PACLITAXEL – PCT only – Specialist	•	
Inj 30 mg	5	Paclitaxel Ebewe
Inj 100 mg	1	Paclitaxel Ebewe
91.67	•	✓ Paclitaxel Actavis
Inj 150 mg	1	Paclitaxel Ebewe
137.50	•	✓ Anzatax
101.00		Paclitaxel Actavis
Inj 300 mg36.53	1	Paclitaxel Ebewe
275.00		✓ Anzatax
213.00		✓ Paclitaxel Actavis
lni 600 mg 72 06	1	✓ Paclitaxel Ebewe
Inj 600 mg	•	Baxter
Inj 1 mg for ECP0.17	1 mg	

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
PEGASPARGASE – PCT only – Special Authority see SA1325 I	below				
Inj 3,750 IU per 5 ml	3,005.00	1	v 0	ncaspar S29	

SA1325 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has newly diagnosed acute lymphoblastic leukaemia; and
- 2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
- 3 Treatment is with curative intent.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has relapsed acute lymphoblastic leukaemia; and
- 2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
- 3 Treatment is with curative intent.

PENTOSTATIN [DEOXYCOFORMYCIN] - PCT only - Specialist

Inj 10 mgC	BS	1 🖌	Nipent S29
PROCARBAZINE HYDROCHLORIDE - PCT - Retail pharmacy-Special	ist		
Cap 50 mg498	3.00 5	50 🖌	Natulan S29
TEMOZOLOMIDE - Special Authority see SA1063 below - Retail pharma	асу		
Cap 5 mg	3.00	5 🖌	Temaccord
Cap 20 mg	6.00	5 🖌	Temaccord
Cap 100 mg175	5.00	5 🖌	Temaccord
Cap 250 mg410		5 🖌	Temaccord

➡SA1063 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Patient has newly diagnosed glioblastoma multiforme; or
 - 1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
- 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
- 3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m².

Notes: Indication marked with a * is an Unapproved Indication. Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Reapplications will not be approved.

Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

THALIDOMIDE - PCT only - Specialist - Special Authority see SA1124 on the next page

Cap 50 mg	 	 	378.00	28	Thalomid
Cap 100 mg	 	 	756.00	28	 Thalomid

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	lbsidised	Generic	
\$	Per	~	Manufacturer	

SA1124 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Fither:

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis*.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period. Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Indication marked with * is an Unapproved Indication.

TRETINOIN

Cap 10 mg – PCT – Retail pharmacy-Specialist	100	Vesanoid
VINBLASTINE SULPHATE		
Inj 10 mg – PCT – Retail pharmacy-Specialist	1	Hospira
137.50	5	Hospira
Inj 1 mg for ECP – PCT only – Specialist	1 mg	Baxter
VINCRISTINE SULPHATE		
Inj 1 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist	5	Hospira
Inj 1 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	5	Hospira
Inj 1 mg for ECP – PCT only – Specialist	1 mg	✓ Baxter
VINORELBINE – PCT only – Specialist		
Inj 10 mg per ml, 1 ml 12.85	1	Navelbine
42.00		Vinorelbine Ebewe
Inj 10 mg per ml, 5 ml64.25	1	Navelbine
210.00		Vinorelbine Ebewe
Inj 1 mg for ECP1.45	1 mg	Baxter

Protein-tyrosine Kinase Inhibitors

,774.06	60	Sprycel
,214.20	60	Sprycel
,692.58	60	Sprycel
	30	 Sprycel
	,214.20 ,692.58	,214.20 60 ,692.58 60

SA0976 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz, and prescriptions should be sent to: (0.4) 400 4000

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: cmlgistcoordinator@pharmac.govt.nz
Wellington	

.

Special Authority criteria for CML - access by application

- a) Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.

continued....

b) Maximum dose of 140 mo/day for accelerated or blast phase, and 100 mo/day for chronic phase CML.

Subsidy	Ful	ly Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per •	 Manufacturer 	

continued...

- c) Subsidised for use as monotherapy only.
- d) Initial approvals valid seven months.
- e) Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Note: Dasatinib is indicated for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.

Guideline on discontinuation of treatment for patients with CML

- a) Prescribers should consider discontinuation of treatment if, after 6 months from initiating therapy, a patient did not obtain a haematological response as defined as any one of the following three levels of response:
 - a) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5×10^9 /L, platelets > 100 × 10⁹/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - b) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0×10^{9} /L, platelets > 20×10^{9} /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - c) return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).</p>
- Prescribers should consider discontinuation of treatment if, after 18 months from initiating therapy, a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

ERLOTINIB -	Retail pharmacy-Specialist – Special Authority see SA1411 below		
Tab 100 m	g1,133.00	30	 Tarceva
Tab 150 m	g1,700.00	30	Tarceva

➡SA1411 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
 - 1.2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
 - 1.3 Either:
 - 1.3.1 Patient is treatment naive; or
 - 1.3.2 Both:
 - 1.3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and
 - 1.3.2.2 Patient has not received prior treatment with gefitinib; and
 - 1.4 Erlotinib is to be given for a maximum of 3 months; or
- 2 The patient received funded erlotinib prior to 31 December 2013 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

GEFITINIB - Retail pharmacy-Specialist

Tab 250 mg – Special Authority see SA1226 on the next			
page1,70	0.00 3	30 (Iressa

Subsidy (Manufacturer's Price)	S	Fully Subsidised	Brand or Generic
\$	Per	~	Manufacturer

➡SA1226 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

- Either:
 - 1 All of the following:
 - 1.1 Patient has treatment naive locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
 - 1.2 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
 - 1.3 Gefitinib is to be given for a maximum of 3 months; or
 - 2 The patient received gefitinib treatment prior to 1 August 2012 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

IMATINIB MESILATE

	Tab 100 mg - Special Authorit	y see SA1460 below -		
	[Xpharm]		60	Glivec
*	Cap 100 mg		60	Imatinib-AFT

a) Brand switch fee payable (Pharmacode 2461099) - see page 207 for details

b) No patient co-payment payable

c) Note: Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA0643 in Section B of the Pharmaceutical Schedule.

SA1460 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website <u>http://www.pharmac.govt.nz</u>, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: cmlgistcoordinator@pharmac.govt.nz

Wellington

Special Authority criteria for GIST - access by application

Funded for patients:

- a) With a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST).
- b) Maximum dose of 400 mg/day.
- c) Applications to be made and subsequent prescriptions can be written by an oncologist.
- d) Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined).

LAPATINIB DITOSYLATE - Special Authority see SA1191 below - Retail pharmacy

Tab 250 mg	1,899.00	70	🖌 Tykerb
------------	----------	----	----------

SA1191 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
- 1.3 Lapatinib not to be given in combination with trastuzumab; and
- 1.4 Lapatinib to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on trastuzumab; and
 - 2.4 Lapatinib not to be given in combination with trastuzumab; and
 - 2.5 Lapatinib to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
- 3 Lapatinib not to be given in combination with trastuzumab; and
- 4 Lapatinib to be discontinued at disease progression.

PAZOPANIB - Special Authority see SA1190 below - Retail pharmacy

Tab 200 mg		30	 Votrient
Tab 400 mg	2,669.40	30	 Votrient

SA1190 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 Both:
 - 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
 - 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
 - The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of \leq 70; or
 - 5.6 \geq 2 sites of organ metastasis; and
- 6 Pazopanib to be used for a maximum of 3 months.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

- Both:
 - 1 No evidence of disease progression; and
 - 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

SUNITINIB - Special Authority see SA1266 below - Retail pharmacy

Cap 12.5 mg2,315.38	3 28	Sutent
Cap 25 mg	7 28	Sutent
Cap 50 mg	4 28	 Sutent

SA1266 Special Authority for Subsidy

Initial application — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
 - 2.4 Both:
 - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
 - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
 - The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of \leq 70; or
 - 5.6 ≥ 2 sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Initial application — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Either:
 - 2.1 The patient's disease has progressed following treatment with imatinib; or
 - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Renewal — (**RCC**) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

Subsidy	Ful	ly Brand or	
(Manufacturer's Price)	Subsidise	d Generic	
\$	Per •	 Manufacturer 	

1 No evidence of disease progression; and

2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6

Renewal — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
 - 1.2 The patient has had a partial response (a decrease in size of ≥ 10% or decrease in tumour density in Hounsfield Units (HU) of ≥ 15% on CT and no new lesions and no obvious progression of non measurable disease); or
 - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of $\geq 10\%$ and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Endocrine Therapy			
For GnRH ANALOGUES - refer to HORMONE PREPARATIONS,	Trophic Hormone	es, page 89	
BICALUTAMIDE - Special Authority see SA0941 below - Retail p	harmacy		
Tab 50 mg	4.90	28	 Bicalaccord
Bicalaccord to be Sole Supply on 1 October 2014			
SA0941 Special Authority for Subsidy			
Initial application from any medical practitioner. Approvals valid advanced prostate cancer.	d without further	renewal un	less notified where the patient has
FLUTAMIDE – Retail pharmacy-Specialist			
Tab 250 mg		30	Flutamin S29 S29
	55.00	100	 Flutamin
MEGESTROL ACETATE – Retail pharmacy-Specialist			
Tab 160 mg	51.55	30	✓ Apo-Megestrol
OCTREOTIDE			
Inj 50 mcg per ml, 1 ml		5	Octreotide MaxRx
Inj 50 mcg per ml, 1 ml vial		5	🖌 DBL
Inj 100 mcg per ml, 1 ml	22.40	5	 Octreotide MaxRx
Inj 100 mcg per ml, 1 ml vial		5	🖌 DBL
Inj 500 mcg per ml, 1 ml		5	 Octreotide MaxRx
Inj 500 mcg per ml, 1 ml vial		5	V DBL
(Octreotide MaxRx Inj 50 mcg per ml, 1 ml to be delisted 1 Decem			
(Octreotide MaxRx Inj 100 mcg per ml, 1 ml to be delisted 1 Decer	,		
(Octreotide MaxRx Inj 500 mcg per ml, 1 ml to be delisted 1 Decer	nber 2014)		

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	
OCTREOTIDE LAR (SOMATOSTATIN ANALOGUE) – Special A	uthority see SA1016 b	elow – Retail pha	armacy
Inj LAR 10 mg prefilled syringe	1,772.50	1 🖌 S	andostatin LAR
Inj LAR 20 mg prefilled syringe	2,358.75	1 🖌 S	andostatin LAR
Inj LAR 30 mg prefilled syringe	2,951.25	1 🖌 S	andostatin LAR

SA1016 Special Authority for Subsidy

Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed: and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.
- Note: Indications marked with * are Unapproved Indications.

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application - (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 The patient has acromedaly: and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed: or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Renewal — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks

Initial application - (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Any of the following:

- 1 VIPomas and Glucagonomas for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma: and
 - 2.2 Either:
 - 2.2.1 Patient has failed surgery; or
 - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed: or
- 3 Both:
 - 3.1 Insulinomas; and
 - 3.2 Surgery is contraindicated or has failed; or

 Fully Subsidised	Brand or Generic
\$ Per 🖌	Manufacturer

continued...

4 For pre-operative control of hypoglycaemia and for maintenance therapy; or

5 Both:

- 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
- 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item

Renewal — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. TAMOXIEEN CITRATE

Tab 10 mg2.63	60	Genox
17.50	100	Genox
Tab 20 mg2.63	30	Genox
8.75	100	🖌 Genox
	Tab 20 mg2.63	Tab 10 mg 2.63 60 17.50 100 Tab 20 mg 2.63 30

Aromatase Inhibitors

ANASTROZOLE * Tab 1 mg26.55	30	 ✓ Aremed ✓ Arimidex ✓ DP-Anastrozole
EXEMESTANE * Tab 25 mg14.50 Aromasin to be Sole Supply on 1 October 2014	30	✓ Aromasin
LETROZOLE * Tab 2.5 mg4.85	30	✓ Letraccord

Immunosuppressants

Cytotoxic Immunosuppressants

AZATHIOPRINE – Retail pharmacy-Specialist * Tab 50 mg – For azathioprine oral liquid formulation re	fer		
page 209	,	100	🗸 Azamun
* Inj 50 mg		1	✓ Imuran
MYCOPHENOLATE MOFETIL - Special Authority see SA104	1 below - Retail p	harmacy	
Tab 500 mg		50	Cellcept
Cap 250 mg	25.00	100	 Cellcept
Powder for oral lig 1 g per 5 ml - Subsidy by endorsement		165 ml OP	 Cellcept

Mycophenolate powder for oral liquid is subsidised only for patients unable to swallow tablets and capsules, and when the prescription is endorsed accordingly.

➡SA1041 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Transplant recipient; or
- 2 Both:

Patients with diseases where

(Manı	Subsidy	Fully	Brand or
	ufacturer's Price)	Subsidised	Generic
	\$ Per	~	Manufacturer

continued...

- 2.1 Steroids and azathioprine have been trialled and discontinued because of unacceptable side effects or inadequate clinical response; and
- 2.2 Either:
 - Patients with diseases where
 - 2.2.1 Cyclophosphamide has been trialled and discontinued because of unacceptable side effects or inadequate clinical response; or
 - 2.2.2 Cyclophosphamide treatment is contraindicated.

Fusion Proteins

ETANERCEPT - Special Authority see SA1450 below - Re	etail pharmacy		
Inj 25 mg		4	 Enbrel
Inj 50 mg autoinjector	1,899.92	4	 Enbrel
Inj 50 mg prefilled syringe	1,899.92	4	 Enbrel

SA1450 Special Authority for Subsidy

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

- Either:
 - 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or
 - 2 All of the following:
 - 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
 - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
 - 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria: Either:

ner:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and

Subsidy (Magy facture of Price)	0	Fully bsidised	Brand or	
(Manufacturer's Price)	Su	bsiaisea	Generic	
\$	Per	~	Manufacturer	

continued...

- 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Initial application — (ankylosing spondylitis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

- 25-34 years Male: 7.5 cm; Female: 5.5 cm
- 35-44 years Male: 6.5 cm; Female: 4.5 cm
- 45-54 years Male: 6.0 cm; Female: 5.0 cm
- 55-64 years Male: 5.5 cm; Female: 4.0 cm
- 65-74 years Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

Subsidy	F	ully	Brand or
(Manufacturer's Price)	Subsidi	sed	Generic
\$	Per	~	Manufacturer

continued...

- 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (pyoderma gangrenosum) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, cyclosporine, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Indications marked with * are Unapproved Indications (refer to Interpretations and Definitions).

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a named specialist or rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

(Manu	Subsidy ufacturer's Price)	Ful Subsidise	,	
	\$ P	Per	 Man 	ufacturer

continued...

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

1 Either:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

3 Either:

- 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	lbsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 2 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Fither:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Fither:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician: or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician: and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria: All of the following:

- 1 Patient has shown clinical improvement: and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses.

Immune Modulators

ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist Inj 50 mg per ml, 5 ml2,137.50	5	🖌 ATGAM	
BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Specialist Subsidised only for bladder cancer. Inj 2-8 × 100 million CFU149.37	1	✔ OncoTICE	
Monoclonal Antibodies			
Monocional Antibodica			
ADALIMUMAB – Special Authority see SA1449 below – Retail pharmacy			
Inj 20 mg per 0.4 ml prefilled syringe1,799.92	2	🖌 Humira	
Inj 40 mg per 0.8 ml prefilled pen1,799.92	2	 HumiraPen 	
Inj 40 mg per 0.8 ml prefilled syringe1,799.92	2	🖌 Humira	

► SA1449 Special Authority for Subsidy

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Fither:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept: or

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (Crohn's disease) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
 - 1.2 Either:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 1.2.1 The patient has experienced intolerable side effects from etanercept; or
- 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
 - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Initial application — (ankylosing spondylitis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

	Subsidy	Fully	Brand or
(Ma	nufacturer's Price)	Subsidised	Generic
(114		Per 🗸	Manufacturer

continued...

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application. Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

25-34 years - Male: 7.5 cm; Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm

45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for juvenile idiopathic arthritis; or
- 2 All of the following:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 2.1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.2 Patient diagnosed with JIA; and
- 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
- 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Initial application — (fistulising Crohn's disease) only from a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 A Baseline Fistula Assessment has been completed and is no more than 1 month old at the time of application; and
- 4 The patient will be assessed for response to treatment after 4 months' adalimumab treatment (see Note).

Note: A maximum of 4 months' adalimumab will be subsidised on an initial Special Authority approval for fistulising Crohn's disease. **Initial application — (pyoderma gangrenosum)** only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Note: Indications marked with * are Unapproved Indications (refer to (Interpretations and Definitions).

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

1 Fither:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

3 Either:

- 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 4 Either:
 - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Renewal — (Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Either:
 - 2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 2.1.2 CDAI score is 150 or less; or
 - 2.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Subsidy	Full	y Brand or
(Manufacturer's Price)	Subsidise	d Generic
\$	Per 🖌	 Manufacturer

continued...

Note: A treatment course is defined as a minimum of 12 weeks adalimumab treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-adalimumab baseline on a 10 point scale, or by 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a named specialist or rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (fistulising Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or

Subsidy (Manufacturer's Price)	S	Fully ubsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and

2 Either:

- 2.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
- 2.2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Renewal — (pyoderma gangrenosum) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses.

RITUXIMAB - PCT only - Specialist - Special Authority	see SA1152 below		
Inj 100 mg per 10 ml vial	1,075.50	2	Mabthera
Inj 500 mg per 50 ml vial	2,688.30	1	Mabthera
Inj 1 mg for ECP	5.64	1 mg	 Baxter

➡SA1152 Special Authority for Subsidy

Initial application — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: Fither:

- 1 Both:
 - 1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Initial application — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Fither:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
 - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Subsidy	Fully		Brand or	
(Manufacturer's Price)	Subsidised		Generic	
\$	Per	~	Manufacturer	

continued...

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Initial application — (Chronic Lymphocytic Leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 The patient is rituximab treatment naive; and
- 3 Either:
 - 3.1 The patient is chemotherapy treatment naive; or
 - 3.2 Both:
 - 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
 - 3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and
- 4 The patient has good performance status; and
- 5 The patient has good renal function (creatinine clearance \geq 30 ml/min); and
- 6 The patient does not have chromosome 17p deletion CLL; and
- 7 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and
- 8 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to <2.

Renewal — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Renewal — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

	Subsidy (Manufacturer's Price) \$	Per		Brand or Generic Manufacturer	
TRASTUZUMAB – PCT only – Specialist – Speci	al Authority see SA1192 below				
Inj 150 mg vial		1	🖌 Н	erceptin	
Inj 440 mg vial		1	🖌 Н	erceptin	
Ini 1 ma for ECP		l ma	🖌 В	axter	

SA1192 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Trastuzumab not to be given in combination with lapatinib; and
 - 1.4 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on lapatinib; and
 - 2.4 Trastuzumab not to be given in combination with lapatinib; and
 - 2.5 Trastuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

Initial application — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria: All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Renewal — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

continued...

- 3 Any of the following:
 - 3.1 All of the following:
 - 3.1.1 The patient has not previously received lapatinib treatment for metastatic breast cancer; and
 - 3.1.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.1.3 Trastuzumab to be discontinued at disease progression; or
 - 3.2 All of the following:
 - 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 3.2.2 The cancer did not progress whilst on lapatinib; and
 - 3.2.3 Trastuzumab not to be given in combination with lapatinib; and
 - 3.2.4 Trastuzumab to be discontinued at disease progression; or
 - 3.3 All of the following:
 - 3.3.1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 3.3.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.3.3 Trastuzumab to be discontinued at disease progression.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

Other Immunosuppressants

CICLOSPORIN

Cap 25 mg Cap 50 mg Cap 100 mg	88.91 177.81	50 50 50	 Neoral Neoral Neoral
Oral liq 100 mg per ml SIROLIMUS – Special Authority see SA0866 below – Retail pharr		50 ml OP	✓ <u>Neoral</u>
Tab 1 mg Tab 2 mg Oral liq 1 mg per ml	1,626.00	100 100 60 ml OP	 Rapamune Rapamune Rapamune

SA0866 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR<30 ml/min; or
- · Rapidly progressive transplant vasculopathy; or
- · Rapidly progressive obstructive bronchiolitis; or
- · HUS or TTP; or
- · Leukoencepthalopathy; or
- Significant malignant disease

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
TACROLIMUS - Special Authority see SA0669 below - Retail pl	narmacy			
Cap 0.5 mg		100	• •	acrolimus Sandoz Prograf
Note: Wastage of up to a maximum of 90% of each pack	may be claimed on Pi	rograf.		-
Cap 1 mg		100		acrolimus Sandoz Prograf
Note: Wastage of up to a maximum of 90% of each pack Cap 5 mg - For tacrolimus oral liquid formulation refer, page	,	rograf.		·
209		50	• •	acrolimus Sandoz Prograf
Note: Wastage of up to a maximum of 90% of each pack	may be claimed on Pi	rograf.		-
(Prograf Cap 0.5 mg to be delisted 1 November 2014) (Prograf Cap 1 mg to be delisted 1 November 2014) (Prograf Cap 5 mg to be delisted 1 November 2014)		-		

► SA0669 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.

Note: Subsidy applies for either primary or rescue therapy.

	Subsidy (Manufacturer's Pric		Fully Subsidised	Brand or Generic
	\$	Per	~	Manufacturer
Antiallergy Preparations				
SA1367 Special Authority for Subsidy				
Initial application only from a relevant specialist. Approvals valio Both:	I for 2 years for app	lications	meeting th	e following criteria:
1 RAST or skin test positive; and				
2 Patient has had severe generalised reaction to the sensi				
Renewal only from a relevant specialist. Approvals valid for 2 y benefiting from treatment.	ears where the trea	atment re	emains app	propriate and the patient is
BEE VENOM ALLERGY TREATMENT – Special Authority see S		tail pharr	nacy	
Maintenance kit - 6 vials 120 mcg freeze dried venom, 6 dilu- ent 1.8 ml		1 OP		lbay
Treatment kit - 1 vial 550 mcg freeze dried venom. 1 diluen		TOP	• •	libay
9 ml, 3 diluent 1.8 ml		1 OP	VA	lbay
WASP VENOM ALLERGY TREATMENT – Special Authority see	SA1367 above - F	Retail pha	armacy	-
Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze	•	·		
dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml		1 OP	V A	lbay
Treatment kit (Yellow jacket venom) - 1 vial 550 mcg freeze dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml		1 OP	~	lbay
	203.00	101	• •	libay
Antihistamines				
CETIRIZINE HYDROCHLORIDE				
* Tab 10 mg *‡ Oral liq 1 mg per ml		100 200 ml		Zetop Zetirizine - AFT
	0.02	200 111	•	
*‡ Oral lig 2 mg per 5 ml		500 ml	v F	listafen
* Tab 2 mg	1.01	20		
	(5.99)		F	Polaramine
	2.02	40	-	Polaramine
st Oral lig 2 mg per 5 ml	(8.40) 1.77	100 ml	Г	Olaramine
	(10.29)		F	Polaramine
FEXOFENADINE HYDROCHLORIDE				
* Tab 60 mg		20	_	
* Tab 100 mg	(11.53)	10	I	elfast
* Tab 120 mg	4.74 (11.53)	10	т	elfast
	14.22	30		
	(29.81)		Т	elfast
LORATADINE				
* Tab 10 mg		100 100 ml		. <u>orafix</u> .oraPaed
* Oral liq 1 mg per ml	4.25	200 ml	• =	.oraPaed .oraPaed

	Subsidy (Manufacturer's \$	Price) Subs Per	Fully Brand or sidised Generic Manufacturer
PROMETHAZINE HYDROCHLORIDE * Tab 10 mg	1.99	50	✓ Allersoothe
* Tab 25 mg	2.99	50	✓ Allersoothe
*‡ Oral liq 5 mg per 5 ml		100 ml	Allersoothe
* Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO	11.00	5	✓ Hospira
TRIMEPRAZINE TARTRATE			
the second	2.79	100 ml OP	
	(8.06)		Vallergan Forte
Inhaled Corticosteroids			
BECLOMETHASONE DIPROPIONATE			
Aerosol inhaler, 50 mcg per dose	9.30	200 dose OP	🖌 Qvar
Aerosol inhaler, 50 mcg per dose CFC-free	8.54	200 dose OP	✓ Beclazone 50
Aerosol inhaler, 100 mcg per dose		200 dose OP	🖌 Qvar
Aerosol inhaler, 100 mcg per dose CFC-free		200 dose OP	 Beclazone 100
Aerosol inhaler, 250 mcg per dose CFC-free	22.67	200 dose OP	 Beclazone 250
BUDESONIDE			
Powder for inhalation, 100 mcg per dose	17.00	200 dose OP	 Pulmicort Turbuhaler
Powder for inhalation, 200 mcg per dose	19.00	200 dose OP	 Pulmicort Turbuhaler
Powder for inhalation, 400 mcg per dose		200 dose OP	 Pulmicort Turbuhaler
FLUTICASONE			
Aerosol inhaler, 50 mcg per dose CFC-free	7.50	120 dose OP	Flixotide
Powder for inhalation, 50 mcg per dose		60 dose OP	 Flixotide Accuhaler
Powder for inhalation, 100 mcg per dose	7.50	60 dose OP	 Flixotide Accuhaler
Aerosol inhaler, 125 mcg per dose CFC-free		120 dose OP	Flixotide
Aerosol inhaler, 250 mcg per dose CFC-free		120 dose OP	✓ Flixotide
Powder for inhalation, 250 mcg per dose	13.60	60 dose OP	 Flixotide Accuhaler

Inhaled Long-acting Beta-adrenoceptor Agonists

Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor Agonists

The addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended:

- For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 mcg beclomethasone or budesonide (or 100 mcg fluticasone).
- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 mcg beclomethasone or budesonide (or 200 mcg fluticasone).

Note:

Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).

EFORMOTEROL FUMARATE – See prescribing guideline above			
Powder for inhalation, 6 mcg per dose, breath activated	10.32	60 dose OP	
	(16.90)		Oxis Turbuhaler
Powder for inhalation, 12 mcg per dose, and monodose de-			
vice	20.64	60 dose	
	(35.80)		Foradil

	Subsidy (Manufacturer's \$		Fully Brand or sidised Generic ✔ Manufacturer
SALMETEROL – See prescribing guideline on the previous pag Aerosol inhaler CFC-free, 25 mcg per dose Powder for inhalation, 50 mcg per dose, breath activated		120 dose OP 60 dose OP	 ✓ Serevent ✓ Serevent Accuhaler
Inhaled Corticosteroids with Long-Acting Beta-			
		-	
BUDESONIDE WITH EFORMOTEROL – Special Authority see Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg Powder for inhalation 100 mcg with eformoterol fumarat		- Retail pharmac 120 dose OP	y Vannair
6 mcg		120 dose OP	 Symbicort Turbuhaler 100/6
Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg Powder for inhalation 200 mcg with eformoterol fumarat		120 dose OP	✓ Vannair
6 mcg		120 dose OP	 Symbicort Turbuhaler 200/6
Powder for inhalation 400 mcg with eformoterol fumarat 12 mcg – No more than 2 dose per day		60 dose OP	✓ Symbicort Turbuhaler 400/12
 SA1179 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals value Either: All of the following: Patient is a child under the age of 12; and Has been treated with inhaled corticosteroids 200 mcg per day fluticasone; and 	of at least 400	mcg per day be	clomethasone or budesonide, or
 The prescriber considers that the patient would product; or All of the following: 	receive addition	nal clinical benefi	t from switching to a combinatior
 2 All of the following: 2.1 Patient is over the age of 12; and 2.2 Has been treated with inhaled corticosteroids 500 mcg per day fluticasone; and 2.3 The prescriber considers that the patient would product. 			
Renewal from any relevant practitioner. Approvals valid for 2 y benefiting from treatment.	years where the	treatment remai	ns appropriate and the patient is
FLUTICASONE WITH SALMETEROL Aerosol inhaler 50 mcg with salmeterol 25 mcg Aerosol inhaler 125 mcg with salmeterol 25 mcg Powder for inhalation 100 mcg with salmeterol 50 mcg – N		120 dose OP 120 dose OP	✓ Seretide✓ Seretide
more than 2 dose per day Powder for inhalation 250 mcg with salmeterol 50 mcg – N		60 dose OP	 Seretide Accuhaler
more than 2 dose per day		60 dose OP	 Seretide Accuhaler
Beta-Adrenoceptor Agonists			
SALBUTAMOL			
Oral liq 400 mcg per ml Infusion 1 mg per ml, 5 ml	118.38	150 ml 10	✓ <u>Ventolin</u>
Inj 500 mcg per ml, 1 ml $$ – Up to 5 inj available on a PSO	(130.21) 12.90	5	Ventolin Ventolin

	Subsidy (Manufacturer's \$		Fully Brand or sidised Generic ✔ Manufacturer
Inhaled Beta-Adrenoceptor Agonists			
SALBUTAMOL Aerosol inhaler, 100 mcg per dose CFC free – Up to 1000 dose available on a PSO		200 dose OP	 ✓ Respigen ✓ Salamol Ventolin
Nebuliser soln, 1 mg per ml, 2.5 ml – Up to 30 neb available on a PSO		20	✓ <u>Asthalin</u>
Nebuliser soln, 2 mg per ml, 2.5 ml – Up to 30 neb available on a PSO		20	✓ Asthalin
TERBUTALINE SULPHATE Powder for inhalation, 250 mcg per dose, breath activated	22.00	200 dose OP	Bricanyl Turbuhaler
Inhaled Anticholinergic Agents			
IPRATROPIUM BROMIDE Aerosol inhaler, 20 mcg per dose CFC-free Nebuliser soln, 250 mcg per ml, 1 ml – Up to 40 neb available		200 dose OP	✓ Atrovent
on a PSO Nebuliser soln, 250 mcg per ml, 2 ml – Up to 40 neb available	3.26	20	✓ <u>Univent</u>
on a PSO		20	✓ <u>Univent</u>
TIOTROPIUM BROMIDE – Special Authority see SA1193 below Powder for inhalation, 18 mcg per dose		acy 30 dose	✓ Spiriva

SA1193 Special Authority for Subsidy

Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and
- 2 In addition to standard treatment, the patient has trialled a short acting bronchodilator of at least 40 mcg ipratropium q.i.d for one month; and
- 3 Either:

The patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:

- 3.1 Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or
- 3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and

Applicant must state recent measurement of:

- 4 All of the following:
 - 4.1 Actual FEV1 (litres); and
 - 4.2 Predicted FEV1 (litres); and
 - 4.3 Actual FEV $_1$ as a % of predicted (must be below 60%); and
- 5 Either:
 - 5.1 Patient is not a smoker (for reporting purposes only); or
 - 5.2 Patient is a smoker and has been offered smoking cessation counselling; and
- 6 The patient has been offered annual influenza immunisation.

Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

	Subsidy (Manufacturer's Price	e) Subs	. ,	Brand or Generic
	\$	Per	~	Manufacturer
continued				
 Patient is compliant with the medication; and Patient has experienced improved COPD symptom control Applicant must state recent measurement of: All of the following: 	bl (prescriber deter	mined); and		
3.1 Actual FEV ₁ (litres); and 3.2 Predicted FEV ₁ (litres); and 3.3 Actual FEV ₁ as a % of predicted.				
Inhaled Beta-Adrenoceptor Agonists with Antich	olinergic Age	nts		
SALBUTAMOL WITH IPRATROPIUM BROMIDE Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg				
per dose CFC-free Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per		0 dose OP	🖌 Du	olin HFA
vial, 2.5 ml – Up to 20 neb available on a PSO	3.75	20	✓ Du	olin
Leukotriene Receptor Antagonists				
MONTELUKAST - Special Authority see SA1421 below - Retail	pharmacy			

Prescribing Guideline: Clinical evidence indicates that the effectiveness of montelukast is strongest when montelukast is used in short treatment courses.

Tab 4 mg18.48	28	Singulair
Tab 5 mg	28	Singulair
Tab 10 mg	28	 Singulair

➡SA1421 Special Authority for Subsidy

Initial application — (Pre-school wheeze) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years; and
- 2 The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention.

Renewal — (Pre-school wheeze) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (exercise-induced asthma) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has been trialled with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and
- 2 Patient continues to receive optimal inhaled corticosteroid therapy; and
- 3 Patient continues to experience frequent episodes of exercise-induced bronchoconstriction.

Initial application — (aspirin desensitisation) only from a clinical immunologist or allergist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient is undergoing aspirin desensitisation therapy under the supervision of a Clinical Immunologist or Allergist; and
- 2 Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter's triad; and
- 3 Nasal polyposis, confirmed radiologically or surgically; and
- 4 Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.

\$ Per 112 dose OP 112 dose OP 112 dose OP 112 dose OP 25 5 51 100 50 500 ml 00 6 //www.pharmac.gov	 Intal Spincaps Intal Forte CFC Free DBL Aminophylline Nuelin-SR Nuelin Pulmozyme
07 112 dose OP 04 50 dose 07 112 dose OP 25 5 51 100 50 500 ml 00 6 //www.pharmac.gov	 Tilade Intal Spincaps Intal Forte CFC Free DBL Aminophylline Nuelin-SR Nuelin Pulmozyme
94 50 dose 97 112 dose OP 25 5 51 100 50 500 ml 90 6 //www.pharmac.gov	 Intal Spincaps Intal Forte CFC Free DBL Aminophylline Nuelin-SR Nuelin Pulmozyme
94 50 dose 97 112 dose OP 25 5 51 100 50 500 ml 90 6 //www.pharmac.gov	 Intal Spincaps Intal Forte CFC Free DBL Aminophylline Nuelin-SR Nuelin Pulmozyme
94 50 dose 97 112 dose OP 25 5 51 100 50 500 ml 90 6 //www.pharmac.gov	 Intal Spincaps Intal Forte CFC Free DBL Aminophylline Nuelin-SR Nuelin Pulmozyme
7 112 dose OP 25 5 51 100 50 500 ml 00 6 //www.pharmac.gov	 Intal Forte CFC Free DBL Aminophylline Nuelin-SR Nuelin Pulmozyme
7 112 dose OP 25 5 51 100 50 500 ml 00 6 //www.pharmac.gov	 Intal Forte CFC Free DBL Aminophylline Nuelin-SR Nuelin Pulmozyme
25 5 51 100 50 500 ml)0 6 //www.pharmac.gov	 ✓ DBL Aminophylline ✓ Nuelin-SR ✓ Nuelin ✓ Pulmozyme
51 100 50 500 ml 00 6 /www.pharmac.gov	 ✓ Nuelin-SR ✓ Nuelin ✓ Pulmozyme
51 100 50 500 ml 00 6 /www.pharmac.gov	 ✓ Nuelin-SR ✓ Nuelin ✓ Pulmozyme
51 100 50 500 ml 00 6 /www.pharmac.gov	 ✓ Nuelin-SR ✓ Nuelin ✓ Pulmozyme
51 100 50 500 ml 00 6 /www.pharmac.gov	 ✓ Nuelin-SR ✓ Nuelin ✓ Pulmozyme
50 500 ml 10 6 //www.pharmac.gov	 Nuelin Pulmozyme
50 500 ml 10 6 //www.pharmac.gov	 Nuelin Pulmozyme
00 6 //www.pharmac.gov	
00 6 //www.pharmac.gov	
00 6 //www.pharmac.gov	
/www.pharmac.gov	
1 0	t.nz or:
1 0	t.nz or:
0 571	
armac.govt.nz	
	aediatricians who have experien
50 90 ml OP	✓ Biomed
50 90 mil Ol	♥ Diolilea
35 200 dose OP	
	Alanase
5)	Alanase
35 200 dase OP	
	Butacort Aqueous
	Dote and Amore and
51 200 dose OP 75)	Butacort Aqueous
.4.7	.35 200 dose OP .85) .46 200 dose OP .75) .35 200 dose OP .85) .61 200 dose OP

	Subsidy (Manufacturer's P \$	Price) Sul Per	bsidised G	rand or eneric lanufacturer
IPRATROPIUM BROMIDE Aqueous nasal spray, 0.03%	4.03	15 ml OP	✔ <u>Univ</u>	ent
Respiratory Devices				
MASK FOR SPACER DEVICE a) Up to 20 dev available on a PSO b) Only on a PSO c) Only for children aged six years and under Size 2	2.99	1		<u>it Paediatric</u> sk
PEAK FLOW METER a) Up to 10 dev available on a PSO b) Only on a PSO Low range Normal range		1	✓ Brea	<u>th-Alert</u> th-Alert
SPACER DEVICE a) Up to 20 dev available on a PSO b) Only on a PSO 230 ml (single patient)		1		ce Chamber
			Plu	us
800 ml SPACER DEVICE AUTOCLAVABLE a) Up to 5 dev available on a PSO b) Only on a PSO	8.50	1	✓ <u>Volu</u>	mauc
230 ml (autoclavable) – Subsidy by endorsement Available where the prescriber requires a spacer devic endorsed accordingly.		1 of sterilisatior	•	ce Chamber oclave and the PSO is
Respiratory Stimulants				
CAFFEINE CITRATE Oral liq 20 mg per ml (10 mg base per ml)		25 ml OP	🖌 Bion	ned

	<u> </u>		
	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or osidised Generic Manufacturer
Ear Preparations			
CETIC ACID WITH 1, 2- PROPANEDIOL DIACETATE AND BEN For Vosol ear drops with hydrocortisone powder refer Standar Ear drops 2% with 1, 2-Propanediol diacetate 3% and		ge 212	
benzethonium chloride 0.02%	6.97	35 ml OP	✔ Vosol
LUMETASONE PIVALATE Ear drops 0.02% with clioquinol 1%	4.46	7.5 ml OP	 Locacorten-Viaform ED's
			✓ Locorten-Vioform
RIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN	I AND NYSTAT	IN	
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g	5 16	7.5 ml OP	Kenacomb
5 5 51 5		7.5 111 07	
Ear/Eye Preparations			
EXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN			
Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml	4.50	8 ml OP	
9	(9.27)	• • .	Sofradex
RAMYCETIN SULPHATE			
Ear/Eye drops 0.5%	4.13 (8.65)	8 ml OP	Soframycin
Eye Preparations	(0.00)		Containijoni
	by stated athem	vice	
re preparations are only funded for use in the eye, unless explicit	lly stated other	wise.	
Anti-Infective Preparations			
CICLOVIR			
Eye oint 3%		4.5 g OP	Zovirax
HLORAMPHENICOL Eve oint 1%	2.76	4 g OP	✓ Chlorsig
Eye drops 0.5%		10 ml OP	✓ <u>Chlorafast</u>
Funded for use in the ear*. Indications marked with * are U	napproved Indi	cations.	
IPROFLOXACIN Eye Drops 0.3%	12 43	5 ml OP	Ciloxan
For treatment of bacterial keratitis or severe bacterial conju			
JSIDIC ACID			
Eye drops 1%	4.50	5 g OP	 Fucithalmic
ENTAMICIN SULPHATE Eye drops 0.3%	11 /0	5 ml OP	✓ Genoptic
BOPAMIDINE ISETHIONATE	11.40	5 m 0r	
Eye drops 0.1%	2.97	10 ml OP	
<i>,</i> ,	(7.99)		Brolene

			SENSORT UNGAN	3
	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or osidised Generic ✓ Manufacturer	
TOBRAMYCIN				
Eye oint 0.3% Tobrex to be Sole Supply on 1 October 2014	10.45	3.5 g OP	 Tobrex 	
Eye drops 0.3% Tobrex to be Sole Supply on 1 October 2014	11.48	5 ml OP	 Tobrex 	
Corticosteroids and Other Anti-Inflammatory Pr	eparations			
DEXAMETHASONE				
* Eye oint 0.1%		3.5 g OP	Maxidex	
* Eye drops 0.1%	4.50	5 ml OP	Maxidex	
DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYM	IYXIN B SULPH	ATE		
* Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin				
b sulphate 6,000 u per g	5.39	3.5 g OP	Maxitrol	
Maxitrol to be Sole Supply on 1 October 2014 Eye drops 0.1% with neomycin sulphate 0.35% and polymy-				
xin b sulphate 6,000 u per ml		5 ml OP	✓ Maxitrol	
Maxitrol to be Sole Supply on 1 October 2014	4.00			
DICLOFENAC SODIUM				
* Eye drops 0.1%		5 ml OP	 Voltaren Ophtha 	
Voltaren Ophtha to be Sole Supply on 1 October 2014				
FLUOROMETHOLONE				
* Eye drops 0.1%	3.80	5 ml OP	✓ <u>Flucon</u>	
LEVOCABASTINE				
Eye drops 0.5 mg per ml	8.71	4 ml OP		
	(10.34)		Livostin	
LODOXAMIDE				
Eye drops 0.1%	8.71	10 ml OP	Lomide	
Lomide to be Sole Supply on 1 October 2014				
PREDNISOLONE ACETATE				
* Eye drops 0.12%		5 ml OP	Pred Mild	
* Eye drops 1%	4.50	5 ml OP	Pred Forte	
SODIUM CROMOGLYCATE				
Eye drops 2%	1.18	5 ml OP	Rexacrom	
Glaucoma Preparations - Beta Blockers				
BETAXOLOL				
* Eye drops 0.25%		5 ml OP	Betoptic S	
Betoptic S to be Sole Supply on 1 October 2014				
* Eye drops 0.5%	7.50	5 ml OP	 Betoptic 	
Betoptic to be Sole Supply on 1 October 2014				

LE	VOBUNOLOL		
*	Eye drops 0.25%7.00	5 ml OP	🖌 Betagan
*	Eye drops 0.5%7.00	5 ml OP	 Betagan

SENSORY ORGANS

SENSORY ORGANS

	Subsidy	Drice) Out	Fully Brand or
	(Manufacturer's) \$	Price) Sub Per	sidised Generic Manufacturer
IMOLOL			
★ Eye drops 0.25%		5 ml OP	Arrow-Timolol
Arrow-Timolol to be Sole Supply on 1 October 2014		0	• • • • • • • • • • • • • • • • • • • •
✤ Eye drops 0.25%, gel forming	3.30	2.5 ml OP	Timoptol XE
¥ Eye drops 0.5%		5 ml OP	✓ Arrow-Timolol
Arrow-Timolol to be Sole Supply on 1 October 2014			
Eye drops 0.5%, gel forming	3.78	2.5 ml OP	Timoptol XE
Glaucoma Preparations - Carbonic Anhydrase Ir	nhibitors		
CETAZOLAMIDE			
 Tab 250 mg – For acetazolamide oral liquid formulation refer, 			
page 209		100	🖌 Diamox
Diamox to be Sole Supply on 1 October 2014		100	
BRINZOLAMIDE			
₭ Eye Drops 1%	9 77	5 ml OP	✓ Azopt
			• Arohi
ORZOLAMIDE HYDROCHLORIDE ₭ Eye drops 2%	0.77		
Eye drops 2%	9.77 (13.95)	5 ml OP	Trucont
	(13.95)		Trusopt
ORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEATE			
Eye drops 2% with timolol maleate 0.5%		5 ml OP	Cosopt
Glaucoma Preparations - Prostaglandin Analogu	les		
IMATOPROST			
₭ Eye drops 0.03%		3 ml OP	🗸 Lumigan
ATANOPROST			J. J.
k Eye drops 50 mcg per ml, 2.5 ml	1 99	2.5 ml OP	✓ Hysite
		2.0 111 01	• <u>Ilyone</u>
	10.50		. / Turustan
Eye drops 0.004%		2.5 ml OP	 Travatan
Glaucoma Preparations - Other			
BRIMONIDINE TARTRATE			
₭ Eye Drops 0.2%	4.32	5 ml OP	 Arrow-Brimonidine
Arrow-Brimonidine to be Sole Supply on 1 October 2014			
RIMONIDINE TARTRATE WITH TIMOLOL MALEATE			
Eye drops 0.2% with timolol maleate 0.5%		5 ml OP	 Combigan
ILOCARPINE HYDROCHLORIDE			
₭ Eye drops 1%	4.26	15 ml OP	Isopto Carpine
Isopto Carpine to be Sole Supply on 1 October 2014		-	
₭ Eye drops 2%	5.35	15 ml OP	Isopto Carpine
Isopto Carpine to be Sole Supply on 1 October 2014			•
€ Eye drops 4%		15 ml OP	Isopto Carpine
a) Subsidised for oral use pursuant to the Standard Formu	lae.		
b) Isopto Carpine to be Sole Supply on 1 October 2014			
Eye drops 2% single dose - Special Authority see SA0895			
on the next page – Retail pharmacy		20 dose	
	(32.72)		Minims

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

SA0895 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient has to use an unpreserved solution due to an allergy to the preservative; or
- 2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be "tools of trade" and are not approved as special authority items. **Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Mydriatics and Cycloplegics

ATROPINE SI	ULPHATE
-------------	---------

* Eye drops 1%	15 ml OP	✓ <u>Atropt</u>	
CYCLOPENTOLATE HYDROCHLORIDE * Eye drops 1%	15 ml OP	 Cyclogyl 	
TROPICAMIDE			
* Eye drops 0.5%7.15	15 ml OP	Mydriacyl	
* Eye drops 1%	15 ml OP		

Preparations for Tear Deficiency

For acetylcysteine eye drops refer Standard Formulae, page 212

HYPROMELLOSE		
✤ Eye drops 0.5%	15 ml OP	Methopt
HYPROMELLOSE WITH DEXTRAN	15 ml OD	
* Eye drops 0.3% with dextran 0.1%	15 ml OP	 Poly-Tears
* Eye drops 1.4%2.68	15 ml OP	✓ Vistil
* Eye drops 3%	15 ml OP	Vistil Forte

Preservative Free Ocular Lubricants

SA1388 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Both:

1 Confirmed diagnosis by slit lamp of severe secretory dry eye; and

2 Either:

2.1 Patient is using eye drops more than four times daily on a regular basis; or

2.2 Patient has had a confirmed allergic reaction to preservative in eye drop.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient continues to require lubricating eye drops and has benefited from treatment.

CARBOMER - Special Authority see SA1388 above - Retail pha	rmacy		
Ophthalmic gel 0.3%, 0.5 g	8.25	30	Poly-Gel
MACROGOL 400 AND PROPYLENE GLYCOL - Special Authori	ty see SA1388 abov	ve – Retail p	harmacy
Eye drops 0.4% and propylene glycol 0.3%, 0.4 ml	4.30	24	Systane Unit Dose
SODIUM HYALURONATE - Special Authority see SA1388 above	e – Retail pharmacy	/	
Eye drops 1 mg per ml		10 ml OP	✓ <u>Hylo-Fresh</u>
Note: Hylo-Fresh has a 6 month expiry after opening. The	Pharmacy Handbo	ook restriction	n allowing one bottle per month is
not relevant and therefore only the prescribed dosage to the	ne nearest OP may	be claimed.	

	Subsidy (Manufacturer's Pri \$	ce) Sub: Per	Fully sidised	Brand or Generic Manufacturer
Other Eye Preparations				
NAPHAZOLINE HYDROCHLORIDE * Eye drops 0.1%	4.15	15 ml OP	🗸 N	aphcon Forte
OLOPATADINE Eye drops 0.1%	17.00	5 ml OP	🗸 Pa	atanol
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN * Eye oint with soft white paraffin	3.63	3.5 g OP	🗸 R	efresh Night Time
PARAFFIN LIQUID WITH WOOL FAT * Eye oint 3% with wool fat 3%	3.63	3.5 g OP	✓ P	oly-Visc
RETINOL PALMITATE Eye oint 138 mcg per g	3.80	5 g OP	🗸 V	itA-POS

VARIOUS

	Subsidy		Fully	Brand or
	(Manufacturer's Pri \$	ice) Su Per	bsidised	Generic Manufacturer
Various				
lay only be claimed once per patient.				
PHARMACY SERVICES				
₭ Brand switch fee	4.33	1 fee	🖌 B	SF
				Arrow-Fluoxetine
				SF Imatinib-AFT
a) The Dharmonda for DOE Instinity AFT is 0401000			V B	SF Trexate
 a) The Pharmacode for BSF Imatinib-AFT is 2461099 - b) The Pharmacode for BSF Arrow-Fluoxetine is 24611 		26		
c) The Pharmacode for BSF Trexate is 2465353 - see a	1.0	30		
BSF Arrow-Fluoxetine Brand switch fee to be delisted 1 Octob	1 0			
BSF Imatinib-AFT Brand switch fee to be delisted 1 October 2	,			
BSF Trexate Brand switch fee to be delisted 1 December 2014	4)			
Agents Used in the Treatment of Poisonings				
Antidotes				
CETYLCYSTEINE – Retail pharmacy-Specialist				
Inj 200 mg per ml, 10 ml		10	🖌 <u>M</u>	artindale
				Acetylcysteine
Inj 200 mg per ml, 30 ml	219.00	4	V A	cetadote
IALOXONE HYDROCHLORIDE				
a) Up to 5 inj available on a PSO				
b) Only on a PSO		_		
Inj 400 mcg per ml, 1 ml		5	V He	ospira
Removal and Elimination				
CHARCOAL				
Oral liq 50 g per 250 ml		250 ml OP	🖌 Ca	arbosorb-X
a) Up to 250 ml available on a PSO				
b) Only on a PSO				
EFERIPRONE – Special Authority see SA1042 below – Reta				
Tab 500 mg		100		erriprox
Oral liq 100 mg per 1 ml		250 ml OP	V Fe	erriprox
nitial application only from a relevant specialist. Approvals			ess notif	ed where the patient ha
itial application only from a relevant specialist. Approvals een diagnosed with chronic transfusional iron overload due to	congenital inherited	anaemia.		ed where the patient ha
itial application only from a relevant specialist. Approvals een diagnosed with chronic transfusional iron overload due to lote: For the purposes of this Special Authority, a relevant spe	congenital inherited	anaemia.		ed where the patient ha
nitial application only from a relevant specialist. Approvals even diagnosed with chronic transfusional iron overload due to Jote: For the purposes of this Special Authority, a relevant spe DESFERRIOXAMINE MESYLATE	o congenital inherited ecialist is defined as a	anaemia.	gist.	
nitial application only from a relevant specialist. Approvals been diagnosed with chronic transfusional iron overload due to Note: For the purposes of this Special Authority, a relevant spe DESFERRIOXAMINE MESYLATE	o congenital inherited ecialist is defined as a	anaemia. a haematolog	gist.	ed where the patient ha
nitial application only from a relevant specialist. Approvals been diagnosed with chronic transfusional iron overload due to lote: For the purposes of this Special Authority, a relevant special Septement of the purposes of the Sylart E	o congenital inherited ecialist is defined as a 	anaemia. a haematoloo 10	gist.	
Description of the second	o congenital inherited ecialist is defined as a 	anaemia. a haematolog	gist. 🖌 He	·

INTRODUCTION

The following extemporaneously compounded products are eligible for subsidy:

- The "Standard Formulae".
- Oral liquid mixtures for patients unable to swallow subsidised solid dose oral formulations.
- The preparation of syringe drivers when prescribed by a general practitioner.
- Dermatological preparations
 - a) One or more subsidised dermatological galenical(s) in a subsidised dermatological base.
 - b) Dilution of proprietary Topical Corticosteroid-Plain preparations with a dermatological base (Retail pharmacyspecialist).
 - c) Menthol crystals only in the following bases:

Aqueous cream

Urea cream 10%

Wool fat with mineral oil lotion

Hydrocortisone 1% with wool fat and mineral oil lotion

Glycerol, paraffin and cetyl alcohol lotion.

Glossary

Dermatological base: The products listed in the Barrier creams and Emollients section and the Topical Corticosteroids-Plain section of the Pharmaceutical Schedule are classified as dermatological bases for the purposes of extemporaneous compounding and are the bases to which the dermatological galenicals can be added. Also the dermatological bases in the Barrier Creams and Emollients section of the Pharmaceutical Schedule can be used for diluting proprietary Topical Corticosteroid-Plain preparations. The following products are dermatological bases:

- Aqueous cream
- Cetomacrogol cream BP
- Collodion flexible
- Emulsifying ointment BP
- Hydrocortisone with wool fat and mineral oil lotion
- Oil in water emulsion
- Urea cream 10%
- White soft paraffin
- Wool fat with mineral oil lotion
- Zinc and castor oil ointment BP
- Proprietary Topical Corticosteroid-Plain preparations

Dermatological galenical: Dermatological galenicals will only be subsidised when added to a dermatological base. More than one dermatological galenical can be added to a dermatological base.

The following are dermatological galenicals:

- Coal tar solution up to 10%
- Hydrocortisone powder up to 5%
- Menthol crystals
- · Salicylic acid powder
- Sulphur precipitated powder

Standard formulae: Standard formulae are a list of fomulae for ECPs that are subsidised. Their ingredients are listed under the appropriate therapeutic heading in Section B of the Pharmaceutical Schedule and also in Section C.

Explanatory notes

Oral liquid mixtures

Oral liquid mixtures are subsidised for patients unable to swallow subsidised solid oral dose forms where no suitable alternative proprietary formulation is subsidised. Suitable alternatives include dispersible and sublingual formulations, oral liquid formulations or rectal formulations. Before extemporaneously compounding an oral liquid mixture, other alternatives such as dispersing the solid dose form (if appropriate) or crushing the solid dose form in jam, honey or soft foods such as yoghurt should be explored.

The Emixt website **www.pharminfotech.co.nz** has evidence-based formulations which are intended to standardise compounded oral liquids within New Zealand.

Pharmaceuticals with standardised formula for compounding in Ora products

Acetazolamide 25 mg/ml	Flecainide 20 mg/ml	Pyrazinamide 100 mg/ml
Allopurinol 20 mg/ml	Gabapentin 100 mg/ml	Rifabutin 20 mg/ml
Amlodipine 1 mg/ml	Gabapentin (Neurontin) 100 mg/ml	Sildenafil 2 mg/ml
Azathioprine 50 mg/ml	Hydrocortisone 1 mg/ml	Sotalol 5 mg/ml
Baclofen 10 mg/ml	Labetolol 10 mg/ml	Sulphasalazine 100 mg/ml
Carvedilol 1 mg/ml	Levetiracetam 100 mg/ml	Tacrolimus 1 mg/ml
Clopidogrel 5 mg/ml	Levodopa with carbidopa (5 mg lev-	Terbinafine 25 mg/ml
Diltiazem hydrochloride 12 mg/ml	odopa + 1.25 mg carbidopa)/ml	Ursodeoxycholic acid 50 mg/ml
Dipyridamole 10 mg/ml	Metoclopramide 1 mg/ml	Valganciclovir 60 mg/ml*
Domperidone 1 mg/ml	Metoprolol tartrate 10 mg/ml	Verapamil hydrochloride 50 mg/ml
Enalapril 1 mg/ml	Nitrofurantoin 10 mg/ml	

*Note this is a DCS formulation

PHARMAC endorses the recommendations of the Emixt website and encourages New Zealand pharmacists to use these formulations when compounding is appropriate. The Emixt website also provides stability and expiry data for compounded products. For the majority of products compounded with Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet or Ora-Sweet SF a four week expiry is appropriate.

Please note that no oral liquid mixture will be eligible for Subsidy unless all the requirements of Section B and C of the Schedule applicable to that pharmaceutical are met.

Some community pharmacies may not have appropriate equipment to compound all of the listed products, please use appropriate clinical judgement.

Subsidy for extemporaneously compounded oral liquid mixtures is based on:

Solid dose form	qs
Preservative	qs
Suspending agent	qs
Water	to 100%

or

Solid dose form

qs

Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF to 100% Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients such as flavouring and colouring agents, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The majority of extemporaneously compounded oral liquid mixtures should contain a preservative and suspending agent.

- Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and Ora-Sweet SF when used correctly are an appropriate preservative and suspending agent.
- Methylcellulose 3% is considered a suitable suspending agent and compound hydroxybenzoate solution or methyl hydroxybenzoate 10% solution are considered to be suitable preservatives. Usually 1 ml of these preservative solutions is added to 100 ml of oral liquid mixture.

Some solid oral dose forms are not appropriate for compounding into oral liquid mixtures and should therefore not be used/considered for extemporaneously compounded oral liquid mixtures. This includes long-acting solid dose formulations, enteric coated tablets or capsules, sugar coated tablets, hard gelatin capsules and chemotherapeutic agents.

The following practices will not be subsidised:

- Where a Standard Formula exists in the Pharmaceutical Schedule for a solid dose form, compounding the solid dose form in Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF.
- Mixing one or more proprietary oral liquids (eg an antihistamine with pholcodine linctus).
- Extemporaneously compounding an oral liquid with more than one solid dose chemical.
- Mixing more than one extemporaneously compounded oral liquid mixture.
- · Mixing one or more extemporaneously compounded oral liquid mixtures with one or more proprietary oral liquids.
- The addition of a chemical/powder/agent/solution to a proprietary oral liquid or extemporaneously compounded oral mixture.

Standard formulae

A list of standard formulae is contained in this section. All ingredients associated with a standard formula will be subsidised and an appropriate compounding fee paid.

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.


Dermatological Preparations

Proprietary topical corticosteroid preparations may be diluted with a dermatological base (see page 208) from the Barrier Creams and Emollients section of the Pharmaceutical Schedule (Retail pharmacy-Specialist). Dilution of proprietary topical corticosteroid preparations should only be prescribed for withdrawing patients off higher strength proprietary topical corticosteroid products where there is no suitable proprietary product of a lower strength available or an extemporaneously compounded product with up to 5% hydrocortisone is not appropriate. (In general proprietary topical corticosteroid preparations should not be diluted because dilution effects can be unpredictable and may not be linear, and usually there is no stability data available for diluted products).

One or more dermatological galenicals may be added to a dermatological base (including proprietary topical corticosteroid preparations). Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The addition of dermatological galenicals to diluted proprietary Topical Corticosteroids-Plain will not be subsidised.

The flow diagram on the next page may assist you in deciding whether or not a dermatological ECP is subsidised.



EXTEMPORANEOUSLY COMPOUNDED PRODUCTS AND GALENICALS

to 100 ml

Standard Formulae

ACETYLCYSTEINE EYE DROPS Acetylcysteine inj 200 mg per ml, 10 ml Suitable eye drop base	qs qs
ASPIRIN AND CHLOROFORM APPLICAT Aspirin Soluble tabs 300 mg Chloroform	•
CODEINE LINCTUS PAEDIATRIC (3 mg pr Codeine phosphate Glycerol Preservative Water	er 5 ml) 60 mg 40 ml qs to 100 ml
CODEINE LINCTUS DIABETIC (15 mg per Codeine phosphate Glycerol Preservative Water	⁵ ml) 300 mg 40 ml qs to 100 ml
FOLINIC MOUTHWASH Calcium folinate 15 mg tab Preservative Water (Preservative should be used if quantity sup more than 5 days. Maximum 500 ml per pro-	
MAGNESIUM HYDROXIDE 8% MIXTURE Magnesium hydroxide paste 29% Methyl hydroxybenzoate Water	275 g 1.5 g to 1,000 ml
METHADONE MIXTURE Methadone powder Glycerol Water	qs qs to 100 ml
METHYL HYDROXYBENZOATE 10% SOL Methyl hydroxybenzoate Propylene glycol (Use 1 ml of the 10% solution per 100 ml o mixture)	10 g to 100 ml
OMEPRAZOLE SUSPENSION Omeprazole capules or powder Sodium bicarbonate powder BP	qs 8.4 g

PHENOBARBITONE ORAL LIQUID Phenobarbitone Sodium Glycerol BP Water	1 g 70 ml to 100 ml
PHENOBARBITONE SODIUM PAEDIATR LIQUID (10 mg per ml)	IC ORAL
Phenobarbitone Sodium	400 mg
Glycerol BP	4 ml
Water	to 40 ml
PILOCARPINE ORAL LIQUID	
Pilocarpine 4% eye drops	qs
Preservative	qs
Water	to 500 ml
(Preservative should be used if quantity sum ore than 5 days.)	ipplied is for
SALIVA SUBSTITUTE FORMULA	
Methylcellulose	5 g
Preservative	qs
Water	to 500 ml
(Preservative should be used if quantity su more than 5 days. Maximum 500 ml per p	
SODIUM CHLORIDE ORAL LIQUID	
Sodium chloride inj 23.4%, 20 ml	qs
Water	qs
(Only funded if prescribed for treatment of	hyponatraemia)
VANCOMYCIN ORAL SOLUTION (50 mg	per ml)
Vancomycin 500 mg injection	10 vials
Glycerol BP	40 ml
Water	to 100 ml
(Only funded if prescribed for treatment of difficile following metronidazole failure)	Clostridium
VOSOL EAR DROPS	
WITH HYDROCORTISONE POWDER 1%	
Hydrocortisone powder	1%
Vosol Ear Drops	to 35 ml

Water

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy		Fully Brand or bsidised Generic
	(Manufacturer's I \$	Per Su	Manufacturer
		1.	
Extemporaneously Compounded Preparations	and Galenica	IIS	
ENZOIN			
Tincture compound BP	2.44	50 ml	
	(5.10)		PSM
	24.42	500 ml	
	(38.00)		PSM
CHLOROFORM – Only in combination			
Only in aspirin and chloroform application.			
Chloroform BP		500 ml	V PSM
CODEINE PHOSPHATE - Safety medicine; prescriber may dete	ermine dispensing	g frequency	
Powder – Only in combination	12.62	5 g	
	(25.46)		Douglas
	63.09	25 g	
	(90.09)		Douglas
a) Only in extemporaneously compounded codeine linctus			ediatric.
b) ‡ Safety cap for extemporaneously compounded oral li	quid preparations	S.	
	10.00	100	
Collodion flexible		100 ml	✓ PSM
OMPOUND HYDROXYBENZOATE - Only in combination			
Only in extemporaneously compounded oral mixtures.			
Soln		100 ml	Midwest
	34.18		David Craig
LYCERIN WITH SODIUM SACCHARIN – Only in combination			
Only in combination with Ora-Plus.	05 50	170	4.0.0
Suspension	35.50	473 ml	Ora-Sweet SF
SLYCERIN WITH SUCROSE – Only in combination			
Only in combination with Ora-Plus.			
Suspension	35.50	473 ml	Ora-Sweet
BLYCEROL			
Liquid – Only in combination	17.86	2,000 ml	✓ healthE
Only in extemporaneously compounded oral liquid prepar	ations.		
IAGNESIUM HYDROXIDE			
Paste 29%	22.61	500 g	✔ PSM
IETHADONE HYDROCHLORIDE			
 a) Only on a controlled drug form 			
b) No patient co-payment payable			
c) Safety medicine; prescriber may determine dispensing fre	quency		
d) Extemporaneously compounded methadone will only be a	reimbursed at the	e rate of the cr	neapest form available (methadol
powder, not methadone tablets). Powder	7 9/	1 g	🖌 AFT
‡ Safety cap for extemporaneously compounded oral liqui		ig	V AFI
ETHYL HYDROXYBENZOATE			
Powder	8 00	25 g	🖌 PSM
	8.00 8.98	20 Y	✓ Midwest
	0.00		+ miuwoot
IETHYLCELLULOSE Powder	26.05	100 ~	✔ MidWest
Powder Suspension – Only in combination		100 g 473 ml	✓ Midwest ✓ Ora-Plus
		110111	VIA-FIUS

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy		Fully Brand or
	(Manufacturer's P	rice) Sul Per	osidised Generic
	\$	Per	 Manufacturer
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCH/	ARIN – Only in c	ombination	
Suspension	•	473 ml	 Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE - Only	y in combination		
Suspension	35.50	473 ml	Ora-Blend
PHENOBARBITONE SODIUM			
Powder – Only in combination		10 g	✓ MidWest
	325.00	100 g	✓ MidWest
a) Only in children up to 12 years		•	
b) ‡ Safety cap for extemporaneously compounded oral lic	quid preparations		
PROPYLENE GLYCOL			
Only in extemporaneously compounded methyl hydroxybenzo	pate 10% solution	า.	
Liq		500 ml	🖌 PSM
	11.25		Midwest
SODIUM BICARBONATE			
Powder BP – Only in combination	8.95	500 g	✓ Midwest
	9.80	Ū	
	(29.50)		David Craig
Only in extemporaneously compounded omeprazole and I	ansoprazole sus	pension.	-
SYRUP (PHARMACEUTICAL GRADE) – Only in combination			
Only in extemporaneously compounded oral liquid preparatio	ins.		
Liq	21.75	2,000 ml	✓ Midwest
WATER			
Tap – Only in combination	0.00	1 ml	✓ Tap water
·			· · · · · · · · · · · · · · · · · · ·

EXPLANATORY NOTES

The list of special foods to which Subsidies apply is contained in this section. The list of available products, guidelines for use, subsidies and charges is reviewed as required. Applications for new listings and changes to subsidies and access criteria will be considered by the special foods sub-committee of PTAC which meets as and when required. In all cases, subsidies are available by Special Authority only. This means that, unless a patient has a valid Special Authority number for their special food requirements, they must pay the full cost of the products themselves.

Eligibility for Special Authority

Special Authorities will be approved for patients meeting conditions specified under the *Conditions and Guidelines* for each product. In some cases there are also limits to how products can be prescribed (for example quantity, use or duration). Only those brands, presentations and flavours of special foods listed in this section are subsidised.

Who can apply for Special Authority?

 Initial Applications:
 Only from a dietitian, relevant specialist or a vocationally registered general practitioner.

 Reapplications:
 Only from a dietitian, relevant specialist or a vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or a vocationally registered general practitioners.

 Very specialist or a vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or a vocationally registered general practitioner. Other general practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

All applications must be made on an official form available from the PHARMAC website www.pharmac.govt.nz. All applications must include specific details as requested on the form relating to the application. Applications must be forwarded to:

Ministry of Health Sector Services Private Bag 3015 WHANGANUI 4540 Freefax 0800 100 131

Subsidies and manufacturer's surcharges

The Subsidies for some special foods are based on the lowest priced product within each group. Where this is so, or where special foods are otherwise not fully subsidised, a manufacturer's surcharge may be payable by the patient. The manufacturer's surcharge is the difference between the price of the product and the subsidy attached to it and may be subject to mark-ups applied at a pharmacy level. As a result the manufacturer's surcharge may vary. Fully subsidised alternatives are available in most cases (as indicated by a tick in the left hand column). Patients should only have to pay a co-payment on these products.

Where are special foods available from?

Distribution arrangements for special foods vary from region to region. Special foods are available from hospital pharmacies providing an outpatient dispensing service as well as retail pharmacies in the Northern, Midland and Central (including Nelson and Blenheim) regions.

Definitions

 Failure to thrive
 An inability to gain or maintain weight resulting in physiological impairment.

 Growth deficiency
 Where the weight of the child is less than the fifth or possibly third percentile for their age, with evidence of malnutrition

Dietitian Prescribing

Prescriptions from Dietitians will be only valid for subsidy where they are for special foods, as listed in this section, or where they are for the following products:

ASCORBIC ACID Tab 100 mg

CALCIUM CARBONATE

- ✓ Tab eff 1.75 g (1 g elemental)
- ✓ Tab 1.25 g (500 mg elemental)
- COMPOUND ELECTROLYTES

Powder for oral soln

DEXTROSE WITH ELECTROLYTES Soln with electrolytes

FERROUS FUMARATE ✓ Tab 200 mg (65 mg elemental)

FERROUS FUMARATE WITH FOLIC ACID

✓ Tab 310 mg (100 mg elemental) with folic acid 350 mcg

FERROUS SULPHATE

- ✓ Tab long-acting 325 mg (105 mg elemental)
- ✓ Oral liq 30 mg (6 mg elemental) per 1 ml

FERROUS SULPHATE WITH FOLIC ACID Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg

FOLIC ACID Tab 0.8 mg

MULTIVITAMINS

PANCREATIC ENZYME

✓ Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease PHOSPHORUS ✓ Tab eff 500 mg (16 mmol)

POTASSIUM CHLORIDE Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)

✔ Tab long-acting 600 mg

POTASSIUM IODATE

✓ Tab 256 mcg (150 mcg elemental iodine)

PYRIDOXINE HYDROCHLORIDE

- ✔ Tab 25 mg
- ✔ Tab 50 mg

SODIUM CHLORIDE ✓ Inj 23.4%, 20 ml

SODIUM FLUORIDE

✓ Tab 1.1 mg (0.5 mg elemental)

THIAMINE HYDROCHLORIDE ✓ Tab 50 mg

VITAMIN A WITH VITAMINS D AND C

✓ Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops

VITAMIN B COMPLEX

✓ Tab, strong, BPC

VITAMINS

- ✓ Tab (BPC cap strength)
- ✓ Cap (fat soluble vitamins A, D, E, K)

Subsidy (Manufacturer's Price) \$ Per Brand or Generic Manufacturer

Fully

Subsidised

Nutrient Modules

Carbohydrate

SA1373 Special Authority for Subsidy

Initial application — (Cystic fibrosis or kidney disease) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Either:

- 1 cystic fibrosis; or
- 2 chronic kidney disease.

Initial application — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 cancer in children; or
- 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 3 faltering growth in an infant/child; or
- 4 bronchopulmonary dysplasia; or
- 5 premature and post premature infant; or
- 6 inborn errors of metabolism; or
- 7 for use as a component in a modular formula.

Renewal — (Cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE SUPPLEMENT – Special Authority see SA1373 above – Hospital pharmacy [HP3]

Powder5.29 400 g C	OP V	Polyca
--------------------	------	--------

Carbohydrate And Fat

➡SA1376 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 Infant or child aged four years or under; and
- 2 cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

- 1 infant or child aged four years or under; and
- 2 Any of the following:
 - 2.1 cancer in children; or
 - 2.2 faltering growth; or
 - 2.3 bronchopulmonary dysplasia; or
 - 2.4 premature and post premature infants.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE AND FAT	SUPPLEMENT - Specia	al Authority see	SA1376 on th	e previous pa	ge –	Hospital pharmacy [HP3]
Powder (neutral)			60.31	400 g OP	V	Duocal Super
						Soluble Powder

Fat

SA1374 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 faltering growth in an infant/child; or
- 2 bronchopulmonary dysplasia; or
- 3 fat malabsorption; or
- 4 lymphangiectasia; or
- 5 short bowel syndrome; or
- 6 infants with necrotising enterocolitis; or
- 7 biliary atresia; or
- 8 for use in a ketogenic diet; or
- 9 chyle leak; or
- 10 acites; or
- 11 for use as a component in a modular formula.

Renewal — (Inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	lbsidised	Generic	
\$	Per	~	Manufacturer	

2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT SUPPLEMENT - Special Authority see SA1374 on the previous page - Hospital pharmacy [HP3]

Emulsion (neutral)	12.30	200 ml OP	✓ Calogen
	30.75	500 ml OP	Calogen
Emulsion (strawberry)	12.30	200 ml OP	 Calogen
Oil	30.00	500 ml OP	MCT oil (Nutricia)
Oil, 250 ml	114.92	4 OP	 Liquigen

Protein

►SA1375 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 protein losing enteropathy; or
- 2 high protein needs; or
- 3 for use as a component in a modular formula.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEM	ENT – Special Authority see SA1375 above – Hospital ph	armacy [HP3]	
Powder		225 g OP	Protifar
	8.95	227 g OP	 Resource Beneprotein
Powder (vanilla)		275 g OP	Promod

Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed)

Respiratory Products

➡SA1094 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has CORD and hypercapnia, defined as a CO2 value exceeding 55 mmHg.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

(Ma	Subsidy anufacturer's Price)	Subsid	Fully lised	Brand or Generic
	\$	Per	~	Manufacturer

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CORD ORAL FEED 1.5KCAL/ML - Special Authority see SA1094 on the previous page - Hospital pharmacy [HP3]

Liquid1.66	237 ml OP	Pulmocare
------------	-----------	-----------

Diabetic Products

SA1095 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

DIABETIC ENTERAL FEED 1KCAL/ML - Special Authority	see SA1095 above -	- Hospital pharm	nacy [HP3]
Liquid	7.50	1,000 ml OP	🖌 Diason RTH
			 Glucerna Select RTH
DIABETIC ORAL FEED 1KCAL/ML - Special Authority see	SA1095 above – Ho	spital pharmacy	[HP3]
Liquid (strawberry)	1.50	200 ml OP	🖌 Diasip
Liquid (vanilla)	1.50	200 ml OP	Diasip
	1.88	250 ml OP	Glucerna Select
	1.78	237 ml OP	
	(2.10)		Resource Diabetic
	(2.10)		Sustagen Diabetic

Fat Modified Products

SA1381 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or
- 3 Modified as a modular feed for adults.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications methods the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT MODIFIED FEED – Special Authority see SA1381 above – Hospital pharmacy [HP3] Powder60.48 400 g OP ✔ Monogen

Subsidy (Manufacturer's Price		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

High Protein Products

SA1378 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 decompensating liver disease without encephalopathy; or
- 2 protein losing gastro-enteropathy.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

HIGH PROTEIN ORAL FEED 1KCAL/ML – Special Authority see SA1378 above -	 Hospital pha 	armacy [HP3]
Liquid1.90	200 ml OP	 Fortimel Regular

Paediatric Products For Children Awaiting Liver Transplant

SA1098 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who requires a liver transplant.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA1098 above – Hospital pharmacy [HP3]

Paediatric Products For Children With Chronic Renal Failure

➡SA1099 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with acute or chronic kidney disease.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA1099 above – Hospital pharmacy [HP3]

Liquid54.00	400 g OP	 Kindergen
-------------	----------	-------------------------------

Subsi	dy Fully	Brand or
(Manufacture	er's Price) Subsidised	Generic
\$	Per 🗸	Manufacturer

Paediatric Products

➡SA1379 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
 - 2.1 the child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
 - 2.2 any condition causing malabsorption; or
 - 2.3 faltering growth in an infant/child; or
 - 2.4 increased nutritional requirements; or
 - 2.5 the child is being transitioned from TPN or tube feeding to oral feeding.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority see Liquid		e – Hospital pha 500 ml OP	armacy [HP3] V Nutrini RTH Pediasure RTH
PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Speci Liquid	,	e SA1379 abov 500 ml OP	 Hospital pharmacy [HP3] Nutrini Energy Multi Fibre Nutrini Energy RTH
PAEDIATRIC ORAL FEED – Special Authority see SA1379 above Powder (vanilla)		armacy [HP3] 850 g OP	✓ Pediasure
PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see Sr Liquid (strawberry) Liquid (vanilla)	1.60	- Hospital pharr 200 ml OP 200 ml OP	nacy [HP3] ✓ Fortini ✓ Fortini
PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA1 Liquid (chocolate) Liquid (strawberry) Liquid (vanilla)	1.07 1.07	Hospital pharma 200 ml OP 200 ml OP 200 ml OP 250 ml OP	acy [HP3] ✓ Pediasure ✓ Pediasure ✓ Pediasure ✓ Pediasure
PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special Au Liquid (chocolate) Liquid (strawberry) Liquid (vanilla)		A1379 above – I 200 ml OP 200 ml OP 200 ml OP 200 ml OP	Hospital pharmacy [HP3] ✓ Fortini Multi Fibre ✓ Fortini Multi Fibre ✓ Fortini Multi Fibre

	Subsidy (Manufacturer's Pr \$	ice) Sub Per	Fully sidised	Brand or Generic Manufacturer
Renal Products				
■SA1101 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocat where the patient has acute or chronic kidney disease. Renewal only from a dietitian, relevant specialist, vocationally req				
mendation of a dietitian, relevant specialist or vocationally registere meeting the following criteria: Both:			0	•
 The treatment remains appropriate and the patient is ben General Practitioners must include the name of the dieti tioner and date contacted. 			ationally	registered general practi-
RENAL ENTERAL FEED 1.8 KCAL/ML – Special Authority see S Liquid		lospital pharn 500 ml OP		P3] epro HP RTH
RENAL ENTERAL FEED 2 KCAL/ML – Special Authority see SA Liquid		spital pharma 500 ml OP] epro RTH
(Nepro RTH Liquid to be delisted 1 December 2014)				•
RENAL ORAL FEED 1.8 KCAL/ML – Special Authority see SA11 Liquid		ital pharmacy 220 ml OP	N 🖌	epro HP (strawberry)
			🖌 N	epro HP (vanilla)
RENAL ORAL FEED 2 KCAL/ML – Special Authority see SA110 ⁻	I above – Hospita	l pharmacy [H	HP3]	
Liquid		200 ml OP	🖌 N	epro (strawberry) epro (vanilla)
	3.80 2.88	237 ml OP	✔ S	uplena
	(3.31)			ovaSource Renal
Liquid (apricot)		125 ml OP		enilon 7.5
Liquid (caramel)		125 ml OP		enilon 7.5
Liquid (apricot) 125 ml		4 OP		enilon 7.5
Liquid (caramel) 125 ml (Nepro (strawberry) Liquid to be delisted 1 December 2014)	11.52	4 OP	VR	enilon 7.5
(Nepro (strawberry) Liquid to be delisted 1 December 2014) (Nepro (vanilla) Liquid to be delisted 1 December 2014)				
(Renilon 7.5 Liquid (apricot) to be delisted 1 December 2014)				
(Renilon 7.5 Liquid (caramel) to be delisted 1 October 2014)				

Specialised And Elemental Products

SA1377 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 malabsorption; or
- 2 short bowel syndrome; or
- 3 enterocutaneous fistulas; or
- 4 eosinophilic oesophagitis; or
- 5 inflammatory bowel disease; or
- 6 patients with multiple food allergies requiring enteral feeding.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
 - 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL ELEMENTAL FEED 1KCAL/ML -	 Special Authority see SA1377 	on the previou	s page – Hospital pharmacy [HP3]
Powder	4.40	79 a OP	🖌 Vital HN

7.50	76 g OP	✓ Alitraq
ORAL ELEMENTAL FEED 0.8KCAL/ML - Special Authority see SA1377 on the p	previous page -	- Hospital pharmacy [HP3]
Liquid (grapefruit), 250 ml carton171.00	18 OP	Elemental 028 Extra
Liquid (pineapple & orange), 250 ml carton 171.00	18 OP	Elemental 028 Extra
Liquid (summer fruits), 250 ml carton171.00	18 OP	 Elemental 028 Extra
ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA1377 on the pre Powder (unflavoured)		Hospital pharmacy [HP3]
SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Authority see SA1377 Liquid12.04		

Paediatric Products For Children With Low Energy Requirements

➡SA1196 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child aged one to eight years; and
- 2 The child has a low energy requirement but normal protein and micronutrient requirements.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

•			Multi Fibre
Liquid	4.00	500 ml OP	Nutrini Low Energy
PAEDIATRIC ENTERAL FEED WITH FIBRE 0.76 KCAL/ML - Sp	pecial Authority se	e SA1196 above	e – Hospital pharmacy [HP3]

Subsidy (Manufacturer's Price)	S	Fully ubsidised	Brand or Generic	
\$	Per	~	Manufacturer	

Standard Supplements

SA1228 Special Authority for Subsidy

Initial application — (Children) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 Any of the following:
 - 2.1 The patient has a condition causing malabsorption; or
 - 2.2 The patient has failure to thrive; or
 - 2.3 The patient has increased nutritional requirements; and
- 3 Nutrition goal has been set (eg reach a specific weight or BMI).

Renewal — (Children) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 A nutrition goal has been set (eg reach a specific weight or BMI).

Initial application — (Adults) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria:

- All of the following:
 - 1 Any of the following:
 - Patient is Malnourished
 - 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
 - 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months; and
 - 2 Any of the following:
 - Patient has not responded to first-line dietary measures over a 4 week period by:
 - 2.1 Increasing their food intake frequency (eg snacks between meals); or
 - 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
 - 2.3 Using over the counter supplements (e.g. Complan); and
 - 3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

Renewal — (Adults) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
 - 1 A nutrition goal has been set (eg reach a specific weight or BMI); and
 - 2 Any of the following:
 - Patient is Malnourished
 - 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
 - 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 2.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months.

Subsid (Manufacturer		
\$	Per 🖌	Manufacturer

Initial application — (Adults transitioning from hospital Discretionary Community Supply) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The patient has had up to a 30 day supply of a 1.0 or a 1.5 kcal/ml Standard Oral Supplement; and
- 2 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 3 Any of the following:
 - Patient is Malnourished
 - 3.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
 - 3.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 3.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Short-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 Is being feed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Is undergoing a bone marrow transplant; or
- 4 Tempomandibular surgery; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or</p>
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being meet.

Renewal — (Short-term medical condition) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a nasogastric tube; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Has undergone a bone marrow transplant; or
- 4 Tempomandibular surgery; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or</p>
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being meet.

Subsidy		Fully	Brand or	
(Manufacturer's Pric	e)	Subsidised	Generic	
\$	Per	~	Manufacturer	

Initial application - (Long-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria): or
- 2 Cystic Fibrosis; or
- 3 Liver disease: or
- 4 Chronic Renal failure: or
- 5 Inflammatory bowel disease: or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula: or
- 9 Severe chronic neurological conditions; or
- 10 Epidermolysis bullosa; or
- 11 AIDS (CD4 count < 200 cells/mm³); or
- 12 Chronic pancreatitis.

Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria): or
- 2 Cystic Fibrosis; or
- 3 Liver disease: or
- 4 Chronic Renal failure: or
- 5 Inflammatory bowel disease: or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome: or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions.

ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1228 on page 225 – Liquid		cy [HP3] ✔ Nutrison Energy
ENTERAL FEED 1KCAL/ML - Special Authority see SA1228 on page 225 - Ho	ospital pharmacy	[HP3]
Liquid	250 ml OP	✓ Isosource Standard ✓ Osmolite
5.29	1,000 ml OP	 Isosource Standard RTH
		 Nutrison Standard RTH
2.65	500 ml OP	Osmolite RTH
5.29	1,000 ml OP	 Osmolite RTH
ENTERAL FEED WITH FIBRE 1 KCAL/ML - Special Authority see SA1228 on		
Liquid1.32	237 ml OP	Jevity
2.65	500 ml OP	Jevity RTH
5.29	1,000 ml OP	Jevity RTH
		Nutrison Multi Fibre

SPECIAL FOODS

	Subsidy (Manufacturer's	Price) Sub	Fully Brand or sidised Generic
	\$	Per	 Manufacturer
NTERAL FEED WITH FIBRE 1.5KCAL/ML - Special Authority	y see SA1228 on	page 225 – Ho	spital pharmacy [HP3]
Liquid	1.75	250 ml OP	Ensure Plus HN
	7.00	1,000 ml OP	Ensure Plus RTH
			Jevity HiCal RTH
			Nutrison Energy
			Multi Fibre
RAL FEED (POWDER) – Special Authority see SA1228 on pa	age 225 – Hospita	al pharmacy [HF	23]
Powder (chocolate)		900 g OP	 Sustagen Hospital
		-	Formula
	13.00	850 g OP	✓ Ensure
Powder (vanilla)	3.67	350 g OP	✓ Fortisip
	10.22	900 g OP	 Sustagen Hospital
		0	Formula
	13.00	850 g OP	✓ Ensure
RAL FEED 1.5KCAL/ML - Special Authority see SA1228 on p	page 225 – Hospi	ital pharmacy [H	IP31
Additional subsidy by endorsement is available for patients I	0 1		1
molysis bullosa. The prescription must be endorsed accord			,,.
Liquid (banana) - Higher subsidy of \$1.26 per 200 ml with	th		
Endorsement	0.72	200 ml OP	
	(1.26)		Ensure Plus
	(1.26)		Fortisip
Liquid (chocolate) – Higher subsidy of up to \$1.33 per 237 r	()		i ei tielp
Liquid (chocolate) – Higher subsidy of up to \$1.33 per 237 r with Endorsement.	nl	200 ml OP	
Liquid (chocolate) – Higher subsidy of up to \$1.33 per 237 r with Endorsement	nl 0.72	200 ml OP	·
	nl 0.72 (1.26)		Ensure Plus
	nl 0.72 (1.26) 0.85	200 ml OP 237 ml OP	Ensure Plus
	nl 0.72 (1.26) 0.85 (1.33)	237 ml OP	·
	nl 0.72 (1.26) 0.85 (1.33) 0.72		Ensure Plus Ensure Plus
with Endorsement	nl (1.26) 0.85 (1.33) 0.72 (1.26)	237 ml OP	Ensure Plus
with Endorsement	nl	237 ml OP 200 ml OP	Ensure Plus Ensure Plus
with Endorsement	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl	237 ml OP	Ensure Plus Ensure Plus Fortisip
with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl	237 ml OP 200 ml OP	Ensure Plus Ensure Plus
with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml wit	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl0.72 (1.26) th	237 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip
with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) nl 0.72 (1.26) th 0.72	237 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus
with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml wit	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) nl 0.72 (1.26) th 0.72 (1.26) th 0.72 (1.26)	237 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus Ensure Plus
with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml wit Endorsement	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) nl 0.72 (1.26) th 0.72 (1.26) (1.26) (1.26)	237 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus
 with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with Endorsement Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement 	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) nl 0.72 (1.26) th 0.72 (1.26) (1.26) (1.26) 0.72	237 ml OP 200 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus Ensure Plus
with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml wit Endorsement	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) nl 0.72 (1.26) th 0.72 (1.26) (1.26) (1.26) n- 0.72	237 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus Ensure Plus Fortisip
 with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with Endorsement Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement 	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) nl 0.72 (1.26) th 0.72 (1.26) (1.26) 0.72 (1.26) n- 0.72 (1.26) 0.72	237 ml OP 200 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus Ensure Plus
 with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with Endorsement Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 r 	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) th 0.72 (1.26) th 0.72 (1.26) (1.26) n- 0.72 (1.26) n- 0.72 (1.26) n-	237 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus Ensure Plus Fortisip
 with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with Endorsement Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement 	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) th 0.72 (1.26) th 0.72 (1.26) (1.26) n- 0.72 (1.26) n- 0.72 (1.26) nn 0.72 (1.26) nn 0.72	237 ml OP 200 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus Fortisip Fortisip
 with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml wit Endorsement Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 r with Endorsement 	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) th 0.72 (1.26) th 0.72 (1.26) (1.26) n- (1.26) n- (1.26) n- (1.26) n- (1.26) nl 0.72 (1.26) nl	237 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus Ensure Plus Fortisip
 with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml wit Endorsement Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 r with Endorsement 	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) th 0.72 (1.26) th 0.72 (1.26) (1.26) n- (1.26) n- (1.26) n- (1.26) nl 0.72 (1.26) nl 0.72 (1.26) nl	237 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus Fortisip Fortisip
 with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml wit Endorsement Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 r with Endorsement 	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) nl 0.72 (1.26) th 0.72 (1.26) (1.26) n- (1.26) n- (1.26) nl 0.72 (1.26) nl 0.72 (1.26) nl 0.72 (1.26) nl 0.72	237 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus Fortisip Fortisip Fortisip
 with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml wit Endorsement Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 r with Endorsement 	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) nl 0.72 (1.26) th 0.72 (1.26) (1.26) nl 0.72 (1.26) nl 0.72	237 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus Fortisip Fortisip
 with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml wit Endorsement Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 r with Endorsement 	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) th 0.72 (1.26) (1.26) (1.26) (1.26) n- 0.72 (1.26) nn 0.72 (1.26) nl 0.72 (1.26) nl 0.72 (1.26) nl 0.72 (1.26) 0.85	237 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus Fortisip Fortisip Fortisip Ensure Plus
 with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml wit Endorsement Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 r with Endorsement 	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) nl 0.72 (1.26) th 0.72 (1.26) (1.26) nl 0.72 (1.26) nl 0.72	237 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus Fortisip Fortisip Fortisip
 with Endorsement Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml wit Endorsement Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 r with Endorsement Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 r with Endorsement 	nl 0.72 (1.26) 0.85 (1.33) 0.72 (1.26) nl 0.72 (1.26) th 0.72 (1.26) (1.26) (1.26) (1.26) n- 0.72 (1.26) nn 0.72 (1.26) nl 0.72 (1.26) nl 0.72 (1.26) nl 0.72 (1.26) 0.85	237 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP 200 ml OP	Ensure Plus Ensure Plus Fortisip Ensure Plus Fortisip Fortisip Fortisip Ensure Plus

SPECIAL FOODS

	Subsidy (Manufacturer's P \$		Fully dised	Brand or Generic Manufacturer
ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see Additional subsidy by endorsement is available for patients be molysis bullosa. The prescription must be endorsed according Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with	eing bolus fed thr gly.			
Endorsement	0.72 (1.26)	200 ml OP	F	ortisip Multi Fibre
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with				
Endorsement	0.72 (1.26)	200 ml OP	F	ortisip Multi Fibre
Liquid (vanilla) – Higher subsidy of \$1.26 per 200 ml with Endorsement		200 ml OP	F	ortisip Multi Fibre

High Calorie Products

SA1195 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 faltering growth in an infant/child; or
 - 1.3 increased nutritional requirements; or
 - 1.4 fluid restricted; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements or is fluid restricted.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

	Subsidy (Manufacturer's \$		Sub: Per	Fully sidised	Brand or Generic Manufacturer
ENTERAL FEED 2 KCAL/ML – Special Authority see SA1195 on Liquid	• •	•	lospital p ml OP		cy [HP3] utrison Concentrated
	11.00	1,000) ml OP	🖌 T	wo Cal HN RTH
ORAL FEED 2 KCAL/ML – Special Authority see SA1195 on the p Additional subsidy by endorsement is available for patients bei molysis bullosa. The prescription must be endorsed according Liquid (vanilla) – Higher subsidy of \$1.90 per 200 ml with	ing bolus fed th				•
Endorsement	0.96 (1.90)	200	ml OP	Τ\	wo Cal HN
Food Thickeners					
►SA1106 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vocat where the patient has motor neurone disease with swallowing diso Renewal only from a dietitian, relevant specialist, vocationally regi mendation of a dietitian, relevant specialist or vocationally registere meeting the following criteria:	rder. stered genera	l practit	ioner or g	jeneral	practitioner on the recom-

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Feed Thickener
 Karicare Aptamil

Healtheries Simple Baking Mix

FOOD THICKENER - Special Authority see SA1106 above - Hospital pharmacy [HP3]

Powder7.25	380 g OP
------------	----------

Gluten Free Foods

The funding of gluten free foods is no longer being actively managed by PHARMAC from 1 April 2011. This means that we are no longer considering the listing of new products, or making subsidy, or other changes to the existing listings. As a result we anticipate that the range of funded items will reduce over time. Management of Coeliac disease with a gluten free diet is necessary for good outcomes. A range of gluten free options are available through retail outlets.

SA1107 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

- 1 Gluten enteropathy has been diagnosed by biopsy; or
- 2 Patient suffers from dermatitis herpetiformis.

GLUTEN FREE BAKING MIX - Special Authority see SA1107 above - Hospital pharmacy [HP3]

Powder	2.81	1,000 g OP
	(5.15)	

	Subsidy (Manufacturer's Pr \$	rice) Subsi Per	Fully Brand or idised Generic ✔ Manufacturer
GLUTEN FREE BREAD MIX - Special Authority see SA1107 of	on the previous pag	e – Hospital ph	armacy [HP3]
Powder		1,000 g OP	
	(7.32)		NZB Low Gluten
			Bread Mix
	4.77		
	(8.71)		Bakels Gluten Free
			Health Bread Mix
	3.51		
	(10.87)		Horleys Bread Mix
GLUTEN FREE FLOUR - Special Authority see SA1107 on the	e previous page – H	lospital pharma	acy [HP3]
Powder		2,000 g OP	
	(18.10)	-	Horleys Flour
GLUTEN FREE PASTA - Special Authority see SA1107 on the	previous page – H	osnital nharma	rv [HP3]
Buckwheat Spirals		250 g OP	oy [in o]
	(3.11)	200 9 01	Orgran
Corn and Vegetable Shells	()	250 g OP	e giun
	(2.92)		Orgran
Corn and Vegetable Spirals	()	250 g OP	- 5
5	(2.92)	0	Orgran
Rice and Corn Lasagne Sheets		200 g OP	0
·	(3.82)	-	Orgran
Rice and Corn Macaroni	2.00	250 g OP	-
	(2.92)		Orgran
Rice and Corn Penne	2.00	250 g OP	
	(2.92)		Orgran
Rice and Maize Pasta Spirals		250 g OP	
	(2.92)		Orgran
Rice and Millet Spirals		250 g OP	
	(3.11)		Orgran
Rice and corn spaghetti noodles		375 g OP	•
	(2.92)		Orgran
Vegetable and Rice Spirals		250 g OP	•
Italian lang at da anaghatti	(2.92)	000 - 00	Orgran
Italian long style spaghetti		220 g OP	Oraron
	(3.11)		Orgran

Foods And Supplements For Inborn Errors Of Metabolism

SA1108 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Dietary management of homocystinuria; or
- 2 Dietary management of maple syrup urine disease; or
- 3 Dietary management of phenylketonuria (PKU); or
- 4 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Supplements For Homocystinuria

AMINOACID FORMULA WITHOUT METHIONINE - Special Aut	thority see SA110	8 above – Hos	pital pharmacy [HP3]
Powder		500 g OP	 XMET Maxamum

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully sidised	Brand or Generic Manufacturer
Supplements For MSUD				
MINOACID FORMULA WITHOUT VALINE, LEUCINE AND I Hospital pharmacy [HP3]	SOLEUCINE - Sp	pecial Authority	see SA1	108 on the previous page
Powder		500 g OP		SUD Maxamaid SUD Maxamum
Supplements For PKU				
MINOACID FORMULA WITHOUT PHENYLALANINE – Spei 193]	cial Authority see S	SA1108 on the p	revious	page – Hospital pharma
Tabs		75 OP	🖌 Pi	hlexy 10
Powder (unflavoured) 29 g sachets		30	🖌 Pl	KU Anamix Junior
Infant formula	174.72	400 g OP	🖌 Pl	KU Anamix Infant
Powder (orange)		500 g OP	🖌 XI	P Maxamaid
	320.00		🖌 XI	P Maxamum
Powder (unflavoured)		500 g OP	🖌 XI	P Maxamaid
	320.00		🖌 XI	P Maxamum
Liquid (berry)		125 ml OP		KU Anamix Junior LQ
Liquid (citrus)		62.5 ml OP	🖌 Pl	KU Lophlex LQ 10
	31.20	125 ml OP	🖌 Pl	KU Lophlex LQ 20
Liquid (juicy berries)		62.5 ml OP	🖌 Pl	KU Lophlex LQ 10
	31.20	125 ml OP	🖌 Pl	KU Lophlex LQ 20
Liquid (juicy orange)		62.5 ml OP	🖌 Pl	KU Lophlex LQ 10
	31.20	125 ml OP	🖌 Pl	KU Lophlex LQ 20
Liquid (orange)		125 ml OP		KU Anamix Junior LQ
Liquid (unflavoured)		125 ml OP		KU Anamix Junior LQ
Liquid (forest berries), 250 ml carton		18 OP	🖌 Ea	asiphen Liquid

LOW PROTEIN BAKING MIX – Special Authority see SA1108 on the previous page – Hospital pharmacy [HP3]						
Powder	22 500 g OP	Loprofin Mix				
LOW PROTEIN PASTA - Special Authority see SA1108 on the previous pa	ge – Hospital pharn	nacy [HP3]				
Animal shapes11.	91 500 g OP	Loprofin				
Lasagne	95 250 g OP	Loprofin				
Low protein rice pasta11.9	91 500 g OP	Loprofin				
Macaroni	95 250 g OP	 Loprofin 				
Penne	91 500 g OP	 Loprofin 				
Spaghetti11.9	91 500 g OP	 Loprofin 				
Spirals11.	91 500 g OP	 Loprofin 				

Infant Formulae

For Premature Infants

PRETERM POST-DISCHARGE INFANT FORMULA – Special Authority see SA1198 on the next page – Hospital pharmacy [HP3] Powder15.25 400 g OP V S-26 Gold Premgro

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	ubsidised	Generic	
\$	Per	~	Manufacturer	

SA1198 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth; and
- 2 Either:
 - 2.1 The infant has faltering growth (downward crossing of percentiles); or
 - 2.2 The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula.

For Williams Syndrome

SA1110 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

LOW CALCIUM INFANT FORMULA – Special Authority see SA1110 above – Hospital pharmacy [HP3]

Powder	 	400 g OP	Locasol

Gastrointestinal and Other Malabsorptive Problems

Powder	48.5 g OP	Vivonex Pediatric
53.00	400 g OP	Neocate LCP
Powder (unflavoured)53.00	400 g OP	Elecare
	•	Elecare LCP
		Neocate Advance
		Neocate Gold
Powder (vanilla)53.00	400 g OP	Elecare
	0	Neocate Advance

➡SA1219 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 An assessment as to whether the infant can be transitioned to a cows milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and

Subsidy (Manufacturer's Price)		Fully bsidised	Brand or Generic	
\$	Per	~	Manufacturer	

- continued...
 - 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
 - 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

. Karicare Aptamil

SA1380 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
 - 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
 - 1.2 Either:
 - 1.2.1 Soy milk formula has been trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Step Down from Amino Acid Formula) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The infant is currently receiving funded amino acid formula; and
- 2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
Ketogenic Diet			
SA1197 Special Authority for Subsidy Initial application only from a metabolic physician or paediatr intractable epilepsy, pyruvate dehydrogenase deficiency or gluc ketogenic diet.	0 11		
Renewal only from a metabolic physician or paediatric neurolo diet and the patient is benefiting from the diet.	gist. Approvals valid for	2 years where th	e patient is on a ketogeni
HIGH FAT LOW CARBOHYDRATE FORMULA - Special Author	ority see SA1197 above	- Retail pharmad	су

Powder (unflavoured)	300 g OP	✓ KetoCal 4:1 ✓ KetoCal 3:1
Powder (vanilla)35.50	300 g OP	✓ KetoCal 4:1

Pharmaceuticals and quantities that may be obtained on a Practitioner's Supply Order

ADRENALINE ✓ Inj 1 in 1,000, 1 ml ampoule5 ✓ Inj 1 in 10,000, 10 ml ampoule5
AMINOPHYLLINE ✓ Inj 25 mg per ml, 10 ml ampoule5
AMIODARONE HYDROCHLORIDE ✓ Inj 50 mg per ml, 3 ml ampoule6
AMOXICILLIN ✓ Cap 250 mg
AMOXICILLIN WITH CLAVULANIC ACID ✓ Tab 500 mg with clavulanic acid 125 mg
clavulanic acid 62.5 mg per 5 ml 200 ml ASPIRIN ✓ Tab dispersible 300 mg
ATROPINE SULPHATE Inj 600 mcg per ml, 1 ml ampoule
AZITHROMYCIN V Tab 500 mg – See note on page 978
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE] V Tab 2.5 mg – See note on page 60150
BENZATHINE BENZYLPENICILLIN ✓ Inj 1.2 mega u per 2.3 ml
BENZTROPINE MESYLATE ✓ Inj 1 mg per ml, 2 ml
BENZYLPENICILLIN SODIUM (PENICILLIN G) ✓ Inj 600 mg (1 million units) vial
BLOOD GLUCOSE DIAGNOSTIC TEST METER ✓ Meter with 50 lancets, a lancing device and 10 diagnostic test strips – Subsidy by endorsement – See note on page 301
BLOOD GLUCOSE DIAGNOSTIC TEST STRIP ✓ Blood glucose test strips – See note on page 30
BLOOD KETONE DIAGNOSTIC TEST METER Meter – See note on page 29 1

CEFTRIAXONE	
✓ Inj 500 mg vial – Subsidy by See note on page 96	endorsement – 5
Inj 1 g vial – Subsidy by endo note on page 96	orsement – See
CHARCOAL ✓ Oral liq 50 g per 250 ml	250 ml
CHLORPROMAZINE HYDROC	HIORIDE
✓ Tab 10 mg	
✓ Tab 25 mg	
✓ Tab 100 mg	
✓ Inj 25 mg per ml, 2 ml	
CIPROFLOXACIN	
✔ Tab 250 mg - See note on pa	age 1005
✓ Tab 500 mg – See note on pa	
CO-TRIMOXAZOLE	
✓ Tab trimethoprim 80 mg and	
sulphamethoxazole 400 m	ıq30
✓ Oral lig trimethoprim 40 mg a	•
sulphamethoxazole 200 m	
5 ml	
COMPOUND ELECTROLYTES	
✓ Powder for oral soln	
CONDOMS	
✓ 49 mm	144
✓ 52 mm	
✓ 52 mm extra strength	
✓ 53 mm	
✓ 53 mm (chocolate)	
✓ 53 mm (strawberry)	
54 mm, shaped	
✓ 55 mm	
✔ 56 mm	
✓ 56 mm, shaped	
✔ 60 mm	
CYPROTERONE AC	CETATE WITH
ETHINYLOESTRADIOL	
✓ Tab 2 mg with ethinyloestrad	iol 35 mcg and
	84
DEXAMETHASONE	
✓ Tab 1 mg – Retail pharmacy-	Specialist 30
✓ Tab 4 mg – Retail pharmacy-	
DEXAMETHASONE PHOSPHA	
✓ Inj 4 mg per ml, 1 ml ampoul	
page 84	5
	continued

✓ fully subsidised brand available

PRACTITIONER'S SUPPLY ORDERS

(continued) ✓ Inj 4 mg per ml, 2 ml ampoule – See note on	Tab 35 mcg with norethisterone 1 mg and 7 inert tab
page 84	
	✓ Tab 35 mcg with norethisterone 500 mcg
DIAPHRAGM	and 7 inert tab
✓ 65 mm – See note on page 78	1
✓ 70 mm – See note on page 78	
✓ 75 mm – See note on page 78	
✓ 80 mm – See note on page 78	1 01
DIAZEPAM	✓ Grans for oral liq 250 mg per 5 ml
✓ Inj 5 mg per ml, 2 ml – Subsidy by	✔ Inj 1 g vial
endorsement – See note on page 138	5 FLUPENTHIXOL DECANOATE
✓ Rectal tubes 5 mg	
✓ Rectal tubes 10 mg	, , ,
	✓ Inj 100 mg per ml, 1 ml
DICLOFENAC SODIUM	
✓ Inj 25 mg per ml, 3 ml ampoule	
✓ Suppos 50 mg	
DIGOXIN	✓ Inj 25 mg per ml, 1 ml
✓ Tab 62.5 mcg	✓ Inj 100 mg per ml, 1 ml
✓ Tab 250 mcg	
• 100 200 mog	✓ Tab 40 mg
DOXYCYCLINE	✓ Ini 10 mg per ml. 2 ml ampoule
Tab 50 mg	.30
✓ Tab 100 mg	
ERGOMETRINE MALEATE	✓ Inj 1 mg syringe kit
✓ Inj 500 mcg per ml, 1 ml ampoule	5 GLUCOSE [DEXTROSE]
	✓ Inj 50%, 10 ml ampoule
ERYTHROMYCIN ETHYL SUCCINATE	✓ Inj 50%, 90 ml bottle
✓ Tab 400 mg	
✓ Grans for oral liq 200 mg per 5 ml	
✓ Grans for oral liq 400 mg per 5 ml 200) ml ✓ Tab 600 mcg ✓ Oral spray, 400 mcg per dose
ERYTHROMYCIN STEARATE	✔ Oral spray, 400 mcg per dose
Tab 250 mg	.30 HALOPERIDOL
J J	✓ Tab 500 mcg
ETHINYLOESTRADIOL WITH DESOGESTREL	🖌 Tab 1.5 mg
Tab 20 mcg with desogestrel 150 mcg and 7	🖌 Tab 5 mg
inert tab	• • • • • • • • • • • • • • • • • • •
Tab 30 mcg with desogestrel 150 mcg and 7	🗸 lnj 5 mg per ml, 1 ml
inert tab	.84 HALOPERIDOL DECANOATE
ETHINYLOESTRADIOL WITH LEVONORGESTREL	✓ Inj 50 mg per ml, 1 ml
✓ Tab 20 mcg with levonorgestrel 100 mcg and	✓ Inj too ing per ml, 1 ml
7 inert tab	
✓ Tab 50 mcg with levonorgestrel 125 mcg and	HIDROCORTISONE
7 inert tab	84 ✓ Inj 100 mg vial
Tab 30 mcg with levonorgestrel 150 mcg	
✓ Tab 30 mcg with levonorgestrel 150 mcg and	✓ Inj 1 mg per ml, 1 ml
7 inert tab	
	HYOSCINE N-BUTYLBROMIDE
ETHINYLOESTRADIOL WITH NORETHISTERONE	🖌 lnj 20 mg, 1 ml
✓ Tab 35 mcg with norethisterone 1 mg	.63 cc

inert tab
UCLOXACILLIN 7 Cap 250 mg
LUPENTHIXOL DECANOATE / Inj 20 mg per ml, 1 ml
UPHENAZINE DECANOATE / Inj 12.5 mg per 0.5 ml, 0.5 ml
JROSEMIDE [FRUSEMIDE] 7 Tab 40 mg
LUCAGON HYDROCHLORIDE 'Inj 1 mg syringe kit5
LUCOSE [DEXTROSE] / Inj 50%, 10 ml ampoule5 / Inj 50%, 90 ml bottle
LYCERYL TRINITRATE 'Tab 600 mcg100 'Oral spray, 400 mcg per dose250 dose
ALOPERIDOL Tab 500 mcg
ALOPERIDOL DECANOATE / Inj 50 mg per ml, 1 ml5 / Inj 100 mg per ml, 1 ml
YDROCORTISONE / Inj 100 mg vial5
YDROXOCOBALAMIN Inj 1 mg per ml, 1 ml6
YOSCINE N-BUTYLBROMIDE 'Inj 20 mg, 1 ml5
continued

(continued)

INTRA-UTERINE DEVICE ✓ IUD40 ✓ IUD 29.1 mm length × 23.2 mm width40 ✓ IUD 33.6 mm length × 29.9 mm width40
IPRATROPIUM BROMIDE ✓ Nebuliser soln, 250 mcg per ml, 1 ml
IVERMECTIN V Tab 3 mg – See note on page 72100
KETONE BLOOD BETA-KETONE ELECTRODES
LEVONORGESTREL Tab 30 mcg
LIDOCAINE [LIGNOCAINE] Gel 2%, 10 ml urethral syringe – Subsidy by endorsement – See note on page 1315
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE ✓ Inj 1%, 5 ml ampoule
LIDOCAINE [LIGNOCAINE] WITH CHLORHEXIDINE Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes – Subsidy by endorsement – See note on page 1315
LOPERAMIDE HYDROCHLORIDE ✓ Tab 2 mg
• Oup 2 mg
✓ Cop L Ing Solution MASK FOR SPACER DEVICE ✓ Size 2 – See note on page 201
MASK FOR SPACER DEVICE
MASK FOR SPACER DEVICE ✓ Size 2 – See note on page 201
MASK FOR SPACER DEVICE ✓ Size 2 – See note on page 201

 Inj 30 mg per ml, 1 ml ampoule – Only on a controlled drug form5
NALOXONE HYDROCHLORIDE / Inj 400 mcg per ml, 1 ml5
NICOTINE
 ✓ Patch 7 mg – See note on page 159
 Lozenge 2 mg – See note on page 159
 ✓ Gum 2 mg (Mint) – See note on page 159
NORETHISTERONE Tab 350 mcg84
✓ Tab 5 mg
OXYTOCIN ✔ Inj 5 iu per ml, 1 ml ampoule5 ✔ Inj 10 iu per ml, 1 ml ampoule5
Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml
PARACETAMOL
✓ Tab 500 mg
PEAK FLOW METER ✓ Low range10
Normal range 10
PETHIDINE HYDROCHLORIDE Inj 50 mg per ml, 1 ml – Only on a controlled
drug form5 ✓ Inj 50 mg per ml, 2 ml – Only on a controlled drug form5
PHENOXYMETHYLPENICILLIN (PENICILLIN V)
 ✓ Cap potassium salt 250 mg
Grans for oral liq 125 mg per 5 ml 200 ml
Grans for oral liq 250 mg per 5 ml 300 ml
PHENYTOIN SODIUM ✔ Inj 50 mg per ml, 2 ml5 ✔ Inj 50 mg per ml, 5 ml5
PHYTOMENADIONE
✓ Inj 2 mg per 0.2 ml
✓ Inj 10 mg per ml, 1 ml5 continued
continuea

✓ fully subsidised brand available

PRACTITIONER'S SUPPLY ORDERS

(continued)	
 PIPOTHIAZINE PALMITATE ✓ Inj 50 mg per ml, 1 ml – Subsidy by endorsement – See note on page 1505 ✓ Inj 50 mg per ml, 2 ml – Subsidy by endorsement – See note on page 1505 	
PREDNISOLONE SODIUM PHOSPHATE ✓ Oral liq 5 mg per ml – See note on page 85	
PREDNISONE V Tab 5 mg	
PREGNANCY TESTS - HCG URINE Cassette	
PROCAINE PENICILLIN ✓ Inj 1.5 g in 3.4 ml syringe5	
PROCHLORPERAZINE ✓ Tab 5 mg	
PROMETHAZINE HYDROCHLORIDE ✔ Inj 25 mg per ml, 2 ml5	
SALBUTAMOL ✓ Inj 500 mcg per ml, 1 ml ✓ Aerosol inhaler, 100 mcg per dose CFC free free 1000 dose ✓ Nebuliser soln, 1 mg per ml, 2.5 ml 30	
SALBUTAMOL WITH IPRATROPIUM BROMIDE Vebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml	

SILVER SULPHADIAZINE ✔ Crm 1%250 g
SODIUM BICARBONATE ✔ Inj 8.4%, 50 ml
SODIUM CHLORIDE ✓ Inf 0.9% - See note on page 51
SPACER DEVICE ✓ 230 ml (single patient)20 ✓ 800 ml
SPACER DEVICE AUTOCLAVABLE ✓ 230 ml (autoclavable) – Subsidy by endorsement – See note on page 201
TRIMETHOPRIM V Tab 300 mg
VERAPAMIL HYDROCHLORIDE V Inj 2.5 mg per ml, 2 ml ampoule5
WATER ✓ Purified for inj, 5 ml – See note on page 51
ZUCLOPENTHIXOL DECANOATE

Rural Areas for Practitioner's Supply Orders

NORTH ISLAND

Northland DHB Dargaville Hikurangi Kaeo Kaikohe Kaitaia Kawakawa Kerikeri Mangonui Maungaturoto Moerewa Naunauru Paihia Rawene Ruakaka Russell Tutukaka Waipu Whangaroa

Waitemata DHB

Helensville Huapai Kumeu Snells Beach Waimauku Warkworth Wellsford

Auckland DHB

Great Barrier Island Oneroa Ostend

Counties Manukau DHB Tuakau

Waiuku

Waikato DHB

Coromandel Huntly Kawhia Matamata Morrinsville Ngatea Otorohanga Paeroa Pauanui Beach Putaruru Raglan Tairua Taumarunui Te Aroha Te Kauwhata Te Kuiti Tokoroa Waihi Whangamata Whitianga

Bay of Plenty DHB

Edgecumbe Katikati Kawerau Murupara Opotiki Taneatua Te Kaha Waihi Beach Whakatane

Lakes DHB Mangakino

Turangakino

Tairawhiti DHB

Ruatoria Te Araroa Te Karaka Te Puia Springs Tikitiki Tokomaru Bay Tolaga Bay

Taranaki DHB

Eltham Inglewood Manaia Oakura Okato Opunake Patea Stratford Waverley

Hawkes Bay DHB

Chatham Islands Waipawa Waipukurau Wairoa Whanganui DHB Bulls Marton Ohakune Raetihi Taihape Waiouru

MidCentral DHB

Dannevirke Foxton Levin Otaki Pahiatua Shannon Woodville

Wairarapa DHB

Carteron Featherston Greytown Martinborough

SOUTH ISLAND

Nelson/Marlborough DHB

Havelock Mapua Motueka Murchison Picton Takaka Wakefield

West Coast DHB

Dobson Greymouth Hokitika Karamea Reefton South Westland Westport Whataroa

Canterbury DHB

Akaroa Amberley Amuri Cheviot Darfield Diamond Harbour Hanmer Springs Kaikoura Leeston Lincoln Methven Oxford Rakaia Rolleston Rotherham Templeton Waikari

South Canterbury DHB

Fairlie Geraldine Pleasant Point Temuka Twizel Waimate

Southern DHB

Alexandra Balclutha Cromwell Gore Kurow I awrence Lumsden Mataura Milton Oamaru Oban Otautau Outram Owaka Palmerston Queenstown Ranfurly Riverton Roxburah Tapanui Te Anau Tokonui Tuatapere Wanaka Winton

SECTION F: PART I

A Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule:

- a) is exempt from any requirement to dispense in Monthly Lots;
- b) will only be subsidised if it is dispensed in a 90 Day Lot unless it is under the Dispensing Frequency Rule.

A Community Pharmaceutical that is an oral contraceptive and that is identified with a * within the other sections of the Pharmaceutical Schedule:

- a) is exempt from any requirement to dispense in Monthly Lots;
- b) will only be subsidised if it is dispensed in a 180 Day Lot unless it is is under the Dispensing Frequency Rule.

SECTION F: PART II: CERTIFIED EXEMPTIONS AND ACCESS EXEMPTIONS TO MONTHLY DISPENSING

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule, may be dispensed in a 90 Day Lot if:

a) the Community Pharmaceutical is identified with a ▲ within the other sections of the Pharmaceutical Schedule and the prescriber/pharmacist has endorsed/annotated the Prescription item(s) on the Prescription to which the exemption applies "certified exemption".

In endorsing/annotating the Prescription items for a certified exemption, the prescriber/pharmacist is certifying that:

- i) the patient wished to have the medicine dispensed in a quantity greater than a Monthly Lot; and
- ii) the patient has been stabilised on the same medicine for a reasonable period of time; and
- iii) the prescriber/pharmacist has reason to believe the patient will continue on the medicine and is compliant.
- b) a patient, who has difficulty getting to and from a pharmacy, signs the back of the Prescription to qualify for an Access Exemption. In signing the Prescription, the patient or his or her nominated representative must also certify which of the following criteria they meet:
 - i) have limited physical mobility;
 - ii) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
 - iii) are relocating to another area;
 - iv) are travelling extensively and will be out of town when the repeat prescriptions are due.

SECTION F: PART III: FLEXIBLE AND VARIABLE DISPENSING PERIODS FOR PHARMACY

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule, may be dispensed in variable dispensing periods under the following conditions:

- a) for stock management where the original pack(s) result in dispensing greater than 30 days supply,
- b) to synchronise a patients medication where multiple medicines result in uneven supply periods, note if dispensing a medicine other than a Pharmaceutical identified with a * please refer to Section F; Part II
- Note the total quantity and dispensing period can not exceed the total quantity and period prescribed on the prescription.



The following Community Pharmaceuticals are identified with a ▲ within the other sections of the Pharmaceutical Schedule and may be dispensed in a 90 Day Lot if endorsed as a certified exemption in accordance with paragraph (a) in Section F Part II above.

ALIMENTARY TRACT AND METABOLISM

INSULIN ASPART

INSULIN ASPART WITH INSULIN ASPART PROTAMINE

INSULIN GLARGINE

INSULIN GLULISINE

INSULIN ISOPHANE

INSULIN ISOPHANE WITH INSULIN NEUTRAL

INSULIN LISPRO

INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE

INSULIN NEUTRAL

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

DESMOPRESSIN ACETATE Nasal drops 100 mcg Minirin per ml Nasal spray 10 mcg per Desmopressin-PH&T dose

MUSCULOSKELETAL SYSTEM

PYRIDOSTIGMINE BROMIDE

NERVOUS SYSTEM

AMANTADINE HYDROCHLORIDE

APOMORPHINE HYDROCHLORIDE

ENTACAPONE

GABAPENTIN

GABAPENTIN (NEURONTIN)

LACOSAMIDE

LAMOTRIGINE

LISURIDE HYDROGEN MALEATE

PRAMIPEXOLE HYDROCHLORIDE

ROPINIROLE HYDROCHLORIDE

TOLCAPONE

TOPIRAMATE

VIGABATRIN

CARDIOVASCULAR SYSTEM

AMIODARONE HYDR	OCHLORIDE
Tab 100 mg	Cordarone-X
Tab 200 mg	Cordarone-X

DISOPYRAMIDE PHOSPHATE

FLECAINIDE ACETATE

Tab 50 mg	Tambocor
Tab 100 mg	Tambocor
Cap long-acting 100 mg	Tambocor CR
Cap long-acting 200 mg	Tambocor CR

MEXILETINE HYDROCHLORIDE

MINOXIDIL

NICORANDIL

PROPAFENONE HYDROCHLORIDE

SECTION G: SAFETY CAP MEDICINES

Pharmacists are required, under the Code of Ethics of the Pharmacy Council of New Zealand, to endeavour to use safety caps when dispensing any of the medicines listed in Section G in an oral liquid formulation pursuant to a prescription or Practitioner's Supply Order. This includes all proprietary and extemporaneously compounded oral liquid preparations of those pharmaceuticals listed in Section G of the Pharmaceutical Schedule. These medicines will be identified throughout Section B of the Pharmaceutical Schedule with the symbol '‡'.

Exemptions

Oral liquid preparations of the pharmaceuticals listed in Section G of the Pharmaceutical Schedule will be dispensed in a container with a safety cap unless:

- the practitioner has endorsed the Prescription or Practitioner's Supply Order, stating that, the Pharmaceutical is not to be dispensed in a container with a safety cap; or
- the Contractor has annotated the Prescription or Practitioner's Supply Order stating that, because of infirmity of the particular person, the Pharmaceutical to be used by that person should not be dispensed in a container with a safety cap; or
- the Pharmaceutical is packaged in an Original Pack so designed that on the professional judgement of the Contractor, transfer to a container with a safety cap would be inadvisable or a retrograde procedure.

Reimbursment

Pharmacists will be reimbursed according to their agreement. Where an additional fee is paid on safety caps it will be paid on all dispensings of oral liquid preparations for those pharmaceuticals listed in Section G of the Pharmaceutical Schedule unless the practitioner has endorsed or the contractor has annotated the Prescription or Practitioner's Supply Order that a safety cap has not been supplied.

Safety Caps (NZS 5825:1991)

20 mm	. Clic-Loc, United Closures & Plastics PLC, England
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
24 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
28 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
	PDL Squeezlok
	PDL FG

SAFETY CAP MEDICINES

ALIMENTARY TRACT AND METABOLISM

FERROUS SULPHATE Oral liq 30 mg (6 mg elemental) per 1 ml

CARDIOVASCULAR SYSTEM

AMILORIDE HYDROCHLORIDE Oral liq 1 mg per ml Biomed

CAPTOPRIL Oral lig 5 mg per ml Capoten

CHLOROTHIAZIDE Oral lig 50 mg per ml Biomed

DIGOXIN Oral liq 50 mcg per ml Lanoxin

FUROSEMIDE [FRUSEMIDE] Oral liq 10 mg per ml Lasix

SPIRONOLACTONE Oral liq 5 mg per ml Biomed

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

LEVOTHYROXINE

Tab 25 mcg Tab 50 mcg Tab 100 mcg

Synthroid Eltroxin Synthroid

Synthroid

Eltroxin

(Extemporaneously compounded oral liquid preparations)

LEVOTHYROXINE (MERCURY PHARMA)

Tab 50 mcg Mercury Pharma Tab 100 mcg Mercury Pharma (Extemporaneously compounded oral liquid preparations)

INFECTIONS - AGENTS FOR SYSTEMIC USE

QUININE SULPHATE Tab 300 mg Q 300 (Extemporaneously compounded oral liquid preparations)

NERVOUS SYSTEM

ALPRAZOLAM Tab 250 mcg Xanax Tab 500 mcg Xanax Tab 1 mg Xanax (Extemporaneously compounded oral liquid preparations)

CARBAMAZEPINE

Oral liq 100 mg per 5 ml Tegretol

CLOBAZAM Tab 10 mg Frisium (Extemporaneously compounded oral liquid preparations)

CLONAZEPAM Oral drops 2.5 mg per Rivotril ml

DIAZEPAM

Tab 2 mg Arrow-Diazepam Tab 5 mg Arrow-Diazepam (Extemporaneously compounded oral liquid preparations)

ETHOSUXIMIDE Oral liq 250 mg per 5 ml Zarontin

LORAZEPAM

Tab 1 mg Ativan Tab 2.5 mg Ativan (Extemporaneously compounded oral liquid preparations)

LORMETAZEPAM

Tab 1 mg Noctamid (Extemporaneously compounded oral liquid preparations)

METHADONE HYDROCHLORIDE

Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Biodone Biodone Forte Biodone Extra Forte

MORPHINE HYDROCHLORIDE

Oral liq 1 mg per mlRA-MorphOral liq 2 mg per mlRA-MorphOral liq 5 mg per mlRA-MorphOral liq 10 mg per mlRA-Morph

NITRAZEPAM

Tab 5 mg Nitrados (Extemporaneously compounded oral liquid preparations)

OXAZEPAM

Tab 10 mg Ox-Pam Tab 15 mg Ox-Pam (Extemporaneously compounded oral liguid preparations)

OXYCODONE HYDROCHLORIDE Oral lig 5 mg per 5 ml OxyNorm

Oral lig 5 mg per 5 mil Oxy

PARACETAMOL

Oral liq 120 mg per 5 ml Paracare Ethics Paracetamol Oral liq 250 mg per 5 ml Paracare Double Strength PHENYTOIN SODIUM Oral liq 30 mg per 5 ml Dilantin

SODIUM VALPROATE Oral liq 200 mg per 5 ml

Epilim S/F Liquid Epilim Syrup

TEMAZEPAM Tab 10 mg Normison (Extemporaneously compounded oral liquid preparations)

TRIAZOLAM

Tab 125 mcg Hypam Tab 250 mcg Hypam (Extemporaneously compounded oral liquid preparations)

RESPIRATORY SYSTEM AND ALLERGIES

CETIRIZINE HYDROCHLORIDE Oral liq 1 mg per ml Cetirizine - AFT

CHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Histafen

DEXTROCHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Polaramine

PROMETHAZINE HYDROCHLORIDE Oral liq 5 mg per 5 ml Allersoothe SALBUTAMOL Oral liq 400 mcg per ml Ventolin

THEOPHYLLINE Oral liq 80 mg per 15 ml Nuelin

TRIMEPRAZINE TARTRATE Oral liq 30 mg per 5 ml Vallergan Forte

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

CODEINE PHOSPHATE Powder Douglas (Extemporaneously compounded oral liquid preparations)

METHADONE HYDROCHLORIDE Powder AFT (Extemporaneously compounded oral liquid preparations)

PHENOBARBITONE SODIUM Powder MidWest (Extemporaneously compounded oral liquid preparations)

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
Vaccinations			
ADULT DIPHTHERIA AND TETANUS VACCINE – [Xpharm] Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml .	0.00		ADT Booster ADT Booster
 Any of the following: 1) For vaccination of patients aged 45 and 65 years old; or 2) For vaccination of previously unimmunised or partially in 3) For revaccination following immunosuppression; or 4) For boosting of patients with tetanus-prone wounds; or 5) For use in testing for primary immunodeficiency diseas paediatrician. 		dation of an inte	rnal medicine physician or
Note: Please refer to the Immunisation Handbook for appropriate	schedule for catch up	programmes.	
 BACILLUS CALMETTE-GUERIN VACCINE – [Xpharm] For infants at increased risk of tuberculosis. Increased risk is 1) living in a house or family with a person with current or p 2) having one or more household members or carers who w to 40 per 100,000 for 6 months or longer; or 	bast history of TB; or vithin the last 5 years liv	-	
 during their first 5 years will be living 3 months or longer Note a list of countries with high rates of TB are available at www.h Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin) 	ealth.govt.nz/tuberculo		
Danish strain 1331, live attenuated, vial with diluent	·	• • -	BCG Vaccine BCG Vaccine
BCG Vaccine to be Sole Supply on 1 October 2014			
DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE - [Xpharr	n]		
 Funded for any of the following criteria: 1) A single vaccine for pregnant woman between gestational 2) A course of up to four vaccines is funded for children from or 	n age 7 to 17 years inclu	usive to complete	e full primary immunisation;
 A course of up to four vaccines is funded for children from suppression. 	age 7 to 17 years incl	lusive for reimmu	unisation following immuno-
Notes: Tdap is not registered for patients aged less than 10 ye schedule for catch up programmes. Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg per- tussis filamentous haemagluttinin and 2.5 mcg pertactir	-	ne Immunisation	Handbook for appropriate
in 0.5 ml syringe	0.00	1 🖌 E	Boostrix

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully idised	Brand or Generic Manufacturer
DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE	– [Xpharm]			
Funded for any of the following:				
 A single dose for children up to the age of 7 who have A course of four vaccines is funded for catch up progra immunisation; or 				s) to complete full primary
 An additional four doses (as appropriate) are funded for or post splenectomy; pre- or post solid organ transplat or 				
4) Five doses will be funded for children requiring solid or				
Note: Please refer to the Immunisation Handbook for appropria		o programm	ies.	
Inj 30 IU diphtheria toxoid with 40 IU tetanus toxo				
25 mcg pertussis toxoid, 25 mcg pertussis filamento haemagluttinin, 8 mcg pertactin and 80 D-antigen un				
poliomyelitis virus in 0.5ml syringe		1	🖌 in	fanrix IPV
		10		fanrix IPV
DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B A				E B VACCINE - [Xnharm]
Funded for patients meeting any of the following criteria:				
 Up to four doses for children up to the age of 10 for prin 	marv immunisation: or			
2) Up to four doses (as appropriate) for children are fund		n for patien	ts post	HSCT, or chemotherapy
pre- or post splenectomy; renal dialysis and other seve	erely immunosuppressiv	e regimens	; or	
Up to five doses for children up to the age of 10 receiving				
Note: A course of up-to four vaccines is funded for catch up		`	0	, , ,
primary immunisation. Please refer to the Immunisation Handbo		schedule fo	r catch	up programmes.
Inj 30IU diphtheriatoxoid with 40IU tetanustoxoid, 25mcg pe				
tussistoxoid, 25mcg pertussisfilamentoushaemagluttin 8 mcgpertactin, 80 D-AgUpoliovirus, 10mcghepatitis				
surfaceantigen in 0.5ml syringe	0.00	1	🖌 In	fanrix-hexa
		10		fanrix-hexa
HAEMOPHILUS INFLUENZAE TYPE B VACCINE - [Xpharm]				
Inj 10 mcg vial with diluent syringe	0.00	1		ct-HIB
			•	
One dose for patients meeting any of the following:				
One dose for patients meeting any of the following: 1) For primary vaccination in children; or				
 For primary vaccination in children; or For revaccination of children following immunosuppres 				
1) For primary vaccination in children; or				
 For primary vaccination in children; or For revaccination of children following immunosuppres For children aged 0-18 years with functional asplenia; of For patients pre- and post-splenectomy; or 	or			
 For primary vaccination in children; or For revaccination of children following immunosuppres: For children aged 0-18 years with functional asplenia; of For patients pre- and post-splenectomy; or For use in testing for primary immunodeficiency disea paediatrician. 	or	dation of a	n inter	nal medicine physician or
 For primary vaccination in children; or For revaccination of children following immunosuppres: For children aged 0-18 years with functional asplenia; of For patients pre- and post-splenectomy; or For use in testing for primary immunodeficiency disea paediatrician. HEPATITIS A VACCINE – [Xpharm] 	or	dation of a	n inter	nal medicine physician o
 For primary vaccination in children; or For revaccination of children following immunosuppres For children aged 0-18 years with functional asplenia; of For patients pre- and post-splenectomy; or For use in testing for primary immunodeficiency disea paediatrician. HEPATITIS A VACCINE – [Xpharm] Funded for patients meeting any of the following criteria: 	or	dation of a	n inter	nal medicine physician o
 For primary vaccination in children; or For revaccination of children following immunosuppres For children aged 0-18 years with functional asplenia; of For patients pre- and post-splenectomy; or For use in testing for primary immunodeficiency disea paediatrician. HEPATITIS A VACCINE - [Xpharm] Funded for patients meeting any of the following criteria: Two vaccinations for use in transplant patients; or 	or ases, on the recommer	dation of a	n inter	nal medicine physician oi
 For primary vaccination in children; or For revaccination of children following immunosuppres: For children aged 0-18 years with functional asplenia; of For patients pre- and post-splenectomy; or For use in testing for primary immunodeficiency disea paediatrician. HEPATITIS A VACCINE – [Xpharm] Funded for patients meeting any of the following criteria: Two vaccinations for use in children with chronic liver disea 	or ases, on the recommer lisease; or	dation of a	n inter	nal medicine physician o
 For primary vaccination in children; or For revaccination of children following immunosuppres For children aged 0-18 years with functional asplenia; of For patients pre- and post-splenectomy; or For use in testing for primary immunodeficiency disea paediatrician. HEPATITIS A VACCINE – [Xpharm] Funded for patients meeting any of the following criteria: Two vaccinations for use in transplant patients; or Two vaccinations for use in children with chronic liver d One dose of vaccine for close contacts of known hepatient 	or ases, on the recommer lisease; or titis A cases; or			nal medicine physician o
 For primary vaccination in children; or For revaccination of children following immunosuppres For children aged 0-18 years with functional asplenia; of For patients pre- and post-splenectomy; or For use in testing for primary immunodeficiency disea paediatrician. HEPATITIS A VACCINE – [Xpharm] Funded for patients meeting any of the following criteria: Two vaccinations for use in transplant patients; or Two vaccinations for use in children with chronic liver d One dose of vaccine for close contacts of known hepat One dose for any of the following on the recommendat 	or ases, on the recommer lisease; or litits A cases; or ion of a local medical of			nal medicine physician or
 For primary vaccination in children; or For revaccination of children following immunosuppres For children aged 0-18 years with functional asplenia; of For patients pre- and post-splenectomy; or For use in testing for primary immunodeficiency disea paediatrician. HEPATITIS A VACCINE - [Xpharm] Funded for patients meeting any of the following criteria: Two vaccinations for use in transplant patients; or Two vaccinations for use in children with chronic liver d One dose of vaccine for close contacts of known hepatiant 	or ases, on the recommer lisease; or litis A cases; or ion of a local medical of n Ashburton district; or			nal medicine physician o
 For primary vaccination in children; or For revaccination of children following immunosuppres For children aged 0-18 years with functional asplenia; of For patients pre- and post-splenectomy; or For use in testing for primary immunodeficiency disea paediatrician. HEPATITIS A VACCINE – [Xpharm] Funded for patients meeting any of the following criteria: Two vaccinations for use in transplant patients; or Two vaccinations for use in children with chronic liver d One dose of vaccine for close contacts of known hepat One dose for any of the following on the recommendat Children, aged 1-4 years inclusive who reside i 	or ases, on the recommer lisease; or litis A cases; or ion of a local medical of n Ashburton district; or Ashburton; or	ficer of hea	lth:	nal medicine physician o
 For primary vaccination in children; or For revaccination of children following immunosuppres: For children aged 0-18 years with functional asplenia; of For patients pre- and post-splenectomy; or For use in testing for primary immunodeficiency disea paediatrician. HEPATITIS A VACCINE – [Xpharm] Funded for patients meeting any of the following criteria: Two vaccinations for use in children with chronic liver d One dose of vaccine for close contacts of known hepat One dose for any of the following on the recommendat a) Children, aged 1-9 years inclusive, who attend c) Children, aged 1-9 years, who attend a 	or ases, on the recommer lisease; or litis A cases; or ion of a local medical of n Ashburton district; or Ashburton; or a preschool or school in	ficer of hea	lth: n; or	
 For primary vaccination in children; or For revaccination of children following immunosuppres: For children aged 0-18 years with functional asplenia; of For patients pre- and post-splenectomy; or For use in testing for primary immunodeficiency disea paediatrician. HEPATITIS A VACCINE – [Xpharm] Funded for patients meeting any of the following criteria: Two vaccinations for use in transplant patients; or Two vaccinations for use in children with chronic liver d One dose of vaccine for close contacts of known hepatient Children, aged 1-9 years inclusive, residing in A Children, aged 1-9 years inclusive, who attend a for children in Ashburton. 	ases, on the recommen lisease; or litis A cases; or ion of a local medical of n Ashburton district; or Ashburton; or a preschool or school in a school with children ag	ficer of hea h Ashburtor ged 9 years	lth: h; or s old or	less, in Ashburton funded
 For primary vaccination in children; or For revaccination of children following immunosuppres: For children aged 0-18 years with functional asplenia; of For patients pre- and post-splenectomy; or For use in testing for primary immunodeficiency disea paediatrician. HEPATITIS A VACCINE – [Xpharm] Funded for patients meeting any of the following criteria: Two vaccinations for use in children with chronic liver d One dose of vaccine for close contacts of known hepat One dose for any of the following on the recommendat a) Children, aged 1-9 years inclusive, who attend c) Children, aged 1-9 years, who attend c) Children, aged older than 9 years, who attend a 	ases, on the recommer lisease; or litis A cases; or ion of a local medical of n Ashburton district; or Ashburton; or a preschool or school in a school with children as 0.00	ficer of hea	lith: old or	less, in Ashburton funded

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
IEPATITIS B RECOMBINANT VACCINE – [Xpharm] Inj 5 mcg per 0.5 ml vial Funded for any of the following criteria:	0.00	1	✔ <u>н</u>	<u>BvaxPRO</u>
 for household or sexual contacts of known hepatitis B ca for children born to mothers who are hepatitis B surface for children up to the age of 18 years inclusive who are additional vaccination; or for HIV positive patients; or for hepatitis C positive patients; or for patients following immunosuppression; or for transplant patients. 	antigen (HBsAg) posit			sitive serology and requ
Inj 10 mcg per 1 ml vial Funded for any of the following criteria: 1) for household or sexual contacts of known hepatitis B ca		1	✓ <u>H</u>	<u>BvaxPRO</u>
 for children born to mothers who are hepatitis B surface for children up to the age of 18 years inclusive who are additional vaccination; or for HIV positive patients; or for hepatitis C positive patients; or for patients following immunosuppression; or for transplant patients. 				sitive serology and requi
Inj 40 mcg per 1 ml vial Funded for any of the following criteria: 1) for dialysis patients; or 2) for liver or kidney transplant patient.	0.00	1	✓ <u>H</u>	<u>BvaxPRO</u>
 IUMAN PAPILLOMAVIRUS (6, 11, 16 AND 18) VACCINE [HPV] Maximum of three doses for patient meeting any of the follow 1) Females aged under 20 years old; or 2) Patients aged under 26 years old with confirmed HIV inf 	ving criteria:			
 For use in transplant patients. Inj 120 mcg in 0.5 ml syringe 	0.00	1 10		<u>ardasil</u> ardasil
NFLUENZA VACCINE – [Xpharm] Inj 45 mcg in 0.5 ml syringe	90.00	10		luarix fluvac
 A) is available each year for patients who meet the followin a) all people 65 years of age and over; b) people under 65 years of age who: i) have any of the following cardiovascular d a) ischaemic heart disease, b) connestive heart disease 		IARM	AC:	

- b) congestive heart disease,
- c) rheumatic heart disease,
- d) congenital heart disease, or
- e) cerebo-vascular disease;
- ii) have either of the following chronic respiratory disease:
 - a) asthma, if on a regular preventative therapy, or
 - b) other chronic respiratory disease with impaired lung function;
- iii) have diabetes;

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	ubsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- iv) have chronic renal disease;
- v) have any cancer, excluding basal and squamous skin cancers if not invasive;
- vi) have any of the following other conditions:
 - a) autoimmune disease,
 - b) immune suppression,
 - c) HIV,
 - d) transplant recipients,
 - e) neuromuscular and CNS diseases,
 - f) haemoglobinopathies, or
 - g) are children on long term aspirin, or
- vii) are pregnant
- c) people under 18 years of age living within the boundaries of the Canterbury District Health Board.
- children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness;

Unless meeting the criteria set out above, the following conditions are excluded from funding:

- a) asthma not requiring regular preventative therapy,
- b) hypertension and/or dyslipidaemia without evidence of end-organ disease,
- B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.
- C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor.
- D) Stock of the seasonal influenza vaccine is typically available from February until late July with suppliers being required to ensure supply until at least 30 June. Exact start and end dates for each season will be notified each year.

MEASLES, MUMPS AND RUBELLA VACCINE - [Xpharm]

A maximum of two doses for any patient meeting the following criteria:

- 1) For primary vaccination in children; or
- 2) For revaccination following immunosuppression; or
- 3) For any individual susceptible to measles, mumps or rubella.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

Inj 1000 TCID50 measles, 12500 TCID50 mumps and 1000

TCID	50 rubella vial with diluent 0.5 ml vial	0.00	1	✓ <u>M-M-R II</u>
			10	✓ <u>M-M-R II</u>

MENINGOCOCCAL A, C, Y AND W-135 VACCINE - [Xpharm]

For patients pre- and post-splenectomy or children aged 0-16 years with functional asplenia. For organisation and community based outbreaks.

(Menomune Inj 0.5 ml to be delisted 1 October 2014)

	Subsidy (Manufacturer's Price) \$	Sub Per	Fully sidised	Brand or Generic Manufacturer
MENINGOCOCCAL (GROUPS A, C, Y AND W-135) CONGUGAT	E VACCINE – [Xph	arml		
Any of the following:	L F			
1) Up to three doses for patients pre- and post splenectomy				
2) One dose every five years for patients with HIV, comple	ement deficiency (ac	quired or	inherite	d), functional or anatomic
asplenia or pre or post solid organ transplant; or				
 3) One dose for close contacts of meningococcal cases; or 4) A maximum of two doses for bone marrow transplant pat 	ionto: or			
5) A maximum of two doses for patients following immunosi				
Note: children under seven years of age require a second dose th		rst and the	n five v	earlv.
*Immunosuppression due to steroid or other immunosuppressive				
Inj 4 mcg of each meningococcal polysaccharide conjugated				
to a total of approximately 48 mcg of diphtheria toxoid				
carrier per 0.5 ml vial	0.00	1	✓ <u>N</u>	lenactra
MENINGOCOCCAL C CONGUGATED VACCINE - [Xpharm]				
Any of the following:	and for nationto with	functions		tamia contania, ar
 Up to three doses for patients pre- and post splenectomy One dose every five years for patients with HIV, complete 				
asplenia or pre or post solid organ transplant; or	chieffer denoicincy (de	quireu oi	minerite	
 One dose for close contacts of meningococcal cases; or 				
4) A maximum of two doses for bone marrow transplant pat				
5) A maximum of two doses for patients following immunosu				
Note: children under seven years of age require a second dose th *Immunosuppression due to steroid or other immunosuppressive				
Inj 10 mcg in 0.5 ml syringe		1		eisvac-C
		10		eisvac-C
PNEUMOCOCCAL (PCV13) VACCINE - [Xpharm]				
Any of the following:				
1) A primary course of four doses for previously unvaccinate				
2) Up to three doses as appropriate to complete the primary	course of immunisati	on for indiv	riduals u	under the age of 59 months
who have received one to three doses of PCV10; or			N/10. o.	
3) One dose is funded for high risk children who have previo4) Up to an additional four doses (as appropriate) are fund				
HSCT, or chemotherapy; pre- or post splenectomy; funct				
and other severely immunosuppressive regimens up to th				···· / ··· / ···· / ··· / ··· / ···· / ··· / ···· / ··· / ···· / ···· / ···· / ···· / ····· / ···· / ···· / ···· / ···· / ······· / ····· / ········
5) For use in testing for primary immunodeficiency disease	es, on the recommer	ndation of	an inter	rnal medicine physician or
paediatrician.	ata aabadula far aata	h un nrogi		
Note: please refer to the Immunisation Handbook for the appropri Inj 30.8 mcg in 0.5 ml syringe		1 up progr		revenar 13
		10		revenar 13
Prevenar 13 to be Sole Supply on 1 October 2014				
PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE - [X	pharm]			
Either of the following:				
 Up to three doses for patients pre- or post-splenectomy c 		lenia; or		
 Up to two doses are funded for high risk children to the a Inj 575 mcg in 0.5 ml vial (25 mcg of each 23 pneumococcal 				
serotype)		1	V P	neumovax 23
PNEUMOCOCCAL VACCINE – [Xpharm]		•	- 1	
For children aged 6 weeks, 3 months, and 5 months, and 15	months old			
Inj 0.5 ml		1	🗸 S	ynflorix
(Synflorix Inj 0.5 ml to be delisted 1 October 2014)				

	Subsidy (Manufacturer's Price) \$	Sul Per	Fully bsidised	Brand or Generic Manufacturer
POLIOMYELITIS VACCINE – [Xpharm]				
Up to three doses for patients meeting either of the following 1) For partially vaccinated or previously unvaccinated indiv 2) For revaccination following immunosuppression. Note: Please refer to the Immunisation Handbook for appropriate Inj 80D antigen units in 0.5 ml syringe	iduals; or e schedule for catch-u	program	nmes.	201
 ROTAVIRUS LIVE REASSORTANT ORAL VACCINE – [Xpharm Maximum of three doses for patients meeting the following: 1) first dose to be administered in infants aged under 15 w 2) no vaccination being administered to children aged 8 mc Oral susp G1, G2, G3, G4, P1(8)11.5 million CCID50 unit per 2 ml, tube] eeks of age; and onths or over. s	10	_	otaTeq
 VARICELLA VACCINE [CHICKEN POX VACCINE] – [Xpharm] Maximum of two doses for any of the following: For non-immune patients: with chronic liver disease who may in future be of b) with deteriorating renal function before transplant prior to solid organ transplant; or prior to solid organ transplant; or prior to any elective immunosuppression*. For patients at least 2 years after bone marrow transplant For patients at least 6 months after completion of chemod For patients with inborn errors of metabolism at risk of m. For household contacts of paediatric patients who are im compromise where the household contact has no clinica 	tation; or ntation, on advice of th otherapy, on advice of oderate immunosuppre ajor metabolic decomp munocompromised, o	neir specia their speci ession on pensation	alist. cialist. advice c , with no	clinical history of varicella.
 For household contacts of adult patients who have no mised, or undergoing a procedure leading to immune or misel. 	clinical history of vario			

varicella. * immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

initialioouppiooolori ado to otoroia or otri	initial couppiecente anotapy made be for	a doutinone ponoa or groator a
Inj 2000 PFU vial with diluent	0.00	1 Varilrix

- Symbols -

3TC115
50X 3.0 Reservoir
- A -
A-Lices
A-Scabies
Abacavir sulphate114
Abacavir sulphate with
lamivudine
Abilify144
ABM Hydroxocobalamin41
Acarbose
Acarbose
Accu-Chek Ketur-Test
Accu-Chek Performa
Accuretic 10
Accuretic 20
Acetadote207
Acetazolamide204
Acetic acid with 1, 2- propanediol
diacetate and
benzethonium202
Acetic acid with hydroxyquinoline
and ricinoleic acid81
Acetylcysteine207
Aci-Jel81
Aciclovir
Infection109
Sensory202
Acidex24
Acipimox60
Acitretin74
Aclasta125
Aclin121
Act-HIB247
Actinomycin D166
Actrapid28
Actrapid Penfill
Acupan131
Adalat 1058
Adalat Oros58
Adalimumab183
Adapalene66
Adefin XL58
Adefovir dipivoxil107
Adenuric128
ADR Cartridge 1.8
ADR Cartridge 3.0
Adrenaline
Adriamycin167
ADT Booster
Adult diphtheria and tetanus

vaccine	
Advantan	69
Advate	
AFT-Pyrazinamide	106
Agents Affecting the	
Renin-Angiotensin System	53
Agents for Parkinsonism and	
Related Disorders	129
Agents Used in the Treatment of	
Poisonings	
Agrylin	165
Alanase	200
Albay	195
Albendazole	
Albustix	83
Aldara	
Alendronate sodium	123
Alendronate sodium with	
cholecalciferol	123
Alfacalcidol	
Alginic acid	
Alitraq	
Alkeran	161
Allersoothe	
Allopurinol Alpha Adrenoceptor Blockers	127
Alpha Adrenoceptor Blockers	53
Alpha-Keri Lotion	71
Alphamox	98
Alprazolam	
Alu-Tab	24
Aluminium hydroxide	24
Amantadine hydrochloride	
Ambrisentan	64
Amiloride hydrochloride	59
Amiloride hydrochloride with	
furosemide	60
furosemide Amiloride hydrochloride with	
nydrochiorothiazide	60
Aminophylline	200
Amiodarone hydrochloride	55
Amisulpride	
Amitrip	135
Amitriptyline	135
Amlodipine	
Amorolfine	
Amoxicillin	98
Amoxicillin Actavis	98
Amoxicillin with clavulanic	
acid	
Amphotericin B	
Amsacrine	
Amsidine	165

Amyl nitrite6	
Anaesthetics13	1
Anagrelide hydrochloride16	5
Analgesics13	1
Anastrozole17	7
Andriol Testocaps8	5
Androderm8	5
Animas Battery Cap3	2
Animas Cartridge	6
Animas Vibe	2
Antabuse15	9
Antacids and Antiflatulants2	4
Anten13	
Anthelmintics9	6
Antiacne Preparations6	6
Antiallergy Preparations19	5
Antianaemics4	4
Antiandrogen Oral	
Contraceptives	1
Antiarrhythmics5	
Antibacterials9	
Antibacterials Topical6	
Anticholinesterases12	0
Antidepressants13	5
Antidiarrhoeals2	
Antiepilepsy Drugs13	
Antifibrinolytics Haemostatics	0
Antifibrinolytics, Haemostatics	
Antifibrinolytics, Haemostatics and Local Sclerosants	5
Antifibrinolytics, Haemostatics and Local Sclerosants	5 2
Antifibrinolytics, Haemostatics and Local Sclerosants4 Antifungals10 Antifungals Topical6	5 2 7
Antifibrinolytics, Haemostatics and Local Sclerosants	5 2 7 5
Antifibrinolytics, Haemostatics and Local Sclerosants	5 2 7 5 5
Antifibrinolytics, Haemostatics and Local Sclerosants	527555
Antifibrinolytics, Haemostatics and Local Sclerosants	527552
Antifibrinolytics, Haemostatics and Local Sclerosants	52755523
Antifibrinolytics, Haemostatics and Local Sclerosants	52755523
Antifibrinolytics, Haemostatics and Local Sclerosants	527555232
Antifibrinolytics, Haemostatics and Local Sclerosants 4 Antifungals 10 Antifungals Topical 6 Antihistamines 19 Antihypotensives 5 Antimalarials 10 Antimigraine Preparations 14 Antinausea and Vertigo 4 Agents 14 Antiparasitics 10	52755523 25
Antifibrinolytics, Haemostatics and Local Sclerosants 4 Antifungals 10 Antifungals Topical 6 Antihistamines 19 Antihypotensives 5 Antimalarials 10 Antimigraine Preparations 14 Antinausea and Vertigo 4 Agents 14 Antiparasitics 10	52755523 258
Antifibrinolytics, Haemostatics and Local Sclerosants 4 Antifungals 10 Antifungals Topical 6 Antihistamines 19 Antihypotensives 5 Antimalarials 10 Antimigraine Preparations 14 Antinausea and Vertigo Agents 14 Antiparasitics 10 Antiprursitic Preparations 14 Antiparasitics 10 Antiprursitic Preparations 14 Antiparasitics 10 Antiproversitic Preparations 14 Antiparasitics 10 Antiproversitic Preparations 14	52755523 2584
Antifibrinolytics, Haemostatics and Local Sclerosants 4 Antifungals 10 Antifungals Topical 6 Antihistamines 19 Antihypotensives 5 Antimalarials 10 Antimigraine Preparations 14 Antinaus 14 Antinausea and Vertigo 4 Antiparasitics 10 Antipractics 10 Antiprevitic Preparations 6 Antipsychotics 14 Antiprevitic Preparations 10 Antiprevitic Science 10 Antiprevitic Preparations 6 Antiprevitic Preparations 14 Antiprevitic Science 14 Antiprevitic Preparations 14 Antipologies 14 Antipervitic Preparations 14	52755523 2584
Antifibrinolytics, Haemostatics and Local Sclerosants 4 Antifungals 10 Antifungals Topical 6 Antihistamines 19 Antihypotensives 5 Antimalarials 10 Antimugraine Preparations 14 Antinaus 14 Antinausea and Vertigo Agents Agents 14 Antiparasitics 10 Antipsychotics 14 Antipertovirals 14	52755523 25843
Antifibrinolytics, Haemostatics and Local Sclerosants 4 Antifungals 10 Antifungals Topical 6 Antihistamines 19 Antihypotensives 5 Antimalarials 10 Antimigraine Preparations 14 Antinausea and Vertigo 4 Antiparasitics 10 Antipruvitic Preparations 6 Antipsychotics 10 Antiretrovirals 11 Antiretrovirals 11	52755523 25843 6
Antifibrinolytics, Haemostatics and Local Sclerosants 4 Antifungals 10 Antifungals Topical 6 Antihistamines 19 Antihypotensives 5 Antimalarials 10 Antimigraine Preparations 14 Antinaus 14 Antiparasitics 10 Antipravitic Preparations 14 Antiparasitics 10 Antiprovirals 14 Antiretrovirals 11 Antiretrovirals 11 Antiretrovirals 11 Antiretrovirals 11 Antiretrovirals 11 Antiretrovirals 11 Antiretrovirals 12	52755523 25843 6
Antifibrinolytics, Haemostatics and Local Sclerosants 4 Antifungals 10 Antifungals Topical 6 Antihistamines 19 Antihypotensives 5 Antimalarials 10 Antimigraine Preparations 14 Antinaus 14 Antinausea and Vertigo 4 Agents 14 Antiparasitics 10 Antipruritic Preparations 6 Antipsychotics 14 Antiretrovirals 11 Antiretrovirals 11 Antiretrovirals 11 Antirepaires 11 Antirepaires 11 Antiretrovirals 12 Antispasmodics and Other 12	52755523 25843 6
Antifibrinolytics, Haemostatics and Local Sclerosants 4 Antifungals 10 Antifungals Topical 6 Antifungals Topical 6 Antihypotensives 5 Antinalarials 10 Antinaus 14 Antinausea and Vertigo 14 Antiparasitics 10 Antipruritic Preparations 6 Antipsychotics 14 Antiretrovirals 10 Antiretrovirals 11 Antiretrovirals 11 Antiretrovirals 11 Antiretrovirals 12 Antipaysmodics and Other 12 Antispasmodics and Other Actispasmodics and Other	52755523 25843 61
Antifibrinolytics, Haemostatics and Local Sclerosants 4 Antifungals 10 Antifungals Topical 6 Antifungals Topical 6 Antifungals Topical 6 Antifungals Topical 19 Antifypotensives 5 Antimalarials 10 Antinaus 14 Antinausea and Vertigo 14 Antiparasitics 10 Antiparasitics 10 Antipychotics 14 Antiperrations 6 Antipychotics 14 Antiperrations 6 Antipychotics 14 Antiperrations 6 Antipsychotics 14 Antiretrovirals 11 Antiretrovirals 11 Antiretrovirals 11 Antiretrovirals 12 Antipasamodics and Other Agents Altering Gut Motility 2	52755523 25843 61 6
Antifibrinolytics, Haemostatics and Local Sclerosants 4 Antifungals 10 Antifungals Topical 6 Antihistamines 19 Antihypotensives 5 Antimalarials 10 Antinausea and Vertigo 14 Antiparasitics 10 Antipuritic Preparations 14 Antiparasitics 10 Antipruritic Preparations 6 Antipurstics 10 Antipurstics 10 Antipurstics 14 Antiparasitics 10 Antipurstic Preparations 6 Antipurstic Preparations 11 Antiretrovirals 11 Antiretrovirals 11 Antiretrovirals 12 Antispasmodics and Other 12 Agents Altering Gut Motility 2 Antithrombotic Agents 4	52755523 25843 61 6
Antifibrinolytics, Haemostatics and Local Sclerosants 4 Antifungals 10 Antifungals Topical 6 Antihistamines 19 Antihypotensives 5 Antimalarials 10 Antingurane Preparations 14 Antinausea and Vertigo 4 Antiparasitics 10 Antipruritic Preparations 6 Antipychotics 14 Antiretrovirals 10 Antiretrovirals 11 Antiretrovirals 11 Antirepassondics and Other 12 Antipass Altering Gut Motility 2 Antithrombotic Agents 4	52755523 25843 61 67
Antifibrinolytics, Haemostatics and Local Sclerosants 4 Antifungals 10 Antifungals Topical 6 Antihistamines 19 Antihypotensives 5 Antimalarials 10 Antinausea and Vertigo 14 Antiparasitics 10 Antipuritic Preparations 14 Antiparasitics 10 Antipruritic Preparations 6 Antipurstics 10 Antipurstics 10 Antipurstics 14 Antiparasitics 10 Antipurstic Preparations 6 Antipurstic Preparations 11 Antiretrovirals 11 Antiretrovirals 11 Antiretrovirals 12 Antispasmodics and Other 12 Agents Altering Gut Motility 2 Antithrombotic Agents 4	52755523 25843 61 67 3

Antileprotics	105
Antiulcerants	
Antivirals	
Anxiolytics	
Anzatax	
Apidra	
Apidra SoloStar	29
Apo-Allopurinol	
Apo-Amiloride	59
Apo-Amlodipine	57
Apo-Amoxi	
Apo-Azithromycin	
Apo-Bromocriptine	120
Apo-Ciclopirox	
Аро-Сісіорігох	07
Cilazapril/Hydrochlorothiazide .	E 4
Cilazapril/Hydrochiorothiazide .	
Apo-Cimetidine	26
Apo-Clarithromycin	
Alimentary	
Infection	
Apo-Clomipramine	
Apo-Diclo	.120
Apo-Diltiazem CD	
Apo-Doxazosin	
Apo-Folic Acid	45
Apo-Gliclazide	
Apo-Megestrol	.175
APO-Mirtazapine	.137
Apo-Moclobemide	
Apo-Nadolol	57
Apo-Nicotinic Acid	60
Apo-Oxybutynin	82
Apo-Perindopril	53
Apo-Pindolol	57
Apo-Prazo	53
Apo-Prazosin	53
Apo-Prednisone	85
Apo-Prednisone S29	85
Apo-Primidone	.140
Apo-Propranolol	
Apo-Pyridoxine	
Apo-Risperidone	.148
Apo-Ropinirole	.129
Apo-Selegiline	.130
Apo-Selegiline S29	130
Apo-Thiamine	
Apo-Timol	
Apo-Zopiclone	
Apomine	
Apomorphine hydrochloride	120
Aprepitant	
Apresoline	62
Aquasun 30+	
nyuuouii ovt	

Aqueous cream	71
Aratac	
Arava	.121
Aremed	
Arimidex	
Aripiprazole	.144
Aristocort	70
Aromasin	.177
Arrow - Clopid	47
Arrow Amitriptyline	.135
Arrow-Bendrofluazide	60
Arrow-Brimonidine	.204
Arrow-Calcium	42
Arrow-Citalopram	.136
Arrow-Diazepam	.151
Arrow-Doxorubicin	.167
Arrow-Etidronate	.123
Arrow-Fluoxetine	136
Arrow-Gabapentin	138
Arrow-Lamotrigine	140
Arrow-Lisinopril	53
Arrow-Losartan &	
Hydrochlorothiazide	55
Arrow-Meloxicam	101
Arrow-Morphine LA	100
	.133
Arrow-Nifedipine XR	
Arrow-Norfloxacin	.119
Arrow-Ornidazole	.105
Arrow-Quinapril 10	54
Arrow-Quinapril 20	54
Arrow-Quinapril 5	54
Arrow-Ranitidine	26
Arrow-Roxithromycin	98
Arrow-Sertraline	.136
Arrow-Simva 10mg	61
Arrow-Simva 20mg	61
Arrow-Simva 40mg	61
Arrow-Simva 80mg	61
Arrow-Sumatriptan	.142
Arrow-Timolol	.204
Arrow-Tolterodine	83
Arrow-Topiramate	.141
Arrow-Tramadol	.135
Arrow-Venlafaxine XR	137
Arsenic trioxide	
Asacol	
Asamax	20
Ascorbic acid	∠J //1
Aspon 200	121
Aspec 300 Aspen Adrenaline	. 101 69
Aspen Adrenaline Aspirin	03
Aspirin Blood	47
Nervous	.131

Asthalin198	
Atazanavir sulphate115	
Atenolol56	
Atenolol AFT56	
ATGAM183	
Ativan151	
Atomoxetine154	
Atorvastatin61	
Atripla115	
Atropine sulphate	
Cardiovascular55	
Sensory205	
Atropt	
Atrovent198	
Augmentin98	
Auranofin121	
Ava 20 ED79	
Ava 30 ED79	
Avanza137	
Avelox101	
Avomine144	
Avonex153	
Avonex Pen153	
Azacitidine162	
Azamun177	
Azathioprine177	
Azithromycin97	
Azol	
Azopt204	
AZT115	
-B-	
B-D Micro-Fine31	
B-D Ultra Fine31	
B-D Ultra Fine II31	
Bacillus Calmette-Guerin (BCG)	
vaccine	
Bacillus Calmette-Guerin	
vaccine246	
Baclofen128	
Bactroban67	
Bakels Gluten Free Health Bread	
Mix	
Baraclude107	
Barrier Creams and Emollients71	
BCG Vaccine246 Beclazone 100196	
Beclazone 100196 Beclazone 250196	
Beclazone 250196 Beclazone 50	
Beclomethasone	
dipropionate 196, 200	
Ree venom allerav	
Bee venom allergy treatment	

Bendroflumethiazide
[Bendrofluazide] 60
BeneFIX46
Benhex72
Benzathine benzylpenicillin
Benzbromaron AL 100127
Benzbromarone127
Benzoin
Benztrop130
Benztropine mesylate
Benzydamine hydrochloride40
Benzylpenicillin sodium (penicillin
G)
Beta Adrenoceptor Blockers
Beta Cream
Beta Ointment
Beta Scalp
Beta-Adrenoceptor Agonists
Betadine
Betadine Skin Prep72
Betaferon153
Betagan203
Betahistine dihydrochloride143
Betamethasone dipropionate69
Betamethasone dipropionate
with calcipotriol
Betamethasone sodium
phosphate with
betamethasone acetate
Betamethasone valerate
Betamethasone valerate with
clioquinol70
Betamethasone valerate with
Detainethasone valerate with
fusidic acid
fusidic acid70
fusidic acid
fusidic acid 70 Betaxolol 203 Betnovate 69 Betnovate-C 70 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic S 203 Bezafibrate 60 Bezalip 60 Bezalip Retard 60
fusidic acid 70 Betaxolol 203 Betnovate 69 Betnovate-C 70 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic S 203 Bezafibrate 60 Bezalip 60 Bezalip Retard 60 Bicalaccord 175
fusidic acid 70 Betaxolol 203 Betnovate 69 Betnovate-C 70 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Bezaliphrate 60 Bezalip 60 Bicalaccord 175 Bicalutamide 175
fusidic acid 70 Betaxolol 203 Betnovate 69 Betnovate-C 70 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Bezaliphrate 60 Bezalip 60 Bezalip Retard 60 Bicalaccord 175 Bicalutamide 175 Bicillin LA 99
fusidic acid 70 Betaxolol 203 Betnovate 69 Betnovate-C 70 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Bezalip 60 Bezalip Retard 60 Bicalaccord 175 Bicalutamide 175 Bicillin LA 99 BiCNU 161
fusidic acid 70 Betaxolol 203 Betnovate 69 Betnovate-C 70 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Bezalip 60 Bezalip Retard 60 Bicalaccord 175 Bicalutamide 175 Bicillin LA 99 BiCNU 161 Bile and Liver Therapy 27
fusidic acid 70 Betaxolol 203 Betnovate 69 Betnovate-C 70 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Bezalip 60 Bezalip Retard 60 Bicalaccord 175 Bicalutamide 175 Biclilin LA 99 BICNU 161 Bile and Liver Therapy 27 Biltricide 96
fusidic acid 70 Betaxolol 203 Betnovate 69 Betnovate-C 70 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Bezalip 60 Bezalip Retard 60 Bicalaccord 175 Bicalutamide 175 Bicillin LA 99 BiCNU 161 Bile and Liver Therapy 27 Bitricide 96 Bimatoprost 204
fusidic acid 70 Betaxolol 203 Betnovate 69 Betnovate-C 70 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Bezalip 60 Bezalip Retard 60 Bicalucord 175 Bicalutamide 175 BicIllin LA 99 Bile and Liver Therapy 27 Biltricide 96 Bimatoprost 204 Biodone 133
fusidic acid 70 Betaxolol 203 Betnovate 69 Betnovate-C 70 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Betoptic 203 Bezalip 60 Bezalip Retard 60 Bicalaccord 175 Bicalutamide 175 Bicillin LA 99 BiCNU 161 Bile and Liver Therapy 27 Bitricide 96 Bimatoprost 204

Bisacodyl	30
Bismuth trioxide	
Bisoprolol	.56
BK Lotion	./1
Bleomycin sulphate	165
Blood Colony-stimulating	
Factors	. 50
Blood glucose diagnostic test	
meter	. 30
Blood glucose diagnostic test	
strip	. 30
Blood glucose test strips (visually	
impaired)	31
Blood ketone diagnostic test	. 01
meter	20
BNM	. 29
	50
Cardiovascular	.53
Genito-Urinary	
Boceprevir	112
Bonjela	
Boostrix	246
Bortezomib	
Bosentan	.64
Bosvate	.56
Bplex	.41
Breath-Alert	
Brevinor 1/21	
Brevinor 1/28	.80
Brevinor 21	
Bricanyl Turbuhaler	
Brilinta	
Brimonidine tartrate	
Brimonidine tartrate with timolol	-04
maleate	04
	204
Brinzolamide	
Brolene	
Bromocriptine mesylate	
Brufen	
Brufen SR	
BSF Arrow-Fluoxetine	
BSF Imatinib-AFT	207
BSF Trexate	
Buccastem	143
Budesonide	
Alimentary	.24
Respiratory196, 2	200
Budesonide with	
eformoterol	197
Bumetanide	59
Buprenorphine with	
naloxone	158
Bupropion hydrochloride	150
Burinex	
	.09

Buscopan26	
Buspirone hydrochloride151	
Busulphan	
Butacort Aqueous200	
- C -	
Cabergoline 94	
Cabergoline94 Cafergot142	
Caffeine citrate201	
Cal-d-Forte41	
Calamine	
Calcipotriol75	
Calcitonin84	
Calcitriol41	
Calcitriol-AFT41	
Calcium carbonate24, 42	
Calcium Channel Blockers	
Calcium Disodium	
Versenate	
Calcium folinate163	
Calcium Folinate Ebewe163	
Calcium gluconate42	
Calcium Homeostasis84	
Calcium polystyrene	
sulphonate51 Calcium Resonium51	
Calogen219	
Calsource42	
Camptosar164	
Candesartan cilexetil54	
Candestar54	
Canesten67	
Capecitabine163	
Capecitabine Winthrop163	
Capoten53	
Capsaicin	
Musculoskeletal System121	
Nervous131	
Captopril53	
Carafate27	
Carbaccord161	
Carbamazepine138	
Carbimazole89	
Carbomer205	
Carboplatin161	
Carboplatin Ebewe161	
Carbosorb-X207	
Cardinol LA57	
Cardizem CD58	
CareSens	
CareSens II30	
CareSens N30	
CareSens N POP30	
Carmustine 161	

O 111 1 50
Carvedilol56
Catapres59
Catapres-TTS-159
Catapres-TTS-259
Catapres-TTS-359
CeeNU
Cefaclor monohydrate
Cefalexin monohydrate96
Celalexin mononyurate
Cefalexin Sandoz
Cefazolin
Ceftriaxone96
Ceftriaxone-AFT96
Cefuroxime axetil97
Cefuroxime sodium97
Celestone Chronodose84
Celiprolol56
Cellcept177
Celol
Centrally-Acting Agents59
Cephalexin ABM
Cerezyme
Cerezyme
Cetirizine - AFT195
Cetirizine hydrochloride195
Cetomacrogol71
Cetomacrogol with glycerol71
Champix159
Charcoal207
Chemotherapeutic Agents161
Chicken pox vaccine251
Chlorafast
Chlorambucil161
Chloramphenicol202
Chlorhexidine gluconate
Chiomexidine gluconate
Alimentary40
Dermatological70
Chloroform213
Chlorothiazide60
Chlorpheniramine maleate195
Chlorpromazine
hydrochloride144
Chlorsig202
Chlortalidone
[Chlorthalidone]60
Chlorthalidone
Chlorvescent
Cholecalciferol41
Cholestyramine60
Choline salicylate with
cetalkonium chloride 40
Cholvastin61
Ciclopirox olamine67
Ciclosporin193
Cilazapril53

Cilazapril with
hydrochlorothiazide54
Cilicaine99
Cilicaine VK99
Ciloxan202
Cimetidine26
Cipflox100
Ciprofloxacin
Infection100
Sensory
Ciprofloxacin Rex100
Cisplatin161
Cisplatin Ebewe161
Citalopram hydrobromide136
Cladribine163
Clarithromycin
Alimentary26
Infection
Clexane
Climara 10086
Climara 5086
Clindamycin
Clindamycin ABM100
Clobazam138
Clobetasol propionate69, 76
Clobetasone butyrate69
Clofazimine105
Clomazol
Dermatological67
Genito-Urinary81
Clomiphene citrate95
Clomipramine hydrochloride
Clonazepam138, 151
Clonidine
Clonidine BNM
Clonidine hydrochloride59
Clopidogrel47
Clopine145
Clopixol149, 151
Clotrimazole
Dermatological67
Genito-Urinary81
Clozapine145
Clozaril145
Co-Renitec
Co-trimoxazole100
Coal tar
Coal tar with allantoin, menthol,
phenol and sulphur75
Coal tar with salicylic acid and
sulphur75
Coco-Scalp75
Codeine phosphate

Extemporaneous	
Nervous	
Cogentin	
Colaspase [L-asparaginase]	
Colchicine	
Colestid	60
Colestipol hydrochloride	60
Colgout	128
Colifoam	
Colistin sulphomethate	
Colistin-Link	100
Collodion flexible	213
Colofac	26
Coloxyl	
Combigan	204
Comfort	
Comfort Short	
Compound electrolytes	
Compound	
hydroxybenzoate	213
Concerta	157
Condoms	
Condyline	
Contact-D	
Contraceptives - Hormonal	
Contraceptives - Hormonal	
Non-hormonal	70
Copaxone	153
Cordarone-X	55
Corticosteroids and Related	
Agents for Systemic Use	84
Corticosteroids Topical	
Cosmegen	
Cosopt	
Coumadin	
Coversyl	53
Creon 10000	
Creon 25000	37
Crixivan	115
Crotamiton	
Crystaderm	67
Curam	98
Curam Duo	98
Cvite	
Cyclizine hydrochloride	143
Cyclizine lactate	143
Cyclogyl	205
Cyclopentolate	
hydrochloride	205
Cyclophosphamide	
Cycloserine	105
Cyklokapron	
Cyproterone acetate	

Cyproterone acetate with	
ethinyloestradiol	
Cytarabine	.163
Cytotec	
Cytoxan	
- D -	
D-Penamine	
d4T	.115
Dabigatran	49
Dacarbazine	.166
Dactinomycin [Actinomycin	
D]	
Daivobet	75
Daivonex	75
Daktarin	68
Dalacin C	
Dalteparin sodium	
Danazol	
Danthron with poloxamer	
Dantrium	
Dantrolene	
Daonil	
Dapa-Tabs	
Dapsone	
Daraprim	
Darunavir	
Dasatinib	
Daunorubicin	.166
DBL Aminophylline	
DBL Bleomycin Sulfate	.165
DBL Carboplatin	.161
DBL Doxorubicin	.167
DBL Doxorubicin S29	.167
DBL Epirubicin	
Hydrochloride	. 167
DBL Ergometrine	
DBL Gemcitabine	
DBL Leucovorin Calcium	
DBL Morphine Sulphate	133
DBL Pethidine	
Hydrochloride	135
DBL Tobramycin	
DDI	
De Nol	
	21
De-Worm	
Decozol	
Deferiprone	.207
Deoxycoformycin	.169
Depo-Medrol	84
Depo-Medrol with Lidocaine	
Depo-Provera	
Depo-Testosterone	85

Deprim100
Dermol69, 76
Desferrioxamine mesylate207
Desmopressin acetate94
Desmopressin-PH&T94
Detection of Substances in
Urine
Dexamethasone
Hormone
Sensory203
Dexamethasone phosphate
Dexamethasone with framycetin
and gramicidin
Dexamethasone with neomycin
sulphate and polymyxin B
sulphate
Dexamethasone-hameln
Dexamphetamine sulphate155
Dextrochlorpheniramine
maleate
Dextrose51
Dextrose with electrolytes52
DHC Continus
Diabetes27
Diabetes Management
Diacomit141
Diamide Relief24
Diamox
Diaphragm78
Diasip
Diason RTH220
Diazepam138, 151
Diazoxide27
Dibenyline
Diclax SR120
Diclofenac sodium
Musculoskeletal System
Sensory203
Didanosine [DDI]115
Differin
Difflam40
Diflucan102
Diflucortolone valerate
Digestives Including
Enzymes
Digoxin
Dihydrocodeine tartrate
Dilantin
Dilantin Infatab140
Dilatrend
Diltiazem hydrochloride
Dilzem
Dimethicone71

Dipentum25 Diphtheria, tetanus and pertussis	;
vaccine	5
Diphtheria, tetanus, pertussis and polio vaccine	,
Diphtheria, tetanus, pertussis,	
polio, hepatitis B and	
haemophilus influenzae type B	
vaccine	
Diprosone69	
Diprosone OV69	
Dipyridamole	'
Disinfecting and Cleansing	、
Agents	
Disopyramide phosphate55	
Disulfiram159	
Diuretics	
Diurin 40	
Docetaxel166	5
Docetaxel Sandoz166	5
Docusate sodium	3
Docusate sodium with	
sennosides	
Domperidone	
Donepezil hydrochloride	
Donepezil-Rex	
Dopergin	
Dornase alfa200	
Dorzolamide hydrochloride	
Dorzolamide hydrochloride with	
timolol maleate 204	ŀ
Dostinex94	ŀ
Dothiepin hydrochloride135	5
Doxazosin53	5
Doxepin hydrochloride135	
Doxine	
Doxorubicin	
Doxorubicin Ebewe	
Doxycycline	, ,
DP Lotion	
DP Lotn HC	
DP-Anastrozole177	
Dr Reddy's Olanzapine146	
Dr Reddy's Omeprazole27	
Dr Reddy's Ondansetron143	
Dr Reddy's Pramipexole129	
Dr Reddy's Quetiapine147	
Dr Reddy's Risperidone	
Dr Reddy's Terbinafine104 Drugs Affecting Bone	ł
Drugs Alleculty Dolle	

Metabolism	122
Dulcolax	
Duocal Super Soluble	
Powder	218
Duolin	
Duolin HFA	199
Durex Confidence	78
Durex Extra Safe	78
Durex Select Flavours	78
Duride	
Dynacirc-SRO	58
· E ·	
E-Mycin	97
Ear Preparations	202
Ear/Eye Preparations	
Easiphen Liquid	232
Econazole nitrate	68
Efavirenz	
Efavirenz with emtricitabine and	
tenofovir disoproxil	
fumarate	115
Efexor XR	
Effient	
Eformoterol fumarate	
Efudix	
Egopsoryl TA	
Elecare	
Elecare LCP	233
Elemental 028 Extra	
Eligard	
Elocon	
Eloxatin	
Eltrombopag	
Eltroxin	
Emend Tri-Pack	142
EMLA	
Emtricitabine	
Emtricitabine with tenofovir	
disoproxil fumarate	115
Emtriva	115
Emulsifying ointment	71
Enalapril maleate	53
Enalapril maleate with	
Enalapril maleate with hydrochlorothiazide	54
Enbrel	
Endocrine Therapy	175
Endoxan	161
Enerlyte	
Enfuvirtide	116
Enoxaparin sodium	48
Ensure	228
Ensure Plus	228
Ensura Plus HN	228

Ensure Plus RTH	228
Entacapone	129
Entapone	129
Entecavir	107
Entocort CIR	107 24
Enlocon on	
Epiliini Failim Orushahla	140
Epilim Crushable	140
Epilim IV	140
Epilim S/F Liquid	140
Epilim Syrup	140
Epirubicin	167
	167
Éprex	45
Eptacog alfa [Recombinant facto	r
VIIa]	46
ERA	98
Ergometrine maleate	81
Ergotamine tartrate with	
caffeine	142
Erlotinib	
Erythrocin IV	97
Erythromycin ethyl succinate	07
Erythromycin lactobionate	
Erythromycin stearate	97 00
Erythropoietin alfa	90
Erythropoletin alla	45
Erythropoietin beta	45
Escitalopram	136
Eskazole	
Estradot	
Estrofem	86
Etanercept	178
Ethambutol hydrochloride	106
Ethics Aspirin	
Ethics Aspirin EC	47
Ethics Enalapril	
Ethics Paracetamol	132
Ethinyloestradiol	87
Ethinyloestradiol with	
desogestrel	79
Ethinyloestradiol with	
levonorgestrel	70
Ethinyloestradiol with	75
norethisterone	00
Toretriisterone	100
Ethosuximide	138
Etidronate disodium	
Etopophos	167
Etoposide	167
Etoposide phosphate	167
Etravirine	
Eumovate	
Evista	
Exemestane	177
Extemporaneously Compounded	
, , , , , , , , , , , , , , , , , , , ,	

Preparations and	
Galenicals	213
Eye Preparations	202
EZ-fit Paediatric Mask	201
Ezetimibe	61
Ezetimibe with simvastatin	
Ezetrol	
-F-	
Factor eight inhibitors bypassing	-
agent	
Febuxostat	128
Feed Thickener Karicare	
Aptamil	
FEIBA	
Felodipine	
Femtran 100	86
Femtran 50	
Fenpaed	120
Fentanyl	132
Ferodan	42
Ferriprox	
Ferro-F-Tabs	42
Ferro-tab	
Ferrograd	42
Ferrograd F	42
Ferrous fumarate	42
Ferrous fumarate with folic	
acid	42
acid Ferrous sulphate	
Ferrous sulphate	
Ferrous sulphate Ferrous sulphate with folic	42
Ferrous sulphate Ferrous sulphate with folic acid	42 42
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H	42 42 43
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fexofenadine hydrochloride	42 42 43 195
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fexofenadine hydrochloride Fibro-vein	42 42 43 195 46
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fexofenadine hydrochloride Fibro-vein Filgrastim	42 42 195 46 50
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fexofenadine hydrochloride Fibro-vein Filgrastim Finasteride	42 42 195 46 50 82
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fexofenadine hydrochloride Fibro-vein Filgrastim Finasteride Flagyl	42 43 195 46 50 82 105
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fexofenadine hydrochloride Fibro-vein Filgrastim Finasteride Flagyl Flagyl-S	42 42 43 195 46 50 82 105 105
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fibro-vein Fibro-vein Filgrastim Finasteride Flagyl Flagyl Flamazine	42 42 43 195 46 50 82 105 105 67
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fibro-vein Fibro-vein Filgrastim Finasteride Flagyl Flagyl Flagyl-S Flamazine Flecainide acetate	42 42 43 195 46 50 50 105 105 67 55
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fibro-vein Fibro-vein Filgrastim Flagyl-S Flagyl-S Flamazine Flecainide acetate Fleet Phosphate Enema	42 42 43 195 46 50 50 105 105 67 55
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fexofenadine hydrochloride Fibro-vein Filgrastim Finasteride Flagyl Flagyl Flagyl-S Flamazine Fleet Phosphate Enema Flixonase Havfever &	42 42 43 195 46 50 82 105 105 67 55 39
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fexofenadine hydrochloride Fibro-vein Filgrastim Flagyl Flagyl Flagyl Flagyl Fleacainide acetate Flecainide acetate Enema Fleixonase Hayfever & Allergy	42 42 43 195 46 50 82 105 105 67 55 39 39
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fexofenadine hydrochloride Fibro-vein Filgrastim Flagyl Flagyl Flagyl-S Flamazine Flecainide acetate Flecainide acetate Flecainide acetate Fleixonase Hayfever & Allergy Flixotide	42 42 43 195 46 50 82 105 67 55 39 200 196
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fexofenadine hydrochloride Fibro-vein Filgrastim Flagyl Flagyl Flagyl-S Flamazine Flecainide acetate Flecainide acetate Enema Flexonase Hayfever & Allergy Flixotide Flixotide Accuhaler	42 42 43 195 46 50 82 105 105 67 55 39 200 196 196
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fexofenadine hydrochloride Fibro-vein Filgrastim Flagyl Flagyl Flagyl Flagyl-S Flamazine Fleat Phosphate Enema Fleixonase Hayfever & Allergy Flixotide Flixotide Accuhaler Florinef	42 43 195 46 50 82 105 105 55 39 200 196 196 84
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fexofenadine hydrochloride Fibro-vein Filgrastim Flagyl Flagyl Flagyl Flagyl Flamazine Fleat Phosphate Enema Fleixonase Hayfever & Allergy Flixotide Flixotide Accuhaler Florinef Fluanxol	42 43 195 46 50 82 105 105 67 55 39 200 196 196 196 84 149
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fexofenadine hydrochloride Fibro-vein Filgrastim Filagyl Flagyl Flagyl-S Flamazine Fleaphosphate Enema Flecainide acetate Flet Phosphate Enema Flixonase Hayfever & Allergy Flixotide Flixotide Flixotide Florinef Fluanxol Fluarix	42 43 195 46 50 82 105 105 67 55 39 200 196 196 84 149 248
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fibro-vein Filgrastim Filgrastim Filgrastim Flagyl Flagyl Flagyl Flamazine Flecainide acetate Flecainide acetate Fleet Phosphate Enema Flocainide acetate Flixotide Accuhaler Flixotide Accuhaler Florinef Fluanxol Fluanxi Flucloxacillin	42 42 43 195 105 105 105 105 105 105 105 105
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fibro-vein Filgrastim Filgrastim Filgrastim Flagyl Flagyl Flagyl Flamazine Flecainide acetate Flecainide acetate Fleet Phosphate Enema Fleet Phosphate Enema Flet Phosphate Enema Flixotide Accuhaler Flixotide Accuhaler Florinef Fluanxol Fluanxol Flucloxacillin Flucloxin	42 43 195 105 105 105 105 105 105 105 105 105 105 196 196 196 196
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fibro-vein Filgrastim Filgrastim Flagyl Flagyl Flagyl Flagyl Flagyl Flecainide acetate Flecainide acetate Flecainide acetate Flecainide acetate Fleat Phosphate Enema Flexinide Accuhaler Flixotide Accuhaler Florinef Fluarix Flucloxacillin Flucloxin Flucon	42 43 195 46 50 105 105 105 105 105 67 55 39 200 196 196 196 196 196 196
Ferrous sulphate Ferrous sulphate with folic acid Ferrum H Fibro-vein Filgrastim Filgrastim Filgrastim Flagyl Flagyl Flagyl Flamazine Flecainide acetate Flecainide acetate Fleet Phosphate Enema Fleet Phosphate Enema Flet Phosphate Enema Flixotide Accuhaler Flixotide Accuhaler Florinef Fluanxol Fluanxol Flucloxacillin Flucloxin	42 43 195 46 50 105 105 67 55 39 200 196 196 196 196 196 196 196

Fludara Oral163
Fludarabine Ebewe163
Fludarabine phosphate163
Fludrocortisone acetate
Fluids and Electrolytes51
Flumetasone pivalate
Fluocortolone caproate with
fluocortolone pivalate and
cinchocaine
Fluorometholone
Fluorouracil Ebewe
Fluorouracil sodium
Dermatological77
Oncology164
Fluoxetine hydrochloride
Flupenthixol decanoate
Fluphenazine decanoate
Flutamide175
Flutamin
Flutamin S29175
Fluticasone196
Fluticasone propionate200
Fluticasone with salmeterol197
Foban67
Folic acid45
Food Thickeners230
Foods And Supplements For
Foods And Supplements For Inborn Errors Of
Foods And Supplements For Inborn Errors Of Metabolism231
Inborn Errors Of
Inborn Errors Of Metabolism231
Inborn Errors Of Metabolism 231 Foradil 196 Forteo 124
Inborn Errors Of Metabolism
Inborn Errors Of Metabolism 231 Foradil 196 Forteo 124 Fortimel Regular 221 Fortini 222 Fortini Multi Fibre 222 Fortisip 228 Fortisip Multi Fibre 229 Fosamax 123 Fragmin 48 Franycetin sulphate 202 Freestyle Optium 29, 30 Freestyle Optium Ketone 29 Frisium 138 Frumil 60
Inborn Errors Of Metabolism 231 Foradil 196 Forteo 124 Fortimel Regular 221 Fortini 222 Fortini Multi Fibre 222 Fortisip 228 Fortisip Multi Fibre 229 Fosamax 123 Fosamax Plus 123 Fragmin 48 Franycetin sulphate 202 Freestyle Optium 29, 30 Freestyle Optium Ketone 29 Frisium 138 Frumil 60 Frusemide 59
Inborn Errors Of Metabolism 231 Foradil 196 Forteo 124 Fortimel Regular 221 Fortini 222 Fortini Multi Fibre 222 Fortisip 228 Fortisip Multi Fibre 229 Fosamax 123 Fragmin 48 Fragmin 48 Franycetin sulphate 202 Freestyle Optium 29, 30 Freestyle Optium Ketone 29 Frisium 138 Frumil 60 Frusemide 59
Inborn Errors Of Metabolism 231 Foradil 196 Forteo 124 Fortimel Regular 221 Fortini 222 Fortini Multi Fibre 222 Fortisip 228 Fortisip Multi Fibre 229 Fosamax 123 Fosamax Plus 123 Fragmin 48 Franycetin sulphate 202 Freestyle Optium 29, 30 Freestyle Optium Ketone 29 Frisium 138 Frumil 60 Frusemide 59 Fusemide 59 Fusemide 59 Fuscinct 70
Inborn Errors Of Metabolism 231 Foradil 196 Forteo 124 Fortimel Regular 221 Fortini 222 Fortini Multi Fibre 222 Fortisip 228 Fortisip Multi Fibre 229 Fosamax 123 Fragmin 48 Framycetin sulphate 202 Freestyle Optium 29, 30 Freestyle Optium Ketone 29 Friusmide 59 Frusmide 59 Frusemide 59 Fucicort 70 Fucidin 100
Inborn Errors Of Metabolism 231 Foradil 196 Forteo 124 Fortimel Regular 221 Fortini 222 Fortini Multi Fibre 222 Fortisip 228 Fortisip Multi Fibre 229 Fosamax 123 Fosamax 123 Fragmin 48 Framycetin sulphate 202 Freestyle Optium 29, 30 Freestyle Optium Ketone 29 Frusemide 59 Frusemide 59 Frusemide 59 Frusemide 59 Frusemide 59 Frusemide 29 Fortisin 100 Fuciort 70 Fucidin 100 Fucithalmic 202
Inborn Errors Of Metabolism 231 Foradil 196 Forteo 124 Fortimel Regular 221 Fortini 222 Fortini Multi Fibre 222 Fortisip 228 Fortisip Multi Fibre 229 Fosamax 123 Fosamax Plus 123 Fragmin 48 Franycetin sulphate 202 Freestyle Optium Ketone 29 Frisium 138 Frumil 60 Frussemide 59 Frusemide 59 Frusemide 59 Fucicort 70 Fucidin 100 Fucidin 202
Inborn Errors Of Metabolism 231 Foradil 196 Forteo 124 Fortimel Regular 221 Fortimi 222 Fortini Multi Fibre 222 Fortisip 228 Fortisip Multi Fibre 229 Fosamax 123 Fosamax 123 Fragmin 48 Framycetin sulphate 202 Freestyle Optium 29, 30 Freestyle Optium Ketone 29 Frusemide 59 Frusemide 59 Frusemide 59 Frusemide 59 Fuciort 70 Fucitin 100 Fucithalmic 202
Inborn Errors Of Metabolism 231 Foradil 196 Forteo 124 Fortimel Regular 221 Fortini 222 Fortini Multi Fibre 222 Fortisip 228 Fortisip Multi Fibre 229 Fosamax 123 Fosamax Plus 123 Fragmin 48 Franycetin sulphate 202 Freestyle Optium Ketone 29 Frisium 138 Frumil 60 Frussemide 59 Frusemide 59 Frusemide 59 Fucicort 70 Fucidin 100 Fucidin 202

Infection	100
Sensory	
Fuzeon	116
- G -	
Gabapentin	138
Gabapentin (Neurontin)	139
Gamma benzene	
hexachloride	72
Gardasil	248
Gastrosoothe	26
Gaviscon Double Strength	24
Gaviscon Infant	
Gefitinib	
Gemcitabine Actavis 1000	
Gemcitabine Actavis 200	
Gemcitabine Ebewe	
Gemcitabine hydrochloride	164
Gemfibrozil	
Gemzar	
Genoptic	
Genotropin	202
Genox Gentamicin sulphate	
Infection	101
Sensory	
Ginet 84	
Glatiramer acetate	
Glibenclamide	
Gliclazide	
Glipizide	
Glivec	
Glizide	
Glucagen Hypokit	28
Glucagon hydrochloride	
Glucerna Select	220
Glucerna Select RTH	220
Glucose [Dextrose]	51
Gluten Free Foods	230
Glycerin with sodium	
saccharin	. 213
Glycerin with sucrose	213
Glycerol	
Alimentary	38
Extemporaneous	
Glyceryl trinitrate	
Alimentary	
Cardiovascular	
Glytrin	
Gold Knight	
Gopten	
Goserelin acetate	 03
Gutron	
Gynaecological	
aynaecological	

Anti-infectives	81
- H -	
Habitrol	159
Haemophilus influenzae type B	
vaccine	247
Haldol	
Haldol Concentrate	
Haloperidol	
Haloperidol decanoate	
Hamilton Sunscreen	
Havrix	
Havrix Junior	
HBvaxPRO	
healthE Dimethicone 5%	
healthE Fatty Cream	
healthE Urea Cream	
Healtheries Simple Baking	
Mix	230
Hemastix	83
Heparin sodium	
Heparinised saline	49
Heparon Junior	
Hepatitis A vaccine	247
Hepatitis B recombinant	
vaccine	248
Hepsera	
Herceptin	
Hexamine hippurate	119
Hiprex	119
Histafen	
Holoxan	
Horleys Bread Mix	
Horlevs Flour	231
Horleys Flour Hormone Replacement Therapy	-
Systemic	85
HPV	
Humalog	
Humalog Mix 25	
Humalog Mix 50	28
Human papillomavirus (6, 11, 16	
and 18) vaccine [HPV]	248
Humatin	
Humira	183
HumiraPen	183
Humulin 30/70	28
Humulin NPH	28
Humulin R	
Hybloc	56
Hydralazine	
Hydralazine hydrochloride	63
Hydrea	167
Hydrocortisone	
Dermatological	69

Hormone	
	84
Hydrocortisone acetate	25
Hydrocortisone butyrate69	9.76
Hydrocortisone with	,
cinchocaine	26
Hydrocortisone with	20
miconazole	70
miconazole	70
Hydrocortisone with natamycin	=0
and neomycin	70
Hydrocortisone with wool fat and	
mineral oil	
Hydroderm Lotion	71
Hydrogen peroxide	
Alimentary	40
Dermatological	67
Hydroxocobalamin	41
Hydroxychloroquine	121
Hydroxyurea	167
Hydroxyurea	. 107
Hygroton	60
Hylo-Fresh	.205
Hyoscine hydrobromide	.143
Hyoscine N-butylbromide	26
Hypam	.154
Hyperuricaemia and	
Antigout	. 127
Hypnovel	
Hypromellose	
Hypromellose with Dextran	205
Hysite	204
•	
-1-	
Ibiamox	98
Ibiamox Ibuprofen	98 120
Ibiamox Ibuprofen Idarubicin hydrochloride	98 120 167
Ibiamox Ibuprofen Idarubicin hydrochloride	98 120 167
Ibiamox Ibuprofen	98 120 167 161
Ibiamox Ibuprofen Idarubicin hydrochloride Ifosfamide Ikorel	98 120 167 161 63
Ibiamox Ibuprofen Idarubicin hydrochloride Ifosfamide Ikorel Iloprost	98 120 167 161 63 65
Ibiamox Ibuprofen Idarubicin hydrochloride Ifosfamide Ikorel Iloprost Imatinib mesilate	98 .120 .167 63 63 65 172
Ibiamox Ibuprofen Idarubicin hydrochloride Ifosfamide Ikorel Iloprost Imatinib mesilate Imatinib-AFT	98 .120 .167 .161 63 65 .172 172
Ibiamox Ibuprofen Idarubicin hydrochloride Ifosfamide Ikorel Iloprost Imatinib mesilate Imatinib-AFT Imiglucerase	98 120 167 63 65 172 39
Ibiamox Ibuprofen Idarubicin hydrochloride Ifosfamide Ikorel Iloprost Imatinib mesilate Imatinib-AFT Imiglucerase Imipramine hydrochloride	98 120 167 63 65 172 39 39 35
Ibiamox Ibuprofen Idarubicin hydrochloride Ifosfamide Ikorel Iloprost Imatinib mesilate Imatinib-AFT Imiglucerase Imipramine hydrochloride Imiquimod	98 120 167 63 65 172 39 39 76
Ibiamox	98 .120 .167 63 65 172 39 135 76 116
Ibiamox	98 .120 .167 .161 63 65 .172 39 39 76 76 116 77
Ibiamox	98 .120 .167 .161 63 65 .172 39 39 35 76 116 177 77
Ibiamox	98 .120 .167 .161 63 65 .172 .172 39 39 39 35 76 116 177 77 60
Ibiamox	98 .120 .167 .161 63 65 .172 39 .135 76 .116 .177 60 .115
Ibiamox	98 .120 .167 .161 63 65 .172 39 .135 76 .116 .177 60 .115
Ibiamox	98 .120 .167 .161 63 72 .172 39 .135 76 .116 .177 60 .115 .247
Ibiamox	98 .120 .167 .161 63 72 .172 39 .135 76 .116 .177 60 .115 .247 .247
Ibiamox	98 .120 .167 .161 65 .172 39 .135 76 .116 .177 60 .115 247 247 232

Influvac248

Inhaled Anticholinergic

• ·	
Agents	. 198
Inhaled Corticosteroids	196
Inhaled Long-acting	
Beta-adrenoceptor	
Agonists	. 196
Innovacon hCG One Step	
Pregnancy Test	82
Inset 30	34
Inset II	35
Insulin aspart	28
Insulin aspart with insulin aspart	
protamine	28
Insulin glargine	
Insulin glulisine	29
Insulin isophane	28
Insulin isophane with insulin	
neutral	28
Insulin lispro	
Insulin lispro with insulin lispro	
protamine	28
Insulin neutral	28
Insulin pen needles	31
Insulin pump	
Insulin pump accessories	
Insulin pump infusion set (steel	
cannula)	
Insulin pump infusion set (teflon	
cannula, angle insertion with	
insertion device)	34
Insulin pump infusion set (teflon	
cannula, angle insertion)	34
Insulin pump infusion set (teflon	
cannula, straight insertion with	
insertion device)	35
Insulin pump infusion set (teflon	00
cannula, straight insertion)	36
Insulin pump reservoir	36
Insulin syringes, disposable with	00
attached needle	31
Intal Forte CFC Free	200
Intal Spincaps	
Intelence	
Interferon alfa-2a	
Interferon alfa-2b	
Interferon beta-1-alpha	
Interferon beta-1-beta	153
Intra-uterine device	78
Intron-A	
Invega Sustenna	
IPOL	
Ipratropium bromide198,	201
Iressa	171
Irinotecan	
	.104

Irinotecan Actavis 100	164
Irinotecan Actavis 40	164
Irinotecan-Rex	
Iron polymaltose	43
Isentress	116
Ismo 20	62
Ismo 40 Retard	
Isoniazid	
Isoprenaline	63
Isoptin	
Isopto Carpine	204
Isosorbide mononitrate	62
Isosource Standard	227
Isosource Standard RTH	
Isotretinoin	
Ispaghula (psyllium) husk	38
Isradipine	58
Isuprel	63
Itch-Soothe	68
Itraconazole	103
Itrazole	103
Ivermectin	72
- J -	

Jadelle	80
Jevity	.227
Jevity HiCal RTH	.228
Jevity RTH	.227

- K -

Kaletra	116
Kemadrin	130
Kenacomb	202
Kenacort-A	85
Kenacort-A40	85
Ketocal 3:1	235
KetoCal 4:1	235
Ketoconazole	
Dermatological	76
Infection	103
Ketogenic Diet	235
Ketone blood beta-ketone	
electrodes	
Ketoprofen	120
Ketostix	
Kindergen	221
Kinson	129
Kivexa	115
Klacid	97
Kliogest	87
Kliovance	87
Kogenate FS	46
Konakion MM	47
Konsyl-D	38

·L·
L-asparaginase
Labetalol
Lacosamide
Lactulose
Laevolac
Lamictal140
Lamivudine108, 115
Lamivudine Alphapharm115
Lamotrigine140
Lamprene105
Lanoxin
Lanoxin PG55
Lansoprazole27
Lantus
Lantus SoloStar
Lanvis
Lapatinib ditosylate172
Largactil
Lasix
Latanoprost204
Lax-Sachets
Lax-Tab
Laxatives
Laxofast 120
Laxofast 50
Laxsol
Leflunomide121
Lenalidomide167
Letraccord177
Letrozole177
Leukeran FC161
Leukotriene Receptor
Antagonists
Leunase
Leuprorelin93
Leustatin163
Levetiracetam140
Levetiracetam-Rex140
Levobunolol203
Levocabastine203
Levodopa with benserazide129
Levodopa with carbidopa129
Levomepromazine maleate145
Levonorgestrel
Genito-Urinary80-81
Hormone87
Levothyroxine89
Levothyroxine (mercury
pharma)
Lidocaine [Lignocaine]131
Lidocaine [Lignocaine]

hydrochloride Lidocaine [Lignocaine] with	131
Lidocaine [Lignocaine] with	
chlorhexidine	131
Lidocaine [Lignocaine] with prilocaine	101
Lidocaine-Claris	101
Liluocalite-Claris	70
Lifestyles Flared Lignocaine84,	121
Hormone	84
Nervous	
Lioresal Intrathecal	128
Lipazil	60
Lipazil Lipid-Modifying Agents	60
Lipitor	61
Liquigen	219
Lisinopril	53
Lisuride hydrogen maleate	129
Lithicarb FC	145
Lithium carbonate	145
Livostin	203
Locacorten-Viaform ED's	202
Local preparations for Anal and	
Rectal Disorders	
Locasol	233
Loceryl	67
Locoid69	, 76
Locoid Crelo	
Locoid Lipocream	
Locorten-Vioform	
Lodoxamide	
Logem Lomide	140
Lomide	
Loniten	
Loniteri Loperamide hydrochloride	03
Lopinavir with ritonavir	116
Lopinavii with monavii	56
Lopresor	232
Loprofin Mix	232
Lorafix	195
LoraPaed	195
Loratadine	195
Lorazepam	151
Lormetazepam	153
Losartan potassium	E 4
Losartan potassium with	
hydrochlorothiazide	55
Lostaar	55 54
Lostaar Lovir	55 54 109
Lostaar Lovir Loxalate	55 54 109 136
Lostaar Lovir Loxalate Loxamine	55 54 109 136 136
Lostaar Lovir Loxalate	55 54 109 136 136 93

Lumigan	204
Lycinate	
Lyderm	74
- M -	
m-Cefuroxime	97
m-Eslon	133
M-M-R II	
m-Mometasone	70
Mabthera	190
Macrogol 3350 with potassium	
chloride, sodium bicarbonate	
and sodium chloride	38
Macrogol 400 and propylene	
glycol	205
Madopar 125	129
Madopar 250	
Madopar 62.5	129
Madopar HBS	129
Madopar Rapid	129
Magnesium hydroxide	
Magnesium sulphate	
Malathion Malathion with permethrin and	/4
piperonyl butoxide	74
Maprotiline hydrochloride	125
Marovan	50
Marevan Marine Blue Lotion SPF 50+	50 76
Marquis Black	
Marquis Conforma	
Marquis Protecta	78
Marquis Selecta	78
Marguis Sensolite	
Marquis Supalite	
Marquis Titillata	
MarquisTantiliza	78
Martindale Acetylcysteine	207
Marvelon 28	79
Mask for spacer device	
Mast Cell Stabilisers	
Maxidex	
Maxitrol	
MCT oil (Nutricia)	219
Measles, mumps and rubella	
vaccine	249
Mebendazole	96
Mebeverine hydrochloride	
Medrol Medroxyprogesterone acetate	84
Genito-Urinary	00
Hormone	
Mefenamic acid	
Megestrol acetate	
Meloxicam	

Melphalan161
Menactra
Meningococcal (groups A, C, Y
and W-135) congugate
vaccine
Meningococcal A, C, Y and
Meningococcal A, C, Y and
W-135 vaccine
Meningococcal c congugated
vaccine
Menomune
Menthol68
Mercaptopurine164
Mercilon 2879
Mesalazine25
Mesna168
Mestinon120
Metabolic Disorder Agents
Metamide143
Metformin hydrochloride29
Methadone hydrochloride
Extemporaneous213
Nervous133
Methatabs133
Methopt205
Methotrexate
Methotrexate Ebewe
Methotrexate Sandoz
Methyl hydroxybenzoate
Methylcellulose
Methylcellulose with glycerin and
sodium saccharin
Methylcellulose with glycerin and
sucrose
Methyldopa
Methylphenidate
hydrochloride156
Methylphenidate hydrochloride
extended-release157
Methylprednisolone84
Methylprednisolone
aceponate 69
Methylprednisolone acetate84
Methylprednisolone acetate with
lidocaine [Lignocaine]
Methylprednisolone sodium
succinate84
Methylxanthines200
Metoclopramide
hydrochloride143
Metoclopramide hydrochloride
with paracetamol
Metolazone
Metopirone95

Metoprolol - AFT CR	56
Metoprolol succinate	56
Metoprolol tartrate	56
Metronidazole	105
Metyrapone	95
Mexiletine hydrochloride	55
Mexiletine Hydrochloride	
USP	55
Miacalcic	84
Mianserin hydrochloride	
Micolette	
Miconazole	
Miconazole nitrate	
Dermatological	68
Genito-Urinary	
Micreme	
Micreme H	
Microgynon 30	
Microgynon 50 ED	
Microlut	
Midazolam	
Midazolarn	
Minerals	
Minidiab	
Minirin MiniTT380 Slimline	94
	/8
• • · · ·	~~
Mino-tabs	99
Minocycline hydrochloride	99
Minocycline hydrochloride Minomycin	99 99
Minocycline hydrochloride Minomycin Minor Skin Infections	99 99 72
Minocycline hydrochloride Minomycin Minor Skin Infections Minoxidil	99 99 72 63
Minocycline hydrochloride Minomycin Minor Skin Infections Minoxidil Mirena	99 99 72 63 87
Minocycline hydrochloride Minomycin Minor Skin Infections Minoxidil Mirena Mirtazapine	99 99 72 63 87 137
Minocycline hydrochloride Minomycin Minor Skin Infections Minoxidil Mirena Mirtazapine Misoprostol	99 99 72 63 87 137 26
Minocycline hydrochloride Minorycin Minor Skin Infections Minoxidil Mirena Mirtazapine Misoprostol Mitomycin C	99 72 63 87 137 26 168
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Mirtazapine Misoprostol Mitomycin C Mitozantrone	99 99 72 63 63 137 26 168 168
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Mirtazapine Misoprostol Mitomycin C Mitozantrone Mitozantrone Ebewe	99 72 63 87 137 26 168 168 168
Minocycline hydrochloride Minomycin Minoxidil Mirena Mistazapine Misoprostol Mitomycin C Mitozantrone Ebewe Mitozantrone Ebewe	99 72 63 87 137 26 168 168 168 168
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Mirtazapine Misoprostol Mitomycin C Mitozantrone Mitozantrone Ebewe	99 72 63 87 137 26 168 168 168 168
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Mirtazapine Mitazapine Mitozantrone C Mitozantrone Ebewe Mitozantrone Ebewe Mixtard 30 Moclobemide Modafinil	99 99 72 63 63 137 26 168 168 168 168 136 136 157
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Mirtazapine Mitazapine Mitozantrone Mitozantrone Ebewe Mitozantrone Ebewe Mixtard 30 Moclobemide Modafinil Modavigil	99 72 63 137 137 137 168 168 168 168 168 136 157 157
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Mirtazapine Mitazapine Mitozantrone C Mitozantrone Ebewe Mitozantrone Ebewe Mixtard 30 Moclobemide Modafinil	99 72 63 137 137 137 168 168 168 168 168 136 157 157
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Mirtazapine Misoprostol Mitoraprostol Mitozantrone Ebewe Mitozantrone Ebewe Mixtard 30 Moclobemide Modafinil Modavigil Modexate Moduretic	99 72 63 87 137 26 168 168 168 168 168 136 128 136 157 157 149 60
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Mirtazapine Misoprostol Mitozantrone Mitozantrone Ebewe Mitozantrone Ebewe Moclobemide Modafinil Modavigil Modacate Moduretic Mogine	99 72 63 87 26 168 168 168 168 136 28 136 157 157 149 60 140
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Mirtazapine Misoprostol Mitoraprostol Mitozantrone Ebewe Mitozantrone Ebewe Mixtard 30 Moclobemide Modafinil Modavigil Modexate Moduretic	99 72 63 87 26 168 168 168 168 136 28 136 157 157 149 60 140
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Mirtazapine Misoprostol Mitozantrone Mitozantrone Ebewe Mitozantrone Ebewe Moclobemide Modafinil Modavigil Modacate Moduretic Mogine	99 72 63 87 26 168 168 168 168 168 168 168 167 157 157 149 60 140 70
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Misaprostol Mitozantrone C Mitozantrone Ebewe Mitozantrone Ebewe Mitozantrone Ebewe Modafinil Modafinil Modavigil Modavigil Modavigil Modavigil Modecate Moduretic Mogine Mometasone furoate Monogen Montelukast	99 72 63 87 137 26 168 168 168 168 168 168 136 157 157 149 60 140 70 220
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Misoprostol Mitozantrone C Mitozantrone Ebewe Mitozantrone Ebewe Mitozantrone Ebewe Motolobemide Moclobemide Modafinil Modavigil Modavigil Modavigil Modavigil Modavigi Modecate Mogine Mometasone furoate Monogen Monotelukast Moroctocog alfa [Recombinant	99
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Mitzapine Mitozantrone C Mitozantrone Ebewe Mitozantrone Ebewe Mitozantrone Ebewe Motolobemide Modafinil Modafinil Modavigil Modecate Moderetic Mogine Mometasone furoate Mongen Montelukast Moroctocog alfa [Recombinant factor VIII]	99 72 63 87 137 26 168 168 168 168 168 168 168 167 157 157 157 157 70 220 199 46
Minocycline hydrochloride Minomycin Minoxidil Mirena Misoprostol Mitozantrone C Mitozantrone Ebewe Mitozantrone Ebewe Mitozantrone Ebewe Moclobemide Moclobemide Modafinil Modavigil Modavigil Modavigil Modecate Moduretic Mogine Mometasone furoate Monogen Montelukast	99 72 63 87 137 26 168 168 168 168 168 168 168 167 157 157 157 157 70 220 199 46
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Mirtazapine Mitozantrone C Mitozantrone Ebewe Mitozantrone Ebewe Mitozantrone Ebewe Motolobemide Modafinil Modafinil Modavigil Modecate Moderetic Mogine Mongen Montelukast Moroctocog alfa [Recombinant factor VIII]	99 72 63 87 137 26 168 168 168 168 168 168 168 168 167 157 157 157 157 220 199 46 133
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidi Mirena Mirtazapine Mitazapine Mitozantrone C Mitozantrone Ebewe Mitozantrone Ebewe Mitozantrone Ebewe Mitozantrone Ebewe Motolobemide Modafinil Modafinil Modavigi Modecate Moduretic Mogine Mongen Montelukast Moroctocog alfa [Recombinant factor VIII] Morphine hydrochloride Morphine sulphate	99 72 63 87 26 168 168 168 168 168 28 136 28 136 29 49 49 40 70 70 70
Minocycline hydrochloride Minomycin Minor Skin Infections Miroxidil Mirena Mirtazapine Mitozantrone C Mitozantrone Ebewe Mitozantrone Ebewe Mitozantrone Ebewe Motolobemide Modafinil Modafinil Modavigil Modecate Moderetic Mogine Mongen Montelukast Moroctocog alfa [Recombinant factor VIII]	99 72 63 87 26 87 26 168 168 28 28 26 28 26 27 20 20 49 20

Mouth and Throat	40
Moxifloxacin	
MSUD Maxamaid	
MSUD Maxamum	
Mucilaginous laxatives with	
stimulants	38
Mucolytics	
Multiload Cu 375	78
Multiload Cu 375 SL	
Multiple Sclerosis	
Treatments	. 152
Multivitamins	41
Mupirocin	
Muscle Relaxants	128
Mvite	
Myambutol	
Mycobutin	
Mycophenolate mofetil	
Mycostatin	
Mydriacyl	
Mylan Atenolol	
Mylan Fentanyl Patch	
Mylanta P	
Myleran	
Myocrisin	
Myometrial and Vaginal Hormone	
Preparations	81
- N -	
Nadolol	
Nalcrom	
Naloxone hydrochloride	
Naltraccord	
Naltrexone hydrochloride	
Naphazoline hydrochloride	206

Naloxone hydrochloride	207
Naltraccord	159
Naltrexone hydrochloride	159
Naphazoline hydrochloride	206
Naphcon Forte	
Naprosyn SR 1000	120
Naprosyn SR 750	
Naproxen	120
Nardil	
Nasal Preparations	200
Natulan	
Nausicalm	143
Navelbine	170
Navoban	144
Nedocromil	200
Nefopam hydrochloride	
Neisvac-C	
Neo-Mercazole	
Neocate Advance	233
Neocate Gold	233
Neocate LCP	233
Neoral	
NeoRecormon	

Neostigmine metilsulfate120
Neotigason74
Nepro (strawberry)223
Nepro (vanilla)
Nepro HP (strawberry)223
Nepro HP (vanilla)
Nepro HP RTH
Nepro RTH223
Nerisone
Neulactil146
Neulastim
NeuroKare42
Neurontin
Nevirapine114
Nevirapine Alphapharm114
Nicorandil
Nicotine
Nicotinic acid60
Nifedipine
Nifuran119
Nilstat
Alimentary40
Genito-Urinary81
Infection103
Nipent169
Nitrados154
Nitrates62
Nitrazepam154
Nitroderm TTS62
Nitrofurantoin119
Nizoral103
Noctamid153
Nodia24
Noflam 250120
Noflam 500120
Non-Steroidal Anti-Inflammatory
Drugs 120
Nonacog alfa [Recombinant
factor IX]
Norethisterone
Genito-Urinary80
Hormone88
Norflex128
Norfloxacin119
Noriday 2880
Norimin80
Normacol Plus
Normison154
Norpress136
Nortriptyline hydrochloride
Norvir
NovaSource Renal
Novasource Renai
110vaueuli

NovoMix 30 FlexPen28	
NovoRapid28	B
NovoRapid Penfill28	
NovoSeven RT46	
Novoseven RT46	6
Noxafil104	4
Nozinan145	5
Nuelin200	0
Nuelin-SR200	0
Nupentin138	В
Nutrient Modules217	7
Nutrini Energy Multi Fibre222	2
Nutrini Energy RTH222	2
Nutrini Low Energy Multi	
Fibre	4
Nutrini RTH222	
Nutrison Concentrated230	
Nutrison Energy227	
Nutrison Energy Multi Fibre	ß
Nutrison Multi Fibre227	7
Nutrison Standard RTH22	7
Nyefax Retard	
Nystatin	0
Alimentary40	n
Dermatological	
Genito-Urinary8	
Infection100	
	0
NZB Low Gluten Bread Mix 23	1
NZB Low Gluten Bread Mix23	1
- 0 -	1
- O - Octocog alfa [Recombinant factor	
- O - Octocog alfa [Recombinant factor VIII]46	6
- O - Octocog alfa [Recombinant factor VIII]	6
- O - Octocog alfa [Recombinant factor VIII]	6 5
- O - Octocog alfa [Recombinant factor VIII]	6 5 6
- O - Octocog alfa [Recombinant factor VIII]	6 5 6 5
- O - Octocog alfa [Recombinant factor VIII]	65656
- O - Octocog alfa [Recombinant factor VIII]	65656
- O - Octocog alfa [Recombinant factor VIII]	656566
- O - Octocog alfa [Recombinant factor VIII]	656566
- O - Octocog alfa [Recombinant factor VIII]	65 6566 7
- O - Octocog alfa [Recombinant factor VIII]	65 6566 7
- O - Octocog alfa [Recombinant factor VIII]	65 6566 7 17
- O - Octocog alfa [Recombinant factor VIII]	65 6566 7 17
- O - Octocog alfa [Recombinant factor VIII]	65 6566 7 177
- O - Octocog alfa [Recombinant factor VIII]	65 6566 7 177 7
- O - Octocog alfa [Recombinant factor VIII]	65 6566 7 177 71
- O - Octocog alfa [Recombinant factor VIII]	65 6566 7 177 719
- O - Octocog alfa [Recombinant factor VIII]	65656671777196
- O - Octocog alfa [Recombinant factor VIII]	65 6566 7 177 71966
- O - Octocog alfa [Recombinant factor VIII]	65 6566 7 177 719660
- O - Octocog alfa [Recombinant factor VIII]	65 6566 7 177 7196606
- O - Octocog alfa [Recombinant factor VIII]	65 65566 7 177 71966065

Omezol Relief27	7
Omnitrope89)
Oncaspar169)
OncoTICE	3
Ondansetron	Ŕ
Ondansetron ODT-DRLA	ź
One-Alpha41	
Onelink	
Onkotrone168	
Onrex143	
Ora-Blend214	
Ora-Blend SF214	ļ
Ora-Plus213	3
Ora-Sweet213	3
Ora-Sweet SF213	3
Orabase40)
Oracort40	
Oral Supplements/Complete Diet	
(Nasogastric/Gastrostomy	
Tube Feed)	2
Oratane	
Orgran	
Ornidazole105	
Orphenadrine citrate128	
Orphenadrine hydrochloride130	
Ortho All-flex78	3
Ortho-tolidine83	
Oruvail SR120)
Osmolite	
Osmolite RTH227	7
Ospamox98	3
Other Endocrine Agents	
Other Oestrogen	
Preparations	7
Other Progestogen	
Preparations	7
Other Skin Preparations	7
Ovestin	
Genito-Urinary81	1
Hormone87	
Ox-Pam	
Oxaliplatin	
Oxaliplatin Actavis 100162	2
Oxaliplatin Actavis 50162)
Oxaliplatin Ebewe162	
Oxazepam151	
Oxis Turbuhaler196	3
Oxpentifylline63	3
Oxybutynin82	
Oxycodone ControlledRelease	
Tablets(BNM)	1
Tablets(BNM)	1
Oxycodone Orion134	1
	٠.

OxyContin134
Oxydone BNM134
OxyNorm134
Oxytocin
,
Oxytocin BNM81
Ozole102
- P -
Pacifen128
Pacific Buspirone151
Paclitaxel
Paclitaxel Actavis
Paclitaxel Ebewe
Paediatric Seravit41
Paliperidone150
Pamidronate BNM124
Pamidronate disodium124
Pamisol124
Panadol132
Pancreatic enzyme
Pantoprazole27
Pantoprazole Actavis 2027
Pantoprazole Actavis 4027
Panzytrat
Papaverine hydrochloride63
Para Plus74
Para-amino salicylic acid106
Paracare132
Paracare Double Strength132
Paracetamol132
Paracetamol + Codeine
(Relieve)134
Paracetamol with codeine
Paradigm 1.8 Reservoir
Paradigm 3.0 Reservoir
Paradigm 522
Paradiam 700
Paradigm 722
Paradigm Mio MMT-92135
Paradigm Mio MMT-92335
Paradigm Mio MMT-92535
Paradigm Mio MMT-94135
Paradigm Mio MMT-94335
Paradigm Mio MMT-94535
Paradigm Mio MMT-96535
Paradigm Mio MMT-97535
Paradigm Quick-Set
MMT-386
Paradigm Quick-Set
MMT-387 36
Paradigm Quick-Set
MMT-396
IVIIVI I-390
Paradigm Quick-Set
MMT-397
Paradigm Quick-Set

MMT-398	36
Paradigm Quick-Set MMT-399	00
NINI 1-399	30
Paradigm Silhouette MMT-368	3/
Paradiam Silbouette	04
Paradigm Silhouette MMT-377	34
Paradigm Silhouette	04
Paradigm Silhouette MMT-378	34
Paradiam Silhouatta	
MMT-381	34
Paradigm Silhouette	
MMT-382	34
Paradigm Silhouette	
MMT-383	34
Paradigm Silhouette	
MMT-384	
Paradigm Sure-T MMT-864	33
Paradigm Sure-T MMT-866	33
Paradigm Sure-T MMT-874	
Paradigm Sure-T MMT-876	
Paradigm Sure-T MMT-884	
Paradigm Sure-T MMT-886	
Parafast	
Paraffin	72
Paraffin liquid with soft white	
paraffin	. 206
paraffin	206
paraffin Paraffin liquid with wool fat	206
paraffin Paraffin liquid with wool fat Paraldehyde	206 138
paraffin Paraffin liquid with wool fat Paraldehyde Paramax	206 138 142
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Parasiticidal Preparations	206 138 142 72
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Parasiticidal Preparations Parnate	206 138 142 72 136
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Parasiticidal Preparations Parnate Paromomycin	206 138 142 72 136 101
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Parasiticidal Preparations Parnate Paromomycin Paroxetine hydrochloride	206 138 142 72 136 101 136
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Parasiticidal Preparations Parnate Paromomycin Paroxetine hydrochloride Paser	206 138 142 72 136 101 136 106
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Parasiticidal Preparations Parnate Paromomycin Paroxetine hydrochloride Paser Patanol	206 138 142 72 136 101 136 106 206
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Paramax Paroxeticidal Preparations Paroxetine hydrochloride Paser Patanol Paxam	206 138 142 72 136 101 136 106 206 151
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Paramax Paroxeticidal Preparations Paroxetine hydrochloride Paser Patanol Paxam	206 138 142 72 136 101 136 106 206 151
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Paramax Paroxeticidal Preparations Paroxetine hydrochloride Paser Patanol Paxam Pazopanib	206 138 142 72 136 101 136 106 206 151 173
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Parasiticidal Preparations Paroxetine hydrochloride Paser Patanol Paxam Pazopanib Peak flow meter	206 138 142 72 136 101 136 106 206 151 173 201
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Parasiticidal Preparations Parnate Paromomycin Paroxetine hydrochloride Paser Patanol Paxam Paxam Pazopanib Peak flow meter Pedialyte - Bubblegum	206 138 142 72 136 101 136 206 151 173 201 52
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Parasiticidal Preparations Parnate Paroxetine hydrochloride Paser Patanol Paxam Pazopanib Peak flow meter Pedialyte - Bubblegum Pediasure	206 138 142 72 136 101 136 106 206 151 173 201 52 222
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Parasiticidal Preparations Parnate Paroxetine hydrochloride Paser Patanol Paxam Pazopanib Peak flow meter Pedialyte - Bubblegum Pediasure RTH	206 138 142 72 136 101 136 106 206 151 201 52 222 222
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Parasiticidal Preparations Parnate Paroxetine hydrochloride Paser Patanol Pazopanib Pazopanib Peak flow meter Pedialyte - Bubblegum Pediasure RTH Pegaspargase	206 138 142 72 136 101 136 101 136 201 201 221 222 222 169
paraffin Paraffin liquid with wool fat Paraffin liquid with wool fat Paraamax Parasiticidal Preparations Parnate Paromomycin Paroxetine hydrochloride Paser Patanol Paser Patanol Paxam Pazopanib Peak flow meter Pediasure Pediasure Pediasure RTH Pegaspargase Peasasys	206 138 142 72 136 101 136 101 136 201 201 221 222 222 169
paraffin Paraffin liquid with wool fat Paraffin liquid with wool fat Paraamax Parasiticidal Preparations Parnate Paromomycin Paroxetine hydrochloride Paser Patanol Paser Patanol Paxam Pazopanib Peak flow meter Pediasure Pediasure Pediasure Pediasure RTH Pegaspargase Pegasys RBV Combination	206 138 142 72 136 101 136 206 151 201 222 222 222 169 117
paraffin Paraffin liquid with wool fat Paraldehyde Paramax Parasiticidal Preparations Parnate Paromomycin Paroxetine hydrochloride Paser Patanol Paser Patanol Paxam Pazopanib Pedialyte - Bubblegum Pediasure Pediasure Pediasure RTH Pegaspargase Pegasys RBV Combination Pack	206 138 142 72 136 101 136 206 151 201 222 222 222 169 117
paraffin	206 138 142 72 136 101 136 206 151 201 222 222 222 169 117 177 50
paraffin	206 138 142 72 136 101 136 206 151 201 222 222 169 117 117 50 117
paraffin	206 138 142 72 136 101 136 206 151 201 222 222 169 117 117 50 117
paraffin	206 138 142 72 136 101 136 206 151 201 222 222 169 117 117 50 117 51
paraffin	206 138 142 72 136 101 136 101 136 206 151 52 222 169 117 50 117 50 117 51
paraffin	206 138 142 72 136 101 136 206 206 206 201 151 173 201 52 222 169 117 117 117 117 117 117
paraffin	206 138 142 72 136 101 136 206 201 201 222 222 222 169 117 117 50 117 121 28 28 28

Pentostatin
[Deoxycoformycin]169
Pentoxifylline [Oxpentifylline]64
Pepti Junior Gold Karicare
Aptamil
Peptisoothe
Peptisorb224
Perhexiline maleate
Pericyazine146
Perindopril53
Permethrin74
Persantin
Peteha106
Pethidine hydrochloride135
Petniaine nyarochioriae
Pevaryl
Pexsig
Pharmacare
Pharmacy Services207
Phenelzine sulphate136
Phenobarbitone140
Phenobarbitone sodium
Extemporaneous214
Nervous154
Phenoxybenzamine
hydrochloride
Phenoxymethylpenicillin
(Penicillin V)
Phenytoin sodium138, 140
Phenytoin sodium138, 140 Phlexy 10232
Phenytoin sodium
Phenytoin sodium138, 140 Phlexy 10232 Phosphate-Sandoz52 Phosphorus52
Phenytoin sodium
Phenytoin sodium138, 140 Phlexy 10232 Phosphate-Sandoz52 Phosphorus52
Phenytoin sodium
Phenytoin sodium 138, 140 Phlexy 10 232 Phosphate-Sandoz 52 Phosphorus 52 Phytomenadione 47 Pilocarpine hydrochloride 204
Phenytoin sodium 138, 140 Phlexy 10 232 Phosphate-Sandoz 52 Phosphorus 52 Phytomenadione 47 Pilocarpine hydrochloride 204 Pimafucort 70
Phenytoin sodium 138, 140 Phlexy 10 232 Phosphate-Sandoz 52 Phosphorus 52 Phytomenadione 47 Pilocarpine hydrochloride 204 Pimafucort 70 Pindolol 57
Phenytoin sodium 138, 140 Phlexy 10 232 Phosphate-Sandoz 52 Phosphorus 52 Phytomenadione 47 Pilocarpine hydrochloride 204 Pimafucort 70 Pindolol 57 Pinetarsol 76 Pinorax 39
Phenytoin sodium 138, 140 Phlexy 10
Phenytoin sodium 138, 140 Phlexy 10 232 Phosphate-Sandoz 52 Phosphorus 52 Phytomenadione 47 Pilocarpine hydrochloride 204 Pimafucort 70 Pindolol 57 Pinetarsol 76 Pinorax 39 Pinorax Forte 39 Pioglitazone 29 Pipotil 150
Phenytoin sodium 138, 140 Phlexy 10 232 Phosphate-Sandoz 52 Phosphorus 52 Phytomenadione 47 Pilocarpine hydrochloride 204 Pimafucort 70 Pindolol 57 Pinetarsol 76 Pinorax 39 Pinorax Forte 39 Pioglitazone 29 Pipotil 150
Phenytoin sodium 138, 140 Phlexy 10
Phenytoin sodium 138, 140 Phlexy 10
Phenytoin sodium 138, 140 Phlexy 10 232 Phosphate-Sandoz 52 Phosphorus 52 Phytomenadione 47 Pilocarpine hydrochloride 204 Pimafucort 70 Pindolol 57 Pinetarsol 76 Pinorax 39 Pioglitazone 29 Pipotli 150 Pipothiazine palmitate 150 Pizacord 29 Pizotifen 142
Phenytoin sodium 138, 140 Phlexy 10 232 Phosphate-Sandoz 52 Phosphorus 52 Phytomenadione 47 Pilocarpine hydrochloride 204 Pimafucort 70 Pindolol 57 Pinetarsol 76 Pinorax 39 Pinoglitazone 29 Pipothiazine palmitate 150 Pizacord 29 Pizotifen 142 PKU Anamix Infant 232
Phenytoin sodium 138, 140 Phlexy 10 232 Phosphate-Sandoz 52 Phosphorus 52 Phytomenadione 47 Pilocarpine hydrochloride 204 Pimafucort 70 Pindolol 57 Pinetarsol 76 Pinorax 39 Pioglitazone 29 Pipottil 150 Pizactord 29 Pizotifen 142 PKU Anamix Infant 232 PKU Anamix Junior 232
Phenytoin sodium 138, 140 Phlexy 10 232 Phosphate-Sandoz 52 Phosphorus 52 Phytomenadione 47 Pilocarpine hydrochloride 204 Pimafucort 70 Pindolol 57 Pinetarsol 76 Pinorax 39 Pioglitazone 29 Piportil 150 Pizotifen 142 PKU Anamix Infant 232 PKU Anamix Junior 232
Phenytoin sodium 138, 140 Phlexy 10 .232 Phosphate-Sandoz .52 Phosphorus .52 Phytomenadione .47 Pilocarpine hydrochloride .204 Pimafucort .70 Pindolol .57 Pinetarsol .76 Pinorax .39 Pioglitazone .29 Pipothiazine palmitate .150 Pizactord .29 Pizotifen .142 PKU Anamix Infant .232 PKU Anamix Junior .232 PKU Anamix Junior LQ .232 PKU Lophlex LQ 10 .332
Phenytoin sodium 138, 140 Phlexy 10

Pneumococcal (PPV23)
polysaccharide vaccine
Pneumococcal vaccine250
Pneumovax 23250
Podophyllotoxin77
Polaramine195
Poliomyelitis vaccine251
Poloxamer
Poly-Gel205
Poly-Tears
Poly-Visc206
Polycal217
Polyvinyl alcohol205
Polyvinyi alconor
Posaconazole104
Postinor-181
Potassium chloride51-52
Potassium citrate
Potassium iodate42
Povidone iodine72
Pradaxa49
Pramipexole hydrochloride129
Prasugrel47
Pravastatin61
Praziquantel96
Prazosin53
Pred Forte203
Pred Mild203
Prednisolone acetate203
Prednisolone sodium
phosphate85
Prednisone85
Pregnancy Tests - hCG Urine82
Premarin
Premia 2.5 Continuous87
Premia 5 Continuous
Prevenar 13250
Prezista115
Priadel145
Primacin105 Primaquine phosphate105
Primaquine prospnate
Primidone
Primolut N
Probenecid128
Probenecid-AFT128
Procaine penicillin
Prochlorperazine143
Proctosedyl26
Procyclidine hydrochloride130
Procytox
Prodopa59
Progesterone

Proglicem	27
Proglycem2	27
Prograf19	94
Progynova	
Prokinex14	13
Promethazine hydrochloride19	96
Promethazine theoclate14	
Promod21	
Propafenone hydrochloride	55
Propamidine isethionate20	
Propranolol	
Propylene glycol21	
Propylthiouracil	
Protamine sulphate4	
Protaphane	
Protaphane Penfill2	28
Protifar21	
Protionamide10)6
Provera	
PSO236-23	
Psoriasis and Eczema	
Preparations7	74
PTU	39
Pulmicort Turbuhaler19	96
Pulmocare22	
Pulmozyme20	
Puri-nethol16	
Pyrazinamide10	
Pyridostigmine bromide12	20
PyridoxADE4	
Pyridoxine hydrochloride4	
Pyrimethamine10	
Pytazen SR4	
-Q-	
Q 300	15
Questran-Lite	
Quetapel14	
Quetiapine14	
Quick-Set MMT-390	
	0

FIOVEIA	Respiratory Sumularits
PSO236–239	Retinol palmitate
Psoriasis and Eczema	ReTrieve
Preparations74	Retrovir
PTU89	Revlimid
Pulmicort Turbuhaler196	Revolade
Pulmocare220	Rexacrom
Pulmozyme200	Reyataz
Puri-nethol164	Ridal
Pyrazinamide106	Ridaura s29
Pyridostigmine bromide120	Rifabutin
PyridoxADE41	Rifadin
Pyridoxine hydrochloride41	Rifampicin
Pyrimethamine102	Rifaximin
Pytazen SR47	Rifinah
- Q -	Rilutek
Q 300105	Riluzole
Questran-Lite	Riodine
Quetapel147	Risedronate Sandoz
Quetiapine147	Risedronate sodium
Quick-Set MMT-39036	Risperdal
Quick-Set MMT-39136	Risperdal Consta
Quick-Set MMT-39236	Risperdal Quicklet
Quick-Set MMT-39336	Risperidone
Quinapril54	Risperon
Quinapril with	Ritalin
hydrochlorothiazide	Ritalin LA
Quinine sulphate105	Ritalin SR
Qvar196	Ritonavir
- R -	Rituximab
RA-Morph133	Rivaroxaban
Raloxifene hydrochloride124	Rivotril
Raltegravir potassium	Rizamelt
Ramipex129	Rizatriptan
Tampon	Deferen A

Ranbaxy-Cefaclor	06
Ranitidine	90
Ranitidine Relief	20
Ranitidine Reliet	26
Ranmoxy	98
Rapamune	193
Reandron 1000	85
Recombinant factor IX Recombinant factor VIIa	46
Recombinant factor VIIa	45
Recombinant factor VIII	46
Rectogesic	26
Redipred	85
Refresh Night Time	206
Renilon 7.5	223
Resonium-A	52
Resource Beneprotein	219
Resource Diabetic	220
Respigen	198
Respiratory Devices	201
Respiratory Stimulants	201
Retinol palmitate	201
ReTrieve	200
Retrovir	00
Retrovir	
Revlimid	167
Revolade	45
Rexacrom	203
Reyataz	115
Ridal	148
Ridaura s29	121
Rifabutin	106
Rifadin	107
Rifampicin	107
Rifaximin	27
Rifinah	106
Rilutek	130
Riluzole	130
Riodine	72
Risedronate Sandoz	124
Risedronate sodium	124
Risperdal	148
Risperdal Consta	150
Pisperdal Quicklet	1/10
Risperdal Quicklet Risperidone148	150
Risperon	140
	140
Ritalin	156
Ritalin LA	15/
Ritalin SR	156
Ritonavir	116
Rituximab	190
Rivaroxaban	49
Rivotril	138
Rizamelt	142
Rizatriptan	142
Roferon-A	117

Ropinirole hydrochloride129
RotaTeg
Rotavirus live reassortant oral
vaccine251
Roxane
Alimentary24
Cardiovascular57
Roxithromycin
Rubifen
Rubifen SR156
Rythmodan55
Rytmonorm55
,
- \$ -
S-26 Gold Premgro232
Sabril141
Salamol198
Salazopyrin25
Salazopyrin EN25
Salbutamol197-198
Salbutamol with ipratropium
bromide 199
Salicylic acid76
Salmeterol197
Sandomigran142
Sandostatin LAR176
Scalp Preparations76
Scopoderm TTS143
Sebizole76
Sedatives and Hypnotics153
Selegiline hydrochloride130
Senna
Senokot
SensoCard
Serenace
Seretide
Seretide Accuhaler
Serevent197
Serevent Accuhaler197
Serophene95
Seroquel147 Sertraline
Sevredol
Sex Hormones Non Contraceptive
Shield 49
Shield Blue
Shield XL78
Silagra64
Sildenafil64
Silhouette MMT-37134
Silhouette MMT-37334
Silver sulphadiazine67
Simethicone24

Simvastatin	
Sindopa	.129
Sinemet	.129
Sinemet CR	.129
Singulair	.199
Sirolimus	.193
Siterone	85
Slow-Lopresor	56
Sodibic	
Sodium acid phosphate	20
Sodium alginate	24
Sodium aurothiomalate	101
Sodium biographanata	. 12 1
Sodium bicarbonate Blood51	
Biood	-52
Extemporaneous	
Sodium calcium edetate	.207
Sodium	
carboxymethylcellulose	40
Sodium chloride	
Blood	51
Respiratory	.200
Sodium citrate with sodium lauryl	
sulphoacetate	39
Sodium citro-tartrate	
Sodium cromoglycate	
Alimentary	25
Respiratory	
Sensory	
Sodium fluoride	
Sodium hyaluronate	205
Sodium nitroprusside	205
	29
Sodium polystyrene sulphonate	
Sodium tetradecyl sulphate	46
Sodium valproate	
Sofradex	
Soframycin	
Solian	.144
Solifenacin succinate	83
Solox	27
Solu-Cortef	84
Solu-Medrol	84
Somatropin (Genotropin)	89
Somatropin (Omnitrope)	89
Sotacor	
Sotalol	
Space Chamber	201
Space Chamber Plus	201
Space Chamber Plus	201
Spacer device	201
Spacer device autociavable	.201
Span-K	
Spiractin	59
	.198

Spironolactone	50
Spironolactone	59
Spirotone	59
Sporanox	103
Sprycel	170
Staphlex	
Stavudine [d4T]	
Stelazine	
Stemetil	143
Stesolid	138
Stimulants/ADHD	
Treatments	. 154
Stiripentol	141
Stocrin	
Stomahesive	
Strattera	
Stromectol	
Suboxone	
Sucralfate	
Sulfadiazine sodium	
Sulindac	
Sulphasalazine	
Sulphur	
Sumatriptan	
Sunitinib	
Sunscreens	
Sunscreens, proprietary	76
Suplena	223
Sure-T MMT-863	33
Sure-T MMT-865	33
Sure-T MMT-873	33
Sure-T MMT-875	33
Sure-T MMT-883	33
Sure-T MMT-885	
Sustagen Diabetic	
Sustagen Hospital Formula	228
Sustanon Ampoules	85
Sutent	174
Symbicort Turbuhaler 100/6	107
Symbicort Turbuhaler 200/6	107
• · · · · · · ·	
400/12	107
Symmetrel	129
Sympathomimetics	63
Synacthen	85
Synacthen Depot	85
Synflorix	250
Synthroid	89
Syntometrine	81
Syrup (pharmaceutical grade)	
grade)	. 214
Systane Unit Dose	205
-T-	
Tacrolimus	

Tacrolimus Sandoz	
Tambocor	55
Tambocor CR	55
Tamoxifen citrate	177
Tamsulosin hydrochloride	82
Tamsulosin-Rex	82
Tap water	
Tar with triethanolamine lauryl	
sulphate and fluorescein	. 76
Tarceva	
Tasmar	
Taxotere	
Tegretol	
Tegretol CR	138
Telfast	
Temaccord	
Temazepam	
Temozolomide	
Tenofovir disoproxil	109
fumarate	
Tenoxicam	121
Tepadina	
Terazosin	
Terbinafine	
Terbutaline sulphate	198
Teriparatide	
Testosterone	
Testosterone cypionate	85
Testosterone esters	85
Testosterone undecanoate	
Tetrabenazine	130
Tetrabromophenol	
Tetracosactrin	85
Tetracyclin Wolff	100
Tetracycline	
Teva	165
Thalidomide	
Thalomid	169
Theophylline	200
Thiamine hydrochloride	41
THIO-TEPÁ	162
Thioguanine	165
Thiotepa	162
Thymol glycerin	40
Thyroid and Antithyroid	
Agents	. 89
Ticagrelor	47
Tilade	
Tilcotil	
Timolol	
Cardiovascular	57
Sensory	
Timoptol XE	

Tiotropium bromide	198
TMP	
Tobramycin	
Infection	102
Sensory	
Tobrex	
Tofranil	
Tofranil s29	
Tolcapone	
Tolterodine	
Tolvon	
Topamax	141
Topical Products for Joint and	
Muscular Pain	
Topiramate	141
Total parenteral nutrition	
(TPN)	51
TPN	
Tracleer	
Tramadol hydrochloride	135
Tramal SR 100	
Tramal SR 150	
Tramal SR 200	135
Trandate	
Trandolapril	
Tranexamic acid	
Tranylcypromine sulphate	
Trastuzumab	
Travatan	
Travoprost	
Treatments for Dementia	150
Treatments for Substance	156
	150
Dependence	
Trental 400	64
Tretinoin	
Dermatological	
Oncology	
Trexate	165
Triamcinolone acetonide	
Alimentary	40
Dermatological	70
Hormone	85
Triamcinolone acetonide with	
gramicidin, neomycin and nyst	atin
Dermatological	70
Sensory	
Triazolam	
Trichozole	
Triclosan	
Trifluoperazine	
hydrochloride	149
Trimeprazine tartrate	196
Trimethoprim	

Trisequens87
Trisul
Trophic Hormones
Tropicamide205
Tropisetron144
Trusopt204
Truvada115
TT380 Slimline78
Two Cal HN230
Two Cal HN RTH230
Tykerb172
- U -
Ultraproct25
Univent
Ural
Urea
Urex Forte
Urinary Agents
Urinary Tract Infections119
Uromitexan
Ursodeoxycholic acid
Ursosan
Utrogestan88
- V -
Vaccinations246
Valaciclovir109
Valcyte109
Valganciclovir109
Vallergan Forte196
Valtrex109
Vancomycin102
Vannair
Varenicline tartrate159
Varicella vaccine [Chicken pox
vaccine] 251
Varilrix251
Various207
Vasodilators63
Vasopressin Agonists94
Velcade165
Venlafaxine137
Ventavis65
Ventolin197, 198
Vepesid167
Verapamil hydrochloride58
Vergo 16143
Vermox
Verpamil SR58

Vesicare83 Vfend104 Viaderm KC70

	INDEX
Generic Chemicals and	Brands

	112
Vidaza	162
Videx EC	115
Vigabatrin	141
Vimpat	
Vinblastine sulphate	170
Vincristine sulphate	170
Vinorelbine	
Vinorelbine Ebewe	170
Viramune Suspension	114
Viread	
Vistil	205
Vistil Forte	205
VitA-POS	206
Vitabdeck	42
Vitadol C	41
Vital HN	224
Vitamin A with vitamins D and	
С	
C Vitamin B complex Vitamins	41 41–42
C Vitamin B complex Vitamins Vivonex Pediatric	41 41–42 233
C Vitamin B complex Vitamins	41 41–42 233
C Vitamin B complex Vitamins Vivonex Pediatric	41 41–42 233 224
C Vitamin B complex Vitamins Vivonex Pediatric Vivonex TEN	41 41–42 233 224 64
C Vitamin B complex Vitamins Vivonex Pediatric Vivonex TEN Volibris	41 41–42 233 224 64 120
C Vitamin B complex Vitamins Vivonex Pediatric Vivonex TEN Volibris Voltaren	41 41–42 233 224 64 120 120
C Vitamin B complex Vitamins Vivonex Pediatric Vivonex TEN Volibris Volibris Voltaren D Voltaren D Voltaren Ophtha Volumatic	41 41–42 233 224 64 120 120 203 201
C Vitamin B complex Vitamins Vivonex Pediatric Vivonex TEN Volibris Volibris Voltaren D Voltaren Ophtha	41 41–42 233 224 64 120 120 203 201
C Vitamin B complex Vitamins Vivonex Pediatric Vivonex TEN Volibris Volibris Voltaren D Voltaren D Voltaren Ophtha Volumatic	41 41–42 233 224 64 120 203 201 201 104
C Vitamin B complex Vitamins Vivonex Pediatric Vivonex TEN Volibris Volibris Voltaren D Voltaren D Voltaren Ophtha Volumatic Voriconazole	41 41–42 233 224 64 120 203 201 201 104 202

Vytorin	62
- W -	
Warfarin sodium	50
Wart Preparations	76
Wasp venom allergy	
treatment	. 195
Water	
Blood	51
Extemporaneous	.214
Wool fat with mineral oil	71

- X -

Xanax	151
Xarelto	49
Xeloda	163
Xifaxan	27
XMET Maxamum	231
XP Maxamaid	232
XP Maxamum	232
Xylocaine	131
Xylocaine Viscous	131
Xyntha	46

- Z -

Zantac	26
Zapril	53
Zarator	61
Zarontin	138
Zaroxolyn	59
Zarzio	50
Zavedos	167
Zeffix	108

Zeldox	149
Zerit	115
Zetlam	108
Zetop	195
Ziagen	
Zidovudine [AZT]	115
Zidovudine [AZT] with	
lamivudine	115
Zinc and castor oil	71
Zinc sulphate	43
Zincaps	43
Zinnat	
Ziprasidone	149
Zithromax	97
Zoladex	93
Zoledronic acid	125
Zopiclone	
Zostrix	
Zostrix HP	131
Zovirax	
Zuclopenthixol decanoate	151
Zuclopenthixol	
hydrochloride	149
Zyban	159
Zypine	
Zypine ODT	
Zyprexa	
Zyprexa Relprevv	
Zyprexa Zydis	
• • • •	